<SEC-DOCUMENT>0001558370-23-013483.txt : 20230807
<SEC-HEADER>0001558370-23-013483.hdr.sgml : 20230807
<ACCEPTANCE-DATETIME>20230807070219
ACCESSION NUMBER:		0001558370-23-013483
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230807
DATE AS OF CHANGE:		20230807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		231145557

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20230630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/7/2023 10:12:14 AM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: 18dd88a5-e7c2-4457-a8c6-9cf85d42008e -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:plx="http://www.protalix.com/20230630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" xs:nil="true" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_mbkcZ_Nd20m45FPQ8bvgjQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" xs:nil="true" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_uH3B7P4yAkaoJyxywZubCQ"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityCentralIndexKey" id="Tc_WKImfigiu0il-Yb9zrSGyw_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:CurrentFiscalYearEndDate" id="Tc_-rivtPWdLUCrPnB5myXwrQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:DocumentFiscalYearFocus" id="Tc_kx2QpFpFyUq6WhUlXv7gxA_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_1GIvMbX7iE6qvbOyyAl1gg_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:AmendmentFlag" id="Tc_k8S2F6cOw02mltjOKX8RHA_6_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jMPvUoYVVEu_xO49zfmz6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2f7dHNiIfkWbGa0IWZYg0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2xh1OXXKFE-Kulcz9V8NMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDq4696d-UOcccu_7Cvwag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_lBFN3DQNxUiobmz6_ZkcBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dL4kaY7_k0Gt7Ul51ddaLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CAoUZ3xsTECjrgCTvfsWpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jB7j7aZTuECzxWimg8CXLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li-HD8Y0uUCsTeiv7eapQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsElhEMx2ES3jtK9Y9EB9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b3NmpKIJr0-JCDPkDs2yZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_FBZ8Tp5vLEKjPPGlg8URdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i4Rr-h0DiEmI3X2F-6HTrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TjGEUWhlV0-DICU_0AaPHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_r6SoXt1a2UaK8KRu3WmzvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_piQqP256hEOa27v5mbImJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyjWpJkL4Eu5oaahwOaq8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6EY8ZLejPkaK5jN5fkWHzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0fDfLHqQbUOjSUb7SXk8-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DbnmycSCC06iSdpupTbnrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__XyDi3xaVUOhI8hK5ZkSag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_KZqJ5slPPEGfEAtG9oUahg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JGEYQ_-rNEe6Bkb5w86nqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_cxV5YkmyMkOdKBiC71d5Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_YISAxiydmUe42opqwLUlVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_2OozcC2UK0uAy4FUBp84ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_CNF4wwqArE-QJGN7-yi3Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_3xKKEe90x0i1wtZ9ei35MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_nw34ZM_veUiZ_WWpDb01mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GYEteH5yxkOi3Fycl0MiGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_kHP60lRxy0Cl3Ghw5nGl3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_2htVCHKOakKxo0P6Mt-phw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_oCwNjjGdSkSVxZt-Jq0NGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M8LWQVl8T0y-iXLLBJWW4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2023_To_5_8_2023_WubO3bm2MUSrkueojHRBdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_9vEHwV8JlEq0c99K7nQPGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xg4mR_srVEOznTErp8pnVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_UTKUBS9fE0iLVZ9EFrAJiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WFc9oZvin0GRCHLpUhlF4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rEn92dYq-0ijjN1WMEHxjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GT5dNEEhVU-SSWfxxPmtuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W1NCM3GJAEO9AOQP2LXSDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_KY-ma-SuxE6JsnDPAL7QoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XOS2xaTk5EWDha2vAO2bxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_h_ZFDwKXEkyuUN5mMKV7ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i364BLxb4EuwXvVZ-E3v4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_HUfqWHV6HE6-7_b8ousHhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2023_GhxIuEgHh0-KdnsF3PgcOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_24_2023_Fc4rDyr3_EmtZXvFeu0hug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ri18SJ0PQE-p2S56WmoUmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_o66HQb4RTU6YeX4ytF2Xyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_SZhJbmB8HUGxaWk_ZQO-6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsMember_ORrJrQ2JFkyptwnKkDK9ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_giw5lYGyHk2z5Tsr-qoIyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_Bvgp1anEpkieiOQvLEWBZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_eQMenfm7EU-xHazziK7JOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fpNYRx6x8EuZW-bIDYLU9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aD3nH1aLCUqeL-tmXCvk2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XAvFwxyFCEqwxJ0AjpLtzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Y1sSF-J3QESve0bxhy5HKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JzsNZYTG20y3XtcplisU6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_FWuVkyQiG02-RIndYlC-aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1_rwBZR3HkGX0wF4AjdCSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MMPQZ_UDMEiuFwLxSK6mJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G4WzsvxhnE6EeNdK2xBSHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d5yjCdKWyUm8nc8BaZtkgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NScsocUMtU2QHthjRxtAQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ENltzQ0-bEaXq264zzSKaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_f4fIos5PMUmhCLw2-9tJyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Rk6iSTTZ8E2nfQOmpW14IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2023_To_5_10_2023_kzlqsZvS4kOBpSRWM3vhTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-10</xbrli:startDate><xbrli:endDate>2023-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1pbkqm0PNU-3n1SC2J0weg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Ta0zpsSnik2xFK3Rjys-yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_KuSCtZl5_0aMliO15-tKbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_MK5otss99UeqSBlxwWlVCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_u8htPnnek06B3-QkyDCiAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2023_To_7_14_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_8xJeZMuB3U2g_8i3Y-HmUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-14</xbrli:startDate><xbrli:endDate>2023-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_7_2023_To_7_7_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_16ZP9euma0-A-zyLjLyJAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-07</xbrli:startDate><xbrli:endDate>2023-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DleZZTmqnkqE26Xs8euChA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_4aJya2GEz0u8k1VFkbnZgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_ibjkwjeinUigCNCGceGaYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hzlZO_DQb0WzzjogYuqErw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_21_2023_K3ZvOjH68UyliMbYRqXDCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_A791LfE6c06Ffo0FaCMpfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_RrH2ndyoyUWCJiK_yzGWKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EkdrbNRlwEWh5sJiOa4BPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_JB76OZ74g0mWS8x6-0BM6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxPP66-FEG8RWl0rfhx_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_OdlZNkXl6UaVoC041YLuMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r_ehkfZA20uqfwPPaAkqOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_T2FJkJmPOkmmfxXV-kkOJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CjEp8-HoFkWDhnqgJoKWcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2023_WxO4EWQMiE2Vp9QMbIQlew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_v67Atkda-ku71Q2qAiO_QQ"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3qV8YCA4YkavB_dwU6GMcQ_10_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Gyd8m8j9c0ezUesMH69-PA_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_DEzIZn9FZEqIkBHuDpg9Mg_25_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_MNW3OH0N7EGIPLANOT9oZQ_16_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_29Az6NLHf0aPkOOX7lgx2w_33_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_NjCLqQ7KWk6Q-HmS7qZB5w_11_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_2GOQ0nsFekakUzpWtFzx6g_28_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_MWAzutUR-kaS-S0-9UYuRA_20_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_nSRgNHxWFU-H92c_4P5ICQ_37_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_TWaIr1fvkEC-wVKp7AvnVQ_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_AI2zl9qsRkisTpjggz7TZw_23_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9XaIn3ucDkuPIp0sPbbj_Q_30_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_480KZM66zEaQdZOjkNwHZw_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_0jsdRZvys0SHbphZyMaHiQ_14_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6U8Od15PWU6teh99Rpql3A_31_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_NQjCLbxb9EqEjpBgqapF4Q_39_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_H9dkt68onkiouKSwQwgAwA_22_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gzYqSKO35E6BZW8gI3x9QA_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_yEDHDFZfk0KplkhCFGoCUw_34_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_8-mg9-0bv0WqhS2MXDxbiw_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5WdWTblMjUeT0pK-FtB8CQ_6_12" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_FcQpeS2QMUSw539x2sLD6w_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_76HgycOXrEu1DFgY29kquw_6_9" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Vmeaqo5FBkabe_UXXmL7BA_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3FdqAtg-QkquKsONqBAcYw_7_12" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_0Ncf6ddh8U2WaWytFeW2sw_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ekk8r0vCc0anL7WCzi162A_7_9" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6IrXNofQNE2QdNwj3_zx8Q_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ZbEKE5md2EGkbm08lQVehg_8_12" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_7jNoLHuUg0CXsTnEiCT0QQ_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ukdMAx9UTkyI1jGkEE71LQ_8_9" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:0pt;padding-top:1pt;text-align:right;border-top:3.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">Or</b></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a4f65b78_8c87_4934_a708_262f862e77d5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:DocumentType" id="Narr_4dK64nHMREqzEQeiIeJAMQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:DocumentQuarterlyReport" id="Narr_G8ilk0hK40uQqxnLTGDHdA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:DocumentPeriodEndDate" id="Narr_roXtq4TMD0iHGroZsSBFCQ"><b style="font-size:8pt;font-weight:bold;">June&#160;30, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:DocumentTransitionReport" id="Narr_jIyyXuqd_kydkCUfIwWB1Q"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityFileNumber" id="Narr_retCiUyRWEeWhzyQH0uQ_g"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityRegistrantName" id="Narr_kuoPCtjybkKxxhhCOaBM2Q"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_-u1WdPUCf0ue7jk7MXNjHA_1_1"></a><a id="Tc_OUBXmX99HEKir7pOihTPfg_2_0"></a><a id="Tc_AG-KvYY5g06h92N9Chwe0A_2_1"></a><a id="Tc_TYfIOjQbL0i1_Ddd4in1kg_4_0"></a><a id="Tc_-LIEuJcZ2Eu2_4OnTHHFjA_5_0"></a><a id="Tc_cBxIzWgR8kC8F3_7nOb2BA_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_UVsxDkbbz0yPRKUlPBUV3w_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityTaxIdentificationNumber" id="Narr_w8JQuPXc7kyKhJOmEKcceQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityAddressAddressLine1" id="Narr_DIYfSw3VFkC5Rfy0Z78TJQ"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityAddressAddressLine2" id="Narr_D4EFJiBAj0uOd_7HM2P1HA"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityAddressCityOrTown" id="Narr_d4PIaWBOn0mo8EvhWK9mwg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityAddressStateOrProvince" id="Narr_4MkB6E2SyE6Y-48bnwNIEA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityAddressPostalZipCode" id="Tc_UHG_lbvPPUOXM9zm0sEJzQ_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:CityAreaCode" id="Narr_ZqUBHBo2lUWQMm1SZiOp4Q"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:LocalPhoneNumber" id="Narr_9Z61G6d-nU-Ey_E9YIM9lQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_WNQ47atVS0ayvLKaK__yLA_1_0"></a><a id="Tc_gazQCBXaxkelvZWtNprsgA_1_2"></a><a id="Tc_yBgcHOWew0utIewum-lewg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:Security12bTitle" id="Tc_8CYPE57L9UqhtnO-baF7mg_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:TradingSymbol" id="Tc_kdyPGYR6dEKDXcVHmQrbUw_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:SecurityExchangeName" id="Tc_6b-bEwHJg0CBm-k3RRW8fg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityCurrentReportingStatus" id="Narr_PHwGxvRofEyzjv8M_un70Q"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityInteractiveDataCurrent" id="Narr_v-LA17o_cUGTZKw60TmwvQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_Aym6Cp6ZC0mWy8lqMGRKpA_1_0"></a><a id="Tc_5zGkl5brQUCxq1w0WVHiGQ_1_1"></a><a id="Tc_rNGZJ6hDN0iPWnJ2dCXeEA_1_2"></a><a id="Tc_7PPWtys1PUaaSONdK0UfMw_1_3"></a><a id="Tc_aFm5IehLUkiEKudY8-4Fmw_2_1"></a><a id="Tc_XDTGm1p3ZEaQZZWwQN3EOg_2_2"></a><a id="Tc_lVybSQaah0eOfI4q-CDeFA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityFilerCategory" id="Tc_ecdZrdJXUE2DAtMUstWKFg_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntitySmallBusiness" id="Tc_JwVgLJsHv020MfZQobWHLA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityEmergingGrowthCompany" id="Tc_7x-OrhqzV0CP_-EwLDYT4Q_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="dei:EntityShellCompany" id="Narr_ClU9Zq5g5USgVv6L-MBdEA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On August&#160;1, 2023, approximately <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_8_1_2023_WxO4EWQMiE2Vp9QMbIQlew" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_OCkIvtwYz0OASi_6kE1w0g">71,580,762</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_435df638_e4cb_446a_9af0_e95a4b1c75ab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of June&#160;30, 2023 and December&#160;31, 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Three and Six Months Ended June&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Three and Six Months Ended June&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Six Months ended June&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_98d0a83e_69eb_4204_9c1f_653faae89557"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_aq-_rp5CI0at0HtYBHoa-g_1_2"></a><a id="Tc_bJQTkqel50mxmy5sdsNc0Q_1_5"></a><a id="Tc_jYcrDR_030mM515lvuA1vw_3_0"></a><a id="Tc_9qK4Ylof6UmnZB-a_jWW9g_5_0"></a><a id="Tc_pli9SKSJC0iBKZtoUOen4w_6_0"></a><a id="Tc_rFfdjvqfC0K-XU2dTvVDog_6_2"></a><a id="Tc_iGjJ0mjenUWnL0z2t8HOcg_6_5"></a><a id="Tc_fSLHeRYoa0iaQZXIXvU5XQ_7_0"></a><a id="Tc__cjkdBYqF0SnI2CTSj01wg_7_3"></a><a id="Tc_vI_6NsAhrkm1sqltGylnvQ_8_0"></a><a id="Tc_z4B56bzQ60O0mdxh6i3DYQ_9_0"></a><a id="Tc_TYOgx3b-RE6zV2p9s07tuw_10_0"></a><a id="Tc_Nnb0DASVYUaYlYyv7pxk6A_11_0"></a><a id="Tc_7z2bin7PSkeQiRNU8iQ3FA_11_2"></a><a id="Tc_wHIkVWe7LkuUjSL_uLULZA_11_5"></a><a id="Tc_3Pl9mND5OU2p5gNMV_yEzQ_13_0"></a><a id="Tc_VLx1G_OGgE2WWoyntiSe5Q_14_0"></a><a id="Tc_xUfgPS16yEOrK94dSz1MzA_14_2"></a><a id="Tc_-bAMSBdHg0y1E-QY-2-urg_14_5"></a><a id="Tc_AmxN4abK8EeLOJMWykItNQ_15_0"></a><a id="Tc_r68ySeOqOki0k9ZbevBtKA_16_0"></a><a id="Tc_IBreuTvmD0KtyuKNYFkTsQ_16_6"></a><a id="Tc_XLxg2QpfdkCofYdAqFQ2LA_17_0"></a><a id="Tc_ec64e4QIjkahwmsdZrNshQ_18_0"></a><a id="Tc_GMr3bx8kWEKx-pDIPRNPqA_18_2"></a><a id="Tc_mAhneiOR8EaYa8DBfXd0mA_18_5"></a><a id="Tc_JzVneOynUUqIniax7_-seQ_20_0"></a><a id="Tc_-B5CyKXP90iJeHPmx6vkEg_22_0"></a><a id="Tc_8gWYwkxBLU2kfYJKOKYLyA_23_0"></a><a id="Tc_LM1yx64zfU-cuXyx-Fb2uw_24_0"></a><a id="Tc_UVVPm9tlTEmQnyhpB_xW-w_24_2"></a><a id="Tc_ZCPIgE7MjUygobLz2w0Urw_24_5"></a><a id="Tc_6WdTfkqa4kWOMFWQStuh3A_25_0"></a><a id="Tc_m3XVHz5EXkm0m4LNhs-SVQ_26_0"></a><a id="Tc_iq3rmWkZOUaFA6c8cWQeSA_27_0"></a><a id="Tc_xZEJtvFBlE-J5TVVtiUpIw_27_3"></a><a id="Tc_SeTrzMYzzkmCh4TjCAXOIQ_28_0"></a><a id="Tc_vxo_wpK4yUCgeRiSdqM8tQ_28_2"></a><a id="Tc_xDpWQ4pqY0-bPtlD9CP7og_28_5"></a><a id="Tc_9e6TNqAiiEy0sNIeWFbxCA_30_0"></a><a id="Tc_NdI5x4_sM0Saw6eHqMy2BQ_31_0"></a><a id="Tc_-OEvwowYVkOhv_3GaclDvw_31_2"></a><a id="Tc_6Ub_lrveckmRDpMeeqJJEg_31_5"></a><a id="Tc_Pnbe0P9ElkqBOhpmsVemDg_32_0"></a><a id="Tc_tjmIDXEKPkqnpjuC14Y4BA_33_0"></a><a id="Tc_4QL7LhCUmEuWo8XuqQr_jg_34_0"></a><a id="Tc_HgKe6LpaPUCMaySYQhqCxw_34_2"></a><a id="Tc_I3aDyw9BpEeptWaC9luThw_34_5"></a><a id="Tc_4l12GdY2jEW5NWQr0pugQQ_35_0"></a><a id="Tc_smdP5yQNaUicKOJEtminVA_35_2"></a><a id="Tc_cGfFZzawtEi5vFDFUBciqA_35_5"></a><a id="Tc_9nMXEGu9Pk2_QNrDP5RAfg_37_0"></a><a id="Tc_qFmyVKYcaUqWGwBZVyI6xA_39_0"></a><a id="Tc_KzyLAUYPdEeV770BD9W1-w_40_0"></a><a id="Tc_DvXxsNTNcker8XYSDe3bwg_40_2"></a><a id="Tc_6Nf4pbqbhUC-1KnAIm0XdA_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc__ggndNuEY0q00Rnnack2NA_6_3">48,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LgBjCAUuCUW5GjwfhwL5NA_6_6">17,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_kINlhx8B3EGpoZv0mKuKbA_7_6">5,069</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_obXESkiLLUerOBW7iOqZgA_8_3">4,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_h_BCyZapKkGCK0q418QQ8g_8_6">4,586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_wsbbEPBZZEyKBABjc-ouZw_9_3">1,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_EjhY0pXpxkq81ba8bOnLOA_9_6">1,310</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_NZS5dFy0OUexIvWU5TdPAg_10_3">19,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_NiWhLAVj8EWem2UOA2YKlw_10_6">16,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_9lIJZZi83EuVubISiuDa1g_11_3">73,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_XlsGylpYM02inKzwlVXfIw_11_6">44,880</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_9raEolIwTE6NiRlRYHCfOg_14_3">1,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_BGE9XHdi8UOUyneTRR8sfQ_14_6">1,267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_26PPGd7daUWGF9MMo9A9tA_15_3">4,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_8oqpp-KcUUqJLw5SjcEzEA_15_6">4,553</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_gKIftPAe7UiKuOYBaQPxaA_16_3">3,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_qZW30Og26EueDGM_PiLBeA_17_3">5,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_dymNpoflskSYiN6V4cWcZQ_17_6">5,087</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_RAoufPrk9kW6pQdf1Z72Fw_18_3">88,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_PchTUBsPhUeVJjTROzquVg_18_6">55,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#39; EQUITY (NET OF CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_Kn6wWMczV06PwNhEWlapbw_24_3">3,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_wjbIPtOonEiMh7-OXu82HQ_24_6">5,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_ZoyO1iFsrUG0GqJS1UbXGQ_25_3">18,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_VPbEQJ_onkyojhjLjOJcgQ_25_6">12,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_B4NSkW-38kO7zcqk6XbK1w_26_3">1,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_a6oIgCFR-kOr6l64LmYwTA_26_6">1,118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_pKBuMd2MC0S4y1SCrOboYQ_27_6">13,178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_sR0BL8g-906ev0WcLEWOxw_28_3">23,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_jnetS9k4EU292yua6Q4Z6w_28_6">32,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_sSosYVK0qEKFkVRIQGTt3A_31_3">20,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_6g6MkomXy06nwDLidV9kEw_31_6">28,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_fqlP8dZ1_kyBrYU4TJIUvw_32_3">1,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_h5ZEEPF6ek2qB4trUQdGfg_32_6">1,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_g30Fqpy6sUacH2_gqiPIOQ_33_3">4,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_XFYAoUSOTkqLIbApoAl1Tw_33_6">4,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_arXoDI8pHU-M38GnyndoJQ_34_3">26,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_7c2MYTjlbEGyqRmEFtK11A_34_6">33,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_0drEmCywL0WZXWpTlZLoBw_35_3">49,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_dfk1vJUMIU6zVbenvd4P3w_35_6">66,427</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#39; EQUITY (CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Kt1bVOYhwUGVWQD9ZN8bBw_39_3">39,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xlc6R8Nh7EOLDLiYJpmjxg_39_6">10,640</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders&#39; equity (net of capital deficiency)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Jw0WY6k18ka-E110N_Fweg_40_3">88,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Sn1pzxneYkOCes-05cWPqw_40_6">55,787</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_651b6d04_41e2_4fb0_926f_949cc7faf75d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_IjMJQhXCikGsJ5ga4KBbtA_1_2"></a><a id="Tc_e5Gn05NqJUy-gTOUVjqAiA_1_8"></a><a id="Tc_1NEpCUhtSkayQ3rhSmhb_Q_2_2"></a><a id="Tc_GgO2vhYTvkiIm_4Aov0umQ_2_5"></a><a id="Tc_OuyRKCS4KUWyqQLDwZSeIQ_2_8"></a><a id="Tc_QDHiFUbi-0SsOF8EbrG8ug_2_11"></a><a id="Tc__F48Db-_uUydtkPD557IPg_3_0"></a><a id="Tc_0KyxT8gyA0-X7iYtfhb0uw_3_2"></a><a id="Tc_3Kx-MQatg0qLJ-kPsCCLwg_3_5"></a><a id="Tc_tnR3o85xK0GO1CYKnW0wnQ_3_8"></a><a id="Tc_5B1AkY7fTU2WuVEbgHpuDw_3_11"></a><a id="Tc_pEOTkmGKnEWWrXK2E2kVnA_4_0"></a><a id="Tc_iom5j7fDX0G3OUWseMXZIg_5_0"></a><a id="Tc_1ouCVvKYpUOV00efhL_oTA_6_0"></a><a id="Tc_OJf7kajjrEGxFIfJz0H3oQ_7_0"></a><a id="Tc_t4cBv6sdcE64KAS-bVJR2A_8_0"></a><a id="Tc_AcHlCao5ykS31dWlH60EYQ_9_0"></a><a id="Tc_em1BwKgF30eIyFsbObXYgw_10_0"></a><a id="Tc_6mMhUn59rkitObbMOIBOLA_11_0"></a><a id="Tc_cvHIni5sYUu_pyFOcZ0Alw_12_0"></a><a id="Tc_gZ6auzAUQU-qde1pQ0Q3WQ_13_0"></a><a id="Tc_Au-pygHUuEKN1zgzqdyfSQ_14_0"></a><a id="Tc_LlYaTrtMtE6cJ6ZP8e3EUA_14_6"></a><a id="Tc_4hoYST-tJkWNRCu5ACww-Q_14_12"></a><a id="Tc_jL7Gipk-EEqnR51gOMGRNQ_15_0"></a><a id="Tc_7tTK_qbiEkO033R_WGhmYQ_15_2"></a><a id="Tc_9enuy8DT6UinyxlvJEI7UQ_15_5"></a><a id="Tc_KEQidBvRAEC3s4SNxSMinQ_15_8"></a><a id="Tc_mB5KQmlNl0ueYe_6RhOWqQ_15_11"></a><a id="Tc_2nmCFJpymU-J5KbJWGGOGg_16_0"></a><a id="Tc_lTtiUkaAfUKqj7-uUFPm1A_17_0"></a><a id="Tc_-T8wds9ZHUmWJgB9fpVa0g_17_2"></a><a id="Tc_2RQ_p2eY1kiOtf1SkPYzkA_17_5"></a><a id="Tc_8v65Uv6AfEKuUkBZOOBFOQ_17_8"></a><a id="Tc_WuRZaNsGY02qNQcFvdAM4A_17_11"></a><a id="Tc_ptJB838VVkGZm3fF6jv7fw_18_0"></a><a id="Tc_o4-4r6aQD0KBAV_RBcrONg_18_2"></a><a id="Tc_-d498Bto9kOVIdyafM8jTA_18_5"></a><a id="Tc_1lb_B115UE2N90xwj5r4eA_18_8"></a><a id="Tc_biWcrzXb4EutirWSjJNyNg_18_11"></a><a id="Tc_OhGxxCcXPkGvnVu4ruDZEw_19_0"></a><a id="Tc_H_n5RNm6mECe_95SJy1iow_20_0"></a><a id="Tc_OUQIzB-osE-YIg3VYFmWhw_21_0"></a><a id="Tc_YXzhJ_bGYU65kuBe4ezK6w_22_0"></a><a id="Tc_lWOIsmi070y-e09KgYHswA_23_0"></a><a id="Tc_S3gogOtGEU2zMLjRoCZR7A_23_2"></a><a id="Tc_FrXAIf4U5UCGw4YCewLWpQ_23_5"></a><a id="Tc_YKtsGk7jr0CgOkV4G8CRXQ_23_8"></a><a id="Tc_J-Hofr_blEaHwkTJ9nqVkw_23_11"></a><a id="Tc_veFYZIRjCUCXk2r2kJDE1Q_24_0"></a><a id="Tc_Ula2vu3nmUWZ6Y6mjZG8lA_24_2"></a><a id="Tc_xmdKp_-Dw0erK308tsAZRQ_24_5"></a><a id="Tc_jz8Tr61NrUOHwHO-xMeoSw_24_8"></a><a id="Tc__05Q80XdhECGkuMMaWorcA_24_11"></a><a id="Tc_i1iK1-YBgkuZ8B1XdLDd_Q_25_0"></a><a id="Tc_s4UfEqoyuECBOYThJ_JZLw_25_2"></a><a id="Tc_BH-2ucq390W636xYbUjpMg_25_5"></a><a id="Tc_aHMuHoDGGE-Vrd7_0VifRA_25_8"></a><a id="Tc_gV1T6ZZpNkGSlzQqUm3d5Q_25_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7083359%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_YISAxiydmUe42opqwLUlVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_4-qKSm-1d0SGvB48LpLUVQ_3_3">20,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_oCwNjjGdSkSVxZt-Jq0NGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_nLi5Ua9vDU6yFuRxiY_4xA_3_6">12,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DbnmycSCC06iSdpupTbnrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_28tSQcsBOUe_yMOg3rzw1A_3_9">15,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_3xKKEe90x0i1wtZ9ei35MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-iKTPhNKekCMHIPfzu2dgA_3_12">3,382</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_2OozcC2UK0uAy4FUBp84ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_4VaQCYX-Pk2uG5i5zo0jKw_4_3">24,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M8LWQVl8T0y-iXLLBJWW4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ONQeyfVMC06PwM8brxgKwg_4_6">12,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__XyDi3xaVUOhI8hK5ZkSag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_FntgDK7L-UaT5b3OgCwX7g_4_9">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_nw34ZM_veUiZ_WWpDb01mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_fmEkvjS7zEWkXyZsL8ht7w_4_12">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_7nfxKRYll0mhnU1VsZfZ2g_5_3">44,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ZeHLlweEyUexmH43M841lw_5_6">24,838</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vFNNplfRrUKTTLzCkEUkRA_5_9">35,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yxqmdjiLsEKbOgr1DdUTRw_5_12">8,753</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_FcQpeS2QMUSw539x2sLD6w_6_3">9,233</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_8-mg9-0bv0WqhS2MXDxbiw_6_6">10,121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_76HgycOXrEu1DFgY29kquw_6_9">6,148</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_5WdWTblMjUeT0pK-FtB8CQ_6_12">4,087</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_0Ncf6ddh8U2WaWytFeW2sw_7_3">10,322</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Vmeaqo5FBkabe_UXXmL7BA_7_6">16,346</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ekk8r0vCc0anL7WCzi162A_7_9">4,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_3FdqAtg-QkquKsONqBAcYw_7_12">7,579</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_7jNoLHuUg0CXsTnEiCT0QQ_8_3">7,146</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_6IrXNofQNE2QdNwj3_zx8Q_8_6">5,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_ukdMAx9UTkyI1jGkEE71LQ_8_9">4,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_ZbEKE5md2EGkbm08lQVehg_8_12">2,611</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_0xmg5XJzEUGTEY1OSKQwaw_9_3">17,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_zgoCHrGPMEmnnn5vVR0wWA_9_6">7,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc__7cultcQHEOVrNcFpfdauA_9_9">20,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Qkn8GvGz-0KWMl-D9nYrPQ_9_12">5,524</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_pNchChBg906pLK3M6ZDXTg_10_3">2,169</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_8N0F7UZgAU-sqkZNtGKUag_10_6">1,242</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_jUsje8s8MkigasfQm2enuA_10_9">1,305</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_zFAzpOUR4E62EIi9Dm_1Eg_10_12">623</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_pZku5HU7H0aAR4DNH1AGNQ_11_3">918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_82DqNpGfZkeUp84Xs_3fkQ_11_6">1,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_qgkhCiVR-EK-I40oH8MN7w_11_9">531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_6IbSj_M-D0OYW5oDyZpe4g_11_12">813</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_76qiZI0W206PIvWOAuhdug_12_3">1,251</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_Wdk0C2q0A0GoH74y2klkKg_12_6">226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_Kqih_MxP0UmeSwDeA4gIEQ_12_9">774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_2aPVOENwc0WPGcgJNL5n-A_12_12">190</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INCOME (LOSS) BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_P71HOsPkB0GPhDaXqf9QPw_13_3">16,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_V9wV6pVWyE-DdDMMF7ydEQ_13_6">7,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_Qzn7X_7GLUeAXs541fY90Q_13_9">19,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_VZhZpFy3WEeSzIdzGXQB5A_13_12">5,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_gO4f4LVqQUSrg6gDCh7QBw_14_3">503</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_A6xc-Ug2lkmjC_50Om_qoQ_14_9">308</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS) FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_x3nugp_ZDkGMQUzLe40SxA_15_3">16,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_TmtSaC0WT0uC5ZlyQeLxOw_15_6">7,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_O8F-HfyJFkK_0IMUMPQ2iQ_15_9">19,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EocGnRW0HU-QHIjGu1bbOw_15_12">5,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK:</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_V2zcm2OmVkOIVFeyAVlOhg_17_3">0.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_yCgNFJ7iU0qKm_658MTNeg_17_6">0.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_kDo9wd7XX0u1uBbfkBWufA_17_9">0.29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_aO3LIuBV8Ee8QYcscQxVbQ_17_12">0.11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_bpphsVuJsECSBqTh6PYfSg_18_3">0.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_teKIziyBEEKnwe_92r2JCw_18_6">0.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_5dqZxDXrOUupNm3tRhWnYQ_18_9">0.21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_l1osm3-23kuU4lnvn_c2QA_18_12">0.11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE:</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_wlMR0bNcD0CUugd8BUTTDg_21_3">62,378,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_0Pb7ToQwd0m7V968R--ysQ_21_6">46,589,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Xgp8fNnXU0WMJmIuMqiiGw_21_9">67,158,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_iQ3lHPgFZk2-__kZpe-6EA_21_12">47,327,952</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_HlZfkqdqT0qKfTvvtABMNQ_22_3">78,896,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_3WikAhkYdU2USNEfL2arnA_22_6">46,589,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_aKNCbvr4NEub6NOPMzmeSg_22_9">83,200,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_dbFrxJctgkWPu-VCkfQ6Ag_22_12">47,327,952</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_FWuVkyQiG02-RIndYlC-aA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cRA9HpNX4UmZYvhtdWf4bQ_23_3">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ENltzQ0-bEaXq264zzSKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ZRTV6M4GykymfPsZ9WedKA_23_6">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XAvFwxyFCEqwxJ0AjpLtzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NTdM3rL3q0qtG3oSMee8YA_23_9">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G4WzsvxhnE6EeNdK2xBSHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_drUusfKdAEuPChNCcF_Lgw_23_12">28</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JzsNZYTG20y3XtcplisU6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6AUAD1hm5USSVV67-kPRFw_24_3">324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NScsocUMtU2QHthjRxtAQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_VOQTpj0f8Uq3FjA-Yyy9GA_24_6">161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aD3nH1aLCUqeL-tmXCvk2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Lws4T0FZG06sY78-NdAu8w_24_9">144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MMPQZ_UDMEiuFwLxSK6mJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_pi-OadTmg0m5z-sc7prKXA_24_12">85</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Y1sSF-J3QESve0bxhy5HKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_pGTv1-fg2kSx1OxH_kkc-A_25_3">556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d5yjCdKWyUm8nc8BaZtkgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fF1e-ouIZkW3jzD99Bl7tg_25_6">941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fpNYRx6x8EuZW-bIDYLU9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rvTQgiJfJkyEj7sbU_7GMw_25_9">248</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1_rwBZR3HkGX0wF4AjdCSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_FoDnR_LXNUWLggsmFWB_Ag_25_12">175</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_387649f5_56e7_498d_88bc_243e6db12cdc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_vNNxY2sOXkuMBqausdhrrg_1_7"></a><a id="Tc_IxwqetMSWE-9saQODMfRPg_2_2"></a><a id="Tc_eZGIgqNna0uVjjooa5jlnw_2_4"></a><a id="Tc_4-IRhLUZok6OI6QZY27aWw_2_7"></a><a id="Tc_lB0kxI8y-U23liC48-E6BQ_2_10"></a><a id="Tc_FCBjFwGyJk-JKo2vVeeoAg_3_2"></a><a id="Tc_s4q6c_zZXk24G619w6l_8Q_3_4"></a><a id="Tc_QK6smJkSj06jimk-YsAcUg_3_7"></a><a id="Tc_rdFwQhyk8k-J7skbu5O5aQ_3_10"></a><a id="Tc_3Ng1kV8n_Uqoml59ZXG_Bw_3_13"></a><a id="Tc_2uflYvFr6kyXqR8pq9OcNA_4_2"></a><a id="Tc_mO5IG-3H3Uyp_i708-oSYA_5_2"></a><a id="Tc_LWUS7jtTUEmmVqVUGnkd9w_5_4"></a><a id="Tc_-D-P43wysU2UVmEjt7JwwA_6_0"></a><a id="Tc_4QmcZNv5D0CbNLxgKssXGQ_6_4"></a><a id="Tc_UEpkylt1fkaMOEZpYp85oQ_6_7"></a><a id="Tc_BroQkW39LkKSudK70tffzA_6_10"></a><a id="Tc_Pb3AVtTt7Uq8Pq_49aW1UQ_6_13"></a><a id="Tc_uzev2dcchk2U86pThuzBsg_7_0"></a><a id="Tc_e8RRIMND4kC1VUU7X-yu6w_8_0"></a><a id="Tc_2uPb3Iy-3US411zK9ttrCg_9_0"></a><a id="Tc_37-zTBxj0UWVf2mNN1_Wbg_10_0"></a><a id="Tc_9rg0YtX4PU24P9XIw6iPhg_10_5"></a><a id="Tc_wBPBOyoIVECeQzKlQAiCGg_11_0"></a><a id="Tc_Nz-2Tzai-U2i8bYDpvyzdw_11_5"></a><a id="Tc_RHot-Q3D3kGOOjOlPYWlYw_12_0"></a><a id="Tc_kjN8NntL0E-kwkDh3w55Dw_13_0"></a><a id="Tc_bjlJkwU7o06Zo-Ppg7CGIQ_13_4"></a><a id="Tc_pNfmZerJnEG5zKD1bG4ZJw_13_7"></a><a id="Tc_PtrxVfZJRkaB8Qpu3sbfuw_13_10"></a><a id="Tc_EkExpqIsL0iKLZ_ykBahTQ_13_13"></a><a id="Tc_tfjc7Huuz0mkAK-N-nKm5w_14_0"></a><a id="Tc_YQ7kyg7gb0iy4ayh3JLedA_14_4"></a><a id="Tc_y9BRWds4dk6teVn0ic5cSw_14_7"></a><a id="Tc_T652dHPoxkSruW6jsJ8H0Q_14_10"></a><a id="Tc_C5sPAauo3UmKz8FtZSk1Mg_14_13"></a><a id="Tc_4QSVE-Hx_EmSOqkW0DsGKA_15_0"></a><a id="Tc_JlMkAJDhGU6OAt6JeaGpOw_16_0"></a><a id="Tc_uo7-IYrrskiP5SFqnDCXLw_17_0"></a><a id="Tc_k5oxrJPgz0az4AoEZ0zfiA_18_0"></a><a id="Tc_CrCev1ESUUa7pXFJSf-hRg_19_0"></a><a id="Tc_E5pcNp-ZVU-FhguDq1xwrg_20_0"></a><a id="Tc_uByHWZEFQUGQVKTJ2r2mOA_20_5"></a><a id="Tc_QRuSRGAWXU-AflE1mp89cw_21_0"></a><a id="Tc_2RKYlXYkxkqw7x26KuXhtQ_22_0"></a><a id="Tc_Rrr6Nl-XIkGgPq-ew-2Dog_22_4"></a><a id="Tc_kXuugZcrLU-BMm3wsqQ0aw_22_7"></a><a id="Tc_aSAUb5YqUEu1JSRdSgqZWg_22_10"></a><a id="Tc_y3MsfhtfpESicNzrxIYBWw_22_13"></a><a id="Tc_4obka9SAZkOS-4jpzT1LtA_23_0"></a><a id="Tc_O-4D8_SQA0yTXxWF79hk9w_23_4"></a><a id="Tc_aSH9KL3_80K3mj8q9lN3RQ_23_7"></a><a id="Tc_RGTGizPakUq_hTVwglxyXQ_23_10"></a><a id="Tc_ryhkaY657E6koSz438sKbg_23_13"></a><a id="Tc_OrJV1gChC0ictWSIYHsRVQ_24_0"></a><a id="Tc_VKBrHRGiOEiHUHtKvr82zw_25_0"></a><a id="Tc_1ZY9kOLjzkKyUWdDgrDZpQ_26_0"></a><a id="Tc_PmVFKWGj60O2pQ9A6S8y8A_27_0"></a><a id="Tc_iADQ4ZG49kiFe1zpH9Bq0w_28_0"></a><a id="Tc_95U8i6skQUKWUgyThP7jAA_28_5"></a><a id="Tc_S2slGR-b50-ngTO95wWpvQ_29_0"></a><a id="Tc_5-k7vkFpoka3aJRT7gFh6Q_30_0"></a><a id="Tc_pr3yBVrA-0WM0PDuf6RgPg_30_4"></a><a id="Tc_5GfGNtmaLES1Hl_XSs54KA_30_7"></a><a id="Tc_ZksNAQVzvUCKE8zqpr3RcA_30_10"></a><a id="Tc_NElPEpGpp0afIUIzPvfiPg_30_13"></a><a id="Tc_Hukb3QZOPEmY-NksYchmkg_31_0"></a><a id="Tc_zpD_rbkd80mqS7ghk7dRtw_31_4"></a><a id="Tc_U3yLGfzHkEaQQ3tBDiaT0g_31_7"></a><a id="Tc_pv_V7Z1ffUO3t-TrJIphdg_31_10"></a><a id="Tc_uWjTRSENwEeYhpFOW0baFA_31_13"></a><a id="Tc_VHCrqLOCl0epWpjckwDtyA_32_0"></a><a id="Tc_9tP8r50AM0ytKY_HxzMJsA_33_0"></a><a id="Tc_pGJnYVRMG0q0OqgNdMidOw_34_0"></a><a id="Tc_OooN6ryrLEmpYO3UEAvi5g_35_0"></a><a id="Tc__gY9hYd5cUCNhjdckBAhsw_36_0"></a><a id="Tc_QQqc3BZGgEeNGip_Vy15GQ_37_0"></a><a id="Tc_jKGNyJJ_1Einii9JMLrUhA_37_5"></a><a id="Tc_5Fxcnh2nNkqXOCYpqrgGGw_38_0"></a><a id="Tc_OwRDSuSFQE6wuhnJ00BcYA_39_0"></a><a id="Tc_bbd9q67eD0ycYrLhpPPn0w_39_4"></a><a id="Tc_6AYsk80bwESoay0lB87-NA_39_7"></a><a id="Tc_O5dcIcWQ4k2x4MMApcLp_g_39_10"></a><a id="Tc_05Q_SZO8eUCRnjT5O_buMg_39_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_TWaIr1fvkEC-wVKp7AvnVQ_6_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_txtYhnl_iEGkeEXMDCc7Kg_6_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TjGEUWhlV0-DICU_0AaPHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EceZ7sNdnkW_ZLged9qo9g_6_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i4Rr-h0DiEmI3X2F-6HTrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ZW5VJqjGkki-tmuvTzrR4w_6_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2021_SZhJbmB8HUGxaWk_ZQO-6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_igViHifht0OXXyFGatDmVA_6_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_Gyd8m8j9c0ezUesMH69-PA_8_2">2,395,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_nJpyd5xLBUKFADPYWCbzCw_8_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_WQnWVRwQ1U2rWyy6f4SXaw_8_8">2,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_nx2LkQe620yrZ3fzdW4AAw_8_14">2,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Au3JqBvay0GmltYHOW7mmw_9_8">293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_V4dtQZSiHkSTW119FUFTgg_9_14">293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_3qV8YCA4YkavB_dwU6GMcQ_10_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_x6Zi9tNvzEWN23Eq71KmdA_10_8">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_BINxbibYOkabopDVY6eCYw_10_14">831</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_NjCLqQ7KWk6Q-HmS7qZB5w_11_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_cR4zJbMP-USFlp7ljqkfFw_11_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_O2yKUS3pFUSXnFeP4PlQwA_11_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W1NCM3GJAEO9AOQP2LXSDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rYMYTzq6UkGgWqiA9HuD9A_12_11">7,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-p26mGeY8EmROqEBF9fZ2Q_12_14">7,620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_480KZM66zEaQdZOjkNwHZw_13_2">48,712,952</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eXuyYAUNBUucZzSXAWei8w_13_5">49</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li-HD8Y0uUCsTeiv7eapQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dWtxgHLSjUqTQ3iyfkNhrg_13_8">372,616</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jB7j7aZTuECzxWimg8CXLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Q9ph2osHjUuulP55PWL_xA_13_11">382,554</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i23R36NgfEa3qtgGdrVhaA_13_14">9,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_piQqP256hEOa27v5mbImJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_0jsdRZvys0SHbphZyMaHiQ_14_2">53,790,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_piQqP256hEOa27v5mbImJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YFLBym2ZQ0W_hUm9jUcveQ_14_5">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CAoUZ3xsTECjrgCTvfsWpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_o0LcMeKeOUaDp87ogSrwTg_14_8">379,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dL4kaY7_k0Gt7Ul51ddaLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pI0wbvv-X0iMwx-FX_j7Rg_14_11">389,861</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DQAz94zO1kK71znHZqnS0g_14_14">10,640</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_MNW3OH0N7EGIPLANOT9oZQ_16_2">12,560,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_QM7cXJReh0S5F3IsbZBIRA_16_5">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_xu6GReVjHUuyIgyouYI1xg_16_8">23,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_oXqJuZS3QUmEynHwM6Lgaw_16_14">23,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_gzYqSKO35E6BZW8gI3x9QA_17_2">4,691,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_GCmu59bN0Uu50oH6gW4XVQ_17_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_o5do_UwRA0C3MQYGQwuSVw_17_8">7,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_wHnN3GwLHkyI84xcdhqohQ_17_14">7,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kaMLdECPI0eapIb_M0qosA_18_8">812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_mQ4RofHhYUC4lv4eDZs2bA_18_14">812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_J24KzQtt2UOwmpG_-igKIQ_19_8">172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_zVPCTPj9hE-KGfmG-09aJQ_19_14">172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_MWAzutUR-kaS-S0-9UYuRA_20_2">538,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_XXzmhVQ40EmH6LK-K59G6Q_20_8">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_ka12FmCpSkWobUFJsjdnGw_20_14">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rEn92dYq-0ijjN1WMEHxjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_8Tt52m09VUSK7QBIi7f7Uw_21_11">16,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_wZP8nBGoYku-ialSfez_dA_21_14">16,208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_H9dkt68onkiouKSwQwgAwA_22_2">71,580,762</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QcFQVWKLkkuYqdyXUBAG-g_22_5">72</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2f7dHNiIfkWbGa0IWZYg0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_IhGzRhScfUmZFNfc7J-Avw_22_8">412,582</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jMPvUoYVVEu_xO49zfmz6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PH2hHM6PP0-_cWicfNQ2EQ_22_11">373,653</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iqnX9WLM50iv6bS9STbJzw_22_14">39,001</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyjWpJkL4Eu5oaahwOaq8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_AI2zl9qsRkisTpjggz7TZw_23_2">46,316,129</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyjWpJkL4Eu5oaahwOaq8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_X1iHt0wPJEeiSv_G47leHQ_23_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b3NmpKIJr0-JCDPkDs2yZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZOQDIiNN10GRVmfWM-57Ng_23_8">369,688</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsElhEMx2ES3jtK9Y9EB9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_aHOzd5gos0yiOg3cJESquQ_23_11">377,220</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2022_FBZ8Tp5vLEKjPPGlg8URdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rVYOSszYfEql5XSZfwCx3w_23_14">7,486</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_DEzIZn9FZEqIkBHuDpg9Mg_25_2">2,395,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_3t7xL7rL60af0JxwGQLFYQ_25_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_Yp249L7cVkClJ9FfpCo_zQ_25_8">2,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_LzYm4ncx5kOuY2fy1jmJ1A_25_14">2,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_eYNv5lFyQEmYC7S97PXHhw_26_8">144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MFZF7pqPBUuQJNO9Oy7nPw_26_14">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_dGXCev7GbUGzryy-EPwY7A_27_8">144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_PQMf-ntXWEGOcOpJOOAJUA_27_14">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_2GOQ0nsFekakUzpWtFzx6g_28_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_Ebp7qinQPEClp5qitqRO5Q_28_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_mi6adTt3tkeqW753PLQSJQ_28_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GT5dNEEhVU-SSWfxxPmtuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_24V1PHNMG0O4JVHVNGs7yw_29_11">5,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9z5zEYxMOEKRWKv7n84bmw_29_14">5,334</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_9XaIn3ucDkuPIp0sPbbj_Q_30_2">48,712,952</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LPDAVaGgiUmnjScSyWYmIQ_30_5">49</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li-HD8Y0uUCsTeiv7eapQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qYoZqzEmOU2QAwlYcL6edQ_30_8">372,616</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jB7j7aZTuECzxWimg8CXLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pAkN05BFnkesysvHx30YPw_30_11">382,554</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_L4lM0PiAB0uLDeLSrWQG4w_30_14">9,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_r6SoXt1a2UaK8KRu3WmzvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_6U8Od15PWU6teh99Rpql3A_31_2">62,002,649</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_r6SoXt1a2UaK8KRu3WmzvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_nrOn92z5kkyme37exVQDMQ_31_5">62</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDq4696d-UOcccu_7Cvwag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6FHxMp4QhUOR5IaEgGpS6g_31_8">393,938</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2xh1OXXKFE-Kulcz9V8NMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_w_kRU7htQk6uN6Hs9_ZViA_31_11">392,992</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_3_31_2023_lBFN3DQNxUiobmz6_ZkcBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rgKhBh0RekyGhNSmn-JFxQ_31_14">1,008</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_29Az6NLHf0aPkOOX7lgx2w_33_2">4,347,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_LVWM22aTNUevgQeS9z-MqA_33_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_nbX6mqJPd0qKVURb2QaOvQ_33_8">9,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc__YRBf3k-TUaK9uxKDk8xAA_33_14">9,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_yEDHDFZfk0KplkhCFGoCUw_34_2">4,691,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_JqQTui0jWk2rYOKQUDW-SA_34_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_6N8tBUvPuUy7H_Smh99j6w_34_8">7,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_7dgRASNt0E6i_X9e90AHsg_34_14">7,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ec2FR5WrokGQcJutBi5M8w_35_8">359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BeHaSVBmLUms2EZV_sjbDg_35_14">359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Mv5UFGETskKixN2l7qpWEA_36_8">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_3Rm2oatNSkOvuwVcbNdH6w_36_14">79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_nSRgNHxWFU-H92c_4P5ICQ_37_2">538,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_QQsClkXd-0OnIl2DJUbF9g_37_8">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_swCJG7atw06_SGaNY7JZhA_37_14">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WFc9oZvin0GRCHLpUhlF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_ilEwaURvak2tMXYmO2jufg_38_11">19,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_UYx6e6waq0GPcPA7dOa4Rg_38_14">19,339</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_NQjCLbxb9EqEjpBgqapF4Q_39_2">71,580,762</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pjLz9U9XH0CS2vJTzCDk-A_39_5">72</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2f7dHNiIfkWbGa0IWZYg0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4MPVsh9BTkiU39lSPRJL9Q_39_8">412,582</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jMPvUoYVVEu_xO49zfmz6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_UOXuJ2ugZ0i5AG4120hM9A_39_11">373,653</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bekvQPjFsEKqffTL0Dyu8w_39_14">39,001</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_MOAunn053UWpC-mQh_J2lw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_kYctsxzKlkG1bTUs2xFxyQ">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of June 30, 2023 and 2022 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Vgr5D9fQH06M8cxxk6w8Aw"><ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_A4bUizhqhkK3zbqrpM1UgA">144,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a3071650_01f8_4626_bba8_14472dcee9f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_JrTnJqrGG06lKBWiloPjvQ_1_2"></a><a id="Tc_2BnLBl581k-kNjxe07Mtkw_2_2"></a><a id="Tc_U-EWx3mrKk2czfR0Od0Qww_2_5"></a><a id="Tc_0DKJmeKYmUOO3BGNWwozpA_3_0"></a><a id="Tc_jsL5ke1rzE24Y5f1pGUuEw_4_0"></a><a id="Tc_YeSYOuc-YEm6HT6S-Lk7QQ_4_2"></a><a id="Tc_Ez7266eNQk2Gf6dnfNaw1Q_4_5"></a><a id="Tc_SvSDlnfcU06d2rRPCq_xHQ_5_0"></a><a id="Tc_fRYX79H1fEyRvvno4ZjZKQ_6_0"></a><a id="Tc_UKaD3baleEW2tIPr5Z3gUQ_7_0"></a><a id="Tc_jWIZ31wFEUSkm34UgLgWOg_8_0"></a><a id="Tc_h8m7_aEDv0Ow2P4XjiSFzA_9_0"></a><a id="Tc_gLLHXOk8AEW-Mxz0uWf_mQ_10_0"></a><a id="Tc_mJzrrriO_kKK28IBC5Nk8w_11_0"></a><a id="Tc_rCkd01Yvpk68JeAWSbhlww_12_0"></a><a id="Tc_CX1JeL-bJE-QHCyDJWEJdw_13_0"></a><a id="Tc_YECSfZhc7ku4T089v37x9A_14_0"></a><a id="Tc_vc-OGiaVbkqoNGugoOf2FA_15_0"></a><a id="Tc_OmFduzrNDEKwhvN_DBjBKA_16_0"></a><a id="Tc_A067o-LSo0CBazxMfgHzoQ_17_0"></a><a id="Tc_XLoo_esFQkS870l9u1FvRQ_18_0"></a><a id="Tc_gyHXDaqCPkCwOJJoKn6VbA_19_0"></a><a id="Tc_P5XfRmrXJEqReOLLvkIxig_20_0"></a><a id="Tc_zCwEMzX1V0uSizv89Oj7uA_20_2"></a><a id="Tc_zDMltW8z5EuLZtyGzOYg7w_20_5"></a><a id="Tc_fx3Y_G9CKky7m9AB2i6FGw_22_0"></a><a id="Tc_8AOLlMwF5k2BMcgv2chdTQ_23_0"></a><a id="Tc_74Ni2OV5bUOVeA4oUWOY6Q_23_5"></a><a id="Tc_cg5AmFUnqEmJgvkOwODHrQ_24_0"></a><a id="Tc_LVzeEW52TkmCYfMekPqyOw_24_2"></a><a id="Tc_gaODWABHYkaszTwGi2NFow_25_0"></a><a id="Tc_3xzYlwvsEk-czXcwKppzqg_26_0"></a><a id="Tc_Ogk3vH5b7UKcUrv_Mbqc1A_27_0"></a><a id="Tc_7t8Uvc4O5EqxHJ0Utpp7ww_27_2"></a><a id="Tc_uBgVuJeCtEa9DV-44u224w_27_5"></a><a id="Tc_mOB1UYC7A0qvUNLt_0Ljfg_29_0"></a><a id="Tc_5GwWj3O_Zk2KUWMQJ1Bgvw_30_0"></a><a id="Tc_Wj27LZZAZUKAjUqsaV7YiA_30_2"></a><a id="Tc_E4wmL3VfF0qLo6j2F6n2qQ_30_5"></a><a id="Tc_C2NSpRVPXUOO-_4r8CCtwQ_31_0"></a><a id="Tc_j-RN-NkczEuX8DLUaDLDsQ_32_0"></a><a id="Tc_T1vtaxcv6Uaghsw96sbmPA_32_2"></a><a id="Tc_tlkWRs1uvEeiuySa6kXK2w_32_5"></a><a id="Tc_3xQTSk1S9kytwQc5pGeYaA_33_0"></a><a id="Tc_JN2mr05DFUyM0iXO-9_rnw_33_2"></a><a id="Tc_UqbxFGns8kyAkpBlecupCg_33_5"></a><a id="Tc_SWNJTWBazUyEXCcgZvBcsA_34_0"></a><a id="Tc_IUS9SB5rbUeShOGbt2DQqQ_35_0"></a><a id="Tc_pszoYqBLp0ueGYXrFWIb9A_36_0"></a><a id="Tc_m2V42iIfx0yH9Nst0sZ7iQ_36_2"></a><a id="Tc_RE8t8SGb00elUAuZfhnMww_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_Jgu7GTYfTU-x9R-eJxgB4Q_4_3">16,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_LqicAZw14U2rx56qfYn0gw_4_6">7,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_JNAqxXLDHUypUMEAxmMdXQ_6_3">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_DqEZmEDO2UKTJhFs_qd4Eg_6_6">1,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_balL8tToVUmXTU8yRE21Wg_7_3">573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_xutU0ZTxBEG9vi-hONlAjA_7_6">538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_Ra8ZEHgzGUGnlhr3qTGUkA_8_3">152</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_CxvCpcPuMkOesj4JOxsdBQ_8_6">952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_CWgms5QIckeCBKm0THsxwg_9_3">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_UReAT2QOckiqPQaN-Iscww_9_6">449</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_SHK1nrep8kGRhAbHmvbVyw_10_3">3,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc__U_VwaiUaUmFOTjoMDR--A_11_3">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_gd-ngNSICkO7YiYbkVhdWg_11_6">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on conversions of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_SBFnf1FWtEKf6iLAiDmYmA_12_3">421</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_SJh9lLqfBUeUjzzmzKJWGg_13_3">148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_mY2H_4nMjU2BUIsGiHKl1Q_13_6">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_7Bcx4lszrEyzqYrpZF4kHQ_15_3">13,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_eUWer4q4706wxXPlK61ynQ_15_6">2,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_U5RZGWLHhE63SLe3KxM9cw_16_3">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_ZwllQ6dNhUmbCeU09nxYGg_16_6">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_gRhBEm0MRU2CXaMP9hq7iA_17_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_kB2EdpWR-UCd4bNPPrTNZg_17_6">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_72ojakGjxkuFSjWIesJ0gw_18_3">2,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_Q5kdm1a4Y0umdWkr3tRoaw_18_6">1,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_wSutqQOjCEufBhFDSxlOkA_19_3">3,643</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_y3gjqtGacUa8Ayaz1-40bw_19_6">4,864</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_4PaoNV6sw06n-yzX3dvDqw_20_3">1,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ksq1Lrp8mUygJZMS-wn97g_20_6">13,185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_SHoIdTmu30WRqTQViitPfA_23_6">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_xjxTAo-SXE2IqIjEnrkZXw_24_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_A67FhrBrfEyIuyx_BFQBfw_25_3">452</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_BKlL8dGK6kaxEQzoRSNjIA_25_6">357</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts paid (funded) in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_IkYHWCTGtEWXD7c0ps6NSA_26_3">38</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_Q_vmozBbMUu77Tn5M8vwqg_26_6">457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_wcttmeosnkuksZp2Gg6YBQ_27_3">4,510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Q17aCUFDkkWPGVXPaz50JA_27_6">15,900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_9kjOY_r-m0WpevbaMTWnhQ_30_3">23,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_LGrN3mu8rU28UmTZDZLmQw_30_6">2,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_7_KvVxuHIEemG30b-anJaQ_31_3">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_flwPPnxHwEqbCwSHJMs02A_31_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_yxrKgl15ZkChN5xzXkS2GQ_32_3">24,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_IKus3PV4xEieyzYXYKmsuA_32_6">2,643</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_2NaLJfCkgECICpqmrgp2DA_33_3">78</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_YHblCjTdGEy7rVJ5ZyFtCQ_33_6">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_E7XHBtjd8ESZRiPiHFTnLw_34_3">31,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_epL4cDKtHEaKpL0rN-P_UA_34_6">26,493</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_DJSnrCBjikWZS2V96d94lg_35_3">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2021_SZhJbmB8HUGxaWk_ZQO-6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_TcJAZDbsiUygjNAbS28Xzg_35_6">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_9JzFimtaP0Gn-9FUMKUDJg_36_3">48,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_142x3DnkVEGEaf9-Icmd-g_36_6">12,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_4h0fJYsxnU2JfGKazYG-sg_1_2"></a><a id="Tc_5W40QO7Hb0qXT0Yr--BKPA_2_2"></a><a id="Tc_g9Gfgqt-R0qv_OhkMTolQA_2_5"></a><a id="Tc_zvO-XG4Bsky7kVo-9H32Fg_3_0"></a><a id="Tc_x4OuyBOeKUSRrsNIoR23_g_4_0"></a><a id="Tc_rTun3ujUHUKQXL2FL4kGwQ_4_2"></a><a id="Tc_hQ4sTJOkDU2KK5hraqu6aA_4_5"></a><a id="Tc_NvHJVIFO6UqDkhxrFZzwng_5_0"></a><a id="Tc_yMwayVvZ1Uy1x-arX-503Q_5_2"></a><a id="Tc_Oc5JlzFKmkGwbeuz3X4wsA_5_5"></a><a id="Tc_defbYzFgQUC6eDyiSuduUA_6_0"></a><a id="Tc_mI5CohrCQUuwbZLAG4-udw_6_2"></a><a id="Tc_R99PvL78DkyuM3WcMuqDqA_6_5"></a><a id="Tc_A-GYnLjr9kmrOhz5pVjBIg_6_6"></a><a id="Tc_A-mR626fXkOcW0In_KOqaA_7_0"></a><a id="Tc_WCdYM4eD_kGPZnBLUOBe0g_8_0"></a><a id="Tc_0-d1XtRuP0e_uRQYnuAoNg_8_2"></a><a id="Tc_fBTk9myS6USyWQEqg1t92A_8_5"></a><a id="Tc_MpLcGGGfDkmRHnBvR0ZXeQ_9_0"></a><a id="Tc_o3Yg_29hHkmuKa5gS9NajA_9_2"></a><a id="Tc_Q07zoCHvZki4MNaG6MODoQ_9_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_HDub6LWrS0OlQOsxB2GuMg_4_3">348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_6p4JguLJyUK-xSeN9K7BaA_4_6">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_CKXenSxsZ0urRE0G9F66OQ_5_3">1,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_F-JIbNE0ykGWj6w52HT0Lw_5_6">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_6XoTJ8L4_k20eJLmq5BG2A_6_3">7,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_QoFmz4iBfkq2dOQqp4myrg_8_3">1,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_AkO5yXb1N0uqdJP-FseplQ_8_6">1,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_GoZXGar3nk2hyilpcFVDpg_9_3">78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_-MbUTbdY90Sx1PX2DF6TAg_9_6">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_6jL8Cna2wkGt-gFOjcMx3A" continuedAt="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_0Vcq21rM8E2DYpcvGwsovA" continuedAt="Tb_0Vcq21rM8E2DYpcvGwsovA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). The Company&#8217;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), the Company&#8217;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> except in Brazil where it is marketed as BioManguinhos alfataliglicerase) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into <ix:nonFraction unitRef="Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_REGXMh_xMkO45yD5E1FfMw">two</ix:nonFraction> exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Currently, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfPatientsEnrolled" scale="0" id="Narr_N-wlShUx6Ua55JByB_BFGQ">126</ix:nonFraction> patients are enrolled, and <ix:nonFraction unitRef="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfPatientsActivelyParticipating" scale="0" id="Narr_BMnwtnKhYkKnolcBV1nu0Q">116</ix:nonFraction> patients are actively participating, in such studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont1" continuedAt="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont2"><ix:continuation id="Tb_0Vcq21rM8E2DYpcvGwsovA_cont1" continuedAt="Tb_0Vcq21rM8E2DYpcvGwsovA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">In addition to Elfabrio, the Company successfully developed taliglucerase alfa, an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease, that has been approved for marketing in the United States, Brazil, Israel and other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase I First in Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of the date hereof, <ix:nonFraction unitRef="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ" contextRef="As_Of_3_21_2023_K3ZvOjH68UyliMbYRqXDCw" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfPatientsDosed" scale="0" id="Narr_Dy3kyzu40EypwiNYp2SXoQ">13</ix:nonFraction> patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ri18SJ0PQE-p2S56WmoUmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_G7YnNzWP3kODZzNgxorNvg">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_MK5otss99UeqSBlxwWlVCw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_X89trQ8cEECsOA-cXA0ELg">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_UTKUBS9fE0iLVZ9EFrAJiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nQ6C_NpYLE6Nkegq4uRNrA">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_UTKUBS9fE0iLVZ9EFrAJiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_PxrYtFB5nUujt2Gq_z4awA">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xg4mR_srVEOznTErp8pnVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5y-m0CHSPEKr1OiudLA0Vw">13,980,060</ix:nonFraction> ATM Shares for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xg4mR_srVEOznTErp8pnVQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_SmPlsAp_X0C3uwgj43FpJg">20.0</ix:nonFraction>&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont2" continuedAt="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont3"><ix:continuation id="Tb_0Vcq21rM8E2DYpcvGwsovA_cont2" continuedAt="Tb_0Vcq21rM8E2DYpcvGwsovA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">the Agent, ATM Shares having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Ta0zpsSnik2xFK3Rjys-yg" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_rzZMOWduvE-ejI0K0fAKYQ">20.0</ix:nonFraction>&#160;million. As of June&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_KuSCtZl5_0aMliO15-tKbA" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_bZFPyrWdf02bGqBWNUrPAQ">6.4</ix:nonFraction>&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Rk6iSTTZ8E2nfQOmpW14IQ" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_mz-eUuD0Zk-stJDDHrNbeQ"><ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_f4fIos5PMUmhCLw2-9tJyg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_R9HOdvCDD06rcffvAbV58g">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CjEp8-HoFkWDhnqgJoKWcQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_T0jGiwDAKkCPA689MSJ7Uw">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CjEp8-HoFkWDhnqgJoKWcQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_Lq4UBrzRqES1fcYxRve0Yw">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_T2FJkJmPOkmmfxXV-kkOJA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_H-lpF0IT6EGIJ282j3tEDA">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_T2FJkJmPOkmmfxXV-kkOJA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_MK7v6S86h0G4GCTH4dKNdg">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_RrH2ndyoyUWCJiK_yzGWKA" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_LXDpd5AXREK58MjrUxsD1w">20.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug substance from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_ibjkwjeinUigCNCGceGaYw" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_VlaL2wp7n06GMA5l4ewirA">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hzlZO_DQb0WzzjogYuqErw" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_lHfbdLo2XUKM5ivaybg4-Q">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DleZZTmqnkqE26Xs8euChA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_vJA61wAle0aOMy5icF9GEw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_4aJya2GEz0u8k1VFkbnZgg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_KcIbDZXdU0iSevgQrRnptQ">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;<ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_JB76OZ74g0mWS8x6-0BM6A" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_KNcAua-6wUq0QU5EjJBq7g">seven years</ix:nonNumeric>&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r_ehkfZA20uqfwPPaAkqOQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr__t10HczutkqMtt4aDX-JBA">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_OdlZNkXl6UaVoC041YLuMA" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_C2Vbgu84IkG-CsFEDBtQ_Q">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxPP66-FEG8RWl0rfhx_w" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_T9flW29aQECYu2NOxzPaDw">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#8220;Brazil Agreement&#8221;) for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EkdrbNRlwEWh5sJiOa4BPw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_-wrATaKEY0eAG5Uq2w02cQ">7.50</ix:nonFraction>% Senior Secured </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont3" continuedAt="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont4"><ix:continuation id="Tb_0Vcq21rM8E2DYpcvGwsovA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EkdrbNRlwEWh5sJiOa4BPw" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_bD0_gp2uqE2CTX2hkdHoMQ">7.5</ix:nonFraction>&#160;million. As of June&#160;30, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of June&#160;30, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_LBsTi4gHxUmsWEA9O07EFQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_qmcJlG6JhEaFt3pwCqTTvQ" continuedAt="Tb_qmcJlG6JhEaFt3pwCqTTvQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_u8htPnnek06B3-QkyDCiAw" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_USqmp6VXOUCePxUYhPchEg">two</ix:nonFraction> performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6jL8Cna2wkGt-gFOjcMx3A_cont4"><ix:continuation id="Tb_qmcJlG6JhEaFt3pwCqTTvQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_RrH2ndyoyUWCJiK_yzGWKA" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_7bDL5-c9a0mux7yKwRi6Jg">20.0</ix:nonFraction>&#160;million (see also note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_thOWrpoZUkun7sKUtSK9Cg_1_2"></a><a id="Tc_E8MhV4k0-U6mNx1_WPQUfA_1_5"></a><a id="Tc_ghROprVmDEqqKBTQj9aKLQ_2_0"></a><a id="Tc_1iW6ARugvUiRc3bi0GSAnw_2_2"></a><a id="Tc_mGgNcBze_UKdwjpKWRZWjw_2_5"></a><a id="Tc_pIlnS6vEa0Sy0Gw327KgwA_3_0"></a><a id="Tc_HqIeUWGgg0udeYTImM7Kew_3_2"></a><a id="Tc_wxkcsIb6jE-1njxegu5nXQ_3_5"></a><a id="Tc_El8LRObn2EGVsTwzoh0qZg_4_0"></a><a id="Tc_JLK9eiAOYEGHHfg6R9MZvQ_5_0"></a><a id="Tc_qXcZe8Poz029Uwc2dAJBdw_6_0"></a><a id="Tc_7ryLNewWa0uQN3C0FxhR6Q_6_2"></a><a id="Tc_PcjT9eWGVEKOw4AjTu2xhA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_rONcfdT-mkOxZ6YeiVP3GA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2023 and December&#160;31, 2022 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_6EV4x1KiQ02yBMasY0XQqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_5svsUQ15YkCqzvn3yz7XlQ_3_3">4,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_nY9SPnT4UEu5ovEMUOgAtA_3_6">3,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_CL_tLYBRwk-nCBI5YvMm-A_4_3">3,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_QmmPoqkuAU2aFRmfosLl4w_4_6">2,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_epwPGtR5TEWuo8-6TJKQEg_5_3">11,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_YdsyhHo-a0SrCTCynvxcQw_5_6">10,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_yfnS7o4mO0aI8ACf93gn_A_6_3">19,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Bcr670I-skerW1PZywwxUw_6_6">16,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_ZfTIyIfqGkajaMwJXPhwcQ" continuedAt="Tb_ZfTIyIfqGkajaMwJXPhwcQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_2YNLdt0O4k-S2JU_1pFw2g_1_5"></a><a id="Tc_FVN6foQ_d0WWMp6ahyeaYg_2_0"></a><a id="Tc_3jyDP8XuKE2blpD33dAKKg_3_0"></a><a id="Tc_JLE5JuA5b0mb7NUHHiZEow_4_0"></a><a id="Tc_AELsQeJswUS2__XM-LNO-Q_4_6"></a><a id="Tc_xlrNgi4ERUi11iPoY3fpyg_5_0"></a><a id="Tc_y19eIIM75EqAYzK9AhmrwA_5_6"></a><a id="Tc_B6GmyO3NeEeiLGE6pHq0Ig_6_0"></a><a id="Tc_a31l0hFRI0S0OHDUM8rSpg_6_6"></a><ix:continuation id="Tb_ZfTIyIfqGkajaMwJXPhwcQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of June&#160;30, 2023, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_xFK6t9CTkku9o7iyNgjq5g">20.4</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_Dm6N8IoEKEussmMyUQ4DcQ">28.1</ix:nonFraction>&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_0NUrzxe3Q0iOA-RPzk3tHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_KY-ma-SuxE6JsnDPAL7QoQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_C9a57KKHxEyiZw6q3BanJw_2_5">2.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_v67Atkda-ku71Q2qAiO_QQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i364BLxb4EuwXvVZ-E3v4Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_nWv_aUq3VkejrkxiOiFTgA_3_5">1.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XOS2xaTk5EWDha2vAO2bxQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_H8KU9XPQ4UKcLv8bKIXrgQ_4_5">5.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_h_ZFDwKXEkyuUN5mMKV7ag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_ERaBlByAVk6JoERUEYUKDg_5_5">60.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_HUfqWHV6HE6-7_b8ousHhQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_2hgQMFJ9EUK6eKDToEyQvA_6_5">12.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8e26df07_0199_4efa_b94b_f1cf525bf56a"></a><a id="Tc_4fSABsiM9ku8JBDTAgTetA_1_2"></a><a id="Tc_PkgJ3gOk502gPehVrmFZsw_1_8"></a><a id="Tc_3b0NlucqbkCi6yFWcYh3Sw_2_0"></a><a id="Tc_umv_CBzMDEika76yzdDOHw_2_2"></a><a id="Tc_jMJyI60JOESrTkFy-SXf9g_2_5"></a><a id="Tc_OqXdTIcYMEiYrdta3yiafg_2_8"></a><a id="Tc_v3RpFda170ml9o-9CW0Cfw_2_11"></a><a id="Tc_2Adajip3lEmDBInBKKHp6Q_3_0"></a><a id="Tc_YsZOaBF4z0WFqgg61vgP1Q_3_2"></a><a id="Tc_WHZZAO1qjkO_p9ggVFKqmA_3_5"></a><a id="Tc_yxZobUWgu0SohO1CXabcTA_3_8"></a><a id="Tc_g5zDLYTT80-V0GZWikVJ4w_3_11"></a><a id="Tc_l_84i1G2jUeLaA4pULL9hA_4_0"></a><a id="Tc_H6UofXkQV0uL6sCnEz_d6w_4_2"></a><a id="Tc_9t298YGLXk22x8OkwFKDIA_4_3"></a><a id="Tc_VO1MgsieNUS5KSONkKRxsw_4_5"></a><a id="Tc_hIxn_Lh_n0WkOz7QZv5GJw_4_6"></a><a id="Tc_npCQCqYtG0OgMt05J2LsCQ_4_8"></a><a id="Tc_C8uOHDlx50qKQD2X6qiWAw_4_11"></a><a id="Tc_ihqWJgBm8kW-0rpnSS0WKQ_5_0"></a><a id="Tc_iKkPK0brdkaHeGBX_1g2QA_5_2"></a><a id="Tc_WaEPhdbjok-TyHFxgCoKdg_5_5"></a><a id="Tc_4fqkkxDhAEiE-_SjL6S5cA_5_6"></a><a id="Tc_MDh5TT7YvUyUZLlAM2FReg_5_8"></a><a id="Tc_oe0TNOSicUm0FZSm0fLNJQ_5_11"></a><a id="Tc_vRUDZiFklkiD2uyBlW99UA_6_0"></a><a id="Tc_SSN_DUVWV0m7oUQ0tyiOIA_6_2"></a><a id="Tc_Zj_ELJHFN0GUqWdc3X-INg_6_5"></a><a id="Tc__cVwMh6Xk0WShOWR5L0ziw_6_8"></a><a id="Tc_7eUTzURbN0WBDck1sDybLw_6_11"></a><a id="Tc_0FSSewNN1kiPtMZzLyvrPg_7_0"></a><a id="Tc_ex1K0NHGo0-srtwnk9TUcw_7_2"></a><a id="Tc_fAMu2uPfSke-j3KoHVXfGQ_7_5"></a><a id="Tc_dA6vhhYu20Ko9X1XkkjNRA_7_8"></a><a id="Tc_LmrLlXGOB0C-i4T-Y7BDfw_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="plx:RevenueDisclosureTextBlock" id="Tb_HXimdGxHYUCdGFi6StNHkw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_KkdaVx47-ke-iU-FDNCG_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6EY8ZLejPkaK5jN5fkWHzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_w0zdve-DPUu1CoZ4f_R6AA_3_3">3,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_CNF4wwqArE-QJGN7-yi3Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_TqHBD8Rrgkao0WpxHhE2cA_3_6">3,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_KZqJ5slPPEGfEAtG9oUahg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_qNrZ1FOEa0uS93IgKotffg_3_9">5,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GYEteH5yxkOi3Fycl0MiGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_RUqy6Q0UV02PirCrEik8oA_3_12">6,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_cxV5YkmyMkOdKBiC71d5Iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_8rZBBjRyp0KaJ26vDlJkDg_4_9">2,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_2htVCHKOakKxo0P6Mt-phw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_c9kX1cCBtU6Xq26rhOIyJw_4_12">5,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0fDfLHqQbUOjSUb7SXk8-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_cvsFTLZcvkWQpxbba4OBPA_5_3">11,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JGEYQ_-rNEe6Bkb5w86nqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_puDzc2hZR0uMWbqwRmoz3A_5_9">11,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_kHP60lRxy0Cl3Ghw5nGl3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MnRdIEmfwUatVgTUqIKUeA_5_12">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DbnmycSCC06iSdpupTbnrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Ohbox0tDvUmmCUpuyGuvAQ_6_3">15,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_3xKKEe90x0i1wtZ9ei35MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rFsAaQ_hYkCWilaOYZnVAQ_6_6">3,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_YISAxiydmUe42opqwLUlVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_LqWYkeHdkkGHojrol9-gSQ_6_9">20,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_oCwNjjGdSkSVxZt-Jq0NGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_0lLQ6rYk7UyCpjUU8ppeCA_6_12">12,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__XyDi3xaVUOhI8hK5ZkSag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_09qDg4FmmEWNcHFIAIwbeg_7_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_nw34ZM_veUiZ_WWpDb01mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_mlHxEFCRMkWhXuY4hWtbEw_7_6">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_2OozcC2UK0uAy4FUBp84ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_nWZ8zYmdYkaL20XGFy1AnA_7_9">24,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M8LWQVl8T0y-iXLLBJWW4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_X7zdaM7jg0616QijzHcgUw_7_12">12,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_wu7tq9xrr0CRzlnZYnGkrw" continuedAt="Tb_wu7tq9xrr0CRzlnZYnGkrw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_7_24_2023_Fc4rDyr3_EmtZXvFeu0hug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_k4gYxo-rv0ihyXqm5vs19A">144,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_7_25_2023_GhxIuEgHh0-KdnsF3PgcOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_kymJG-_BAE6yDEPiR8qgLw">185,000,000</ix:nonFraction> (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(b)</b></span><b style="font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the six months ended June&#160;30, 2023, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_9vEHwV8JlEq0c99K7nQPGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_P0EgSojbPUi1rJbgaa_AQw">12,560,150</ix:nonFraction> shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_9vEHwV8JlEq0c99K7nQPGw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_nYiKMEeq4EOR_7reWgciwg">24.9</ix:nonFraction>&#160;million in connection with such sales.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_wu7tq9xrr0CRzlnZYnGkrw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(c)</b></span><b style="font-weight:bold;background:#ffffff;">Exercise of Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;8, 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1pbkqm0PNU-3n1SC2J0weg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Narr_4IhlSE3yikil3zb6iwgSdg">301,810</ix:nonFraction> shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company generated net proceeds equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_5_8_2023_To_5_8_2023_WubO3bm2MUSrkueojHRBdw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_1kGHtaTTREeQu4371ykMsQ">0.7</ix:nonFraction>&#160;million from the exercise of the warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;10, 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_5_10_2023_To_5_10_2023_kzlqsZvS4kOBpSRWM3vhTg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Narr_BoaIP353M06QHkkrRtXfXw">237,012</ix:nonFraction> shares of Common Stock in connection with the cashless exercise of a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="As_Of_5_10_2023_o66HQb4RTU6YeX4ytF2Xyw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_vY6y7zumjEW74tSr7Xoodg">845,000</ix:nonFraction> shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_5_10_2023_To_5_10_2023_kzlqsZvS4kOBpSRWM3vhTg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_WQt6tecbWUSo0SH4M1wRrw">no</ix:nonFraction>t generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(d)</b></span><b style="font-weight:bold;background:#ffffff;">Conversion of 2024 Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the six months ended June&#160;30, 2023, the Company issued, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_rAmTB8IyEkmzXiM9G09qxw">4,691,623</ix:nonFraction> shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during the six months ended June&#160;30, 2023, the Company paid to the converting holders $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA" decimals="-5" format="ixt:numdotdecimal" name="plx:PaymentsToDebtHoldersOnConversion" scale="6" id="Narr_nx5GYr8Ay0qP6eaXFTZQbw">0.9</ix:nonFraction>&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionDecreaseInPrincipalAmount" scale="6" id="Narr_Sv0KlcsSIk6LT7Oh2PU_Ow">8.3</ix:nonFraction>&#160;million.</p></ix:continuation><a id="_9d6e618e_db3f_4f9f_bf4b_001e1f565bb3"></a><a id="Tc_zOeeltZkTEiKVEAXuYovKg_1_3"></a><a id="Tc_rs9b8XKlOUGXemtzYF_XoA_1_9"></a><a id="Tc_J0MgPNx3QEeEhBfoQMuAng_2_0"></a><a id="Tc_6EOXZbZT0EurlFaMqVjCJw_2_3"></a><a id="Tc_ghNSkDVGD0Wibvq9lNE10w_2_6"></a><a id="Tc_3x4blhx16UG6M9jCLhxhlw_2_9"></a><a id="Tc_4qaP9A63JESfgN3bEFb4zg_2_12"></a><a id="Tc_TMbnLNzXxE2BXKORXg961Q_3_0"></a><a id="Tc_FOxVbxOH4kaWIPLTBAb3Qg_4_0"></a><a id="Tc_3rvQmCostECCHNv5w_5YVQ_4_2"></a><a id="Tc_xMOQriX0Qkub9Qr0rrYPHg_4_5"></a><a id="Tc_yThejHEdhkOAQgltF3xPUA_4_8"></a><a id="Tc_m5BIQOvv50ygcScDBZFYPg_4_11"></a><a id="Tc_4TmBkjILj0y9JAxwnfd4Sw_5_0"></a><a id="Tc_QpWSPCOQlUO5UxiLa7e6TQ_6_0"></a><a id="Tc_UAzT0B1afUGyzfp3BBfP6w_6_2"></a><a id="Tc_6iW5ZMGxOEWrfHj9qyND9g_6_6"></a><a id="Tc_CCsTEXGDGk2C1FBlhrr-oA_6_8"></a><a id="Tc_mflEjTOQu0Kzn8mDHTCJdg_6_12"></a><a id="Tc_7jq4YdV0vk2NjSsNRGjI7g_7_0"></a><a id="Tc_nEC_fYDGb0-p4njDpLVMlQ_7_2"></a><a id="Tc_cu1qkscBiUm5SWU85pGvVQ_7_5"></a><a id="Tc_syMYjPz-VkKKX_MFQcR-Dw_7_8"></a><a id="Tc_WpN54PyNJUqZ1ZtkalmytA_7_11"></a><a id="Tc_5WMVnJgDlUG18XnQSSiAPw_8_0"></a><a id="Tc_EFWK0jrxgUyxsibD6WVOtw_9_0"></a><a id="Tc_ceYogNy2g0OpLlf9y6TX9Q_10_0"></a><a id="Tc_o2mNpN1kI0Gubr3iYcghtg_10_6"></a><a id="Tc_4aO7Frs_DUut5upEHLT9OQ_10_12"></a><a id="Tc_L0eoAdyQTkWbfVvOwYvq-g_11_0"></a><a id="Tc_ykVppgeGAkWtFIDcNmuV7g_11_6"></a><a id="Tc_dEvEGx8r20ekm-7RyMWAGg_11_12"></a><a id="Tc_FO5yifSahECPfMg0UfVv4g_12_0"></a><a id="Tc_lgreDQTnaUm6_35iifa5EA_12_6"></a><a id="Tc_28SAz7oQG0-oWxmF2oZe-A_12_9"></a><a id="Tc_oZGUiX0dKUCNttfiY9GD6g_12_12"></a><a id="Tc_wltHAtRVXEy9mlqbweXRnw_13_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_HSUJlFT3XUyXb6owKoKidA" continuedAt="Tb_HSUJlFT3XUyXb6owKoKidA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of the Company&#8217;s Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii) the conversion of the convertible notes using the&#160;&#8220;if-converted&#8221;&#160;method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_vQzs88IJX0iabDZ7ltLPXw" continuedAt="Tb_vQzs88IJX0iabDZ7ltLPXw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_GeTpM4m3uU2yVt4d4bOvXA_4_3">19,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2c8Yq1NLRUCz2YmECNFnZg_4_6">5,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_eUS5JKNABUuo2vtxNWySRw_4_9">16,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_615JsyBhHEqe4O4ynckIcQ_4_12">7,620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_Qm5iCPfDoEC8k9ER0-Bb6Q_6_3">1,749</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_G0MQ2legWESLb0eDLqyZDA_6_9">2,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_pCx-69TQj0i7OB-tyWnIFg_7_3">17,590</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_0YXpHVtpp06LXVF4cgBLTQ_7_6">5,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_Mv3TXUhqvkCRxN3CPTHUnA_7_9">14,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_gWVtrTWMZ0aX2ZMazdhBHQ_7_12">7,620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_33Exhrx1IE69gTwlA8sJJQ_9_3">67,158,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_tmGWS3dwdEKYdsIZzOOZzA_9_6">47,327,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4_dq9sq4vU-2yUEcJuG8TQ_9_9">62,378,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_UElJaFQ6CEWmTMyTJd9uaQ_9_12">46,589,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_cQFR_0CD-EquRs78h8g2lA_10_3">14,355,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_9aEqQ4hxOkSZMWXp4Gu4NA_10_9">15,274,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_hFmHCEi_o0KneFQuAU9L3Q_11_3">1,555,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_Yw9t52uKP06jFGJBhl5kJQ_11_9">1,243,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Tc_sgHkj1LBF0esFv_dXP_XEw_12_3">131,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_NkcIgnfvX06v-22CES5f2g_13_3">83,200,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_BIFp0yXfRE2hG98xlmUARA_13_6">47,327,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_-tXb8XZf6UeWe9bb95X-qg_13_9">78,896,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_-AolbiO9_UG7u5kHue9VRA_13_12">46,589,976</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HSUJlFT3XUyXb6owKoKidA_cont1"><ix:continuation id="Tb_vQzs88IJX0iabDZ7ltLPXw_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_giw5lYGyHk2z5Tsr-qoIyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_OCtcaFBhl0quNE7Dg1JZkg">16,158,086</ix:nonFraction> shares of Common Stock underlying outstanding stock options and warrants of the Company for the six months ended June&#160;30, 2023 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsMember_ORrJrQ2JFkyptwnKkDK9ZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_jwWN8GU2z06cP2PjmiYMWw">1,896,733</ix:nonFraction> shares of Common Stock underlying outstanding stock options of the Company for the three months ended June&#160;30, 2023 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_Bvgp1anEpkieiOQvLEWBZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_TBWxTfWirUGQxZMZenjIFA">32,960,732</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_eQMenfm7EU-xHazziK7JOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_a9e0y-2nKkaE58vmSrNvSg">32,982,043</ix:nonFraction> shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three and six months ended June&#160;30, 2022, respectively, because the effect would be anti-dilutive.</p></ix:continuation><a id="Tc_HamK7sJvJECgoYHpG3YWLQ_1_2"></a><a id="Tc_7CVIhwposEWrBMMgApmkDg_1_5"></a><a id="Tc_7IG2eSemSkaMxGiy1Tf2oA_2_0"></a><a id="Tc_dan3lgz12kCdQTLPU2t5zQ_2_2"></a><a id="Tc_tMVkHW0CgEyzwcsS2kdR-w_2_5"></a><a id="Tc_NvI4-xPBX0qYpVrvhDSe5Q_3_0"></a><a id="Tc_ypYAMvnmmU2MoNWeoAsjBw_3_2"></a><a id="Tc_FbE8bzLlUECSwAGSm7NiXw_3_5"></a><a id="Tc_zAftM6b7M0qTpnl4ipWrxg_4_0"></a><a id="Tc_65PTz4IXqESRtpgXXsuyYw_5_0"></a><a id="Tc_iuwmhH-pSEK9Ztass_HlFQ_5_2"></a><a id="Tc_vtxsVA3Iz0-qHJIz2obbJg_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_qP4dqcrbDEegixppkqrvog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_niaLYGtE-EKXIOpUIfQfLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_w_L0zA53IUOQFYfWPn00xg_3_3">3,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_4Ah4D1Wmb0aZG_xsOqfEpA_3_6">3,633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_De5g7Rdaa0GCVE8DKo-e1Q_4_3">3,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_fFr9jDt3a0KGCqmQGsoItA_4_6">3,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_2Gl2x9wxCkCuDsqY5Ri1ew_5_3">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_vopwg4oSmUqtM4Rbv8lXOg_5_6">503</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_5bBnKCZu8keFt-ZwzpiJgg">3</ix:nonFraction>% for the six months ended June&#160;30, 2023, compared to an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_pJ_kihsK7ECU_SQLYEht8g">0</ix:nonFraction>% for the six months ended June&#160;30, 2022. For the six months ended June&#160;30, 2023, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw" contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_IPWcPDw8_UKgwsWqUb8-BA">21</ix:nonFraction>% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In the second quarter ended June&#160;30, 2023, following the regulatory approvals for Elfabrio in May 2023, the receipt of the $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_5_31_2023_A791LfE6c06Ffo0FaCMpfA" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentToRegulatoryApprovals" scale="6" id="Narr_WdPsrUh300mgC5zA8Goeow">20.0</ix:nonFraction>&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="Narr_j9IxUxoakkC5Ltg3kfd-4A">3.1</ix:nonFraction>&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p></ix:nonNumeric><a id="Tc_J1maKaOqTkuXU7nVmL-JLA_1_2"></a><a id="Tc_HHI11TYqUk66LpxsVUeCQQ_1_5"></a><a id="Tc_ZzkSYOPZxkGGzewv1n4z5Q_2_0"></a><a id="Tc_NttYh4fCt0Gc_hRLV6lhVA_2_2"></a><a id="Tc_TlFgb0O8I0aIpKoTlxJ-9w_2_5"></a><a id="Tc_uBkD4zPL3U6JA1dQgf0-7Q_3_0"></a><a id="Tc_sACiYwMaTkS5o3G7TYfb8Q_4_0"></a><a id="Tc_QVkJyvJ_ckumkVKdMfN09w_4_2"></a><a id="Tc_UNQNMSoErkiGcrioaOfK5g_4_5"></a><a id="Tc_rSunCLp9ZkGubpmgibU-Ig_5_0"></a><a id="Tc_bpaGhdb1S0C23Mbq_ZXPoA_6_0"></a><a id="Tc_oJq6xBfocUqPRUB0ahD8RA_7_0"></a><a id="Tc_UBVHLtfPmkaVJ0crG24Eww_8_0"></a><a id="Tc_5gGr_crriEOU-NVWQmwaOg_9_0"></a><a id="Tc_QJ6LUwqZ_02I-IJFCj1Iqg_10_0"></a><a id="Tc_Yom33DkSs0u2MeT9UfFljA_10_6"></a><a id="Tc_9PhrEs365kqgqRe5D90rPQ_11_0"></a><a id="Tc_c9PI1nStJUCM9zRHU53X5g_12_2"></a><a id="Tc_MVhIKLvUJUWlO2P49NGx3A_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_MqRSRJkOL0G1AUML_rnsAw" continuedAt="Tb_MqRSRJkOL0G1AUML_rnsAw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_iUMOW9FiV0OdgbwjIA3F3w" continuedAt="Tb_iUMOW9FiV0OdgbwjIA3F3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_oICPeBCYYESWx5AJKk2S_w_4_3">1,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_rAdPAiqJCkOcJ6CODx8pqQ_4_6">1,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_S9yAHICVQUG5R3fP40UxDw_5_3">506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_d4oNDZiX0Ee25R555IRGdA_5_6">719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_FL-EYjvPWEGyNap8HhO24A_6_3">1,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_kNtxubWM30GrQKA5-CT-4A_6_6">1,404</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_8ogcg10lY0SCfvOexUzvTg_7_3">8,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_q4SPxrBz7ESQ-PdiP6ujLg_7_6">7,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_8ISD99nT7E6Ccst2ugPeXA_8_3">1,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_T6onMbbOvkuWlbuhg-R7OQ_8_6">781</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_XVIt5HPGSU2MPW46oTnhKA_9_3">3,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_Jjj_oodZUk2Wj04YGLzmsg_9_6">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserve for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_P2jvqg9oFEWT6kdeDN3hfw_10_3">1,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_JT1YQC7Df0S8FikR63fDIg_11_3">348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_8xTdpi9OiEq4IsU3ceUGsA_11_6">143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Z8aJ0XNz8kyWooHb2Dc3Aw_12_3">18,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_sgfGD37f0EqkStFmL1ukUw_12_6">12,271</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_MqRSRJkOL0G1AUML_rnsAw_cont1"><ix:continuation id="Tb_iUMOW9FiV0OdgbwjIA3F3w_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_nFKhYh6yOEGARPOW_luFbA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;14, 2023, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_8xJeZMuB3U2g_8i3Y-HmUA" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_D1L9PCUkrk2OVz-xxYwKyA">1.1</ix:nonFraction>&#160;million, in the aggregate, from sales to Pfizer. On July&#160;7, 2023, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw" contextRef="Duration_7_7_2023_To_7_7_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_16ZP9euma0-A-zyLjLyJAQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_--a6U5K-qkqVPxgAlK89HA">1.0</ix:nonFraction>&#160;million from Chiesi<span style="background:#ffffff;">.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_05682c41_000b_4b7c_88cc_a6c452f1508a"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2022. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio, our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our commercialization partner&#8217;s ability to obtain and maintain reimbursement for Elfabrio, and the extent to which patient assistance programs and co-pay programs are utilized;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen for Elfabrio;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>and the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On May&#160;5, 2023, we announced that the EC had granted marketing authorization to Elfabrio in the European Union for the treatment of adult patients with Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On May&#160;10, 2023, we announced that the FDA had approved Elfabrio (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;28, 2023, we held our Annual Meeting of Stockholders at which our stockholders: (1)&#160;elected the seven persons nominated by our Board of Directors to serve as directors of our Company; (2)&#160;approved, on a non-binding, advisory basis, the compensation of our named executive officers; (3)&#160;approved, on a non-binding, advisory basis, one year as the frequency at which </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.64pt;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:0pt;background:#ffffff;">we will solicit stockholder approval of the compensation of our named executive officers; (4) adopted the amendments to our Amended and Restated 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under such plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of the plan; and (5)&#160;ratified the appointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023. The meeting was adjourned until July&#160;13, 2023 to allow us to continue to solicit stockholder approval for the proposal to increase the amount of shares of common stock authorized for issuance under our Certificate of Incorporation, as amended, from 144,000,000 shares to 185,000,000 shares.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On July&#160;13, 2023, our stockholders approved an amendment to increase the amount of shares of common stock authorized for issuance under our Certificate of Incorporation, as amended from 144,000,000 shares to 185,000,000 shares. The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression, and with the recent approval of Elfabrio, we now have two FDA approved proteins produced through our platform. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20230630x10q005.jpg" alt="Graphic" style="display:inline-block;height:229.64pt;width:540pt;" /></span><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:226.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20230630x10q006.jpg" alt="Graphic" style="display:inline-block;height:226.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Products and Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20230630x10q007.jpg" alt="Graphic" style="display:inline-block;height:170.54pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio (PRX-102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;5, 2023, the EC announced that it had approved the MAA for Elfabrio and on May&#160;9, 2023, the FDA announced that it had approved the BLA for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The EMA approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the CHMP. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with ERT class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for MPGN alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elfabrio, an ERT, is our proprietary, plant cell culture expressed enzyme, and a chemically modified stabilized<span style="letter-spacing:-0.15pt;"> version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme<span style="letter-spacing:-0.15pt;">. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was approximately $2.0&#160;billion in 2022, is forecasted to be approximately $2.0&#160;billion in 2023 and is forecasted to grow at a CAGR of approximately 13% from 2022-2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs. In 2015, we completed a phase&#160;I/II clinical trial of PRX-102, which was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. Our phase&#160;III clinical program, which has now been completed, included the following three separate studies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 36pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20), a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function that was designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 36pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30), a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102\, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 36pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50), a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The 2&#160;mg/kg every four weeks dosage was not approved by the EMA or the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase&#160;I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Overall, 126 subjects who participated in our PRX-102 clinical program have opted, with the advice of the treating physician, to enroll in one of our long-term, open label, extension studies of PRX-102. Such extension studies include 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60) with a total cumulative exposure of approximately 480 patient years (10 subjects who completed an extension study from the phase I/II study, 18 subjects who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 subjects who completed the <i style="font-style:italic;">BRIGHT</i> study, in the 2&#160;mg/kg every four weeks extension study (PB-102-F51) with a total cumulative exposure of approximately 145 patient years. Two of such subjects are being treated with 1&#160;mg/kg every two weeks. As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the open-label extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">A BLA for Elfabrio for the treatment of adult patients with Fabry disease was first submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a CRL. The BLA was resubmitted to the FDA on November&#160;9, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102, which is intended to be initiated post-marketing approval. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi, together with Protalix, participated in an Oral Explanation at a meeting of the EMA&#8217;s Committee for Orphan Medicinal Products (COMP) held on March&#160;21, 2023, as part of the Orphan Drug Designation maintenance process. Following the meeting, Chiesi formally withdrew the application for Orphan Drug Designation for PRX-102. The EC first granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease in December 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study was completed in July 2022. The final analysis confirmed the positive topline results (announced in April 2022) and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of eGFR slope between the agalsidase beta and PRX-102 treatment arms. eGFR is considered a reliable and accepted test to measure kidney function and stage of kidney disease. Additional parameters evaluated include: cardiac assessment, lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry Clinical Events, pharmacokinetics and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Based on the original primary analysis (random intercept random slope (RIRS)), the estimated mean eGFR slopes were                   -2.4&#160;mL/min/1.73 m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year and -2.3 mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year in the PRX-102 and agalsidase beta arms, respectively, and the treatment difference was -0.1 (95% CI: -2.2, 2.1) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year. Based on the ANCOVA adjusted for continuous baseline proteinuria, the estimated mean eGFR slopes were -2.0 and -3.1 mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year in the PRX-102 and agalsidase beta arms, respectively, and the treatment difference was 1.1 (95% CI: -0.8, 3.1) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year. Based on quantile regression model, the median of the eGFR slope in the PRX-102 arm was -2.514&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (95% CI:-3.788, -1.240) and -2.155&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (95% CI:-3.805, -0.505) in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians (95% confidence interval) is -0.359&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.444, 1.726). Additional sensitivity and supportive analyses investigated mean eGFR slopes using other statistical models. These models yielded results similar to the primary analysis and confirming the comparability between the treatment arms. These results supported the robustness of the methodology used for comparisons of treatment effects in the <i style="font-style:italic;">BALANCE</i> study.<span style="white-space:pre-wrap;"> The results of the analyses on eGFR slopes were further supported by the analysis of change from baseline in the average eGFR at the last two visits (100 and 104 weeks). The estimated mean changes were     -3.0 and -3.8 mL/min/1.73 m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in the PRX102 and agalsidase beta arms, respectively. The difference in mean change (PRX-102 &#8211; agalsidase beta) was 0.8 (95% CI: -3.0, 4.6) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> or annualized change of 0.4 (95% CI: -1.5, 2.3) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study population (ITT analysis set) was composed of 47 males (61.0%) and 30 females (39.0%), with a mean (range) age of 44.3 (18-60) years. The mean duration of prior treatment with agalsidase beta was approximately six years. At baseline, mean (SD) eGFR was 73.69&#160;ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (20.32) and median eGFR was 74.51&#160;ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>; mean (SD) eGFR slope was -8.10&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (5.92) and median eGFR slope was -7.25&#160;ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A comparable efficacy response was also observed across biomarkers and functional systems relevant to Fabry disease, as demonstrated via secondary endpoints, where in some cases the trend was in favor of PRX-102 and in some in favor of agalsidase beta, but the actual difference between the two arms is always clinically small, supporting the comparability of the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Key secondary endpoints included Urine protein creatinine ratio (UPCR) as indicator of proteinuria, plasma levels of lyso&#8211;Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, imaging marker of cardiac remodeling (Left Ventricular Mass Index, LVMI, by cardiac MRI), disease severity (by Mainz Severity Score Index, MSSI), pain severity (Short Form Brief Pain Inventory, BPI) and quality of life (EQ-5D-5L). Both treatments showed either a stabilization of clinical parameters (e.g., for eGFR, eGFR slope and UPCR) or prevention of further progression of Fabry disease (e.g., LVMI, MSSI).</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Secondary measures of kidney function</i>. In addition to eGFR levels and slope, the proportion of patients categorized as having severe proteinuria (UPCR &#8805; 1 gr/gr) in the PRX-102 arm remained stable during the study (at baseline, 7/52 [13.5%] and 6/45 [13.3%] 24-month), while in the agalsidase beta arm, the proportion increased slightly with 3/25 (12.0%) and 4/24 (16.7%), respectively. Mean (SE) UPCR data (post-hoc analysis) for the entire study population remained stable throughout the study with a slight advantage for PRX-102 at 24-months compared to agalsidase beta (Table&#160;1).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Biomarkers of Fabry disease</i>. Mean (SE) and median (range) plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> change from baseline to 24 months of treatment in the PRX-102 arm were 3.30 (1.38) and 1.15 (-32.2 to 32.7) nM for PRX-102, and -8.74 (4.85) and -1.50 (-102.3 to </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;">2.4)&#160;nM for agalsidase beta. As expected, a gender difference was noted, with female Fabry patients exhibiting lower values at baseline and no remarkable changes during the study. Overall, the absolute changes of the Fabry biomarkers were minor in both treatment arms and were considered not clinically significant since there was no indication of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> re-accumulation nor of disease progression.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Measures of cardiac disease</i>. LVMi was centrally evaluated based on cardiac MRI. An increase in LVMi is indicative of progressing cardiomyopathy, hence preventing an increase in LVMI represents a therapeutic goal in Fabry patients. In the <i style="font-style:italic;">BALANCE </i>study, the change from baseline in both treatment arms was analyzed by absence/presence of hypertrophy at baseline (defined as a LVMI above 91&#160;g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> for males and LVMI above 77&#160;g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> for females at baseline) and by gender (Kawel-Boehm 2015). Similar results were achieved in the two treatment arms after 24 months, with a slight reduction in the mean (SE) LVMi values in the PRX-102 arm -4.238 (5.731) and a small increase in the agalsidase beta arm 2.417 (9.620) for patients with hypertrophy at baseline. Small differences were observed also in those patients without hypertrophy at baseline in both treatment arms.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Measures of systemic disease burden (MSSI)</i>. Further evidence of the stabilization of the disease is provided by the MSSI overall scores, which remained stable throughout the <i style="font-style:italic;">BALANCE</i> study in both arms, with the baseline score in both groups at the low end of the moderate range (means of 23.18&#160;points in the PRX-102 arm and 25.16&#160;points in the agalsidase beta arm), that slightly decreased (improvement by -2.1&#160;points) in the PRX-102 arm and slightly increased in the agalsidase beta arm (+2.0&#160;points). In this case, the CI of the difference in mean changes did not contain 0, suggesting a difference between the two arms in favor of PRX-102.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Patient reported outcomes</i>. With regards to the patient-reported outcomes (BPI and EQ-5D-5L), the two treatments showed very similar results, with the majority of patients reporting an improvement or no change in both groups, for each domain.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For an overview of primary and secondary endpoints collected in the <i style="font-style:italic;">BALANCE</i> study, please refer to the Table&#160;1 below.</p><a id="_Ref124326188"></a><a id="_Toc124351688"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Table&#160;</b><b style="font-weight:bold;">1</b><b style="font-weight:bold;">: Summary Table of Comparison of Treatment Benefit Data in the </b><span style="font-style:italic;font-weight:bold;">BALANCE</span><b style="font-weight:bold;"> Study, (Mean (SE) [median]), Efficacy Population</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:89.86%;"><tr style="height:11.95pt;"><td style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Parameter</b></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:25.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PRX-102 (N = 52)</b></p></td><td colspan="2" style="vertical-align:top;width:25.94%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Agalsidase beta (N = 25)</b></p></td></tr><tr style="height:13.7pt;"><td rowspan="4" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">eGFR </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">n</b></p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">n</b></p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">73.46 (2.80) [73.45]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">74.16 (4.19) [74.85]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">47</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">70.53 (3.19) [69.35]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">72.05 (4.69) [74.48]</p></td></tr><tr style="height:11.95pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">47</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-3.60 (1.58) [-2.39]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-1.97 (1.51) [-3.20]</p></td></tr><tr style="height:1pt;"><td rowspan="2" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">eGFR slope (ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/yr)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.03 (0.92) [-6.70]<br />Range: -30.5; 6.3</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.25 (0.85) [-7.84]<br />Range: -20.3; -2.8</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">51</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.38 (1.25) [-2.51] <br />Q1; Q3: -4.8; 0.8</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.31 (0.71) [-2.16]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Q1; Q3: -4.6; -0.5</p></td></tr><tr style="height:25.35pt;"><td style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reaching kidney therapeutic goal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">a</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">41 patients (80.4%)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20 patients (80.0%)</p></td></tr><tr style="height:14.4pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">UPCR</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.441 (0.084)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.284 (0.097)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.480 (0.118)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.489 (0.162)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.088 (0.067)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.197 (0.085)</p></td></tr><tr style="height:14.4pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (nM)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26.22 (3.78) [15.20]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.14 (7.08) [17.60]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">29.22 (4.48) [18.80]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19.65 (3.60) [15.30]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.30 (1.38) [1.15]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.74 (4.85) [-1.50]</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LVMI (g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">40</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">75.97 (5.13)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">82.22 (6.34)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">35</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">71.56 (5.20)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">82.43 (8.39)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">28</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-0.64 (2.69)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.29 (3.73)</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MSSI (overall score)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">a</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">49</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.18 (1.42)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25.16 (2.14)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22.11 (1.80)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">27.09 (2.30)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">44</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.07 (0.77)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.04 (1.10)</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BPI (score for pain at its worst)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">b</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5 (0.4)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.6 (0.6)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3 (0.5)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.0 (0.7)</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:89.86%;"><tr style="height:14.4pt;"><td rowspan="1" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-0.1 (0.5)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.6 (0.6)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">BPI=brief pain inventory; eGFR=estimated glomerular filtration rate; lyso-Gb<sub style="font-size:6pt;vertical-align:sub;">3</sub>=globotriaosylsphingosine; LVMI=Left Ventricular Mass Index; MSSI=Mainz Severity Score Index; UPCR=Urine Protein Creatinine Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">a </sup>Wanner 2018; <sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">b </sup>Higher scores indicate higher symptom severity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 (21.2%) patients in the PRX-102 arm experienced a total of 13 events compared to six (24.0%) patients experiencing a total of 51 events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients who received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial, patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 have opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every two weeks in the long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study was completed in December 2019. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Baseline characteristics of the 20 patients who completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were 51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial, 18 have opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every two weeks in a long-term open-label extension study which now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study, which studied the 2&#160;mg/kg every four weeks dosage, was completed in June 2020. This dosage was not approved by the EMA or the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We announced final results from the <i style="font-style:italic;">BRIGHT</i> study in March 2022. The results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the applicable Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60 nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed our phase&#160;I/II clinical trial of PRX-102, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45.0&#160;million, and is entitled to approximately $1.0&#160;billion in potential milestone payments and tiered royalties of 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US). During the quarter ended June&#160;30, 2023, we received net proceeds of $20.0&#160;million representing a milestone payment earned upon the FDA&#8217;s approval of Elfabrio for adult Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement with Chiesi. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement will expire December&#160;31, 2025, unless terminated earlier in accordance with its terms and may be extended by mutual agreement in writing for an additional period of seven years. The Letter Agreement changed our obligations and those of Chiesi under the License Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the License Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen and liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.6&#160;billion in 2022, is forecasted to be approximately $1.6&#160;billion in 2023 and is forecasted to grow at a CAGR of approximately 3.1% from 2022-2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of the October 2015 Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period (i.e., until October 2030).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of severe gout. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of severe gout which we are designing to lower uric acid levels while having low immunogenicity and increased half-life in the circulation. Pre-clinical data demonstrates stable PK profile and long half-life, low immunogenic risk and high specific activity which supports the potential of PRX-115 to be a safe and effective treatment for severe gout. Results from the one-month multiple dosing toxicity studies in two species demonstrate that PRX-115 is well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March&#160;21, 2023, the first patient was dosed in our phase&#160;I First in Human (FIH) clinical trial of PRX-115, a double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of uric acid) and immunogenicity of PRX-115 in patients with elevated uric acid levels (&gt;6.0&#160;mg/dL). The trial is a single ascending dose (SAD) study with up to seven cohorts, and patients are to be randomized 3:1 to receive a single intravenous (IV) dose of PRX-115 or a placebo. The study is being conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines, and is expected to enroll approximately 56 patients with no previous exposure to PEGylated uricase. As of the date hereof, 16 patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout leads to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Severe gout is generally described as a state of gout in which there is a presence of monosodium urate crystals with any of the following: frequent recurrent gout flares, chronic gouty arthritis, subcutaneous tophi or disease elements of gout seen via imaging. It is estimated that approximately 2% of the gout patient population is considered to have chronic refractory disease, and we believe the incidence of severe gout is higher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. However, we believe that new effective, safe therapies are needed to treat severe gout and chronic refractory gout regardless of treatment history. One treatment option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. In particular, 89% of patients treated with Krystexxa developed an immunogenic response associated with a failure to maintain normalization of serum uric acid levels over a 6-month therapy cycle. In addition, a recent phase&#160;IV study demonstrates that co-treatment with Krystexxa and methotrexate prolongs efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">DNase&#160;I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of June&#160;30, 2023, we hold a broad portfolio of over 80 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 45 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the assessment of sales reserves and valuation allowances. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended June&#160;30, 2023 compared to the three months ended June 30, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $15.1&#160;million during the three months ended June&#160;30, 2023, an increase of $11.7&#160;million, or 344%, compared to revenues of $3.4&#160;million for the three months ended June&#160;30, 2022. The increase resulted primarily from an increase of $11.7&#160;million in sales to Chiesi, following the approvals by the FDA and the EMA of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $20.0&#160;million for the three months ended June&#160;30, 2023, an increase of $14.6&#160;million, or 270%, compared to revenues of $5.4&#160;million for the three months ended June&#160;30, 2022. The increase resulted from the $20.0&#160;million regulatory milestone payment from Chiesi in connection with the FDA approval of Elfabrio. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $6.1&#160;million for the three months ended June&#160;30, 2023 an increase of $2.0&#160;million, or 49%, from cost of goods sold of $4.1&#160;million for the three months ended June&#160;30, 2022. <span style="background:#ffffff;">The increase in cost of goods sold was primarily the result of the increase in sales of </span>Elfabrio drug substance<span style="background:#ffffff;"> to Chiesi and royalties payable </span>to the Israel Innovation Authority in<span style="background:#ffffff;"> connection with the Chiesi agreements.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the three months ended June&#160;30, 2023, our total research and development expenses were approximately $4.5&#160;million comprised of approximately $1.7&#160;million in subcontractor-related expenses, approximately $2.0&#160;million of salary and related expenses, approximately $0.1&#160;million of materials-related expenses and approximately $0.7&#160;million of other expenses. For the three months ended June&#160;30, 2022, our total research and development expenses were approximately $7.6&#160;million comprised of approximately $4.4&#160;million in subcontractor-related expenses, approximately $1.6&#160;million of salary and related expenses, approximately $0.7&#160;million of materials-related expenses and approximately $0.9&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses was $3.1&#160;million, or 41%, for the three months ended June&#160;30, 2023 compared to the three months ended June&#160;30, 2022. The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $4.0&#160;million for the three months ended June&#160;30, 2023, an increase of $1.4&#160;million, or 54%, compared to $2.6&#160;million for the three months ended June&#160;30, 2022. The increase resulted primarily from an increase of approximately $1.2&#160;million in salary and related expenses due to one-time cash bonuses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net were $0.8&#160;million for the three months ended June&#160;30, 2023, compared to financial income, net of $0.2&#160;million for the three months ended June&#160;30, 2022. The increase resulted primarily from an increase of $0.6&#160;million in costs related to exchange rates as well as an increase in our convertible notes related expenses of $0.3&#160;million net of a gain recognized due to conversions of a portion of the 2024 Notes of $0.4&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the three months ended June&#160;30, 2023, we recorded income taxes of approximately $0.3&#160;million which were primarily the result of the provision for current taxes in respect of Section&#160;174 of the TCJA. Section 174 eliminated the option to immediately deduct research and development expenses in the year incurred and requires us to capitalize and amortize these expenditures over 15 years (for out of U.S.-based research and development). In addition, during the three months ended June&#160;30, 2023, we released a valuation allowance related to deferred tax assets of the U.S. jurisdiction that resulted in a net benefit to tax expense of $3.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Six months ended June&#160;30, 2023 compared to the six months ended June&#160;30, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $20.1&#160;million during the six months ended June&#160;30, 2023, an increase of $7.7&#160;million, or 62%, compared to revenues of $12.4&#160;million for the six months ended June&#160;30, 2022. The increase resulted primarily from an increase of $11.5&#160;million in sales <span style="background:#ffffff;">to Chiesi, </span>following the approvals by the FDA and the EMA of Elfabrio<span style="background:#ffffff;">, which was </span>partially offset by a decrease of $2.7&#160;million in sales to Brazil and a decrease of $1.0&#160;million in sales to Pfizer, both resulting from timing differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $24.5<span style="direction:rtl;">&#160;</span>million for the six months ended June&#160;30, 2023, an increase of $12.1&#160;million, or 98%, compared to revenues of $12.4&#160;million for the six months ended June&#160;30, 2022. The increase resulted from the $20.0&#160;million regulatory milestone payment from Chiesi in connection with the FDA approval of Elfabrio which was partially offset by a decrease of $7.9&#160;million in revenues recognized in connection with the Chiesi Agreements. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold was $9.2&#160;million for the six months ended June&#160;30, 2023, a decrease of $0.9&#160;million, or 9%, from cost of goods sold of $10.1&#160;million for the six months ended June&#160;30, 2022. <span style="background:#ffffff;">The decrease in cost of goods sold was primarily the result of a decrease </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">in sales of goods to Brazil and to Pfizer which was partially offset by an increase in sales of Elfabrio drug substance to Chiesi. Sales to Chiesi included certain drug substance costs which had already been recognized as research and development expenses as it was produced as part of research and development activities. Accordingly, the related cost of goods sold does not include the costs of such drug substance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the six months ended June&#160;30, 2023, our total research and development expenses were approximately $10.3&#160;million comprised of approximately $5.2&#160;million in subcontractor-related expenses, approximately $3.6&#160;million of salary and related expenses, approximately $0.3&#160;million of materials-related expenses and approximately $1.2&#160;million of other expenses. For the six months ended June&#160;30, 2022, our total research and development expenses were approximately $16.3&#160;million comprised of approximately $10.2&#160;million in subcontractor-related expenses, approximately $3.7&#160;million of salary and related expenses, approximately $0.9&#160;million of materials-related expenses and approximately $1.5&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses was $6.0&#160;million, or 37%, for the six months ended June&#160;30, 2023 compared to the six months ended June&#160;30, 2022<span style="direction:rtl;">. </span>The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and of the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $7.1&#160;million for the six months ended June&#160;30, 2023, an increase of $1.3&#160;million, or 22%, compared to $5.8&#160;million for the six months ended June&#160;30, 2022. The increase resulted primarily from an increase of approximately $0.9&#160;million in salary and related expenses due to one-time cash bonuses, an increase of $0.2&#160;million in professional fees and of $0.2 million in travel, conferences and employee training expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net were $1.3&#160;million for the six months ended June&#160;30, 2023, an increase of $1.1&#160;million, or 550%, compared to $0.2&#160;million for the six months ended June&#160;30, 2022. The increase was primarily due to an increase of $0.7&#160;million in costs related to exchange rates as well as an increase in our convertible notes related expenses of $0.3&#160;million net of a gain recognized due to conversions of a portion of the 2024 Notes of $0.4&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the six months ended June&#160;30, 2023, we recorded income taxes of approximately $0.5&#160;million which were primarily the result of the provision for current taxes in respect of Section&#160;174 of the TCJA. Section 174 eliminated the option to immediately deduct research and development expenses in the year incurred and requires us to capitalize and amortize these expenditures over 15 years (for out of U.S.-based research and development). In addition, during the six months ended June&#160;30, 2023, we released a valuation allowance related to deferred tax assets of the U.S. jurisdiction that resulted in a net benefit to tax expense of $3.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Our sources of liquidity includes our cash and cash equivalents balance. At June 30, 2023, we had $48.2&#160;million in cash and cash equivalents. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">During the year ended December&#160;31, 2022, we raised gross proceeds equal to approximately $8.7&#160;million from the sale of 7,473,038 shares of our common stock under our ATM program. During the six months ended June 30, 2023, we raised gross proceeds equal to approximately $24.9&#160;million from sales of common stock under our ATM program through the sale of 12,560,150 shares of our common stock of which 4,347,668 shares were sold, and gross proceeds of approximately $10.0&#160;million were raised, in the three months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, of a substantial majority of our then outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our 2021 Notes for an aggregate of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">$28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of our common stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of common Stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full. As a result of the conversion of 2024 Notes during the six months ended June&#160;30, 2023, the total principal amount of our remaining 2024 Notes outstanding decreased by approximately $8.3&#160;million. As of June&#160;30, 2023, the total principal amount of our 2024 Notes outstanding was $20.42&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the Indenture dated as of August&#160;24, 2021 between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent, or the 2024 Indenture. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature on September&#160;1, 2024, unless earlier purchased, converted, exchanged or redeemed, and are guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries. <span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of June&#160;30, 2023, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents as of June 30, 2023 are sufficient to satisfy our capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash generated from operations was $2.0&#160;million for the six months ended June&#160;30, 2023. The net income for the six months ended June&#160;30, 2023 of $16.2&#160;million was decreased by an $13.2&#160;million decrease in contracts liability, a $3.1&#160;million increase in deferred tax assets and a $2.8&#160;million increase in inventories. The net income was increased by a $3.6&#160;million increase in accounts payable and accruals, $1.0&#160;million in share-based compensation and $0.6&#160;million in depreciation. Net cash provided by investing activities for the six months ended June&#160;30, 2023 was $4.5&#160;million and consisted primarily of proceeds from sale of short-term deposits. Net cash provided by financing activities was $24.7&#160;million resulting primarily from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $13.2&#160;million for the six months ended June&#160;30, 2022. The net loss for the six months ended June&#160;30, 2022 of $7.6&#160;million was increased by a $2.6&#160;million decrease in contracts liability, a $4.9&#160;million decrease in accounts payable and accruals and $1.0 million financial income, net (mainly exchange differences), and was partially offset by a $1.4&#160;million decrease in inventories and a $1.1&#160;million in share-based compensation. Net cash used in investing activities for the six months ended June&#160;30, 2022 was $15.9&#160;million and consisted primarily of investment in bank deposits. Net cash provided by financing activities was $2.6&#160;million resulting mainly from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2024 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;background:#ffffff;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of June&#160;30, 2023, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June&#160;30, 2023, we issued, in the aggregate, 538,822 shares of our common stock in connection with cash and cashless exercises of our outstanding warrants to purchase shares of our common stock at an exercise price equal to $2.36 per share which were initially issued on March&#160;18, 2020 as part of our private placement of common stock and warrants, or the 2020 Warrants. In connection with the exercises, we generated net proceeds equal to $0.7 million and retired 2020 Warrants to purchase 1,146,810 shares of common stock. As of June&#160;30, 2023, 2020 Warrants to purchase 13,439,712 shares were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, during the six months ended June&#160;30, 2023, we issued, in the aggregate, 4,691,623 shares of our common stock in connection with a number of conversions of 2024 Notes. In connection with such conversions, during the six months ended June&#160;30, 2023, we paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversion of 2024 Notes during the six months ended </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">June&#160;30, 2023, the total principal amount of our remaining 2024 Notes outstanding decreased by approximately $8.3&#160;million. As of June&#160;30, 2023, the total principal amount of our 2024 Notes outstanding was $20.42&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur expenditures in the near future as we increase our research and developments efforts with respect to our product candidates. We cannot anticipate the costs or the timing of the occurrence of such costs. We also expect to increase the revenues generated from the sales of our approved drug products. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts, (v)&#160;payments of principal and interest on our outstanding 2024 Notes and (vi) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of our approved drug products (Elelyso and Elfabrio), corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to milestone payments and royalties that may become payable under the Chiesi Agreements. As of June&#160;30, 2023, shares of our common stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under our 2023&#160;Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the three and six months ended June&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of June&#160;30, 2023 and December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_319fd400_0e9a_41a2_b887_3f67da46a826"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 43% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.648</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.346</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.592</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.360</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.519</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><a id="_bdc8fdc2_2098_4d3a_9c7c_75f3b92d9c2d"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended June&#160;30, 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9fac17b7_49fb_4ed7_a173_ed1f8c5502b9"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_df3a1b35_6440_45ff_96cb_6b2f20ae8106"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;"><span style="background:#ffffff;">Except as set forth below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any current products or future product candidates may cause serious adverse events, or SAEs, undesirable side effects or have other properties that could halt their clinical development, prevent, delay, or cause the withdrawal of their regulatory approval, limit their commercial potential, or result in material negative consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As with most infused products, use of our products or any current or future product candidates could be associated with undesirable side effects or adverse events which can vary in severity and frequency. From time to time, we have observed serious adverse events in clinical studies of our products and product candidates. For example, while conducting clinical trials we have observed treatable anaphylactic reactions. In addition, as indicated in the boxed warning with which Elfabrio was approved by the FDA, patients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. There are postmarketing requirements under the U.S.&#160;Federal Food, Drug, and Cosmetic Act included with the approval of Elfabrio by the FDA. For example, the FDA requires that a worldwide descriptive study be conducted that collects prospective and retrospective data in women and their offspring exposed to Elfabrio during pregnancy and/or lactation to assess risk of pregnancy and material complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant. Furthermore, the approval of pharmaceutical products generally includes requirements related to the preparation of a Risk Evaluation and Mitigation Strategy, or REMS, or a risk management plan as required by the EMA, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use. For example, Chiesi must follow a risk management plan agreed upon with the EMA with respect to Elfabrio, which includes risk minimization measures in connection with risks associated with hypersensitivity reactions and possible medication errors in the home infusion setting. Our product candidates, if approved, may also be subject to certain post-authorization reporting requirements. As an example, the EMA has required that Chiesi submit pharmacovigilance documents intended to provide post-authorization evaluation of Elfabrio&#8217;s risk-benefit balance at defined time points after authorization, beginning within six months of authorization, and that we agree with the National Competent Authority on an educational program about home administration prior to use of Elfabrio in the home setting. Any of the foregoing, including the boxed warning, could prevent us or our collaborators from achieving or maintaining market acceptance of a product or a particular product candidate and could materially harm our business, results of operations, and prospects, and could adversely impact our financial condition, results of operations, ability to raise additional financing or the market price of our common stock.</p><a id="_29073e87_79b4_446f_a5cd_caad49b82788"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1e8a5414_7d41_4389_8cad_7f073a833b96"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ca1eb5c8_d6b0_45ca_a031_18fa14fbfc19"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_50c083fb_89d2_4969_b86f_d9fd2fcddf11"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_eb1108c7_b9a0_4858_a062_31e8a074aa95"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023002102/plx-20221231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">February&#160;27, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230630xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9438b124_4742_4daa_b0be_345ad592ed83"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;7, 2023</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;7, 2023</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>plx-20230630xex3d6.htm
<DESCRIPTION>EX-3.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/7/2023 10:12:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;3.6</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FIFTH CERTIFICATE OF AMENDMENT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">CERTIFICATE OF INCORPORATION OF</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(Pursuant to Section&#160;242 of the<br>General Corporation Law of the State of Delaware)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Protalix BioTherapeutics,&#160;Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The name of the corporation is Protalix BioTherapeutics,&#160;Inc. (the &#8220;Corporation&#8221;). The Certificate of Incorporation of the Corporation was filed with the Secretary of the State of Delaware on March&#160;30, 2016, as amended by that Certificate of Amendment dated August&#160;16, 2016, that Second Certificate of Amendment dated January&#160;15, 2019, that Third Certificate of Amendment dated December&#160;16, 2019 and that Fourth Certificate of Amendment dated August&#160;2, 2022 (the &#8220;Certificate of Incorporation&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Certificate of Amendment to Certificate of Incorporation of the Corporation was duly adopted by the Board of Directors of the Corporation pursuant to a resolution setting forth the proposed amendment of the Certificate of Incorporation and declaring said amendment to be advisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Article&#160;III of the Certificate of Incorporation, as amended, is hereby amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;">&#8220;The Corporation is authorized to issue the following shares of capital stock: (a)&#160;185,000,000 shares of common stock, par value $.001 per share (the &#8220;Common Stock&#8221;); and (b)&#160;100,000,000 shares of preferred stock, par value $.0001 per share (the &#8220;Preferred Stock&#8221;). The voting rights, the rights of redemption and other relative rights and preferences of the Preferred Stock shall be established by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;">The Board of Directors may authorize the issuance of such stock to such persons upon such terms and for such consideration in cash, property or services as the Board of Directors may determine and as may be allowed by law. The just valuation of such property or services shall be fixed by the Board of Directors. All such stock when issued shall be fully paid and exempt from assessment.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The aforesaid amendment was duly adopted in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[Remainder of this page&#160;intentionally left blank.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to Certificate of Incorporation to be signed by its duly authorized President and Chief Executive Officer this 25th day of July, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:49.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:49.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>plx-20230630xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/7/2023 10:12:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN, AS AMENDED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(June&#160;28, 2023)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purposes of the Plan</u><font style="font-weight:normal;white-space:pre-wrap;">.  The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company&#8217;s business.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-weight:normal;white-space:pre-wrap;">.  The following definitions shall apply as used herein and in the individual Award Agreements except as defined otherwise in an individual Award Agreement.  In the event a term is separately defined in an individual Award Agreement, such definition shall supercede the definition contained in this Section&#160;2.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3(I) Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Award granted under Section 3(I).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">102 Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Award granted under Section 102.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrator</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board or any of the Committees appointed to administer the Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Associate</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the respective meanings ascribed to such terms in Rule&#160;12b-2 promulgated under the Exchange Act.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Laws</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the legal requirements relating to the Plan and the Awards under applicable provisions of federal securities laws, state corporate and securities laws, the Code, the rules of any applicable stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to Awards granted to residents therein.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumed</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means that pursuant to a Corporate Transaction either (i)&#160;the Award is expressly affirmed by the Company or (ii)&#160;the contractual obligations represented by the Award are expressly assumed (and not simply by operation of law) by the successor entity or its Parent in connection with the Corporate Transaction with appropriate adjustments to the number and type of securities of the successor entity or its Parent subject to the Award and the exercise or purchase price thereof which at least preserves the compensation element of the Award existing at the time of the Corporate Transaction as determined in accordance with the instruments evidencing the agreement to assume the Award.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the grant of an Option, SAR, Dividend Equivalent Right, Restricted Stock, Restricted Stock Unit or other right or benefit under the Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the written agreement evidencing the grant of an Award executed by the Company and the Grantee, including any amendments thereto.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board of Directors of the Company.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to the termination by the Company or a Related Entity of the Grantee&#39;s Continuous Service, that such termination is for &#8220;Cause&#8221; as such term (or word of like import) is expressly defined in a then-effective written agreement between the Grantee and the Company or such Related Entity, or in the absence of such then-effective written agreement and definition, is based on, in the determination of the Administrator, the Grantee&#8217;s: (i) performance of any act or failure to perform any act in bad faith which is materially detrimental to the Company or a Related Entity as reasonably determined in good faith by a unanimous decision of members of the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">Board</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> entitled to vote thereon; (ii) dishonesty, intentional misconduct or material breach of any agreement with the Company or a Related Entity; (iii) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person; (iv) embezzlement of funds of the Company or a Related Entity; (v) ownership, direct or indirect (i.e., by means of a holding company or family member), of an interest in a person or entity (other than a minority interest in a publicly traded company) in competition with the products or services of the Company or a Related Entity, including those products or services contemplated in a plan adopted by the Board; (vi) any breach of the Grantee&#8217;s fiduciary duties or duties of care to the Company or a Related Entity (except for conduct taken in good faith); (vii) any material failure to carry out a reasonable and legitimate directive of </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the Board</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; or (viii) any material breach of an Employee&#39;s undertakings of confidentiality and non competition.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a change in ownership or control of the Company effected through either of the following transactions:</font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:10pt;">the direct or indirect acquisition by any person or related group of persons (other than an acquisition from or by the Company or by a Company-sponsored employee benefit plan or by a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership (within the meaning of Rule&#160;13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Company&#8217;s stockholders which a majority of the Continuing Directors who are not Affiliates or Associates of the offeror do not recommend such stockholders accept, or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:10pt;">a change in the composition of the Board over a period of twelve (12) months or less such that a majority of the Board members (rounded up to the next whole number) ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who are Continuing Directors.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any committee composed of members of the Board appointed by the Board to administer the Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock of the Company.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Protalix BioTherapeutics, Inc., a Delaware corporation, or any successor entity that adopts the Plan in connection with a Corporate Transaction.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consultant</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any person (other than an Employee or a Director, solely with respect to rendering services in such person&#8217;s capacity as a Director) who is engaged by the Company or any Related Entity to render consulting or advisory services to the Company or such Related Entity.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(q)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Directors</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means members of the Board who either (i)&#160;have been Board members continuously for a period of at least twelve (12) months or (ii)&#160;have been Board members for less than twelve (12) months and were elected or nominated for election as Board members by at least a majority of the Board members described in clause&#160;(i) who were still in office at the time such election or nomination was approved by the Board.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(r)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuous Service</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8221; means that the provision of services to the Company or a Related Entity in any capacity of Employee, Director or Consultant is not interrupted or terminated.  In jurisdictions requiring notice in advance of an effective termination as an Employee, Director or Consultant, Continuous Service shall be deemed terminated upon the actual cessation of providing services to the Company or a Related Entity notwithstanding any required notice period that must be fulfilled before a termination as an Employee, Director or Consultant can be effective under Applicable Laws.  A Grantee&#8217;s Continuous Service shall be deemed to have terminated either upon an actual termination of Continuous Service or upon the entity for which the Grantee provides services ceasing to be a Related Entity.  Continuous Service shall not be considered interrupted in the case of (i)&#160;any approved leave of absence, (ii)&#160;transfers among the Company, any Related Entity, or any successor, in any capacity of Employee, Director or Consultant, or (iii)&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">any change in status as long as the individual remains in the service of the Company or a Related Entity in any capacity of Employee, Director or Consultant (except as otherwise provided in the Award Agreement).  An approved leave of absence shall include sick leave, military leave, or any other authorized personal leave.  For purposes of each Incentive Stock Option granted under the Plan, if such leave exceeds three (3) months, and reemployment upon expiration of such leave is not guaranteed by statute or contract, then the Incentive Stock Option shall be treated as a Non-Qualified Stock Option on the day three (3) months and one (1) day following the expiration of such three (3) month period.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(s)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Transaction</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any of the following transactions, provided, however, that the Administrator shall determine under parts (iv) and (v) whether multiple transactions are related, and its determination shall be final, binding and conclusive:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref519411865"></a><font style="font-size:10pt;">a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state in which the Company is incorporated;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref519411873"></a><font style="font-size:10pt;">the sale, transfer or other disposition of all or substantially all of the assets of the Company;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref519411880"></a><font style="font-size:10pt;">the complete liquidation or dissolution of the Company;</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref519411914"></a><font style="font-size:10pt;">any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A)&#160;the shares of Common Stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B)&#160;in which securities possessing more than forty percent (40%) of the total combined voting power of the Company&#8217;s outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger; or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><a name="_Ref9753959"></a><font style="font-size:10pt;">acquisition in a single or series of related transactions by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule&#160;13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities but excluding any such transaction or series of related transactions that the Administrator determines shall not be a Corporate Transaction (provided however that the Administrator shall have no discretion in connection with a Corporate Transaction for the purchase of all or substantially all of the shares of the Company </font><font style="font-size:10pt;">unless the principal purpose of such transaction is to change the state in which the Company is incorporated</font><font style="font-size:10pt;">).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(t)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Employee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Employee who is a &#8220;covered employee&#8221; under Section&#160;162(m)(3) of the Code.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(u)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Director</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a member of the Board or the board of directors of any Related Entity.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8221; means as defined under the long-term disability policy of the Company or the Related Entity to which the Grantee provides services regardless of whether the Grantee is covered by such policy.  If the Company or the Related Entity to which the Grantee provides service does not have a long-term disability plan in place, &#8220;Disability&#8221; means that a Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determinable physical or mental impairment for a period of not less than ninety (90) consecutive days.  A Grantee will not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Administrator in its discretion.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(w)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividend Equivalent Right</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a right entitling the Grantee to compensation measured by dividends paid with respect to Common Stock.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(x)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">means any person, including an Officer or Director, who is in the employ of the Company or any Related Entity, subject to the control and direction of the Company or any Related Entity as to both the work to be performed and the manner and method of performance.  </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The payment of a director&#8217;s fee by the Company or a Related Entity shall not be sufficient to constitute &#8220;employment&#8221; by the Company.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(y)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(z)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Market Value</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, as of any date, the value of Common Stock determined as follows:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:10pt;">If the Common Stock is listed on one or more established stock exchanges or national market systems, including without limitation the American Stock Exchange, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on the principal exchange or system on which the Common Stock is listed (as determined by the Administrator) on the date of determination (or, if no closing sales price or closing bid was reported on that date, as applicable, on the last trading date such closing sales price or closing bid was reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:10pt;">If the Common Stock is regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized securities dealer, its Fair Market Value shall be the closing sales price for such stock as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, the Fair Market Value of a share of Common Stock shall be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no such prices were reported on that date, on the last date such prices were reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:10pt;">In the absence of an established market for the Common Stock of the type described in (i) and (ii), above, the Fair Market Value thereof shall be determined by the Administrator in good faith.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(aa)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grantee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Employee, Director or Consultant who receives an Award under the Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(bb)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive Stock Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option intended to qualify as an incentive stock option within the meaning of Section&#160;422 of the Code.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(cc)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Israeli Employee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Employees, office holders of the Company or a Related Company (&#8220;Nosei Misra&#8221; - as such term is defined in the Israeli Companies Law 1999) and Directors (excluding those who are considered a &#8220;Controlling Shareholder&#8221; pursuant to Section 32(9) of the Tax Ordinance or otherwise excluded by the Tax Ordinance).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(dd)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Israeli Grantee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Grantees who are residents of the State of Israel or those who are deemed to be residents of the State of Israel for the payment of tax (whether such grantee is entitled to the tax benefits under Section 102 or not).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ee)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ITA</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Israeli Tax Authorities.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ff)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Employee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Consultants or any other person who is not an Israeli Employee.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(gg)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Qualified Stock Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option not intended to qualify as an Incentive Stock Option.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(hh)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Trustee 102 Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean a 102 Option granted pursuant to Section 102(c) of the Tax Ordinance and not held in trust by the Trustee.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Officer</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a person who is an officer of the Company or a Related Entity within the meaning of Section&#160;16 of the Exchange Act and the rules and regulations promulgated thereunder.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(jj)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an option to purchase Shares pursuant to an Award Agreement granted under the Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(kk)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;parent corporation&#8221;, whether now or hereafter existing, as defined in Section&#160;424(e) of the Code.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ll)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance-Based Compensation</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means compensation qualifying as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(mm)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means this Amended and Restated 2006 Stock Incentive Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(nn)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Entity</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Parent or Subsidiary of the Company. With respect to Israeli Grantees of 102 Options, the definition shall further include any entity permitted under Section 102 (a) of the Tax Ordinance.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(oo)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replaced</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means that pursuant to a </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Corporate Transaction&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the Award is replaced with a comparable stock award or a cash incentive program of the Company, the successor entity (if applicable) or Parent of either of them which preserves the compensation element of such Award existing at the time of the Corporate Transaction and provides for subsequent payout in accordance with the same (or a more favorable) vesting schedule applicable to such Award.  The determination of Award comparability shall be made by the Administrator and its determination shall be final, binding and conclusive.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(pp)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Shares issued under the Plan to the Grantee for such consideration, if any, and subject to such restrictions on transfer, rights of first refusal, repurchase provisions, forfeiture provisions, and other terms and conditions as established by the Administrator.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(qq)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Units</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Award which may be earned in whole or in part upon the passage of time or the attainment of performance criteria established by the Administrator and which may be settled for cash, Shares or other securities or a combination of cash, Shares or other securities as established by the Administrator.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(rr)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule&#160;16b-3</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Rule&#160;16b-3 promulgated under the Exchange Act or any successor thereto.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ss)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SAR</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a stock appreciation right entitling the Grantee to Shares or cash compensation, as established by the Administrator, measured by appreciation in the value of Common Stock.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(tt)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(I)</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means section 3(I) of the Tax Ordinance as may be amended from time to time.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(uu)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 102</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means section 102 of the Tax Ordinance as may be amended from time to time.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vv)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Share</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a share of the Common Stock.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ww)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;subsidiary corporation&#8221;, whether now or hereafter existing, as defined in Section&#160;424(f) of the Code.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(xx)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Ordinance</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Israeli Income Tax Ordinance [New Version], 1961 (including as amended pursuant to Amendment 132 thereto) and to the extent not specifically indicated hereunder also the rules, regulations and orders or procedures promulgated thereunder from time to time, as amended or replaced from time to time.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(yy)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trustee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any individual appointed by the Company to serve as trustee and approved by the ITA, in accordance with the provisions of Section 102(a) of the Tax Ordinance and the regulations promulgated thereunder.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(zz)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trustee 102 Option</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a 102 Option granted pursuant to Section&#160;102(b) of the Tax Ordinance and held in trust by the Trustee for the benefit of an Israeli Grantee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Subject to the Plan</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref519414867"></a><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Subject to the provisions of Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8206;10</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">, below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive Stock Options) under the Plan is 12,475,171 Shares.  Notwithstanding the foregoing, any Shares issued from and after November 10, 2014 in connection with Awards other than Options and SARs shall be counted against the limit set forth herein as one and one-half (1.5) Shares for every one (1) Share issued in connection with such Award (and shall be counted as one and one-half (1.5) Shares for every one (1) Share returned or deemed not have been issued from the Plan pursuant to Section 3(b) below in connection with Awards other than Options and SARs).  The Shares to be issued pursuant to Awards may be authorized, but unissued, or reacquired Common Stock.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Any Shares covered by an Award (or portion of an Award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) shall be deemed not to have been issued for purposes of determining the maximum aggregate number of Shares which may be issued under the Plan.  Shares that actually have been issued under the Plan pursuant to an Award shall not be returned to the Plan and shall not become available for future issuance under the Plan, except that if unvested Shares are forfeited, or repurchased by the Company at the lower of their original purchase price or their Fair Market Value at the time of repurchase, such Shares shall become available for future grant under the Plan.  Notwithstanding anything to the contrary contained herein: (i) Shares tendered or withheld in payment of an Option exercise price shall not be returned to the Plan and shall not become available for future issuance under the Plan; (ii) Shares withheld by the Company to satisfy any tax withholding obligation shall not be returned to the Plan and shall not become available for future issuance under the Plan; and (iii) all Shares covered by the portion of an SAR that is exercised (whether or not Shares are actually issued to the Grantee upon exercise of the SAR) shall be considered issued pursuant to the Plan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration of the Plan</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Administrator</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration with Respect to Directors and Officers</u><font style="font-size:10pt;white-space:pre-wrap;">.  With respect to grants of Awards to Directors or Employees who are also Officers or Directors of the Company, the Plan shall be administered by (A)&#160;the Board or (B)&#160;a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws and to permit such grants and related transactions under the Plan to be exempt from </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:0pt;"><font style="font-size:10pt;white-space:pre-wrap;">Section&#160;16(b) of the Exchange Act in accordance with Rule&#160;</font><font style="font-size:10pt;white-space:pre-wrap;">16b-3.  Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration With Respect to Consultants and Other Employees</u><font style="font-size:10pt;white-space:pre-wrap;">.  With respect to grants of Awards to Employees or Consultants who are neither Directors nor Officers of the Company, the Plan shall be administered by (A) the Board or (B) a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws.  Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board.  The Board may authorize one or more Officers to grant such Awards and may limit such authority as the Board determines from time to time.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration With Respect to Covered Employees</u><font style="font-size:10pt;white-space:pre-wrap;">.  Notwithstanding the foregoing, grants of Awards to any Covered Employee intended to qualify as Performance-Based Compensation shall be made only by a Committee (or subcommittee of a Committee) which is comprised solely of two or more Directors eligible to serve on a committee making Awards qualifying as Performance-Based Compensation.  In the case of such Awards granted to Covered Employees, references to the &#8220;Administrator&#8221; or to a &#8220;Committee&#8221; shall be deemed to be references to such Committee or subcommittee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration With Respect to Israeli Grantees</u><font style="font-size:10pt;white-space:pre-wrap;">.  With respect to grants of Awards to Israeli Grantees, the Plan shall be administered by (A) the Board or (B) a Committee or one or more Officers designated by the Board, which Committee or Officers shall be constituted or appointed in such a manner as to satisfy the ITA and the Applicable Laws applicable to Awards for Israeli Grantees.  Once appointed, such Committee or Officer shall continue to serve in its/his/her designated capacity until otherwise directed by the Board.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration Errors</u><font style="font-size:10pt;white-space:pre-wrap;">.  In the event an Award is granted in a manner inconsistent with the provisions of this subsection&#160;(a), such Award shall be presumptively valid as of its grant date to the extent permitted by the Applicable Laws.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Powers of the Administrator</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  Subject to Applicable Laws and the provisions of the Plan (including any other powers given to the Administrator hereunder), and except as otherwise provided by the Board, the Administrator shall have the authority, in its discretion:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:10pt;">to select the Employees, Directors and Consultants to whom Awards may be granted from time to time hereunder;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:10pt;">to determine whether and to what extent Awards are granted hereunder;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:10pt;">to determine the number of Shares or the amount of other consideration to be covered by each Award granted hereunder;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-size:10pt;">to approve forms of Award Agreements for use under the Plan;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-size:10pt;">to determine the terms and conditions of any Award granted hereunder;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><font style="font-size:10pt;">to amend the terms of any outstanding Award granted under the Plan, provided that (A) any amendment that would adversely affect the Grantee&#8217;s rights under an outstanding Award shall not be made without the Grantee&#8217;s written consent, provided, however, that an amendment or modification that may cause an Incentive Stock Option to become a Non-Qualified Stock Option shall not be treated as adversely affecting the rights of the Grantee, (B)&#160;</font><font style="font-size:10pt;white-space:pre-wrap;">the reduction of the exercise price of any Option awarded under the Plan and the base appreciation amount of any SAR awarded under the Plan shall be subject to stockholder approval and (C) canceling an Option or SAR at a time when its exercise price or base appreciation amount (as applicable) exceeds the Fair Market Value of the underlying Shares, in exchange for another Option, SAR, Restricted Stock, or other Award or for cash shall be subject to stockholder approval, unless the cancellation and exchange occurs in connection with a Corporate Transaction.  Notwithstanding the foregoing, canceling an Option or SAR in exchange for another Option, SAR, Restricted Stock, or other Award or for cash with an exercise price, purchase price or base appreciation amount (as applicable) that is equal to or greater than the exercise price or base appreciation amount (as applicable) of the original Option or SAR shall not be subject to stockholder approval;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font><font style="font-size:10pt;">to construe and interpret the terms of the Plan and Awards, including without limitation, any notice of award or Award Agreement, granted pursuant to the Plan;</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(viii)</font><font style="font-size:10pt;">to grant Awards to Employees, Directors and Consultants employed outside the United States on such terms and conditions different from those specified in the Plan as may, in the judgment of the Administrator, be necessary or desirable to further the purpose of the Plan; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ix)</font><font style="font-size:10pt;">to designate Awards as 102 Options (whether through a trustee or not) or 3(I) Options subject to the limitations under the ITA or any other Applicable Law and to determine the type and route of the Trustee 102 Options.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(x)</font><font style="font-size:10pt;">to take such other action, not inconsistent with the terms of the Plan, as the Administrator deems appropriate.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">The express grant in the Plan of any specific power to the Administrator shall not be construed as limiting any power or authority of the Administrator; provided that the Administrator may not exercise any right or power reserved to the Board.  Any decision made, or action taken, by the Administrator or in connection with the administration of this Plan shall be final, conclusive and binding on all persons having an interest in the Plan.</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. In addition to such other rights of indemnification as they may have as members of the Board or as Officers or Employees of the Company or a Related Entity, members of the Board and any Officers or Employees of the Company or a Related Entity to whom authority to act for the Board, the Administrator or the Company is delegated shall be defended and indemnified by the Company to the extent permitted by law on an after-tax basis against all reasonable expenses, including attorneys&#8217; fees, actually and necessarily incurred in connection with the defense of any claim, investigation, action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any Award granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by the Company) or paid by them in satisfaction of a judgment in any such claim, investigation, action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such claim, investigation, action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct; provided, however, that within thirty (30) days after the institution of such claim, investigation, action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at the Company&#8217;s expense to defend the same.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Eligibility</u><font style="font-weight:normal;white-space:pre-wrap;">.  Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants.  Incentive Stock Options may be granted only to Employees of the Company or a Parent or a Subsidiary of the Company.  An Employee, Director or Consultant who has been granted an Award may, if otherwise eligible, be granted additional Awards.  Awards may be granted to such Employees, Directors or Consultants who are residing in non-U.S. jurisdictions as the Administrator may determine from time to time, provided however that Awards to Israeli Grantees under Section 102 or Section 3(I) of the Tax Ordinance shall be subject to Section 20 below.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:35.45pt;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:normal;">The Company does not warrant that the Plan will be recognized by the income tax authorities in any jurisdiction or that future changes will not be made to the provisions of applicable laws or rules or regulations which are promulgated from time to time thereunder, or that any exemption or benefit currently available, whether by the ITA pursuant to Section 102 or otherwise, will not be abolished.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Terms and Conditions of Awards</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Types of Awards</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The Administrator is authorized under the Plan to award any type of arrangement to an Employee, Director or Consultant that is not inconsistent with the provisions of the Plan and that by its terms involves or might involve the issuance of (i)&#160;Shares, (ii)&#160;cash or (iii)&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">an Option, a SAR, or similar right with a fixed or variable price related to the Fair Market Value of the Shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions.  Such awards include, without limitation, Options, SARs, sales or bonuses of Restricted Stock, Restricted Stock Units or Dividend Equivalent Rights, and an Award may consist of one such security or benefit, or two (2)&#160;or more of them in any combination or alternative.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Designation of Award</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  Each Award shall be designated in the Award Agreement.  In the case of an Option, the Option shall be designated as either an Incentive Stock Option or a Non-Qualified Stock Option and with respect to Israeli Grantees may be further designated as 102 Options or 3(I) Options under the Tax Ordinance subject to the qualifications described in Section 20 below.  However, notwithstanding such designation, an Option will qualify as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">422(d) of the Code is not exceeded.  The $100,000 limitation of Section&#160;422(d) of the Code is calculated based on the aggregate Fair Market Value of the Shares subject to Options designated as Incentive Stock Options which become exercisable for </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the first time by a Grantee during any calendar year (under all plans of the Company or any Parent or Subsidiary of the Company).  For purposes of this calculation, Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the Shares shall be determined as of the grant date of the relevant Option.  In the event that the Code or the regulations promulgated thereunder are amended after the date the Plan becomes effective to provide for a different limit on the Fair Market Value of Shares permitted to be subject to Incentive Stock Options, then such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions of Award</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  Subject to the terms of the Plan, the Administrator shall determine the provisions, terms, and conditions of each Award including, but not limited to, the Award vesting schedule, repurchase provisions, rights of first refusal, forfeiture provisions, form of payment (cash, Shares, or other consideration) upon settlement of the Award, payment contingencies, and satisfaction of any performance criteria.  The performance criteria established by the Administrator may be based on any one of, or combination of, the following: (i) increase in share price, (ii) earnings per share, (iii) total stockholder return, (iv) operating margin, (v) gross margin, (vi) return on equity, (vii) return on assets, (viii) return on investment, (ix) operating income, (x) net operating income, (xi) pre-tax profit, (xii) cash flow, (xiii) revenue, (xiv) expenses, (xv) earnings before interest, taxes and depreciation, (xvi) economic value added and (xvii) market share.  The performance criteria may be applicable to the Company, Related Entities and/or any individual business units of the Company or any Related Entity.  Partial achievement of the specified criteria may result in a payment or vesting corresponding to the degree of achievement as specified in the Award Agreement.  In addition, the performance criteria shall be calculated in accordance with generally accepted accounting principles, but excluding the effect (whether positive or negative) of any change in accounting standards and any extraordinary, unusual or nonrecurring item, as determined by the Administrator, occurring after the establishment of the performance criteria applicable to the Award intended to be performance-based compensation.  Each such adjustment, if any, shall be made solely for the purpose of providing a consistent basis from period to period for the calculation of performance criteria in order to prevent the dilution or enlargement of the Grantee&#8217;s rights with respect to an Award intended to be performance-based compensation.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref519412093"></a><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisitions and Other Transactions</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The Administrator may issue Awards under the Plan in settlement, assumption or substitution for, outstanding awards or obligations to grant future awards in connection with the Company or a Related Entity acquiring another entity, an interest in another entity or an additional interest in a Related Entity whether by merger, stock purchase, asset purchase or other form of transaction.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferral of Award Payment</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The Administrator may establish one or more programs under the Plan to permit selected Grantees the opportunity to elect to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other event that absent the election would entitle the Grantee to payment or receipt of Shares or other consideration under an Award.  The Administrator may establish the election procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts, Shares or other consideration so deferred, and such other terms, conditions, rules and procedures that the Administrator deems advisable for the administration of any such deferral program.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separate Programs</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The Administrator may establish one or more separate programs under the Plan for the purpose of issuing particular forms of Awards to one or more classes of Grantees on such terms and conditions as determined by the Administrator from time to time.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Individual Limitations on Awards</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Individual Limit for Options and SARs</u><font style="font-size:10pt;white-space:pre-wrap;">.  The maximum number of Shares with respect to which Options and SARs may be granted to any Grantee in any calendar year shall be 12,475,171 Shares.  Shares which shall not count against the limit set forth in the previous sentence.  The foregoing limitations shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section&#160;</font><font style="font-size:10pt;">&#8206;10</font><font style="font-size:10pt;white-space:pre-wrap;">, below.  To the extent required by Section&#160;</font><font style="font-size:10pt;white-space:pre-wrap;">162(m) of the Code or the regulations thereunder, in applying the foregoing limitations with respect to a Grantee, if any Option or SAR is canceled, the canceled Option or SAR shall continue to count against the maximum number of Shares with respect to which Options and SARs may be granted to the Grantee.  For this purpose, the repricing of an Option (or in the case of a SAR, the base amount on which the stock appreciation is calculated is reduced to reflect a reduction in the Fair Market Value of the Common Stock) shall be treated as the cancellation of the existing Option or SAR and the grant of a new Option or SAR.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Individual Limit for Restricted Stock and Restricted Stock Units</u><font style="font-size:10pt;white-space:pre-wrap;">.  For awards of Restricted Stock and Restricted Stock Units that are intended to be Performance-Based Compensation, the maximum </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:0pt;"><font style="font-size:10pt;white-space:pre-wrap;">number of Shares with respect to which such Awards may be granted to any Grantee in any calendar year shall be 12,475,171 Shares.  The foregoing limitation shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section&#160;</font><font style="font-size:10pt;">&#8206;10</font><font style="font-size:10pt;">, below.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferral</u><font style="font-size:10pt;">. If the vesting or receipt of Shares under an Award is deferred to a later date, any amount (whether denominated in Shares or cash) paid in addition to the original number of Shares subject to such Award will not be treated as an increase in the number of Shares subject to the Award if the additional amount is based either on a reasonable rate of interest or on one or more predetermined actual investments such that the amount payable by the Company at the later date will be based on the actual rate of return of a specific investment (including any decrease as well as any increase in the value of an investment).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Exercise</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The Award Agreement may, but need not, include a provision whereby the Grantee may elect at any time while an Employee, Director or Consultant to exercise any part or all of the Award prior to full vesting of the Award.  Any unvested Shares received pursuant to such exercise may be subject to a repurchase right in favor of the Company or a Related Entity or to any other restriction the Administrator determines to be appropriate.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term of Award</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The term of each Award shall be the term stated in the Award Agreement, provided, however, that the term of an Award shall be no more than ten&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">(10) years from the date of grant thereof.  However, in the case of an Incentive Stock Option granted to a Grantee who, at the time the Option is granted, owns stock representing more than ten&#160;percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the term of the Incentive Stock Option shall be five&#160;(5) years from the date of grant thereof or such shorter term as may be provided in the Award Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferability of Awards</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  Incentive Stock Options or Options to Israeli Grantees may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Grantee, only by the Grantee.  Other Awards shall be transferable (i)&#160;by will and by the laws of descent and distribution and (ii)&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">during the lifetime of the Grantee, to the extent and in the manner authorized by the Administrator but only to the extent such transfers are made to family members, to family trusts, to family controlled entities, to charitable organizations, and pursuant to domestic relations orders or agreements, in all cases without payment for such transfers to the Grantee.  Notwithstanding the foregoing, the Grantee may designate one or more beneficiaries of the Grantee&#8217;s Award in the event of the Grantee&#8217;s death on a beneficiary designation form provided by the Administrator.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time of Granting Awards</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The date of grant of an Award shall for all purposes be the date on which the Administrator makes the determination to grant such Award, or such other date as is determined by the Administrator.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.</font><a name="_Ref519412071"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award Exercise or Purchase Price, Consideration and Taxes</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref519412068"></a><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise or Purchase Price</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The exercise or purchase price, if any, for an Award shall be as follows:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:10pt;">In the case of an Incentive Stock Option:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:144pt;"><font style="display:inline-block;font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">(A)</font><font style="font-size:10pt;">granted to an Employee who, at the time of the grant of such Incentive Stock Option owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the per Share exercise price shall be not less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant; or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:144pt;"><font style="display:inline-block;font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">(B)</font><font style="font-size:10pt;">granted to any Employee other than an Employee described in the preceding paragraph, the per Share exercise price shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:10pt;">In the case of a Non-Qualified Stock Option, the per Share exercise price shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:10pt;">In the case of Awards intended to qualify as Performance-Based Compensation, the exercise or purchase price, if any, shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-size:10pt;">In the case of SARs (other than with respect to Israeli Grantees), the base appreciation amount shall not be less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-size:10pt;">In the case of other Awards, such price as is determined by the Administrator.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><font style="font-size:10pt;">Notwithstanding the foregoing provisions of this Section&#160;</font><font style="font-size:10pt;">&#8206;7</font><font style="font-size:10pt;">&#8206;(a)</font><font style="font-size:10pt;">, in the case of an Award issued pursuant to Section&#160;</font><font style="font-size:10pt;">&#8206;6(d)</font><font style="font-size:10pt;">, above, the exercise or purchase price for the Award shall be determined in accordance with the provisions of the relevant instrument evidencing the agreement to issue such Award.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consideration</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  Subject to Applicable Laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award including the method of payment, shall be determined by the Administrator.  In addition to any other types of consideration the Administrator may determine, the Administrator is authorized to accept as consideration for Shares issued under the Plan the following:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:10pt;">cash;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:10pt;">check;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:10pt;">surrender of Shares or delivery of a properly executed form of attestation of ownership of Shares as the Administrator may require which have a Fair Market Value on the date of surrender or attestation equal to the aggregate exercise price of the Shares as to which said Award shall be exercised;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref519415682"></a><font style="font-size:10pt;">with respect to Options, payment through a broker-dealer sale and remittance procedure pursuant to which the Grantee (A) shall provide written instructions to a Company designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company sufficient funds to cover the aggregate exercise price payable for the purchased Shares and (B) shall provide written directives to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale transaction; or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-size:10pt;">with respect to Options, payment through a &#8220;net exercise&#8221; such that, without the payment of any funds, the Grantee may exercise the Option and receive the net number of Shares equal to (i)&#160;the number of Shares as to which the Option is being exercised, multiplied by (ii)&#160;a fraction, the numerator of which is the Fair Market Value per Share (on such date as is determined by the Administrator) less the Exercise Price per Share, and the denominator of which is such Fair Market Value per Share (the number of net Shares to be received shall be rounded down to the nearest whole number of Shares);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><font style="font-size:10pt;">any combination of the foregoing methods of payment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Administrator may at any time or from time to time, by adoption of or by amendment to the standard forms of Award Agreement described in Section&#160;4(b)(iv), or by other means, grant Awards which do not permit all of the foregoing forms of consideration to be used in payment for the Shares or which otherwise restrict one or more forms of consideration.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  No Shares shall be delivered under the Plan to any Grantee or other person until such Grantee or other person has made arrangements acceptable to the Administrator for the satisfaction of any non-U.S., federal, state, or local income and employment tax withholding obligations, including, without limitation, obligations incident to the receipt of Shares.  Upon exercise or vesting of an Award the Company shall withhold or collect from the Grantee an amount sufficient to satisfy such tax obligations, including, but not limited to, by surrender of the whole number of Shares covered by the Award sufficient to satisfy the minimum applicable tax withholding obligations incident to the exercise or vesting of an Award (reduced to the lowest whole number of Shares if such number of Shares withheld would result in withholding a fractional Share with any remaining tax withholding settled in cash).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">8.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Award</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Procedure for Exercise; Rights as a Stockholder</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:10pt;">Any Award granted hereunder shall be exercisable at such times and under such conditions as determined by the Administrator under the terms of the Plan and specified in the Award Agreement provided however that the standard vesting schedule for Israeli Grantees shall be as set forth in Section 20.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:10pt;">An Award shall be deemed to be exercised when written notice of such exercise has been given to the Company in accordance with the terms of the Award by the person entitled to exercise the Award and full payment for the Shares with respect to which the Award is exercised has been made, including, to the extent selected, use of the broker-dealer sale and remittance procedure to pay the purchase price as provided in Section&#160;7(b).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Award Following Termination of Continuous Service</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  In the event of termination of a Grantee&#8217;s Continuous Service for any reason other than Cause, Disability or death, such Grantee may, but only within twelve&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">(12) months from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator.  To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Award Following Termination of Continuous Service for Cause</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  In the event of termination of a Grantee&#8217;s Continuous Service for Cause, such Grantee may, but only within fourteen&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">(14) days from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator.  To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability of Grantee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  In the event of termination of a Grantee&#8217;s Continuous Service as a result of his or her Disability, such Grantee may, but only within twelve&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">(12) months from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator.  To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Death of Grantee</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  In the event of a termination of the Grantee&#8217;s Continuous Service as a result of his or her death, or in the event of the death of the Grantee during the post-termination exercise periods following the Grantee&#8217;s termination of Continuous Service specified in this Section 8, above, the Grantee&#8217;s estate or a person who acquired the right to exercise the Award by bequest or inheritance may exercise the portion of the Grantee&#8217;s Award that was vested as of the date of termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator, within twelve (12) months from the date of death (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration of the term of such Award as set forth in the Award Agreement).  To the extent that, at the time of death, the Grantee&#8217;s Award was unvested, or if the Grantee&#8217;s estate or a person who acquired the right to exercise the Award by bequest or inheritance does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The holder of an Option shall have none of the rights of a stockholder with respect to the Shares subject to the Option until such shares are transferred to the holder (or the Trustee, if applicable) upon the exercise of the Option.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">9.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Upon Issuance of Shares</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">If at any time the Administrator determines that the delivery of Shares pursuant to the exercise, vesting or any other provision of an Award is or may be unlawful under Applicable Laws, the vesting or right to exercise an Award or to otherwise receive Shares pursuant to the terms of an Award shall be suspended until the Administrator determines that such delivery is lawful and shall be further subject to the approval of counsel for the Company with respect to such compliance.  The Company shall have no obligation to effect any registration or qualification of the Shares under federal or state laws or other Applicable Laws.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">As a condition to the exercise of an Award, the Company may require the person exercising such Award make such representations and warranties  which, in the opinion of the Company, are required to ensure that such exercise, or a subsequent sale or disposition of any Shares obtained upon such exercise, does not contravene any Applicable Law, including inter alia, representations and warranties at the time of any such exercise that the Shares are </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Unless otherwise set forth in an Award Agreement, Shares issued to a Grantee or the Trustee, as applicable, shall be subject to such restrictions as required by the appropriate securities&#8217; law and in the  event  that the  Company&#39;s shares  shall  be  registered  for  trading  in any  public  market, Grantee&#39;s  rights to sell the  Shares  may be  subject  to  certain limitations  (including a lock-up  period),  as will be requested by the Company or its  underwriters,  and the Grantee by executing an Award Agreement unconditionally agrees and accepts any such limitations and undertakes to further execute any agreement as may be requested by the Company or its underwriters from time to time.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">10.</font><a name="_Ref519411969"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments Upon Changes in Capitalization</u><font style="font-weight:normal;white-space:pre-wrap;">.  </font><font style="font-weight:normal;">Subject to any required action by the stockholders of the Company, the number of Shares covered by each outstanding Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards have yet been granted or which have been returned to the Plan, the exercise or purchase price of each such outstanding Award, the maximum number of Shares with respect to which Awards may be granted to any Grantee in any calendar year, as well as any other terms that the Administrator determines require adjustment shall be proportionately adjusted for (i)&#160;any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Shares, or similar transaction affecting the Shares, (ii)&#160;</font><font style="font-weight:normal;white-space:pre-wrap;">any other increase or decrease in the number of issued Shares effected without receipt of consideration by the Company, or (iii) any other transaction with respect to Common Stock including a corporate merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or complete) or any similar transaction; provided, however that conversion of any convertible securities of the Company shall not be deemed to have been &#8220;effected without receipt of consideration.&#8221;  In the event of any distribution of cash or other assets to stockholders other than a normal cash dividend, the Administrator shall also make such adjustments as provided in this Section 10 or substitute, exchange or grant Awards to effect such adjustments (collectively &#8220;adjustments&#8221;).  Any such adjustments to outstanding Awards will be effected in a manner that precludes the enlargement of rights and benefits under such Awards. In connection with the foregoing adjustments, the Administrator may, in its discretion, prohibit the exercise of Awards or other issuance of Shares, cash or other consideration pursuant to Awards during certain periods of time.  Except as the Administrator determines, no issuance by the Company of shares of any class, or securities convertible into shares of any class, shall affect, and no adjustment by reason hereof shall be made with respect to, the number or price of Shares subject to an Award.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.</font><a name="_Ref519415795"></a><a name="_Ref519414809"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Transactions and Changes in Control</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Award to Extent Not Assumed in Corporate Transaction</u><font style="font-size:10pt;white-space:pre-wrap;">.  Effective upon the consummation of a Corporate Transaction, all outstanding Awards under the Plan shall terminate.  However, all such Awards shall not terminate to the extent they are Assumed in connection with the Corporate Transaction.</font></div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceleration of Award Upon Corporate Transaction or Change in Control</u><font style="font-size:10pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Transaction</u><font style="font-size:10pt;white-space:pre-wrap;">.  Except as provided otherwise in an individual Award Agreement, in the event of a Corporate Transaction and:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:144pt;"><font style="display:inline-block;font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">(A)</font><font style="font-size:10pt;">for the portion of each Award that is Assumed or Replaced, then such Award (if Assumed), the replacement Award (if Replaced), or the cash incentive program (if Replaced) automatically shall become fully vested, exercisable and payable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares (or other consideration) at the time represented by such Assumed or Replaced portion of the Award, immediately upon termination of the Grantee&#8217;s Continuous Service if such Continuous Service is terminated by the successor company or the Company without Cause within twelve (12) months after the Corporate Transaction; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:144pt;"><font style="display:inline-block;font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">(B)</font><font style="font-size:10pt;">for the portion of each Award that is neither Assumed nor Replaced, such portion of the Award shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares (or other consideration) at the time represented by such portion of the Award, immediately prior to the specified effective date of such Corporate Transaction, provided that the Grantee&#8217;s Continuous Service has not terminated prior to such date.</font></div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u><font style="font-size:10pt;white-space:pre-wrap;">.  Except as provided otherwise in an individual Award Agreement, following a Change in Control (other than a Change in Control which also is a Corporate Transaction) and upon the termination of the Continuous Service of a Grantee if such Continuous Service is terminated by the Company </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="font-size:10pt;white-space:pre-wrap;">or Related Entity without Cause within twelve (12) months after a Change in Control, each Award of such Grantee which is at the time outstanding under the Plan automatically shall become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value), immediately upon the termination of such Continuous Service.</font></div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Acceleration on Incentive Stock Options</u><font style="font-size:10pt;white-space:pre-wrap;">.  Any Incentive Stock Option accelerated under this Section&#160;</font><font style="font-size:10pt;">&#8206;11</font><font style="font-size:10pt;"> in connection with a Corporate Transaction or Change in Control shall remain exercisable as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section&#160;422(d) of the Code is not exceeded.</font></div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">12.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date and Term of Plan</u><font style="font-weight:normal;white-space:pre-wrap;">.  The Plan shall become effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company.  It shall continue in effect until December 31, 2028 unless sooner terminated.  Subject to Section&#160;</font><font style="font-weight:normal;">&#8206;17</font><font style="font-weight:normal;">, below, and Applicable Laws, Awards may be granted under the Plan upon its becoming effective.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">13.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment, Suspension or Termination of the Plan</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Board may at any time amend, suspend or terminate the Plan; provided, however, that n</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">o such amendment shall be made without the approval of the Company&#8217;s stockholders to the extent such approval is required by Applicable Laws, or if such amendment would lessen the stockholder approval requirements of Section&#160;4(b)(vi) or this Section 13(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No Award may be granted during any suspension of the Plan or after termination of the Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No suspension or termination of the Plan (including termination of the Plan under Section&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8206;11</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, above) shall adversely affect any rights under Awards already granted to a Grantee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">14.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Shares</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company, during the term of the Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">15.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Effect on Terms of Employment/Consulting Relationship</u><font style="font-weight:normal;white-space:pre-wrap;">.  The Plan shall not confer upon any Grantee any right with respect to the Grantee&#8217;s Continuous Service, nor shall it interfere in any way with his or her right or the right of the Company or any Related Entity to terminate the Grantee&#8217;s Continuous Service at any time, with or without cause, including but not limited to, Cause, and with or without notice.  The ability of the Company or any Related Entity to terminate the employment of a Grantee who is employed at will is in no way affected by its determination that the Grantee&#8217;s Continuous Service has been terminated for Cause for the purposes of this Plan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">16.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Effect on Retirement and Other Benefit Plans</u><font style="font-weight:normal;white-space:pre-wrap;">.  Except as specifically provided in a retirement or other benefit plan of the Company or a Related Entity, Awards shall not be deemed compensation for purposes of computing benefits or contributions under any retirement plan of the Company or a Related Entity, and shall not affect any benefits under any other benefit plan of any kind or any benefit plan subsequently instituted under which the availability or amount of benefits is related to level of compensation.  The Plan is not a &#8220;Pension Plan&#8221; or &#8220;Welfare Plan&#8221; under the Employee Retirement Income Security Act of 1974, as amended.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">17.</font><a name="_Ref519414781"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Approval</u><font style="font-weight:normal;white-space:pre-wrap;">.  The grant of Incentive Stock Options under the Plan shall be subject to approval by the stockholders of the Company within twelve (12) months before or after the date the Plan is adopted excluding Incentive Stock Options issued in substitution for outstanding Incentive Stock Options pursuant to Section&#160;</font><font style="font-weight:normal;white-space:pre-wrap;">424(a) of the Code.  Such stockholder approval shall be obtained in the degree and manner required under Applicable Laws.  The Administrator may grant Incentive Stock Options under the Plan prior to approval by the stockholders, but until such approval is obtained, no such Incentive Stock Option shall be exercisable.  In the event that stockholder approval is not obtained within the twelve (12) month period provided above, all Incentive Stock Options previously granted under the Plan shall be exercisable as Non-Qualified Stock Options.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">13</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">18.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unfunded Obligation</u><font style="font-weight:normal;white-space:pre-wrap;">.  Grantees shall have the status of general unsecured creditors of the Company.  Any amounts payable to Grantees pursuant to the Plan shall be unfunded and unsecured obligations for all purposes, including, without limitation, Title&#160;</font><font style="font-weight:normal;white-space:pre-wrap;">I of the Employee Retirement Income Security Act of 1974, as amended.  Neither the Company nor any Related Entity shall be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations.  The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder.  Any investments or the creation or maintenance of any trust or any Grantee account shall not create or constitute a trust or fiduciary relationship between the Administrator, the Company or any Related Entity and a Grantee, or otherwise create any vested or beneficial interest in any Grantee or the Grantee&#8217;s creditors in any assets of the Company or a Related Entity. The Grantees shall have no claim against the Company or any Related Entity for any changes in the value of any assets that may be invested or reinvested by the Company with respect to the Plan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">19.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</u><font style="font-weight:normal;white-space:pre-wrap;">.  Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan.  Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.  Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">20.</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Israeli Grantees</u><font style="font-weight:normal;">. This Section shall apply only to Israeli Grantees and is intended to enable the Company to grant Awards under the Plan pursuant and subject to Section 102 and Section 3(I) of the Tax Ordinance. Accordingly, the Plan is designated to comply with the Tax Ordinance and the rules, regulations and orders or procedures promulgated thereunder from time to time, as amended or replaced from time to time and shall be submitted to the ITA as required thereunder.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:normal;">In any case of contradiction, whether explicit or implied, between the provisions of this Section and the Plan, the provisions set out in this Section shall prevail unless the Administrator decides otherwise to ensure compliance with the Tax Ordinance and other Applicable Laws.</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Eligibility</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. 102 Options may be granted only to Israeli Employees. Non-Employees may only be granted 3(I) Options. The grant of an Award hereunder shall neither entitle the Grantee to participate nor disqualify the Israeli Grantee from participating in, any other grant of Awards pursuant to the Plan or any other option or stock plan of the Company or any Related Company.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Awards in Trust</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grants Made Under Section 102</u><font style="font-size:10pt;">.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:146.4pt;margin:0pt 2.45pt 10pt 0pt;">The Company may designate 102 Options as Trustee 102 Options or Non-Trustee 102 Options. The designation of Non-Trustee 102 Options and Trustee 102 Options shall be subject to the terms and conditions set forth in Section 102 of the Tax Ordinance and the regulations promulgated thereunder.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Trustee 102 Options</u><font style="font-size:10pt;">.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(1) The grant of the Trustee 102 Options shall be made under the Plan and shall be conditional upon the approval of the Plan by the ITA. Trustee 102 Options may be granted at any time after the passage of thirty (30) days following the delivery by the Company to the ITA of a notice pertaining to the appointment of the Trustee and the adoption of the Plan, unless otherwise determined by the ITA. Options which shall be granted pursuant to Section 102 and/or any Shares issued upon exercise of such Options and/or other shares received subsequently following any realization of rights, shall be issued to the Trustee. Each Israeli Grantee in respect of whom a Trustee 102 Option is granted and held in trust by the Trustee shall be referred to as a &#8220;beneficial optionee&#8221; hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(2) Trustee 102 Option(s) may either be classified as Capital Gain Option(s) or Ordinary Income Option(s):</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:170.1pt;"><font style="display:inline-block;font-size:10pt;min-width:45.9pt;text-indent:0pt;white-space:nowrap;">(A)</font><font style="font-size:10pt;">Trustee 102 Option(s) elected and designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) shall be referred to herein as &#8220;Capital Gain Option(s)&#8221; or &#8220;CGO&#8221;.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:170.1pt;"><font style="display:inline-block;font-size:10pt;min-width:45.9pt;text-indent:0pt;white-space:nowrap;">(B)</font><font style="font-size:10pt;">Trustee 102 Option(s) elected and designated by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) shall be referred to herein as &#8220;Ordinary Income Option(s)&#8221; or &#8220;OIO&#8221;.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">14</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(3) The Company&#8217;s election of the type of Trustee 102 Options as CGO or OIO granted to Employees (the &#8220;Election&#8221;) shall be appropriately filed with the ITA 30 days before the date of grant of a Trustee 102 Option, unless otherwise determined by the ITA. Such Election shall become effective beginning the first date of grant of a Trustee 102 Option under this Plan and shall remain in effect until the end of the year following the year during which the Company first granted Trustee 102 Options. The Election shall obligate the Company to grant only the type of Trustee 102 Option it has elected, and shall apply to all Israeli Grantees who were granted Trustee 102 Options during the period indicated herein or therein, all in accordance with the provisions of Section 102(g) of the Tax Ordinance. Notwithstanding, such Election shall not prevent the Company from granting Non-Trustee 102 Options simultaneously.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(4) All Trustee 102 Options must be held in trust by and issued on the name of the Trustee, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(5) With respect to Trustee 102 Options, the provisions of the Plan and/or an Award Agreement shall be subject to the provisions of Section 102 and the ITA&#8217;s permit, and the said provisions and permit shall be deemed an integral part of this Section and of the Award Agreement for the respective Grantees thereof. Any provision of Section 102 and/or the said permit which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in the Plan or the Award Agreement, shall be considered binding upon the Company and the Israeli Grantee.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance to Trustee</u><font style="font-size:10pt;">.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(1) All Trustee 102 Options granted under the Plan and/or any Shares allocated or issued upon exercise of such Trustee 102 Options and/or other and all rights deriving from or in connection therewith, including, without limitation, in accordance with Section 10 above or any bonus shares or stock dividends issued in connection therewith shall be granted by the Company to the Trustee, and the Trustee shall hold each such Trustee 102 Option and the Shares issued upon exercise thereof in trust for such period of time as required by Section 102 or any regulations, rules or orders or procedures promulgated thereunder (the &#8220;Holding Period&#8221;), for the benefit of the Grantees in respect of whom such Trustee 102 Option was granted. All certificates representing Shares issued to the Trustee under the Plan shall be deposited with the Trustee, and shall be held by the Trustee until such time that such Shares are released from the Trust as herein provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(2) In event the requirements for Trustee 102 Options are not met for any reason whatsoever, then the Trustee 102 Options may be treated as Non-Trustee 102 Options, all in accordance with the provisions of Section 102 and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(3) With respect to any Trustee 102 Option, subject to the provisions of Section 102 and any rules or regulations or orders or procedures promulgated thereunder, an Israeli Grantee shall not be entitled to sell or release from Trust the Trustee 102 Option, the Shares received upon the exercise of such Option and/or any<u style="border-bottom-style:solid;border-bottom-width:0.5pt;color:#0000ff;text-decoration-line:underline;text-decoration-style:double;"> </u><font style="white-space:pre-wrap;">right deriving from or in connection therewith, including, without limitation, in accordance with Section 10 above or any bonus shares or stock dividends issued in connection therewith, until the later of: (i) the lapse of the Holding Period required under Section 102, and (ii) the vesting of such Options set forth in the respective Award Agreement (such later date being hereinafter referred to as the &#8220;Release Date&#8221;).  Notwithstanding the foregoing, if such sale or release occurs during the Holding period, the provisions of Section 102 and the rules or regulations promulgated thereunder shall apply and any expenses and/or tax consequences therefrom shall be borne by the Israeli Grantee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(4) Subject to the terms hereof, at any time after the Release Date with respect to any Trustee 102 Options or Shares the following shall apply:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:170.1pt;"><font style="display:inline-block;font-size:10pt;min-width:45.9pt;text-indent:0pt;white-space:nowrap;">(A)</font><font style="font-size:10pt;">Trustee 102 Options granted, and/or Shares or rights issued to the Trustee shall continue to be held by the Trustee, on behalf of the beneficial optionee. From and after the Release Date, upon the written request of any beneficial optionee, the Trustee shall release from the Trust the Trustee 102 Options granted, and/or the Shares or rights issued, on behalf of such beneficial optionee, by executing and delivering to the Company such instrument(s) as the Company may require, giving due notice of such release to such beneficial optionee, provided, however, that the Trustee shall not so release any such Trustee 102 Options and/or Shares and/or rights to such beneficial optionee unless the latter, prior to, or concurrently with, such release, provides the Trustee with evidence, satisfactory in form and substance to the Trustee, that all taxes, if any, required to be paid upon such release have, in fact, been paid.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">15</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:170.1pt;"><font style="display:inline-block;font-size:10pt;min-width:45.9pt;text-indent:0pt;white-space:nowrap;">(B)</font><font style="font-size:10pt;">Alternatively, from and after the Release Date, upon the written instructions of the beneficial optionee to sell any Shares and rights issued upon exercise of Trustee 102 Options, the Trustee shall use its best efforts to effect such sale and shall transfer such Shares to the purchaser thereof concurrently with the receipt, or after having made suitable arrangements to secure the payment, of the purchase price in such transactions. The Trustee shall withhold from such proceeds any and all taxes required to be paid in respect of such sale, shall remit the amount so withheld to the appropriate tax authorities and shall pay the balance thereof directly to the beneficial optionee, reporting to such beneficial optionee and to the Company the amount so withheld and paid to said authorities.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:170.1pt;"><font style="display:inline-block;font-size:10pt;min-width:45.9pt;text-indent:0pt;white-space:nowrap;">(C)</font><font style="font-size:10pt;">Notwithstanding the foregoing, in the event the underwriters of securities of the Company impose restrictions on the transferability of the Shares during a lock-up period, the beneficial optionee shall not be entitled to release from Trust the Trustee 102 Options granted and/or the Shares issued and/or to instruct the Trustee to effect a sale of same, for as long as the restrictions are in effect. In the event the Trustee 102 Options granted and/or the Shares issued have been released from trust the restrictions imposed on the transferability of same shall nevertheless apply to said optionee&#8217;s Trustee 102 Options and/or Shares in the same manner. Consequently, the Israeli Grantee shall sign any documents required in order to effect the restrictions, for as long as the restrictions are in effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:170.1pt;"><font style="display:inline-block;font-size:10pt;min-width:45.9pt;text-indent:0pt;white-space:nowrap;">(D)</font><font style="font-size:10pt;">Upon receipt of the Award, the Israeli Grantee will sign an undertaking to release the Trustee from any liability in respect of any action or decision duly taken and bona fide executed in relation with the Plan, or any Option or Share or rights granted to same thereunder. The Trustee may establish additional terms and conditions in connection with Awards held in trust by the Trustee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Non-Trustee 102 Options</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(1) Awards granted pursuant to this subsection are intended to constitute Non-Trustee 102 Options and shall be subject to the general terms and conditions of the Plan and Section 20, except for provisions of the Plan applying to Trustee 102 Awards or Options under a different tax law or regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(2) With respect to Non-Trustee 102 Options, if the Grantee ceases to be employed by or of service to the Company or a Related Company, the Grantee may be required to extend to the Company a security or guarantee for the payment of tax due at the time of sale of Shares or other rights, all in accordance with the provisions of Section 102 and the rules, regulation or orders promulgated thereunder.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grants Made Under Section 3(I)</u><font style="font-size:10pt;white-space:pre-wrap;">. Awards granted pursuant to this subsection are intended to constitute 3(I) Options and shall be subject to the general terms and conditions of the Plan and Section 20 thereof, except for said provisions of the Plan applying to Awards under a different tax law or regulation. The Administrator may choose to deposit the Awards granted pursuant to Section 3(I) of the Tax Ordinance with a trustee. In such event, said trustee shall hold such Option in trust, until exercised by the Grantee, pursuant to the Company&#39;s instructions from time to time.  If determined by the Administrator, the trustee shall be responsible for withholding any taxes to which a Grantee become liable upon the exercise of Options.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Without derogating from the powers of the Administrator under the Plan, the Administrator shall adopt the form of Award Agreement for Israeli Grantees in form acceptable by the ITA and in compliance with the Tax Ordinance. The Award Agreement shall further indicate the type of Options (102, 3(I), Trustee, Non-Trustee etc.) granted thereunder.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Without derogating from the terms of any Award Agreement or the discretionary authority of the Administrator, the standard vesting for Options to Israeli Grantees shall be as follows:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:10pt;">Twenty five percent (25%) of the Options granted under each Award Agreement shall vest on the end of the first year of Continuous Service following the vesting commencement date determined by the Administrator and if not specified the date of the grant of an Option (the &#8220;First Anniversary&#8221;); and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;text-indent:108pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:10pt;">The remaining 75% of the Options shall vest on a quarterly basis over a period of three years commencing as of the First Anniversary in twelve (12) equal portions subject to Continuous Service of the Grantee.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to all Shares (in contrast to unexercised Options) allocated or issued upon the exercise of Options by the Israeli Grantee, the Grantee shall be entitled to receive dividends in accordance with the </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">16</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quantity of such Shares, subject however to any applicable taxation on distribution of dividends. Subject to the Tax Ordinance and any restrictions imposed by the Trustee or the ITA, during the period in which Shares are held by the Trustee on behalf of the Israeli Grantee, the cash dividends paid with respect thereto shall be paid directly to the Grantee after deduction of withholding tax applicable thereto.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:14pt;font-style:italic;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Without derogating from anything in the Plan, to the extent permitted by Applicable Laws, any tax consequences, attributable to the Israeli Grantee, arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act (of the Company, a Related Company, the Trustee or the Grantee), hereunder, shall be borne solely by the Grantee. The Company and/or or a Related Company and/or the Trustee shall withhold taxes according to the requirements under the Applicable Laws, rules, and regulations, including withholding taxes at source. Furthermore, to the extent permitted by Applicable Law, the Grantee shall agree to indemnify the Company and/or a Related Company and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Grantee. The Administrator and/or the Trustee shall not be required to release any Share certificate to a Grantee until all required payments have been fully made.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Plan, to the extent applicable to Israeli Grantees, shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to Israeli Grantees.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:21.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:center;margin:2pt 0pt 6pt 0pt;">17</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>plx-20230630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/7/2023 10:12:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;7, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>plx-20230630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/7/2023 10:12:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;7, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>plx-20230630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/7/2023 10:12:33 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;7, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>plx-20230630xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/7/2023 10:12:33 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;7, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20230630x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230630x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ',!#@# 2(  A$! Q$!_\0
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M_P"%'U*?=!_Q$7+O^?,__)?_ )(_1NBOSD_X:#^(O_0VW_YK_A1_PT'\1?\
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M+O\ GS/_ ,E_^2/T;HK\Y/\ AH/XB_\ 0VW_ .:_X4?\-!_$7_H;;_\ -?\
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M3_AH/XB_]#;?_FO^%'_#0?Q%_P"AMO\ \U_PH^I3[H/^(BY=_P ^9_\ DO\
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M@ Q3QR _W6!KYLU+PUK?AV-9=0L(A"0#YF]?3)Z^E/U#1&TR&TDU1ETLW?\
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MQ'JSQASY5OF)3QD9SSUKYG\:^$KSP-XHU#0[XJUQ9R%"Z]&'9A]17UZ/VIO
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MZBDK6<J$,(/(EB/S'JV'%0^+?BE\$?$-U>>)K[2KK6-;N(0GV257 W*#C^(
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M;J:$2),(W9/,C.5;!QD>QK[*T3]ICP1X?TY9D\0ZWJ$*0"-=,O8%D<,.G[S
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M4_V:?&_C?Q_K.N:9;V3V%Y*KQ-)=!6("*O([<@URO_#'WQ%_Y]=/_P# Q?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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MYRM^G^78OU?]:+_@_P!;]%J_Q@T/1H[.:4RR6UQIC:J9HP"(X045<\]79PH
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MZ<YKU3XRE%T*PA)P1 M<Q\'$_MKQ3XG9;1K58C'E7'))+9)J[\9[W?-80@Y
M@(_(UHM82;,W\22/---U6/37 >S-Y;I(LK1L^U'*O'@'@\9QGVS7J'B#Q!YN
MC>$0BAY)M0N/ND]44@G\3G\Z\HL65=-;>ORF[0LW<*&0D?Y]*V+:_D70/ARZ
MG>&NM0()/4[R*\Z3_=RCY'HTE[T7YFM'K#C5/G+?.RGGW\NN^^)M]N^-$5R6
MS';0$C:,D,X1$_,N?RKQQ]6-QJ5GG'^JMNG^T4KMOC#XP7X??$W3-2=E>6^O
M[<&%^@MXPH8GUR6/_?->=@>5TYN6R:9ZF*E/VD%'=IH] ;QA;6%[XHGNXC(U
MS>M#'\N=K[;<9]NAYKQC1M0G;4XOEW21E(\[L?=&T?RKH=0UD7R7TP95$FKR
M@KZ8D1<?DM<!HVI>1K-H0V2]Z(S^;5ABZ[>*C'HG^EPPM-*A*7D'C76'M? G
MB D[1?:[<$#V#9_Q_*M;X^R!?V?_  CCC)M>_P#TRKSSXP7[V.@>'8"P6&YE
MN[IE/4DN"#^3BNS_ &@Y/+^ _@\$YRUMC/;]U77337M8OI#]0DT_8R765_P/
M$_"2_:M>N8CRIBA8CU N$8_H*WOAY*NI?%JS;DI+)*>>>"&K"\$7T&FR>(;V
MX4LZ:;LA [R-*H7\LY_"MCX1R_9/&J7[1[A;VDT@SP Q4JI_[Z=?SKS:4;.F
MK=3MK5-*K^1FZNP&O>(/+/R+&=OT\Y?\:N>&YF:+PRO4"2^'YJE9.H3)_:/B
M!@RDF+'!Z?OXZM>'7*2:  W2XN>GNL=7%-3NO/\ ,4ZGN_=^1WVGZCL_9_U^
M7=R)9!]/WZ"HY_$+S_LX0.6)/VY0#]'K$CN2/V9]?D!&//D!/_;RE9/VW_C&
MRS7/)U$#]6_PKU/9VDI?W3SHU;QM_?.!@U!O['O!NX>?)_[YK]EOV+CN_9:^
M'!]=,'_H;U^*D$A.DR#^](Q^M?M5^Q7_ ,FL?#?_ +!8_P#0WHP$;5I/R#'U
M.>DO4]EDZ5C:E]QOH:V9.E8VI?<;Z&O?/"-32/\ D&P?0_S-7*IZ1_R#8/H?
MYFKE !16+K'C30?#^L:9I6I:M:66I:FQ2RM9I0LD[#J%'>MJCS **\G^,/QD
MOOA;XL\)VXT^*[T._,SZG-M8S6T2!?WJX.,*6!;(/&?2M.X^*T6G?$#5=.O9
M[.'PY9Z'#JHO<$N2\K+US@J0!@ 9R>IH6NOK^&H/3\/Q=CT6BN;\,^/])\57
MLUE;?:K6_BC$S6E_;/;RF,G <*X!*D]Q63XG^+>B:!K.J:$9KD:O8V0O9FCT
M^6XBMHF#E9)-F!M^1N-P/;(S0]-QI7.ZHK@H/C%H,<=C%)<W&HW,EG;W<\VG
MZ?*T<*2CY'D W&(-@D!B3@=36=X?^,4<_B;Q=INK^3&NGZW%I6FQV<+M-<!K
M:&4EER<D&1LD   #/K3L[N/];I?FR;Z7_K:_Z'IU%97B3Q/IWA/3#?ZE,88-
MZQH%4N\CL<*BJ.68GH!7G'Q$^/-OH/@FZU+0K>>?5H[Z#3GM;O3YF>TDE9=K
M30@J^,'(&5W' !YI>A1ZY16%)XCBT/3=';6;@"XOI8K42QVSQ(TS@X!0LQC!
M(QAF."0,YK$UGXGZ59>(['3(]3C@D.H-83QR6,DOFR"V:<QI(&4(0H#%B&'!
M7 )R#^OR_P U]XNG]?UT.XHK@-.^-_AC5M&AU.U;4)+6YE$%I_H$H>\<ACMA
M7;F0@(Q.WIBLS4_C/'=:SX&@T)8Y;76=;FTF_2]@DCGMREM-*5"DJ4?=&OW@
M>">.]-*[L'2_]:?\,>I45@^*_&NF>#DM/M[3R7%Y(8K:TM(&GGG8#<P1%!)P
M 2?05DS_ !=\/Q6]D\9OKN>[B:9;.VL99+A(U.&9XPNY #QDCK2 [2BN$NOC
M5X7@GLX+>XNM3GN[(ZA!%IUI)<,\(;:6 4'H>HZBJ#_&S3[GQCX3TO3;::_T
MO7;*>\74HH7*1A"H&3C 'S'<3]W SUH_K\_\F&W]?UW/2J*XS0_BWX=\0ZK;
M6%K+=*]W$\]G-/:R1PW:*,LT+L,. "#QVK'TS]H7P?K$6GR6<FI3+J4;26!7
M39O],V_>6+Y?G8=P.: /2Z*\_P#^%OZ'=MHUY;:JB:?>0W<S026,K3-]G'[P
M;MP\ID((*LI)/ Q5CPY\9?"_BB>SCM+FXB2]M#?6D]W:R017$(4,S1LP ; (
MSCI1_7Y_Y,#N**X&+XU>'KM6%LM_*\EI)>6>ZRE1;Z-5W$P,5Q)P0?ESP:Q/
M!OQTL?$&A^&=7U2XCT)-2T>34Y[*ZLI5("A"SI,6 "#?@94[\@@BCO\ UW_R
M8?U^7^9ZS17"GXS^&8K'4+JZFN]/2QM3>R1WMG)#(\ ('FHK#+KR.16AX:^)
M>B>*M7?3+1[J&]%N+N.*\M7@,T)./,CW ;USCD>HH ZJBO(O%/QLE\/_ !6O
M- F0V&@Z/I U;4KR;2YIVE5F8 1R*ZJ@ 7[Q5]QRH (-=(/C'X?:SLYUCU-Y
M+P,]O:+ITQN)8U"DRB/;N\OYE^;&.:%JK_UV_1@]'9_UI?\ 5'<T5P=_\;/"
MMD^EHES=7\NIVDM[:Q6%I).\D43*LAPH."I89!YZ^E3>'/C%X8\5:CIUGI]U
M.YU*-Y+*>6VDCAN=@RZH[ !F4=5ZC!]*=K_U_78-CMJ*Y+Q9\3]#\&ZU9:1?
MF[EU.]MIKNWM;.TDG>2.(J)" @/3>OX9]*J>'_C-X6\3W^G6MC=SG^T8Y'LY
MYK:2.&X*#+JCL "RC)*]1@^E):[?U_5@>FYW%%<38?&#PUJ.K6EA'/<HUZ9!
M9W,MK(EO=&-2SK%(1M<A58X!Z UF6?[07A"_:Q$$NH2'4%D-CC3IO],*??2'
MY?G8<DJ.< T >DT5P4OQM\+);Z/)'/=W,NK>>MI;6]G)),[P_P"M0H!D,OH>
M>#3M!^-?A7Q)?:;:V5U<DZA(]O;RS6DD<33H"7A+L !( K?*>>#3M<-M3NZ*
MXP_%SPX-;ATWS[G,UW]@CO/LLGV5KC./*$V-N_(QC/7BN7\&_&<ZM< :W?:?
MI@%WJL9A6TDP\%I)M\SS3)M3"\MD'.>-N*2U_K^NXVK?UZ_Y'K=%<'%\:_##
M07TTLM[9QVEA)J9-U92Q>=;(,M+%N7]X,?W<]15WPQ\4] \6ZG#86,MRMQ/;
M"\MOM5K)"MS"<?/&6 #CD9QZT[/;^OZT?W"\_P"OZU7WG7T5ROBCXE:+X1OU
MLKPW<]UY7VB2*RM)+@PQ9QYC[ =JY[GTJOK?Q:\.:#>2V]Q<7$GD1)-=36]K
M)+%:QN,JTS*,1@CGYNU+<#LJ*X#7OCCX3\.:CJ-I>75R3IR0R7D\-I))#;QR
MKN1W=00%(/7-/E^-GA6UL=7N[JYN;*+2H8[FX%S:21N87;:DJ*1ET)_B'% '
M>45Q^F_%;P[J,>H.]Q-I_P!AM_M<JZC;O;MY':50X&Y#TR*K+\9O#*V=_<W,
MUW8+9VIOG2]LY(7DMP0#+&K %UY'(SUH>@;G<T5Q>D_%WPUJ]S<P"YGLGAL_
M[0_T^V>W$MMG!E0N!O49&2/4>M,@^,?AJ2SO[F6:ZLDL[1K]EO+22%Y+<=98
MU8 NO(Y7/44/3<%KL=O17FVH?';08](U:XL8KV>^M--?5(+2:SEB:[A'&^/*
M_.N2H)&<9%/TOXW:-<:1I4]U;Z@NH7=A'J$]G;V$TCVT3Y >0!250D-@GKBG
M;^OO_P F']?E_FCT:BH[>=+J".:)MT<BAU.,9!&14E( HHHH **** "BBB@
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MJ7O-W_JW+_\ (H\,\$_"3Q!X<\7^'=0NHH7BBTK5ENVBF!6&XNKF.9(E!Y(
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MP]\1?%?[7J%UIX\--%HATZTM[FX24W$S2QREF,18"+]TH&?F.YB5&,&O\0/
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M_5_D>4:?8M C2%XY(W"8:-LC()./6DA0YF4<EK4\?5A52R<VPG;8Q4F%5;'
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MF!8 =3]![5X7X(\->(O#FE_#R230;UI[:QU:R,,EN^V&667,*R@#,:,%^\<
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M&VF5G"KGMGN1CTS6KH'CC2=?\%VOBB.[BATF:V^U-.[C9$H'S;FZ?+@@_2O
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MJBV>NZG;7'C*QOY)=6MDAD,<<,BM.UND,?DJ&V\L,G@G'%$5S-)Z:KY7Y?\
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MKB2-8D)4N< F6,9Q^-<2=)2C8WG&HHMZ&??>=<:OJK)!)(0=HVJ3GGM^5/\
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M.^%XX_$$$R,LEFMH]R6C8'&0,CZYSQ7)1O.I/U-JEH0@_(WO"MG% JV>%DD
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MHZ-T8'J#5.3<G+O?\;_YD)))1?0\]^-D$WBSX,ZPNCV\^HR7EO&]O%!"S22
MLI&$QGISC%>;:KX)U:3X>_&&)-#NVO\ 4-566T46K&6X58H-K)QE@"&P1T(-
M?1L,*6\211($C10JJHP !T I]+9NW7_-/]!W>E^AXIX;67P?XB\6V>O^&M4U
MV;6=1AO+%[;3&N8IHO*C55>4_NXC&RMQ*R>JYS7(V'AW6O#GBG0O$=WH>J/I
MNF^+=6GN5MK*2:=89X'CCE6)%+NA8@$H#C.>F2/IFBA-K7RM^7^0K:6_K9_Y
MGS/X0TS6=*UZQ\6:EX=UD:-;^(-5FEL?[/>2YB$Z*(;H0 %W VLOR*2!)G&
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M><'BO1:**38!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I/[U?[O,IJS:\VON=CZG%Q$P)$B$#J0PJ'4;UK&SGFCMY+V6)-XMH&02/[
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M ,N>,4/2_E_]M_\ (_B$=4GW_P#M?_DOP/KEYXX_OR*O^\P%97_"5Z:?%/\
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M?18S+;V\2D*QNNK=!Q6IXZL_MGQ>U2'(7S($!8]OEK*M$^SV4;AE<BXR0.V
M:\#$Q?UB[VU_]*1Z-+^ K>1Z#X#@EN+V-I@/^/2X4E>G"X%><OXPA^'/B7_A
M'Y8@USK @D7!)V OC''?BO<OAO%_;?@^75C;"$7&F2+D# 5N5_I7AWBWPM<Z
MK\<?"$?]GF8)8VLCW6W.P*,GG\*^PA1C>,I;GS?M79Q07PT"R^*]_);1W<FH
MVGF@VTN#$"R#)/?!]*V_@S%>^.Y5?4].GCEMVD\MS:F**.($;57(_E3[KX>:
MKXO^).H:G8316L'VGS9)YU)\QL *H [ "OJ/PCI7D:9 DP1IE4!V5=H8^PK9
MRYMC-=R?P9X?:)$+J0  !FO6-&L2B*. /:N<T>V ('2NVTZ$+&!CBFE83=R&
MZA X!.:QI+4>;D\FN@NP,D;<$BLN2+G^M5<13G7]V1P,5E36JN>.E;4T7R^_
MK58P9S6;0T8K6 'ICWJ"2P!4Y K>>V![57DMQSZU+07.;O\ 2(-2TR>RF7<K
MJ1GZBO(-:^#TUOY@@U&]=\C:6D)^6O=IK?CC@UCW=O('R>E0T4CY$\0Z%J'A
MSQUX=>!9);BTNA* [X).Y>??I73:]IW@6V\57WB2_OIY8[6U8O8^7L985R6W
M>@SGIZ5Z-<?"Z:X\<'Q!<:G),D3EHK9UR%''&?3(S7S7\2-3FT[Q9X_V,J/'
MHGF)N&0<.1S[4G!3CRM%*3B[H]%GO=1\3ZKI&JF-+BQDOH3;M:L'BC@'W  .
M0,8ZT_X/6\1^-'Q1GDX+&&%?J<'^E>,? GQ-+8>(='LC*\B:C*)$C;=\G[S&
M5]N#@>U>U>$]=FT#Q!XWNDD202^(["T.$!P) P(YZ=*YZ=%TI-ON=,JJFK6\
MB#XD1#_A)4R?^6:+GV*M_C7"+8-=HD$:&222>-451R20P _,UZ%\18R/$X1L
M_P (_0UJ?##0K31M+OO&6KK_ *+IC_Z'&_2>XP=H'J!D5\AB*3JXJ4>FOZ'T
MM"?L\/%K>R,CXM7,GP\\+:#\.(BGVB<KJFK2(V<RL<)&/8!1^0]:B_:8NI[6
M_P#!TMO*T4R12LCH<$'"<BN#\6ZK>>)/%<6IWS^9=W3>;(Q]3*_ ] ,8_"NW
M_:4;??>$5SR+>8_^@UZ*J)T*O)LDK>AAR<M:DI;MML\AT^:<0_:UE=+K^T78
M2JQW!EC0YS]374:#-]EN;YY+AGU"2ZMQ<2DY^]YAV_7@Y/O6!HJ#^R()<X/]
MI7'/TB@_QI]D9(=/UN1@5D6]M&#>^V<C^5>?";C)2\CJJ14ERE;4+96N-9P"
M0;I""1CC$E9^JIMMH@.GV;G_ +ZK9U*Y%S<:E<A01/+$YQVR'_Q-96M ?9UV
M?,!;@9_X$*UO[VGD8RVMZC_VA+,0^#/""@$;G?(_[9K_ (U:N=+^U?$KP]&1
M\D%BLK?\!)(_4"G_ !X26\\.^#(T7?F608R.!LBK>OH!9^.[ZZ.$2ST-F#-P
M,\FOJ+727H> MOO//;[4C<ZEJ,Z2DF2Z\P+CJ3TK]IOV1F9OV;? )?[W]G#.
M?]]J_$>/ L&F"Y(;?NS["OVW_9%.?V;/ )_ZA_\ [.U<&"=ZU1G7BE:$3UB3
MI6-J7W&^AK9DZ5C:E]QOH:]L\PU-(_Y!L'T/\S5RJ>D?\@V#Z'^9JY0 4444
M %%<YXD^(?A[PCK.BZ5J^I)97^LRF"PA>-SYSCMD @?\"(J?5?&^B:)XCTG0
M;V_2#5]5#FSM2C%I0@RQR 0,>Y%&X;&Y6-XI\+VWB[3/[/O)[F*S9@9HK>0(
M)U[H_!RI[@8K8)P,U7T[4(M4LHKJ%9DBD!*BX@>%QSCE' 8=.X% $T4201)'
M&H5$ 55'0 =!3ZIS:Q96^J6VFR7427]RCRPVY;YW1,;F ]!N&3[BK,L@BC=V
M#%5!8[5+'\ .3]!1YA;H/HJ"RO(]0M(;F)95CE4,HFB>)P#ZHX#*?8@&IZ "
MBBB@ HI"<#-9OA[Q)IOBK3OM^E7(N[3S'A\P*R_.C%6&& /!!% &G115&XUR
MQM=16PDN4^W- ]RMLN6D:-2 S!1R1D@?4T 7J*@LKN._M(;F(2K'*@=1-$T3
M@'^\C@,I]B 14] !1110 4444 (1D$=*I:)H]MX?TFUTZS4I;6Z!$#')/J2>
MY)R2?>KU% !115/2=8LM=L5O-/N8[RU9G19HFW*2K%6 /LRD?A0!<HHHH **
M** "BBJ5QK-C::G9Z=-=11W]XLCV]NS?/(J8WD#T&Y<GW'K0!2M_".GVOB^\
M\2H)/[3N[2*RD)?Y/+C9F7 ]<N>:VJ*0D $DX H#K<6BJ>E:O9:Y9)>:?<QW
MEJY95FB;<I*DJ<'V((_"KE !116=XB\0Z?X3T*_UG5KD6>F6$+7%S<%681QJ
M,LV%!)P/04!OHC1HJI<ZI;VNEOJ#>;+;+%YW^CP/*[+C/RH@+,<=@"?:K*.)
M$5AD!AD;@0?R/2@5[ZCJ*S-/\2:;JFKZGI=K="6_TTQB[A"L#$77<G)&#D<\
M$UIT#"BBB@ HHHH Q+GPCI]UXPLO$KB3^T[.SEL8B'^3RY&1FR.YRB\UMUF:
MOXDTW0KO3+:^NA;SZE<?9;1"K'S9=I;;P#CA2<G XK3HZ6_KO^H=?Z]/T"BF
MR.(T9SDA1D[02?R')K&TGQEI.M:O-I5K<2?VE!;17DMK-;R0R)%(65&8.HQD
MHW'7CD4 ;=%8FO\ C/2?"\%W/JL\MG;6B1R2W#VTIB =]B@.%*L=W5021D$@
M BI9/%6EP2PQ3W!M9)[O[#"MU$\)GFVEML>\#?PK'*Y& >>#0!K4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KWBZ:?2[G35U#35ABGNHRJAB_W.1R17WKJ%@ V-N<U\Z_M$^$_&/B2&73M
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MP7UZ77;V]US5=4:6YAGOWE1Y!;R^9MB+%8_+8[?D"]<')JUI'C745^&WPO\
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MS D2I"=HP1PVU<@].,UV6B^//$$WB6V\%7&H-)KUIK,QN[HPH#+IP!EB;&W
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M^?X<W_R+!*[MUT_'E_\ DD?4E4[_ %FPTIH5O;ZVLVFW>6+B94+[5+-MR><
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MRL&)"X4G)R5('J0?2M*O+?A1I9^('@3P?XJ\0W4NHZV]C"\DHVI&[JS-N"*
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M9.W#?+GC%1R?![PK+IJ6;6=V=ES]L6\_M.Z^V";;LW_:O-\[.WY?O]..E'_
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M=;_BV_U7J>1^&_B!XQ_X1SPKXHO?$DE\FH^(9=(FTMK.W2 P?:I8E;<J"3S
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MZ 7D_P#\731^S]X"!S_87/\ U^3_ /Q=>B44[L+(\_7X"^!4.1H0SZ_:IO\
MXNIU^"?@Q  NC8QZ7,W_ ,77<T47861Q)^#'@XG/]D'_ ,"IO_BZ8WP3\&-U
MT;_R:F_^+KN:*+A9'"_\*1\% Y_L;G_KZF_^+KK])TJUT/3H+"RB\FU@79''
MN+;1]22:MT4@L,<55GBW U<(S3&3.:!F?#</9DKM+H3TSTI7UH+_ ,L'_,58
M>W!YP/RJNUH#V'Y4 ,_M\?\ /N_YBD_X2 ?\^[_F*4V(]!^5)]B'H/RH /\
MA(!_S[O^8H_X2 ?\^[_F*/L0]!^5'V(>@_*@ _X2 ?\ /N_YBC_A(!_S[O\
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M'Y4?8AZ#\J #_A(!_P ^[_F*/^$@'_/N_P"8H^Q#T'Y4HL0>P_*@!RZX&/\
MJ'_,5(=2:1<)&5)[D]*C6S /0?E4Z6^,<#\J ([>'!YS15Q$ [44 2T44F:
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M\T9H ;L]J4+BES1F@ QBBEHH C+XIAE'K5.:Z"CK^E4I-0"D\_I0!KF8#O\
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MU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H$X/\
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M ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFOK^E
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M_IK,HH T_P#A)=6_Z"-S_P!_31_PDNK?]!&Y_P"_IK,HH T_^$EU;_H(W/\
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M^$EU;_H(W/\ W]-'_"2ZM_T$;G_OZ:S** -/_A)=6_Z"-S_W]-'_  DNK?\
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ME&);F3.U6=4' )/+$ < ]35VZ\(ZG::=+?&.">TB($DMK=13B// W;&./QH
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M75O^@C<_]_36910!I_\ "2ZM_P!!&Y_[^FC_ (275O\ H(W/_?TUF44 :?\
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M&<Y)&<UQP\0:B$T]/MDNVP)-J,_ZK)R<?C4EEXIU73DD6WO7C620RL, _/\
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M"R+:69CBMF\Y5*JY )X)&,>]27-VM]XXU+17M;4:;]BE_<K"HPRP%PP.,@Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?\ ",ZQ_P! J]_\!W_PK[;HH ^)/^$9UC_H%7O_ (#O_A1_PC.L?] J]_\
M =_\*^VZ* /B3_A&=8_Z!5[_ . [_P"%'_",ZQ_T"KW_ ,!W_P *^VZ* /B3
M_A&=8_Z!5[_X#O\ X4?\(SK'_0*O?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#
MO_A1_P (SK'_ $"KW_P'?_"OMNB@#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW
M_P !W_PK[;HH ^)/^$9UC_H%7O\ X#O_ (4?\(SK'_0*O?\ P'?_  K[;HH
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M?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?] J]_P#
M=_\ "OMNB@#S+X8V\MKX/TR*:-XI53#(ZD$?4&NQ?_5_A45S_P A&;_?_I4K
M_P"K_"@#S7XQ6<]]X4FBMH)+B4S1G9$A9L9]!7A7_",ZQ_T"KW_P'?\ PKZX
MTC_D+?\  3_*NCH ^)/^$9UC_H%7O_@._P#A1_PC.L?] J]_\!W_ ,*^VZ*
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M&=8_Z!5[_P" [_X4?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\
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M#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK[;HH ^)/^$9UC_H%7O\
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MQN+&&YB)E WJP<?,,C(/&.>M:DGP?T[_ (5]H?A*&[GALM)EMY8I< NWE.&
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M_"HKG_D(S?[_ /2I7_U?X4 0:1_R%O\ @)_E71USFD?\A;_@)_E71T %%%%
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MSB<@0V+3!8\\D[B<;STXZ<=*5D.\F;/A[Q'%KB2/')!*@<J/L\PF"X./F9>
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M!P5%7*SDK>?Y?YF:NEKY?FOT,*Q_:A@U%=:O(/#5P-(T2S2ZU&YDNE$L;MN
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MMJ7A;5#9SKI2SP7%C(!M&JWKNK#'9'5F'8,">#5)7<5WM\KJ_P" GHI/M?\
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MP5D#R%AN(*JP)."<US?P\^%=YKS2#Q)X5O;E+'PC=PV::CI\BI%<"]E,2HK
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M0,9'<4F[*_S&E=V^1Z_17A'@W]I0WOPHN_$FJZ6\U]I=OI[7BV[!%FDN0G*
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M[QSY385?3DC(KI/!G[0-CX_\4/IFB:;]JM8Y4CDE:]B2Y0-&L@E-LQ#F(A@
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MYT:]>T;3)KMKS4UA1UC#6Y52T989#-Q@=*CT#]G71M%?7O-U"YO8];TM=.O
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MTZ:_NB+:8-!Y:H=J!HQYF2Y&0>WO6MHWAOP]X=T^^\-W?BV?4KS6X2@&HWL
MN&B*; (8T1$  SR$R3RQ8U'XB^&/ACQ=HFB6D^K3I;6UI)IUE-;7,69 X3)!
M*D.P\H'&,=<@BD]]/+];_C8%LK_TM/\ @E#_ (:4\'FVCF0:C+EKA98XK0NU
MOY'E>:9-I(  FC/4]:LW?[0OA.Q6!9C?K<374EJ+4VI\X,B)(Q*YZ;)8V&,D
MAAQUK!T#X.>!8[K688?%MSJEZT=S'?!KVUWPB<0+(2D<:B/_ (]4P, #+<=
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M+^[15VO&(V/*DE9(R!R5(SBO=*IJUB$[A1112*"BBB@ HHHH **** "BBB@
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M3*0P'9.U>H3?!3PI/:K'):W;W"W*W@U ZA<?;1*JE0WVC?YGW25^]T.*JI\
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MRI[T?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\
M/=:ROLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']
MKV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z -7^U[/\
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M_P#GNM']KV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z
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DU&V;I*IK)6U0>M31VZ#UH GN)5NI%V\JN>314L,0'%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20230630x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230630x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '%!#@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH X[Q]\1X?!5QI>GP6$VL:YJKLEEIUNP4OM
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M-?U>\U.]UG2/!%GJ=A;)<RQQM=!K@QRF-& 8L(TX(P=W3I6:?N\[[7^5F_\
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MWC30;RS77]<TBZTZQM?L\<6FZ?Y4MR1@"29V)(8 =$P"2<CI7H]%).W]>O\
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M)Z\R]?Q3_-(\R\+?#WQ]I5G#8W?BC28K6TM6M[>6QTM?.E;;A'E,FX9''"@
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M\JIC,14^*;+M[K6H:E.9KJ]N+B4]7DD+$TW3YY&U"US(Q_>KU8^HJI5C3O\
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M=3I]RB7JH#DVSM&%G'O$7X.>E<)H'[7VFWTG@DW^CWMK;^(8+R1V2SNGFC>
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M78Z1P$[8S&/FRH!^4YKZ)\0^!=#\5ZCIE_JE@+F\TUV>UF$CQM&6^\,J1D'
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M#%)\F]CRQ .,GDXKJM!^#G@[PSJ-E?Z;HR6UU9/*]L_GRL(3("'VJS$ ')X
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M#'::->&_L(A+)B"?.=X^;)//0Y%8/B#]EGX5^*K&.SU7P?:WEM'=3WRQO/,
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MH *L:=_R$+7_ *ZK_,57JQIW_(0M?^NJ_P Q2>PUN?K7X?\ ^0#IO_7M%_Z
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MP6LT,.N^%929H=Q4^5)#D!T8J#\V1E>G->VT5<I.>KWNW\VK"24=MK6_%O\
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M.T8&3FNBNM N?"_C;QCX>U_X*ZI\0=;U_6HK_2M<6,16HB^0KYEX/GM]A7.
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M_$S1];\8^*/B5K%AX<U@6NJ^";9+9&T^56:3J8@I7.\=UZCTK&?X*ZCHNM_
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ML[3PCJ^E>$(+(I_:'B?PW;Z5J E# +&'A;$R8!.<#IUKZ[JI)))KJ3%MMI]
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MY+^U/_R)VG?]?7]*]:\/_P#(!TW_ *]HO_0!7DO[4_\ R)VG?]?7]*^)PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>E,KZ ^8"BBB@04444 %%%% !1110 445-9V<^H7,=M:PR7%Q(P5(HE+,Q]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF$_4_=_7% 'T/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFR!%5Y(@SD#&X^IKB/H"CH_PZB%Q]MUF7^T+HG<(C_JT_#O79(BQJ%50JC@
M# %.HH **** "BBB@ HHHH **** "BBB@".>WBNHFBFC62-A@JPR#7)W?@V;
M3)FNM&E*=S:NWRGZ'M7844 <MHOBWS9OLEY#):W2G!208KJ 0PR.E<QX](BM
M-.E4 2?;$7=CG!5LC/X5T5J<P)]* )68(I+$ #J37G_C#XOZ=H.^WL<7]X,C
MY3\BGW-;/Q.=H_ >KLK%6\M>0<'[ZU\ST ;'B+Q;J?BBY,M]<LX_AB!PB_05
MCT44 %%%% !1110 5/87;V%[!<QG$D3AU/N#FH** /KFPO$U"QM[J,YCFC61
M?H1D5/7(?"C4O[1\#Z>2?GA!A/\ P$D#],5U] !1145S.MK;RS,"5C4L0.N
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M:W.F6F?M%P24$7^\& (_+FE*E.-[K1?\,.-:G*R35WTZ]SJJ*Y+P=\6?"/Q
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M7]$>_45Q4/QG\%W'B0:!'KT#:P;@VOV01R;_ #?[OW<?CT]ZC;XW^!5\4?\
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M/Q;\87/CR!'TV_T-(=%DN8]Z,P4^9''Z.6YQUKQ[X;> I/'UE'I]C%)!=+X
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MN&9YWTJU:1G^\6,2Y)]\UTE%).R:]/PO^=Q-7:?:_P"/+^5OQ"BBBI&%%%%
M!1110 4444 %?G_^TI<?:/C-XA;!&UT3GV11_2OT K\^?VBO^2Q^)/\ KN/_
M $$5V87XV>#G'\"/K^C/-Z***]0^0"BBB@ HHHH **** "OTH^&?_)/?#O\
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MD8/H17FFB_'/XHG4O"J26MO=S:AXMU336LH[Q"MS%%%(5B9S;@Q+&54[E!+
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MVO;\_P#(^M**\1^&O[2S>)O$%QH7C7PE=?#?5EM&U"!-4O8I89K8=7\T;0I
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MOAGPWX"OVTB+PIH6IQWPUB&=VNKN**4RPQ& H%C.[;N?>V0O"C/!]E7WTO\
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M+J%XX8E7J0ID(WGV7)KQ_P 6_M'^*9M4UFZ\,Z'+=:&/"4>M6<KRPH8V<O\
MOF#,"0-NW9URI/0BNF^)_P )/%?BOQ;KUS%;:9K^E:E9+;6L>JW\T<>G,!AC
M]G52DN3SR5/O6#IWP \7V&CV]A_Q*W%SX,'ANZD^TN/(F1I&21!L^=6W@$?+
MCWK%7:N_/\I?K;[]S;1.WI_Z5#].;_(ZO1OCUJ5S=:7H3>$M1N]<ETF/4KIX
MIX/+A0@98DM@^N!7/>&/V@M?U7QGI]E:Z;=:_8W/AQM46UA@CBG:5;N6)B6W
M;5&U!@9Y^M=)X#^&/B;3?&4FMZM#86J-X>CTGRK:Z:8^:I'.2B_*0*Y;P;\(
MOB-\.=?TK5-*@T/4A#H#:5/;7%[)$/--U-*KAA&>%$@XQSDCC&:TE\5UY_\
MM]O_ &TQBO=:?:/YPO\ ^W'HG@_X\Z)XVURQTW3[6YW76G2:AYD@ $>QMK1L
M.H8&N(MOVCK[6_&WA::TTB:T\)7EAJ=S>2SRQ!E-M,(V?[V<+M)QWWC'0U'X
M?^!?BSX=:IHNKZ&VF:U?BPN+/4(KR=[9 \K[S)&0KY /&TCD=Q6;HO[.GBFS
MT#PQI]^^FW30V6L:=J1BN'C"I>3^8LL7R'<0 ,H<=>O'(]-5Y_?[UOE\.O\
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MME>>)#.J&:1=21Y+H2R0_9BGS ,6(E#;=H'!ZU,=7&/73_VS_.7];G1OI?\
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M#CS+FY<(B9(49)X&20/QKXWO+_7+7P/X\\=#Q3X@;6=(\2O%8Q'59_LL40E
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M_P#H+UT=I_J$^@KG/B""=/T['/\ IT?_ *"U=':_ZA/H* .;^*/_ "(6K_\
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M))&VU?NJY1AO4>C9%;T/PE\)VWBNV\1P:/';ZM;:=_9,,L,CHD=KG(B6,,$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\[>
M(?V2[7Q'\2;_ %:2]6TT&Y?SS;0C]X7/+ =@,YKZ)HJXSE#X3GK4*==)5%>Q
M@^$? VB>!M.2RT:PBM(@,%E'SO[L>IK>K#\7^-]!\ Z/-JGB'5;;2K&)2S2W
M#XSCT'4GV%?"WQX_X*,7=^+G2/AM;&Q@.4.M72@RGWC3HOU.?PJ6[ZLVC%15
MHJR/L#XN_'WP7\$]+-UXEU:.&X9<PV$1WW$W^Z@YQ[]!W-?GO\=_V[O&'Q0-
MQIOA\OX7T!B5V0M_I$J_[;#IGT'YU\X:YKVH^)M5N-2U:^GU&_N&W2W-S(9'
M<^Y/-4*10^65YY&DD=I)&.6=SDD^I-,HHH **** "BBB@ KNOA;\;/%_P=U9
M+WPUJTMJN<R6KDM!*/1DZ5PM% 'Z>? C]OWPG\0OLVE>+MGA777P@FE;_1)F
M]G_A)]&QUP,U]60S1W$2R1.LD;#*NIR"/8U^"]>W_ S]KGQS\$)(;2UO3K'A
MY2 =)OF+QJO_ $S/5/PX]J /UZ>-9%(89!KG-8\'07<AN(&:WN!R)(S@@UYS
M\$?VM? OQL@B@M+T:1KI4;]+OG"OGOL;HX_(^U>UT <E8Z_J&D.MOJD37,?0
M7,:_-_P(?X5/+=ZAK_R0;[&U)Y;^-A_2NC>)'^\H/X4JHJ#  % &9IGA^VTT
M$J-SGJS<DUJ 8Z52UG7+#P]827NI7<5E:H,M)*V!^'K7SC\3/VLR/-L/"$.#
MRIU&=<_BB]/Q.?I0![OXU^(>@_#^P^U:S?QVVX'RX0<R2'_94<FOEKXF?M0:
MWXK,MGH8;1M-.5W@_OI![GM^%>.ZQK5]X@U"6^U*[FO;N4Y>:=RS'\3V]JIT
M .EE>>1I)':21CEF8Y)/N:;110 4444 %%%% !6[X3\;ZUX)OUN]'OY;20'E
M5.48>A'0UA44 ?7?PS_:JTK7O*L?$R+I-\<*+H?ZAS[_ -W\>/>O>+>YBNX$
MF@D2:)QN5T.0P]0:_,RN[^'7QF\2?#:95L+LSZ?G+V-P2T1^@_A/N,4 ??<D
M:RH4=0Z$8*L,@UYWXO\ @W8:SON-,86%T>=F/W;'^E5/AM^T'X;^("QV[RC2
M=4/!M;AAAC_LMT->H Y&1R* /(?A=\.+[1_$=Q=ZK;>5]E&V'/(=C_$#WP/Y
MUZ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'P!_P %(_A7K:7>F^.+:ZNKO0B%
MM;JV+EH[63^!PO0!LXSZX'>OA.OW7\3^&M.\8^'M0T35[9+S3;Z%H)X7'#*P
MP?Q]Z_'O]HKX$:G\!?'USH]R'GTN4F33[UEP)HL\9[;AT(H \LHHHH ****
M"BBB@ HHHH **** "BBB@"2VN9K.=)[>5X)D.Y)(V*LI]01TK[#_ &7/VV_&
M.G>)M%\(^)/^*BTZ]G2UBN96Q<09.!S_ !#V-?'%=U\"_P#DL7@__L)0_P#H
M5 '[8UY[\:OB=)\+?"\=_!:"[N9Y/)C#-A5..IKT*O!/VP?^1&TS_K\_]EH
M^9O&GQ#U[Q]?M=:Q?//S\D*G$:>P6N;HHH **** "BBB@ HHHH **** "BBB
M@ HHHH 5':-PR,58'(93@BOMG]FF/Q+)X&%WK]Y+/!.P-E'.,NL8[Y]#VKYV
M^ WPCE^)/B-9[J,KH=DP:X<CB0]HQ_7V^M?<5M;QVEO'!"@CBC4(B*,  =!0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM=?E:WYWT-6[\7Z%8:U!H]SK-A;ZM/CRK&6Y19Y,]-J$Y/X"M>O@_P <>.=
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M!+F/EH+A1B:W?'#HW4']#T/%?F#^T+^R3XK^!=]+=")]8\-,Q\G4H$SL'82
M?=/OTH \*HHHH **** "BBB@ HHHH *[KX%_\EB\'_\ 82A_]"KA:[KX%_\
M)8O!_P#V$H?_ $*@#]L:\$_;!_Y$;3/^OS_V6O>Z\$_;!_Y$;3/^OS_V6@#Y
M"HHHH **** "BBB@ HHHH ***.M !78?#7X7ZQ\3=96TTZ(I;(1]HNW'[N)?
M<]S[=:[+X1?LZZMX\EBO]5632]$R#N88DG'HH[#WK[!\->&--\(Z3#INE6J6
MEK$,!4')/J3W/O0!D_#OX;Z1\-M$2PTR+,C &>Y8?/,V.I]O;M75T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(\6\2?LUQ:WXGUC5+7Q3J&E6NL1>7?6<$*-YIQC(<\@>P_.M71/@7'H^H>
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M-K;:-'KFG/JZ\M8+=1F<?5,[OTKYE^'?BC4K+X@-X>\(>,+[QSX=FT^5GGO
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M0?!=/%]_H?VC69[-KRWTFQA>)I<J"B .S')/\6<$<XHULWV_X/\ DPZI=_\
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MGM4>F?M#Z%K.B6.IV6B^([B/4,-90)IC>;=)MW%XQGE0.I)%-73YNO\ G?\
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MTQ;&,(.IKV[P9X[T3X@:,VJ:'=M=6B2O!()89(98I%.&1XY%5T8=U8 U\X^
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MP3\%M,@L]%;5?$FFZ/#%'I*W$<?FW"Q*NSS&;8!NZG., XS7=T4-WBXK2_\
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M:2$+$N]G=W8E5 !^52 ,\"M.5IM?U>Z5OQ1.ZO\ ULW?_P E9];45\X_LO\
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M:J^FC4;&YTNSDB &_;(KP;W9MO4;3EAV%8EU\8-5U30;)I==T#Q$PU_2K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20230630x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230630x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %6!#@# 2(  A$! Q$!_\0
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M&1^N![T=;!YE^BBD)P"3T% "T50T;7=/\0V9NM-NX[VW#M&9(CD;AP1^%7Z
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MI72_3_@%/6]NO_!.-_9Q_P"2?3?]A*Y_]#KU*J6DZ+8:#:FVTZTALK<N9#%
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M_6B_4MOWVU_6K_(^>+;Q9JW@WP?XTTE;&Y\*W,(&H:=!*ZL\4;$!@",C /\
M.IE\;ZYH\]Q!:^+W\1I=Z'+?.Z[2;.55&,%>GT->P?$+X>V?CO1[FW*PVVH2
M1>3'?/#O>-202!R.#CIFHY/ACI,/AC4=,T^TM-/N[ZT^S37D-N SG;C<0.OK
MC-)W<7WM^C7^7S!637;_ (*_X)Y7X)\9ZRFN^#,^+CXD&NV\@O; [3]EVQ[@
MPQRISUSUYKGOAKK=[I6G?#B.U.Y)9=59X0H/F%22!DC(Y]*]\\&?#K2/!]E:
M^396C:E';I;S7\< 1YL#&3WY^M7[+P3H&G&Q-KI%G ;$NUJ8X@/)+_?*^F>]
M6[<SM_6Y*^&S_K0\A\ >,;VZ.F:WJ/CR.2:_\TW&A21!_)QGY4"\J0!U;BLC
M1_&^J:IXTTVWT_Q9?7VG:U'<*4G:+?!A3M94494CMFO=K+P5H&G:G/J-KH]E
M!?3Y\VXCA4.^>N345CX"\.:9<I<6FB6-M.DAF62*!58.1@MGUJ=&,^=_"&H7
MVE^$O!K)KDM[)=>)TAF@E*.85WL"/4;NO//-:MY\0]?:UU+Q&/%7V?5+756L
MX_"^U=K()=@4K]XM@YR..*]SB\ ^&X)!)'HEBCBY%X&6%01,.DG^][U+)X+T
M&;6UUA]'LGU1>1=F%?,'_ J=];O^OA_R?WB_K\7_ )K[CQ'Q/X@\5W%_\0+Z
MV\1W>G6VA^3+#9QJI!)0$H21P.M>Z>%M1EU;PWIE[/CSI[=)'QTR5&:27PIH
M\XU$2:9;.-1Q]L#1@^?@8&_UXK0M;6*RMXX((UAAC4*D:# 4#H *%HK>G_!&
M]7?^NG_!):***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<WXL?9);]>AKI*XCXB7CVLMD%.-P;-
M $ME-N(.:V[=R?2N L-7F!X(_*NBL]5G*@[A^5 '71'@5-7.Q:G.1]X8^E6%
MU*?:/F'Y4 ;5%8W]I3_WA^5._M6;T7\J ->BLC^U9O1/RH_M6;T3\J ->BLC
M^U9O1/RH_M6;T3\J ->BLC^U9O1/RH_M6;T3\J ->BLC^U9O1/RH_M6;T3\J
M ->BLC^U9O1/RH_M6;T3\J ->BLC^U9O1/RH_M6;T3\J ->BLC^U9O1/RH_M
M6;T3\J ->BLC^U9O1/RH_M6;T3\J ->BLC^U9O1/RJU87DER[!\8 SP* +M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16;=:A+#
M.R*%P/45%_:LWHGY4 :]%9']JS>B?E1_:LWHGY4 :]%9']JS>B?E1_:LWHGY
M4 :]%9']JS>B?E1_:LWHGY4 :]%9']JS>B?E1_:LWHGY4 :]%9']JS>B?E1_
M:LWHGY4 :]%9']JS>B?E1_:LWHGY4 :]%9']JS>B?E1_:LWHGY4 :]%9']JS
M>B?E1_:LWHGY4 :]%9']JS>B?E5^RG:X@WMC.<<4 6**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **:YVHQ'85E?VK-Z)^5 &O161_:LWH
MGY4?VK-Z)^5 &O161_:LWHGY4?VK-Z)^5 &O161_:LWHGY4?VK-Z)^5 &O16
M1_:LWHGY4?VK-Z)^5 &O161_:LWHGY4?VK-Z)^5 &O161_:LWHGY4?VK-Z)^
M5 &O161_:LWHGY4?VK-Z)^5 &O161_:LWHGY4?VK-Z)^5 &O161_:LWHGY4?
MVK-Z)^5 &O161_:LWHGY4?VK-Z)^5 &O16;::A+-<(C!<'/0>U% &E117#_&
MC5;S1?AWJ=W87,UI<IMVRVYPXRPSCWI-V5QI7=CN**\!\-ZM>FUU"X75?'33
MQ:;-,IUBV$=KN"9!#8ZYY%:FF_&S_A&O!OAB*YA;6M:O+$74IGO([?"9QN+R
M'!)/0=35/3^O7_(2U_KT_P SVJBO&=1^)]QJOBSPCJ6BO<7&F7FFW=RVG"3;
MYKHI^5NHR"",UT#?&BQ:#2)8+":Y%[927TJQOEK=$'((QR<\=J3T6O\ 6_\
MDPZ_UY?YGHU%>=^#OB[_ ,)/8WM_<Z.=.TZVA:?[4M]#< J!G!53N4^Q%9A^
M+]]K,"6L>@7FC-K$,B:-J$\B,L\NPE,J.4SQC-#NM 5F>KT5XGX!TS68/%I<
M17**UR6)>WDB\J#+Y29V4"5B-N"I;G\S[93MI<76P4444AA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>>?%.39/IP]FKT.O /VJ/%E_X530I+
M%D5I2X;>H- &KI\G/%=-8N645\EP_&_Q+!]V2W_[\BKL7[0WBV'[LMM_WX%
M'U[!]VK2]!7R O[2GC%1@2VO_?A:D_X:;\9_\];3_P !UH ^O**^0_\ AIOQ
MG_SUM/\ P'6C_AIOQG_SUM/_  '6@#Z\HKY#_P"&F_&?_/6T_P# =:/^&F_&
M?_/6T_\  =: /KRBOD/_ (:;\9_\];3_ ,!UH_X:;\9_\];3_P !UH ^O**^
M0_\ AIOQG_SUM/\ P'6C_AIOQG_SUM/_  '6@#Z\HKY#_P"&F_&?_/6T_P#
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MKRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\
M/6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?
M_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBO
MD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_
M\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T
M_P# =: /KRMC3/\ CU'U-?%?_#3?C/\ YZVG_@.M6(?VJ/&\";%EL\=>;=:
M/M>BOBO_ (:N\=?\];+_ ,!EH_X:N\=?\];+_P !EH ^U**^*_\ AJ[QU_SU
MLO\ P&6C_AJ[QU_SULO_  &6@#[4HKXK_P"&KO'7_/6R_P# 9:/^&KO'7_/6
MR_\  9: /M2BOBO_ (:N\=?\];+_ ,!EH_X:N\=?\];+_P !EH ^U**^*_\
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MKRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\
M/6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?
M_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBO
MD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_
M\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T
M_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\
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MCE5+' &3@#K1INHV^KV%O>VD@FMIT$D;CNIZ4 6:*** "BBB@ HHHH ****
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M74[76].\66VCV%OICVSVRE9)@V"#&L+<,')Z].]6)_&VES_$&XFDU>&33O\
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MCQ2_\&Z]I5Q;P7NBZA:3W#;88Y[5T:0^B@CD_2FWGA#7=/OH+*ZT:_M[R?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW_OS0!^?U%?H#_PI/P)_T*NF_P#?FC_A2?@3_H5=-_[\T ?G]17Z _\ "D_
MG_0JZ;_WYH_X4GX$_P"A5TW_ +\T ?G]17Z _P#"D_ G_0JZ;_WYH_X4GX$_
MZ%73?^_- 'Y_45]UWOP<\$I<NJ^&=/ '815#_P *?\%?]"UI_P#WZH ^&J*^
MY?\ A3_@K_H6M/\ ^_5'_"G_  5_T+6G_P#?J@#X:HK[E_X4_P""O^A:T_\
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M/_"D_ G_ $*NF_\ ?FC_ (4GX$_Z%73?^_- 'Y_45^@#_!3P($8CPMIN<?\
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M?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\
MP$E_^)J[10!2_M:#_GG=?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7
M_@)+_P#$T?VM!_SSNO\ P$E_^)J[10!2_M:#_GG=?^ DO_Q-']K0?\\[K_P$
ME_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\ P$E_^)J[10!2_M:#_GG=
M?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\
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M-']K0?\ /.Z_\!)?_B:NT4 4O[6@_P">=U_X"2__ !-']K0?\\[K_P !)?\
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MBUIO@N]AM'B^U3R%!_K5C7+YV*&;@L=I( ]*ZO0]9@U_38KR!71')4I(,,C
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M-_\ 0>T[_P "4_QH_P"$]\-_]![3O_ E/\:_*^BCZBOY@_XB57_Z!5_X$_\
M(_5#_A/?#?\ T'M._P# E/\ &C_A/?#?_0>T[_P)3_&OROHH^HK^8/\ B)5?
M_H%7_@3_ ,C]4/\ A/?#?_0>T[_P)3_&C_A/?#?_ $'M._\  E/\:_*^BCZB
MOY@_XB57_P"@5?\ @3_R/U0_X3WPW_T'M._\"4_QH_X3WPW_ -![3O\ P)3_
M !K\KZ*/J*_F#_B)5?\ Z!5_X$_\C]4/^$]\-_\ 0>T[_P "4_QH_P"$]\-_
M]![3O_ E/\:_*^BCZBOY@_XB57_Z!5_X$_\ (_5#_A/?#?\ T'M._P# E/\
M&C_A/?#?_0>T[_P)3_&OROHH^HK^8/\ B)5?_H%7_@3_ ,C]4/\ A/?#?_0>
MT[_P)3_&C_A/?#?_ $'M._\  E/\:_*^BCZBOY@_XB57_P"@5?\ @3_R/U0_
MX3WPW_T'M._\"4_QH_X3WPW_ -![3O\ P)3_ !K\KZ*/J*_F#_B)5?\ Z!5_
MX$_\C]-[[QSX=:Z<C7-/(_Z^4_QJ#_A./#W_ $&]/_\  E/\:_,^BCZBOY@_
MXB57_P"@5?\ @3_R/TP_X3CP]_T&]/\ _ E/\:/^$X\/?]!O3_\ P)3_ !K\
MSZ*/J*_F#_B)5?\ Z!5_X$_\C],/^$X\/?\ 0;T__P "4_QH_P"$X\/?]!O3
M_P#P)3_&OS/HH^HK^8/^(E5_^@5?^!/_ "/TP_X3CP]_T&]/_P# E/\ &C_A
M./#W_0;T_P#\"4_QK\SZ*/J*_F#_ (B57_Z!5_X$_P#(_3#_ (3CP]_T&]/_
M / E/\:/^$X\/?\ 0;T__P "4_QK\SZ*/J*_F#_B)5?_ *!5_P"!/_(_3#_A
M./#W_0;T_P#\"4_QH_X3CP]_T&]/_P# E/\ &OS/HH^HK^8/^(E5_P#H%7_@
M3_R/TP_X3CP]_P!!O3__  )3_&C_ (3CP]_T&]/_ / E/\:_,^BCZBOY@_XB
M57_Z!5_X$_\ (_3#_A./#W_0;T__ ,"4_P :/^$X\/?]!O3_ /P)3_&OS/HH
M^HK^8/\ B)5?_H%7_@3_ ,C],/\ A./#W_0;T_\ \"4_QH_X3CP]_P!!O3__
M  )3_&OS/HH^HK^8/^(E5_\ H%7_ ($_\C],/^$X\/?]!O3_ /P)3_&M;3?'
MGAQ;8 Z[IP.3UN4_QK\N:*/J*_F#_B)5?_H%7_@3_P C]4/^$]\-_P#0>T[_
M ,"4_P :/^$]\-_]![3O_ E/\:_*^BCZBOY@_P"(E5_^@5?^!/\ R/U0_P"$
M]\-_]![3O_ E/\:/^$]\-_\ 0>T[_P "4_QK\KZ*/J*_F#_B)5?_ *!5_P"!
M/_(_5#_A/?#?_0>T[_P)3_&C_A/?#?\ T'M._P# E/\ &OROHH^HK^8/^(E5
M_P#H%7_@3_R/U0_X3WPW_P!![3O_  )3_&C_ (3WPW_T'M._\"4_QK\KZ*/J
M*_F#_B)5?_H%7_@3_P C]4/^$]\-_P#0>T[_ ,"4_P :/^$]\-_]![3O_ E/
M\:_*^BCZBOY@_P"(E5_^@5?^!/\ R/U0_P"$]\-_]![3O_ E/\:/^$]\-_\
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MEC#;HRQ/).U@,^U>B5A)6?\ 774][#5UB:2J15M_DT[-?)IH****DZ0HHHH
M**** "OAK_@HY_R&O!G_ %PG_P#0EK[EKX:_X*.?\AKP9_UPG_\ 0EKIP_\
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M%4OS[URW@;QW)X-^(-CXIEMCJ,MM.\[0&7R_,+!@?FP<?>]#32J.3UTM^/\
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MHX %4*ZX<W*N;<^%Q'LO;3]A\%W;TOIV"BBBK.<**** "BBB@ HHHH ****
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M7Z%44?7:G9!_Q#O*/YY_>O\ Y$_/7_ADCXE?] >#_P "D_QH_P"&2/B5_P!
M>#_P*3_&OT*HH^NU.R#_ (AWE'\\_O7_ ,B?GK_PR1\2O^@/!_X%)_C1_P ,
MD?$K_H#P?^!2?XU^A5%'UVIV0?\ $.\H_GG]Z_\ D3\]?^&2/B5_T!X/_ I/
M\:/^&2/B5_T!X/\ P*3_ !K]"J*/KM3L@_XAWE'\\_O7_P B?GK_ ,,D?$K_
M * \'_@4G^-'_#)'Q*_Z \'_ (%)_C7Z%44?7:G9!_Q#O*/YY_>O_D3\]?\
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MR1\2O^@/!_X%)_C1_P ,D?$K_H#P?^!2?XU^A5%'UVIV0?\ $.\H_GG]Z_\
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MKXA_] J'_P "4_QH_P"&6OB'_P! J'_P)3_&OO"BCZ[4[(/^(=Y1_//[U_\
M(GP?_P ,M?$/_H%0_P#@2G^-'_#+7Q#_ .@5#_X$I_C7WA11]=J=D'_$.\H_
MGG]Z_P#D3X/_ .&6OB'_ - J'_P)3_&C_AEKXA_] J'_ ,"4_P :^\**/KM3
ML@_XAWE'\\_O7_R)\'_\,M?$/_H%0_\ @2G^-'_#+7Q#_P"@5#_X$I_C7WA1
M1]=J=D'_ !#O*/YY_>O_ )$^#_\ AEKXA_\ 0*A_\"4_QH_X9:^(?_0*A_\
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MJ[10!2^QW/\ S_R_]^T_PH^QW/\ S_R_]^T_PJ[10!2^QW/_ #_R_P#?M/\
M"C['<_\ /_+_ -^T_P *NT4 4OL=S_S_ ,O_ '[3_"C['<_\_P#+_P!^T_PJ
M[10!2^QW/_/_ "_]^T_PH^QW/_/_ "_]^T_PJ[10!2^QW/\ S_R_]^T_PH^Q
MW/\ S_R_]^T_PJ[10!2^QW/_ #_R_P#?M/\ "C['<_\ /_+_ -^T_P *NT4
M4OL=S_S_ ,O_ '[3_"C['<_\_P#+_P!^T_PJ[10!2^QW/_/_ "_]^T_PKS/X
MPVTJRZ8'N7E)W8+*HQ^0KUFO,OC"NZXTSZ-0!PFG0L"O[P_D*Z[2H&^7]Z?R
M%<[IRC<.:ZO35  .: ->WB;_ )ZG\A5](FR/WA_(57MN5J\H [T ,\IO^>K?
MD*9]GF_Y^G_[Y7_"K&:* *_V>;_GZ?\ [Y7_  H^SS?\_3_]\K_A5BB@"O\
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M7^SS?\_3_P#?*_X4?9YO^?I_^^5_PJQ10!7^SS?\_3_]\K_A1]GF_P"?I_\
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MO^?I_P#OE?\ "K%% %?[/-_S]/\ ]\K_ (4?9YO^?I_^^5_PJQ10!7^SS?\
M/T__ 'RO^%'V>;_GZ?\ [Y7_  JQ10!7^SS?\_3_ /?*_P"%'V>;_GZ?_OE?
M\*L44 5_L\W_ #]/_P!\K_A1]GF_Y^G_ .^5_P *L44 5_L\W_/T_P#WRO\
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MYZ9ZUS]"I4GL@EC<7'XIM'NG_#7/BC_H&Z;_ -\O_C1_PUSXH_Z!NF_]\O\
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MA^@_] 33O_ 2/_"K7]I?].MS_P!^Z/[2_P"G6Y_[]T78^6/8J_\ "'Z#_P!
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MM+_IUN?^_=']I?\ 3K<_]^Z+L.5=AO\ 8&F?] VT_P"_"_X4?V!IG_0.M/\
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M *!-Y_WVM,E_:8TQ5'EZ/=.V>C2JO]#1]3Q'\H?7\-_/^9[-17BG_#3=E_T
MI_\ P('_ ,36YH7QQM]>MWEBTIXRC;2K3C(_\=H>"KK>/Y"6/PTG93_!_P"1
MZ?17!_\ "TU_Z!I_[_\ _P!C3E^**M_S#3_W_P#_ +&I^J5OY?R-/KE#^;\&
M=U5_2/\ 6R?2O-_^%GK_ - X_P#?[_[&K%G\65M68_V66R,?Z_'_ ++1]4K?
MR_D'URA_-^#/5**\U_X7,G_0(/\ X$?_ &-._P"%QK_T"3_X$?\ V-'U2M_+
M^0?7*'\WX,](HKS?_A<:_P#0)/\ X$?_ &-'_"XU_P"@2?\ P(_^QI_5*_\
M+^0?6Z'\WYGI%%>;_P#"XU_Z!)_\"/\ [&C_ (7&O_0)/_@1_P#8T?5*_P#+
M^0?6Z'\WYGI%%>;CXQJ3_P @D_\ @1_]C3O^%PI_T"F_\"/_ +&E]4K?R_D/
MZW1_F_,]&HKSD?&!2<?V4?\ P(_^QIW_  MY?^@4?_ C_P"QH^JUOY?R#ZW1
M_F_,]$HKSO\ X6\O_0*/_@1_]C2CXN*?^86?_ C_ .QH^JUOY?R#ZW1_F_,]
M#HKSS_A;B_\ 0+/_ ($?_8T?\+<7_H%G_P "/_L:7U6M_+^0_K5'^;\ST.BO
M/Q\65(S_ &6?^_\ _P#8T#XKJ3_R##_W_P#_ +&CZK6_E_(/K5'^;\ST"BN!
M_P"%JK_T##_W_P#_ +&C_A:J_P#0,/\ W_\ _L:/JM;^7\@^LT?YOS.^HK@_
M^%IK_P! T_\ ?_\ ^QH_X6FO_0-/_?\ _P#L:7U:KV#ZU1?VOS.AO_\ CZ>J
M]<U/X^%Q*9/L)7/;S?\ ZU-'C88_X\S_ -_/_K4?5ZO8?UFEW.GHKF/^$V'_
M #YG_OY_]:E7QJ"<?8S_ -_/_K4OJ]3L/ZQ3[G345S8\8@G'V0_]_/\ ZU._
MX2\?\^A_[^?_ %J/J]3L'UBGW.BHKGAXM!_Y=3_W\_\ K4O_  EH_P"?4_\
M?S_ZU'L*G8?MZ?<Z"BL'_A*A_P ^Q_[[_P#K4X>)@1_Q['_OO_ZU+V%3L'MZ
M?<W**Q/^$F'_ #[G_OO_ .M2CQ(#_P NY_[[_P#K4>QJ=@]O3[FU16,/$8)Q
M]G_\?_\ K4Y=?W'_ %'_ (__ /6I>QGV'[:'<UZ*RO[=_P"F'_CW_P!:E&N
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M=&3MI\7X7?EV\_D<+IUXJ^OP_C;U[Z[?,]0!R,TM(!@4M>4>R%%%% !1110
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M?^_/_P!E4]I\)GNF8?VFJX&?]1G_ -FH^M4?YOS#ZG7_ )?R. '6I>]>B?\
M"F9/^@LO_@/_ /94[_A3DG_057_OQ_\ 94UBZ/\ -^8_J=?^7\CSFBO1O^%.
MR?\ 057_ +\?_94?\*=D_P"@JO\ WX_^RI_6Z'\WYC^J5_Y?R/.:*]&_X4[)
M_P!!5?\ OQ_]E1_PIV3_ *"J_P#?C_[*CZW0_F_,/JE?^7\CSH=:=7H@^#L@
M_P"8JO\ WX_^RI?^%/2?]!5?^_'_ -E4_6Z/\WYE+"5OY?R/.T^\*D/2O0!\
M'Y <_P!J+_WX_P#LJ<?A%)_T%%_[\?\ V53]:H_S?F+ZI6_E_(\]]*<.E>@?
M\*BD_P"@HO\ WX_^RIP^$<@_YBB_]^/_ +*F\51_F_,%A*W\OY'GU%>@_P#"
MI)/^@HO_ 'X_^RH_X5))_P!!1?\ OQ_]E4_6J/\ -^9?U6M_+^1P2_=%.7[P
MKO1\)Y ,?VFO_?C_ .RI1\*) <_VFO\ WY_^RI_6J/\ -^8_JM;^7\CA:.]=
MY_PJN3_H)+_WY_\ LJ/^%5R?]!)?^_/_ -E2>*HV^+\ROJU7^7\CAJ*[O_A5
MK_\ 027_ +\__94?\*M?_H)+_P!^?_LJS^LTNXEAJO\ *<0OW14@Z"NHF\ O
M;R&/[:&QW\K_ .O3?^$);'_'V/\ OW_]>D\12MN6L-5[',TY/O5TG_"$M_S]
MC_OW_P#7I5\%,#G[6/\ OW_]>H]O3[FGL*G8Y]/O"I*WQX.8'/VH?]^__KT[
M_A$6_P"?H?\ ?'_UZ/;T^X>PJ=C 6E]*WQX28?\ +T/^^/\ Z]+_ ,(DW_/T
M/^^/_KT>WI]QJA4[&&.E2CH*V?\ A%F_Y^1_WQ_]>G#PRP'_ !\#_OC_ .O4
M.M3[C]A4[&+3ATK9_P"$9;_GX'_?'_UZ4>&V'_+P/^^/_KT*M3[@J%3L8Z?>
MJ9.M::^'&!_UX_[Y_P#KT]= *G_7C_OG_P"O4NM"^Y?L9]C,IPZ5I_V$?^>P
M_P"^?_KTHT0@?ZX?]\__ %Z7MH=Q^QGV,Z/J:?6@NC%?^6H_[Y_^O2_V0?\
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MO_Q- %:BJ_V5_P#GYF_\=_PH^RO_ ,_,W_CO^%*PK(L457^RO_S\S?\ CO\
MA1]E?_GYF_\ '?\ "BP618HJO]E?_GYF_P#'?\*/LK_\_,W_ ([_ (4PL6**
MK_97_P"?F;_QW_"C[*__ #\S?^._X4#+%%5_LK_\_,W_ ([_ (4?97_Y^9O_
M !W_  H L457^RO_ ,_,W_CO^%'V5_\ GYF_\=_PH L457^RO_S\S?\ CO\
MA1]E?_GYF_\ '?\ "@"Q15?[*_\ S\S?^._X4?97_P"?F;_QW_"@"Q15?[*_
M_/S-_P"._P"%'V5_^?F;_P =_P * +%%5_LK_P#/S-_X[_A1]E?_ )^9O_'?
M\* +%%5_LK_\_,W_ ([_ (4?97_Y^9O_ !W_  H L5?TC_6R?2LC[*__ #\S
M?^._X5=TNR=Y'Q=SKQVV_P#Q- &]15+^SY/^?ZY_-/\ XFC^SY/^?ZY_-/\
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MKG\T_P#B:/[/D_Y_KG\T_P#B: +M%4O[/D_Y_KG\T_\ B:/[/D_Y_KG\T_\
MB: +M%4O[/D_Y_KG\T_^)H_L^3_G^N?S3_XF@"[15+^SY/\ G^N?S3_XFC^S
MY/\ G^N?S3_XF@"W)_JV^AKGJU9-/DV-_IUST/=/_B:POLK_ //S-_X[_A0!
M8HJO]E?_ )^9O_'?\*/LK_\ /S-_X[_A0!8HJO\ 97_Y^9O_ !W_  H^RO\
M\_,W_CO^% %BBJ_V5_\ GYF_\=_PH^RO_P _,W_CO^% %BBJ_P!E?_GYF_\
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M4^WJ***\T^K"BBB@ HHHH **** "BBB@ J_I'^MD^E4*OZ1_K9/I0!J4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8E__ ,?3U7JQ
M?_\ 'T]5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V-,_X]
M1]36/6QIG_'J/J: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -D_U;?0USU=#)_JV^AKGJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"QI__'Y'^/\ *BC3_P#C\C_'^5% &W1110 4444
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R?ZMOH:YZBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L:?_P ?
*D?X_RHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>plx-20230630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/7/2023 10:12:27 AM-->
<!--Modified on: 8/7/2023 10:12:27 AM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2022" targetNamespace="http://www.protalix.com/20230630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20230630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" id="DisclosureEarningsLossPerShareDetails1">
        <link:definition>40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeDetails">
        <link:definition>40701 - Disclosure - TAXES ON INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" id="DisclosureEarningsLossPerShareDetails">
        <link:definition>40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40901 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" id="DisclosureEarningsLossPerShare">
        <link:definition>10601 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" id="DisclosureTaxesOnIncome">
        <link:definition>10701 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10901 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" id="DisclosureEarningsLossPerShareTables">
        <link:definition>30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" id="DisclosureTaxesOnIncomeTables">
        <link:definition>30703 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AtmEquityOfferingSalesAgreementMember" name="AtmEquityOfferingSalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonePaymentReceived" id="plx_MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExtendedTermOfAgreement" id="plx_ExtendedTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainLossOnDebtConversion" id="plx_GainLossOnDebtConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsToDebtHoldersOnConversion" id="plx_PaymentsToDebtHoldersOnConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtConversionDecreaseInPrincipalAmount" id="plx_DebtConversionDecreaseInPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfPatientsEnrolled" id="plx_NumberOfPatientsEnrolled" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfPatientsActivelyParticipating" id="plx_NumberOfPatientsActivelyParticipating" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfPatientsDosed" id="plx_NumberOfPatientsDosed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OutstandingStockOptionsAndWarrantsMember" id="plx_OutstandingStockOptionsAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsMember" id="plx_OutstandingStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsWarrantsAnd2024NotesMember" id="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentToRegulatoryApprovals" id="plx_MilestonePaymentToRegulatoryApprovals" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReserveForDeductionsFromRevenueCurrent" id="plx_ReserveForDeductionsFromRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FillFinishAgreementMember" id="plx_FillFinishAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>plx-20230630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/7/2023 10:12:27 AM-->
<!--Modified on: 8/7/2023 10:12:27 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureEarningsLossPerShareDetails1" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638269999460117350" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638269999460117350" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638269999460117350" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638269999460117350" xlink:to="plx_ShortTermBankDeposits_638269999460117350" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638269999460117350" xlink:to="us-gaap_AccountsReceivableNetCurrent_638269999460117350" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638269999460117350" xlink:to="us-gaap_OtherAssetsCurrent_638269999460117350" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638269999460117350" xlink:to="us-gaap_InventoryNet_638269999460117350" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638269999460117350" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638269999460117350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638269999460117350" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638269999460127343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638269999460127343" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638269999460127343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638269999460127343" order="5" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638269999460127343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638269999460127343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638269999460127343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638269999460127343" xlink:to="us-gaap_LiabilitiesNoncurrent_638269999460127343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638269999460127343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638269999460127343" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638269999460127343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638269999460127343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638269999460127343" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638269999460127343" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638269999460127343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638269999460127343" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638269999460127343" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638269999460137343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638269999460127343" xlink:to="us-gaap_LiabilitiesCurrent_638269999460137343" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638269999460137343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638269999460137343" xlink:to="us-gaap_AccountsPayableTradeCurrent_638269999460137343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638269999460137343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638269999460137343" xlink:to="us-gaap_AccountsPayableOtherCurrent_638269999460137343" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638269999460137343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638269999460137343" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638269999460137343" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638269999460137343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638269999460137343" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638269999460137343" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638269999460137343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638269999460137343" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638269999460137343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638269999460137343" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638269999460147348" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638269999460147348" xlink:to="us-gaap_OperatingIncomeLoss_638269999460147348" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638269999460147348" xlink:to="us-gaap_Revenues_638269999460147348" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638269999460147348" xlink:to="us-gaap_CostOfRevenue_638269999460147348" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638269999460147348" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638269999460147348" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638269999460147348" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638269999460147348" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638269999460147348" xlink:to="us-gaap_NonoperatingIncomeExpense_638269999460147348" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638269999460147348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638269999460147348" xlink:to="us-gaap_OtherNonoperatingExpense_638269999460147348" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638269999460147348" xlink:to="us-gaap_OtherNonoperatingIncome_638269999460157346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638269999460157346" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638269999460157346" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638269999460157346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638269999460157346" xlink:to="us-gaap_ProceedsFromWarrantExercises_638269999460157346" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638269999460157346" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460157346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460157346" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460157346" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638269999460157346" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638269999460157346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460157346" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638269999460157346" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460157346" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638269999460167343" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460157346" xlink:to="plx_IncreaseDecreaseInBankDeposits_638269999460167343" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_ProfitLoss_638269999460167343" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_ShareBasedCompensation_638269999460167343" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_Depreciation_638269999460167343" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638269999460167343" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638269999460167343" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638269999460167343" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460177348" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638269999460177348" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="plx_GainLossOnDebtConversion_638269999460177348" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638269999460177348" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638269999460177348" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638269999460177348" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_IncreaseDecreaseInInventories_638269999460177348" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638269999460177348" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638269999460177348" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638269999460187346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460167343" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638269999460187346" order="14" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638269999460187346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638269999460187346" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638269999460187346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638269999460187346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638269999460187346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638269999460187346" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" xlink:type="extended" xlink:title="40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638269999460187346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecurities_638269999460187346" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638269999460187346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss_638269999460187346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638269999460197346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638269999460197346" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638269999460197346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638269999460197346" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638269999460197346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638269999460197346" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638269999460197346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638269999460197346" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - TAXES ON INCOME (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460197346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460197346" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638269999460197346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638269999460197346" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638269999460207347" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_InterestPayableCurrent_638269999460207347" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedVacationCurrent_638269999460207347" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638269999460207347" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638269999460207347" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638269999460207347" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_TaxesPayableCurrent_638269999460207347" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638269999460207347" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638269999460207347" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>plx-20230630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/7/2023 10:12:27 AM-->
<!--Modified on: 8/7/2023 10:12:27 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20230630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_FillFinishAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsEnrolled" xlink:label="plx_NumberOfPatientsEnrolled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfPatientsEnrolled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsActivelyParticipating" xlink:label="plx_NumberOfPatientsActivelyParticipating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfPatientsActivelyParticipating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfPatientsDosed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_PaymentsToDebtHoldersOnConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsMember" xlink:label="plx_OutstandingStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_DilutiveSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>plx-20230630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/7/2023 10:12:27 AM-->
<!--Modified on: 8/7/2023 10:12:27 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (net of capital deficiency)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) BEFORE TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for basic calculation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for diluted calculation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnDebtConversion" xlink:to="plx_GainLossOnDebtConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">The amount of gain (loss) on conversion of convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain (Loss) On Debt Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain on conversions of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease in accounts receivable-trade and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts paid (funded) in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Convertible notes conversions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Earnings (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of components of Income Tax Expense (Benefit)</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental Information, Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FillFinishAgreementMember" xlink:to="plx_FillFinishAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtmEquityOfferingSalesAgreementMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to ATM Equity Offering Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">ATM Equity Offering Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsEnrolled" xlink:label="plx_NumberOfPatientsEnrolled" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfPatientsEnrolled" xlink:to="plx_NumberOfPatientsEnrolled_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfPatientsEnrolled_lbl" xml:lang="en-US">Represents the number of patients that were enrolled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfPatientsEnrolled_lbl" xml:lang="en-US">Number Of Patients Enrolled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfPatientsEnrolled_lbl" xml:lang="en-US">Number of patients enrolled</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsActivelyParticipating" xlink:label="plx_NumberOfPatientsActivelyParticipating" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfPatientsActivelyParticipating" xlink:to="plx_NumberOfPatientsActivelyParticipating_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfPatientsActivelyParticipating_lbl" xml:lang="en-US">Represents the number of patients that are actively participating.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfPatientsActivelyParticipating_lbl" xml:lang="en-US">Number Of Patients Actively Participating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfPatientsActivelyParticipating_lbl" xml:lang="en-US">Number of patients actively participating</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfPatientsDosed" xlink:to="plx_NumberOfPatientsDosed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Represents the number of patients that were dosed in the trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Number Of Patients Dosed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Number of patients dosed</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExtendedTermOfAgreement" xlink:to="plx_ExtendedTermOfAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term  of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term of agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentReceived" xlink:to="plx_MilestonePaymentReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received upon achievement of certain milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt Instrument Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt Instrument Fair Value</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted instrument, shares issued</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentsToDebtHoldersOnConversion" xlink:to="plx_PaymentsToDebtHoldersOnConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Payments To Debt Holders On Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Paid to the converting holders</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionDecreaseInPrincipalAmount" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">The amount of decrease in the total principal amount of debt due to conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">Debt Conversion, Decrease In Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">Decrease in principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding stock options and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options And Warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsMember" xlink:label="plx_OutstandingStockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsMember" xlink:to="plx_OutstandingStockOptionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsMember_lbl" xml:lang="en-US">Outstanding stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsMember_lbl" xml:lang="en-US">Outstanding Stock Options</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding stock options and warrants and 2024 notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding Stock Options Warrants And 2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Financial expenses of 2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) for diluted calculation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Weighted average dilutive effect of 2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average dilutive effect of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Weighted average dilutive effect of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MilestonePaymentToRegulatoryApprovals" xlink:label="plx_MilestonePaymentToRegulatoryApprovals" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentToRegulatoryApprovals" xlink:to="plx_MilestonePaymentToRegulatoryApprovals_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_lbl" xml:lang="en-US">Amount of the milestone payments to regulatory approvals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_lbl" xml:lang="en-US">Milestone Payment To Regulatory Approvals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_lbl" xml:lang="en-US">Milestone Payments to regulatory approvals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance related to deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReserveForDeductionsFromRevenueCurrent" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of reserve for deductions from revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve For Deductions From Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve for deductions from revenue</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>plx-20230630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/7/2023 10:12:27 AM-->
<!--Modified on: 8/7/2023 10:12:27 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureEarningsLossPerShare" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureTaxesOnIncome" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureEarningsLossPerShareTables" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureTaxesOnIncomeTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638269999460597352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638269999460597352" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638269999460597352" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638269999460597352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638269999460597352" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638269999460597352" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638269999460597352" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638269999460597352" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638269999460597352" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638269999460597352" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638269999460597352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638269999460597352" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638269999460607351" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638269999460607351" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638269999460607351" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638269999460607351" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638269999460607351" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638269999460607351" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638269999460607351" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638269999460607351" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638269999460607351" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638269999460607351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638269999460607351" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638269999460617353" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638269999460617353" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638269999460617353" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638269999460617353" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638269999460617353" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638269999460617353" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638269999460617353" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638269999460617353" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638269999460617353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638269999460617353" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638269999460627347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638269999460627347" xlink:to="us-gaap_AssetsCurrentAbstract_638269999460627347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638269999460627347" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638269999460627347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638269999460627347" xlink:to="plx_ShortTermBankDeposits_638269999460627347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638269999460627347" xlink:to="us-gaap_AccountsReceivableNetCurrent_638269999460627347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638269999460627347" xlink:to="us-gaap_OtherAssetsCurrent_638269999460627347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638269999460627347" xlink:to="us-gaap_InventoryNet_638269999460627347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638269999460627347" xlink:to="us-gaap_AssetsCurrent_638269999460627347" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638269999460627347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638269999460627347" xlink:to="us-gaap_AssetsNoncurrentAbstract_638269999460627347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638269999460627347" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638269999460637356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638269999460627347" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638269999460637356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638269999460627347" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638269999460637356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638269999460627347" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638269999460637356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638269999460627347" xlink:to="us-gaap_Assets_638269999460637356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638269999460637356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638269999460637356" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460637356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460637356" xlink:to="us-gaap_AccountsPayableTradeCurrent_638269999460637356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460637356" xlink:to="us-gaap_AccountsPayableOtherCurrent_638269999460637356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638269999460637356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460637356" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638269999460637356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638269999460637356" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638269999460647352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638269999460637356" xlink:to="us-gaap_LiabilitiesCurrent_638269999460647352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638269999460647352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638269999460647352" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638269999460647352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638269999460647352" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638269999460647352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638269999460647352" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638269999460647352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" xlink:to="us-gaap_LiabilitiesNoncurrent_638269999460647352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" xlink:to="us-gaap_Liabilities_638269999460647352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638269999460647352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" xlink:to="us-gaap_CommitmentsAndContingencies_638269999460647352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" xlink:to="us-gaap_StockholdersEquity_638269999460657353" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638269999460637356" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638269999460657353" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638269999460657353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460657353" xlink:to="srt_ProductOrServiceAxis_638269999460657353" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638269999460657353" xlink:to="srt_ProductsAndServicesDomain_638269999460657353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638269999460657353" xlink:to="us-gaap_ProductMember_638269999460657353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638269999460657353" xlink:to="us-gaap_LicenseAndServiceMember_638269999460657353" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460657353" xlink:to="us-gaap_StatementLineItems_638269999460657353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638269999460657353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_Revenues_638269999460657353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_CostOfRevenue_638269999460667349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638269999460667349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638269999460667349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_OperatingIncomeLoss_638269999460667349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_OtherNonoperatingExpense_638269999460667349" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_OtherNonoperatingIncome_638269999460667349" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_NonoperatingIncomeExpense_638269999460667349" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638269999460667349" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638269999460667349" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_NetIncomeLoss_638269999460667349" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638269999460667349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_EarningsPerShareBasic_638269999460667349" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_EarningsPerShareDiluted_638269999460677352" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638269999460677352" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460657353" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638269999460677352" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_638269999460677352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460677352" xlink:to="us-gaap_IncomeStatementLocationAxis_638269999460677352" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638269999460677352" xlink:to="us-gaap_IncomeStatementLocationDomain_638269999460677352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638269999460677352" xlink:to="us-gaap_CostOfSalesMember_638269999460677352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638269999460677352" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638269999460677352" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638269999460677352" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638269999460677352" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638269999460677352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460677352" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638269999460677352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638269999460677352" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638269999460687352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638269999460687352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460687352" xlink:to="us-gaap_StatementEquityComponentsAxis_638269999460687352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638269999460687352" xlink:to="us-gaap_CommonStockMember_638269999460687352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638269999460687352" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638269999460687352" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638269999460687352" xlink:to="us-gaap_RetainedEarningsMember_638269999460687352" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638269999460687352" xlink:to="us-gaap_EquityComponentDomain_638269999460687352" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460687352" xlink:to="us-gaap_StatementLineItems_638269999460687352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_StockholdersEquity_638269999460687352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_SharesOutstanding_638269999460687352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638269999460687352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638269999460687352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638269999460687352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638269999460697357" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638269999460697357" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638269999460697357" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638269999460697357" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638269999460697357" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638269999460697357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638269999460697357" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_638269999460697357" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638269999460697357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_NetIncomeLoss_638269999460697357" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_StockholdersEquity_638269999460697357" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638269999460697357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460687352" xlink:to="us-gaap_SharesOutstanding_638269999460697357" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638269999460707354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638269999460707354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_ProfitLoss_638269999460707354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_ShareBasedCompensation_638269999460707354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_Depreciation_638269999460707354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638269999460707354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638269999460707354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460707354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460707354" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638269999460717353" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="plx_GainLossOnDebtConversion_638269999460717353" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638269999460717353" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638269999460717353" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638269999460717353" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638269999460717353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638269999460717353" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638269999460717353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638269999460717353" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638269999460717353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638269999460717353" xlink:to="us-gaap_IncreaseDecreaseInInventories_638269999460717353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638269999460717353" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638269999460717353" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638269999460707354" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638269999460717353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638269999460717353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638269999460717353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638269999460717353" xlink:to="plx_IncreaseDecreaseInBankDeposits_638269999460727357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638269999460717353" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638269999460727357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638269999460717353" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638269999460727357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638269999460717353" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638269999460727357" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638269999460717353" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638269999460727357" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638269999460727357" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638269999460727357" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460727357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638269999460727357" xlink:to="us-gaap_ProceedsFromWarrantExercises_638269999460727357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638269999460727357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638269999460727357" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638269999460727357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638269999460737356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638269999460737356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638269999460737356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638269999460737356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638269999460737356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638269999460737356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6382699994607373561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6382699994607373561" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638269999460737356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638269999460737356" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638269999460737356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638269999460737356" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638269999460737356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638269999460737356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638269999460737356" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638269999460737356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638269999460747352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638269999460737356" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638269999460747352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638269999460747352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638269999460747352" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638269999460747352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638269999460747352" xlink:to="us-gaap_InterestPaidNet_638269999460747352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638269999460747352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638269999460747352" xlink:to="plx_InterestReceivedNet_638269999460747352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638269999460747352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638269999460747352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638269999460757355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638269999460757355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638269999460757355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638269999460757355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_638269999460757355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_638269999460757355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638269999460757355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638269999460757355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShare" xlink:type="extended" xlink:title="10601 - Disclosure - EARNINGS (LOSS) PER SHARE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638269999460757355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638269999460757355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncome" xlink:type="extended" xlink:title="10701 - Disclosure - TAXES ON INCOME">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638269999460767355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638269999460767355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638269999460767355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638269999460767355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10901 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638269999460767355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638269999460767355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638269999460767355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638269999460767355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638269999460767355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638269999460767355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638269999460767355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638269999460767355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638269999460777356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_638269999460777356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460777356" xlink:to="us-gaap_DebtInstrumentAxis_638269999460777356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638269999460777356" xlink:to="us-gaap_DebtInstrumentNameDomain_638269999460777356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638269999460777356" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460777356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460777356" xlink:to="us-gaap_StatementLineItems_638269999460777356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460777356" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638269999460777356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638269999460777356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638269999460777356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" xlink:type="extended" xlink:title="30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638269999460787353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638269999460787353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" xlink:type="extended" xlink:title="30703 - Disclosure - TAXES ON INCOME (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638269999460787353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638269999460787353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638269999460787353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638269999460787353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638269999460787353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638269999460787353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638269999460787353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638269999460787353" xlink:to="us-gaap_TypeOfArrangementAxis_638269999460787353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460787353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638269999460787353" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460787353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460787353" xlink:to="plx_AmendedPfizerAgreementMember_638269999460797355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460787353" xlink:to="plx_ChiesiAgreementsMember_638269999460797355" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638269999460797355" xlink:to="plx_ChiesiUSAgreementMember_638269999460797355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638269999460797355" xlink:to="plx_ChiesiExUSAgreementMember_638269999460797355" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460787353" xlink:to="plx_FillFinishAgreementMember_638269999460797355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460787353" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638269999460797355" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638269999460787353" xlink:to="dei_LegalEntityAxis_638269999460797355" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638269999460797355" xlink:to="dei_EntityDomain_638269999460797355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638269999460797355" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638269999460797355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638269999460787353" xlink:to="srt_StatementGeographicalAxis_638269999460797355" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638269999460797355" xlink:to="srt_SegmentGeographicalDomain_638269999460797355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638269999460797355" xlink:to="country_BR_638269999460797355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638269999460797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638269999460787353" xlink:to="srt_RangeAxis_638269999460797355" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638269999460797355" xlink:to="srt_RangeMember_638269999460807355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638269999460807355" xlink:to="srt_MinimumMember_638269999460807355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638269999460807355" xlink:to="srt_MaximumMember_638269999460807355" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638269999460787353" xlink:to="us-gaap_DebtInstrumentAxis_638269999460807355" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638269999460807355" xlink:to="us-gaap_DebtInstrumentNameDomain_638269999460807355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638269999460807355" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638269999460807355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638269999460807355" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460807355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638269999460787353" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638269999460807355" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638269999460807355" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460807355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638269999460807355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460807355" xlink:to="plx_AtMarketEquityOfferingMember_638269999460807355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460807355" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638269999460817368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638269999460787353" xlink:to="plx_SignificantAccountingPoliciesLineItems_638269999460817368" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638269999460817368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsEnrolled" xlink:label="plx_NumberOfPatientsEnrolled_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_NumberOfPatientsEnrolled_638269999460817368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsActivelyParticipating" xlink:label="plx_NumberOfPatientsActivelyParticipating_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_NumberOfPatientsActivelyParticipating_638269999460817368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_NumberOfPatientsDosed_638269999460817368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638269999460817368" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638269999460817368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638269999460817368" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638269999460827352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638269999460827352" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638269999460827352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638269999460827352" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460827352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460827352" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638269999460827352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638269999460827352" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638269999460827352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638269999460827352" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638269999460827352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_ExtendedTermOfAgreement_638269999460827352" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638269999460827352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_AgreementAmendmentPaymentReceivable_638269999460827352" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638269999460837353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638269999460837353" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638269999460837353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638269999460837353" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638269999460837353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_MilestonePaymentReceived_638269999460837353" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638269999460837353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_PaymentOnNetSalesPercentage_638269999460837353" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638269999460837353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638269999460837353" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638269999460837353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638269999460837353" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_638269999460837353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_RevenuePerformanceObligationNumber_638269999460837353" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638269999460847359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638269999460847359" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_638269999460847359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638269999460817368" xlink:to="plx_MaintainOfMinimumCashBalance_638269999460847359" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638269999460847359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638269999460847359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638269999460847359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638269999460847359" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638269999460847359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638269999460847359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638269999460847359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638269999460847359" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460857383" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460857383" xlink:to="us-gaap_DebtInstrumentAxis_638269999460857383" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638269999460857383" xlink:to="us-gaap_DebtInstrumentNameDomain_638269999460857383" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638269999460857383" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638269999460857383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638269999460857383" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460857383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460857383" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638269999460857383" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638269999460857383" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638269999460857383" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638269999460857383" xlink:to="us-gaap_FairValueInputsLevel3Member_638269999460857383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460857383" xlink:to="us-gaap_MeasurementInputTypeAxis_638269999460857383" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638269999460857383" xlink:to="us-gaap_MeasurementInputTypeDomain_638269999460857383" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638269999460857383" xlink:to="us-gaap_MeasurementInputSharePriceMember_638269999460857383" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638269999460857383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638269999460857383" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638269999460857383" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638269999460867432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638269999460857383" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638269999460867432" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638269999460867432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638269999460857383" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638269999460867432" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_638269999460867432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638269999460857383" xlink:to="plx_MeasurementInputYieldMember_638269999460867432" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638269999460867432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460857383" xlink:to="us-gaap_StatementLineItems_638269999460867432" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638269999460867432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460867432" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638269999460867432" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460867432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460867432" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460867432" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638269999460877374" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638269999460877374" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638269999460877374" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638269999460877374" xlink:to="us-gaap_FairValueInputsLevel3Member_638269999460877374" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460867432" xlink:to="us-gaap_DebtInstrumentAxis_638269999460877374" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638269999460877374" xlink:to="us-gaap_DebtInstrumentNameDomain_638269999460877374" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638269999460877374" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460877374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638269999460867432" xlink:to="us-gaap_StatementLineItems_638269999460877374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460877374" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638269999460877374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460877374" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638269999460877374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_638269999460877374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638269999460877374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460877374" xlink:to="srt_ProductOrServiceAxis_638269999460877374" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638269999460877374" xlink:to="srt_ProductsAndServicesDomain_638269999460887362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638269999460887362" xlink:to="us-gaap_ProductMember_638269999460887362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638269999460887362" xlink:to="us-gaap_LicenseAndServiceMember_638269999460887362" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460877374" xlink:to="srt_StatementGeographicalAxis_638269999460887362" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638269999460887362" xlink:to="srt_SegmentGeographicalDomain_638269999460887362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638269999460887362" xlink:to="plx_PfizerMember_638269999460887362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638269999460887362" xlink:to="country_BR_638269999460887362" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638269999460887362" xlink:to="plx_ChiesiMember_638269999460887362" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638269999460877374" xlink:to="us-gaap_StatementLineItems_638269999460887362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638269999460887362" xlink:to="us-gaap_Revenues_638269999460887362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638269999460887362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638269999460887362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638269999460887362" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638269999460897358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638269999460897358" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460897358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460897358" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638269999460897358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638269999460897358" xlink:to="us-gaap_PrivatePlacementMember_638269999460897358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638269999460887362" xlink:to="us-gaap_DebtInstrumentAxis_638269999460897358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638269999460897358" xlink:to="us-gaap_DebtInstrumentNameDomain_638269999460897358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638269999460897358" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638269999460897358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638269999460887362" xlink:to="us-gaap_ClassOfStockLineItems_638269999460897358" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638269999460897358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="us-gaap_CommonStockSharesAuthorized_638269999460897358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638269999460897358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638269999460897358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638269999460897358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="us-gaap_ProceedsFromWarrantExercises_638269999460897358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638269999460907356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638269999460907356" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="plx_PaymentsToDebtHoldersOnConversion_638269999460907356" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount_638269999460907356" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638269999460897358" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638269999460907356" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638269999460907356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638269999460907356" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638269999460907356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638269999460907356" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638269999460907356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_638269999460907356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638269999460907356" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_638269999460907356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsMember" xlink:label="plx_OutstandingStockOptionsMember_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638269999460907356" xlink:to="plx_OutstandingStockOptionsMember_638269999460917353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638269999460907356" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638269999460917353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638269999460907356" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638269999460917353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638269999460917353" xlink:to="us-gaap_NetIncomeLossAbstract_638269999460917353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638269999460917353" xlink:to="us-gaap_NetIncomeLoss_638269999460917353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638269999460917353" xlink:to="us-gaap_DilutiveSecurities_638269999460917353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638269999460917353" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638269999460917353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638269999460917353" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638269999460917353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638269999460917353" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638269999460917353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638269999460917353" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638269999460917353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638269999460917353" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638269999460917353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638269999460917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638269999460917353" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638269999460917353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638269999460917353" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638269999460927348" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638269999460917353" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638269999460927348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - TAXES ON INCOME (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638269999460927348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638269999460927348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638269999460927348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638269999460927348" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638269999460927348" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_MilestonePaymentToRegulatoryApprovals" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="plx_MilestonePaymentToRegulatoryApprovals_638269999460927348" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638269999460927348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638269999460927348" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638269999460937352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="us-gaap_InterestPayableCurrent_638269999460937352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="us-gaap_AccruedVacationCurrent_638269999460937352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638269999460937352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638269999460937352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="us-gaap_TaxesPayableCurrent_638269999460937352" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638269999460937352" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638269999460937352" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638269999460937352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638269999460937352" xlink:to="us-gaap_AccountsPayableCurrent_638269999460937352" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638269999460947352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638269999460947352" xlink:to="us-gaap_SubsequentEventTypeAxis_638269999460947352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638269999460947352" xlink:to="us-gaap_SubsequentEventTypeDomain_638269999460947352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638269999460947352" xlink:to="us-gaap_SubsequentEventMember_638269999460947352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638269999460947352" xlink:to="us-gaap_TypeOfArrangementAxis_638269999460947352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638269999460947352" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460947352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460947352" xlink:to="plx_PfizerAgreementMember_638269999460947352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638269999460947352" xlink:to="plx_ChiesiAgreementsMember_638269999460947352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638269999460947352" xlink:to="us-gaap_SubsequentEventLineItems_638269999460947352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638269999460947352" xlink:to="us-gaap_CommonStockSharesAuthorized_638269999460947352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230630.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_638269999460947352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638269999460947352" xlink:to="plx_ProceedsFromSaleOfProducts_638269999460947352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025577009856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,580,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025573861232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 48,184<span></span>
</td>
<td class="nump">$ 17,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">4,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,708<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">19,635<span></span>
</td>
<td class="nump">16,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">73,576<span></span>
</td>
<td class="nump">44,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,268<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,637<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">3,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,806<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">88,417<span></span>
</td>
<td class="nump">55,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">3,304<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">18,545<span></span>
</td>
<td class="nump">12,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,109<span></span>
</td>
<td class="nump">32,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">20,132<span></span>
</td>
<td class="nump">28,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,577<span></span>
</td>
<td class="nump">4,169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">26,307<span></span>
</td>
<td class="nump">33,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">49,416<span></span>
</td>
<td class="nump">66,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">39,001<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (net of capital deficiency)</a></td>
<td class="nump">$ 88,417<span></span>
</td>
<td class="nump">$ 55,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025577074992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35,075<span></span>
</td>
<td class="nump">$ 8,753<span></span>
</td>
<td class="nump">$ 44,663<span></span>
</td>
<td class="nump">$ 24,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(6,148)<span></span>
</td>
<td class="num">(4,087)<span></span>
</td>
<td class="num">(9,233)<span></span>
</td>
<td class="num">(10,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(4,475)<span></span>
</td>
<td class="num">(7,579)<span></span>
</td>
<td class="num">(10,322)<span></span>
</td>
<td class="num">(16,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(4,031)<span></span>
</td>
<td class="num">(2,611)<span></span>
</td>
<td class="num">(7,146)<span></span>
</td>
<td class="num">(5,765)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,421<span></span>
</td>
<td class="num">(5,524)<span></span>
</td>
<td class="nump">17,962<span></span>
</td>
<td class="num">(7,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,305)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
<td class="num">(2,169)<span></span>
</td>
<td class="num">(1,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">531<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES), NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(774)<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,647<span></span>
</td>
<td class="num">(5,334)<span></span>
</td>
<td class="nump">16,711<span></span>
</td>
<td class="num">(7,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 19,339<span></span>
</td>
<td class="num">$ (5,334)<span></span>
</td>
<td class="nump">$ 16,208<span></span>
</td>
<td class="num">$ (7,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,158,628<span></span>
</td>
<td class="nump">47,327,952<span></span>
</td>
<td class="nump">62,378,745<span></span>
</td>
<td class="nump">46,589,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,200,641<span></span>
</td>
<td class="nump">47,327,952<span></span>
</td>
<td class="nump">78,896,220<span></span>
</td>
<td class="nump">46,589,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,075<span></span>
</td>
<td class="nump">$ 3,382<span></span>
</td>
<td class="nump">$ 20,141<span></span>
</td>
<td class="nump">$ 12,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 24,522<span></span>
</td>
<td class="nump">$ 12,428<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025576816464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025574516096">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 368,852<span></span>
</td>
<td class="num">$ (374,934)<span></span>
</td>
<td class="num">$ (6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,395,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,620)<span></span>
</td>
<td class="num">(7,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">372,616<span></span>
</td>
<td class="num">(382,554)<span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,712,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">369,688<span></span>
</td>
<td class="num">(377,220)<span></span>
</td>
<td class="num">(7,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46,316,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,395,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(5,334)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">372,616<span></span>
</td>
<td class="num">(382,554)<span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,712,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">379,167<span></span>
</td>
<td class="num">(389,861)<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53,790,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">23,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">538,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,208<span></span>
</td>
<td class="nump">16,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">412,582<span></span>
</td>
<td class="num">(373,653)<span></span>
</td>
<td class="nump">39,001<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">71,580,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">393,938<span></span>
</td>
<td class="num">(392,992)<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">62,002,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">9,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,347,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">538,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,339<span></span>
</td>
<td class="nump">19,339<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 412,582<span></span>
</td>
<td class="num">$ (373,653)<span></span>
</td>
<td class="nump">$ 39,001<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">71,580,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of June 30, 2023 and 2022 &#8211; 144,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025576976224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025573886864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 16,208<span></span>
</td>
<td class="num">$ (7,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred tax asset</a></td>
<td class="num">(3,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnDebtConversion', window );">Gain on conversions of convertible notes</a></td>
<td class="num">(421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability</a></td>
<td class="num">(13,178)<span></span>
</td>
<td class="num">(2,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in accounts receivable-trade and other assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(2,831)<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="num">(4,864)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="num">(13,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(452)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts paid (funded) in respect of employee rights upon retirement, net</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,510<span></span>
</td>
<td class="num">(15,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">23,954<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,666<span></span>
</td>
<td class="nump">2,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">31,073<span></span>
</td>
<td class="num">(26,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">38,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">48,184<span></span>
</td>
<td class="nump">12,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="nump">7,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575622368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). The Company&#8217;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), the Company&#8217;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> except in Brazil where it is marketed as BioManguinhos alfataliglicerase) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Currently, in the aggregate, 126 patients are enrolled, and 116 patients are actively participating, in such studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">In addition to Elfabrio, the Company successfully developed taliglucerase alfa, an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease, that has been approved for marketing in the United States, Brazil, Israel and other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase I First in Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of the date hereof, 13 patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of June&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug substance from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#8220;Brazil Agreement&#8221;) for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of June&#160;30, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of June&#160;30, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575848688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2023 and December&#160;31, 2022 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025576141072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of June&#160;30, 2023, the fair value of the $20.4&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $28.1&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025576476160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025579449568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 144,000,000 to 185,000,000 (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(b)</b></span><b style="font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the six months ended June&#160;30, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $24.9&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(c)</b></span><b style="font-weight:bold;background:#ffffff;">Exercise of Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;8, 2023, the Company issued 301,810 shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company generated net proceeds equal to $0.7&#160;million from the exercise of the warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;10, 2023, the Company issued 237,012 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 845,000 shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(d)</b></span><b style="font-weight:bold;background:#ffffff;">Conversion of 2024 Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the six months ended June&#160;30, 2023, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during the six months ended June&#160;30, 2023, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $8.3&#160;million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575839904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of the Company&#8217;s Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii) the conversion of the convertible notes using the&#160;&#8220;if-converted&#8221;&#160;method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 19,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,620)</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,749)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,620)</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 67,158,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,327,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 62,378,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,589,976</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,355,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,274,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,555,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,243,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 131,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 83,200,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,327,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 78,896,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,589,976</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 16,158,086 shares of Common Stock underlying outstanding stock options and warrants of the Company for the six months ended June&#160;30, 2023 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 1,896,733 shares of Common Stock underlying outstanding stock options of the Company for the three months ended June&#160;30, 2023 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 32,960,732 and 32,982,043 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three and six months ended June&#160;30, 2022, respectively, because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575754512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,633</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,130)</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of 3% for the six months ended June&#160;30, 2023, compared to an effective tax rate of 0% for the six months ended June&#160;30, 2022. For the six months ended June&#160;30, 2023, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In the second quarter ended June&#160;30, 2023, following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025579726016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,216</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,478</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 781</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserve for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,271</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575561728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;14, 2023, the Company collected approximately $1.1&#160;million, in the aggregate, from sales to Pfizer. On July&#160;7, 2023, the Company collected approximately $1.0&#160;million from Chiesi<span style="background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025576983376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). The Company&#8217;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), the Company&#8217;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> except in Brazil where it is marketed as BioManguinhos alfataliglicerase) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Currently, in the aggregate, 126 patients are enrolled, and 116 patients are actively participating, in such studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">In addition to Elfabrio, the Company successfully developed taliglucerase alfa, an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease, that has been approved for marketing in the United States, Brazil, Israel and other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase I First in Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of the date hereof, 13 patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of June&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug substance from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#8220;Brazil Agreement&#8221;) for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of June&#160;30, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of June&#160;30, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025574096896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025579419648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575767184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575767184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 19,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,620)</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,749)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,620)</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 67,158,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,327,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 62,378,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,589,976</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,355,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,274,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,555,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,243,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 131,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 83,200,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,327,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 78,896,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,589,976</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575602016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,633</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,130)</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575767184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,216</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,478</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 781</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserve for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,271</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025569011120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 21, 2023 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfPatientsEnrolled', window );">Number of patients enrolled | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfPatientsActivelyParticipating', window );">Number of patients actively participating | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfPatientsDosed', window );">Number of patients dosed | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,954<span></span>
</td>
<td class="nump">$ 2,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfPatientsActivelyParticipating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of patients that are actively participating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfPatientsActivelyParticipating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfPatientsDosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of patients that were dosed in the trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfPatientsDosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfPatientsEnrolled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of patients that were enrolled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfPatientsEnrolled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025577028560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,352<span></span>
</td>
<td class="nump">$ 3,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">3,318<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">11,965<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 19,635<span></span>
</td>
<td class="nump">$ 16,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025574103168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">1.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">5.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">60.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">12.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025575702912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 20,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt Instrument Fair Value</a></td>
<td class="nump">$ 28,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025568979648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 35,075<span></span>
</td>
<td class="nump">$ 8,753<span></span>
</td>
<td class="nump">$ 44,663<span></span>
</td>
<td class="nump">$ 24,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">15,075<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">20,141<span></span>
</td>
<td class="nump">12,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,402<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
<td class="nump">6,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">5,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">11,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,673<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 24,522<span></span>
</td>
<td class="nump">$ 12,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025570914768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">237,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,954<span></span>
</td>
<td class="nump">$ 2,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentsToDebtHoldersOnConversion', window );">Paid to the converting holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtConversionDecreaseInPrincipalAmount', window );">Decrease in principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionDecreaseInPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in the total principal amount of debt due to conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionDecreaseInPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentsToDebtHoldersOnConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentsToDebtHoldersOnConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025573909056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 19,339<span></span>
</td>
<td class="num">$ (5,334)<span></span>
</td>
<td class="nump">$ 16,208<span></span>
</td>
<td class="num">$ (7,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Financial expenses of 2024 Notes</a></td>
<td class="num">(1,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) for diluted calculation</a></td>
<td class="nump">$ 17,590<span></span>
</td>
<td class="num">$ (5,334)<span></span>
</td>
<td class="nump">$ 14,155<span></span>
</td>
<td class="num">$ (7,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Common Stock outstanding for basic calculation</a></td>
<td class="nump">67,158,628<span></span>
</td>
<td class="nump">47,327,952<span></span>
</td>
<td class="nump">62,378,745<span></span>
</td>
<td class="nump">46,589,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Weighted average dilutive effect of 2024 Notes</a></td>
<td class="nump">14,355,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,274,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average dilutive effect of stock options</a></td>
<td class="nump">1,555,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Weighted average dilutive effect of warrants</a></td>
<td class="nump">131,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Common Stock outstanding for diluted calculation</a></td>
<td class="nump">83,200,641<span></span>
</td>
<td class="nump">47,327,952<span></span>
</td>
<td class="nump">78,896,220<span></span>
</td>
<td class="nump">46,589,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember', window );">Outstanding Stock Options And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,158,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsMember', window );">Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,896,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember', window );">Outstanding Stock Options Warrants And 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,960,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,982,043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025573818928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="nump">$ 3,438<span></span>
</td>
<td class="nump">$ 3,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="num">(3,130)<span></span>
</td>
<td class="num">(3,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentToRegulatoryApprovals', window );">Milestone Payments to regulatory approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance related to deferred tax assets</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentToRegulatoryApprovals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the milestone payments to regulatory approvals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentToRegulatoryApprovals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025574115984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,223<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,526<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,608<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">3,163<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReserveForDeductionsFromRevenueCurrent', window );">Reserve for deductions from revenue</a></td>
<td class="nump">1,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 18,545<span></span>
</td>
<td class="nump">$ 12,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReserveForDeductionsFromRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of reserve for deductions from revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReserveForDeductionsFromRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140025570193728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pfizer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds From Sale Of Products</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds From Sale Of Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>plx-20230630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20230630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20230630.xsd" xlink:type="simple"/>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jMPvUoYVVEu_xO49zfmz6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2f7dHNiIfkWbGa0IWZYg0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2xh1OXXKFE-Kulcz9V8NMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDq4696d-UOcccu_7Cvwag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_lBFN3DQNxUiobmz6_ZkcBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dL4kaY7_k0Gt7Ul51ddaLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CAoUZ3xsTECjrgCTvfsWpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jB7j7aZTuECzxWimg8CXLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li-HD8Y0uUCsTeiv7eapQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsElhEMx2ES3jtK9Y9EB9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b3NmpKIJr0-JCDPkDs2yZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_FBZ8Tp5vLEKjPPGlg8URdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i4Rr-h0DiEmI3X2F-6HTrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TjGEUWhlV0-DICU_0AaPHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_r6SoXt1a2UaK8KRu3WmzvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_piQqP256hEOa27v5mbImJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyjWpJkL4Eu5oaahwOaq8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6EY8ZLejPkaK5jN5fkWHzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0fDfLHqQbUOjSUb7SXk8-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DbnmycSCC06iSdpupTbnrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__XyDi3xaVUOhI8hK5ZkSag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_KZqJ5slPPEGfEAtG9oUahg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JGEYQ_-rNEe6Bkb5w86nqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_cxV5YkmyMkOdKBiC71d5Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_YISAxiydmUe42opqwLUlVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_2OozcC2UK0uAy4FUBp84ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_CNF4wwqArE-QJGN7-yi3Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_3xKKEe90x0i1wtZ9ei35MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_nw34ZM_veUiZ_WWpDb01mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GYEteH5yxkOi3Fycl0MiGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_kHP60lRxy0Cl3Ghw5nGl3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_2htVCHKOakKxo0P6Mt-phw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_oCwNjjGdSkSVxZt-Jq0NGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M8LWQVl8T0y-iXLLBJWW4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2023_To_5_8_2023_WubO3bm2MUSrkueojHRBdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_9vEHwV8JlEq0c99K7nQPGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xg4mR_srVEOznTErp8pnVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_UTKUBS9fE0iLVZ9EFrAJiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WFc9oZvin0GRCHLpUhlF4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rEn92dYq-0ijjN1WMEHxjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GT5dNEEhVU-SSWfxxPmtuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W1NCM3GJAEO9AOQP2LXSDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_KY-ma-SuxE6JsnDPAL7QoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XOS2xaTk5EWDha2vAO2bxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_h_ZFDwKXEkyuUN5mMKV7ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i364BLxb4EuwXvVZ-E3v4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_HUfqWHV6HE6-7_b8ousHhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2023_GhxIuEgHh0-KdnsF3PgcOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_24_2023_Fc4rDyr3_EmtZXvFeu0hug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ri18SJ0PQE-p2S56WmoUmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_o66HQb4RTU6YeX4ytF2Xyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_SZhJbmB8HUGxaWk_ZQO-6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsMember_ORrJrQ2JFkyptwnKkDK9ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_giw5lYGyHk2z5Tsr-qoIyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_Bvgp1anEpkieiOQvLEWBZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_eQMenfm7EU-xHazziK7JOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fpNYRx6x8EuZW-bIDYLU9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aD3nH1aLCUqeL-tmXCvk2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XAvFwxyFCEqwxJ0AjpLtzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Y1sSF-J3QESve0bxhy5HKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JzsNZYTG20y3XtcplisU6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_FWuVkyQiG02-RIndYlC-aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1_rwBZR3HkGX0wF4AjdCSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MMPQZ_UDMEiuFwLxSK6mJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G4WzsvxhnE6EeNdK2xBSHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d5yjCdKWyUm8nc8BaZtkgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NScsocUMtU2QHthjRxtAQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ENltzQ0-bEaXq264zzSKaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_f4fIos5PMUmhCLw2-9tJyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Rk6iSTTZ8E2nfQOmpW14IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_5_10_2023_To_5_10_2023_kzlqsZvS4kOBpSRWM3vhTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-05-10</startDate>
            <endDate>2023-05-10</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1pbkqm0PNU-3n1SC2J0weg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Ta0zpsSnik2xFK3Rjys-yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_KuSCtZl5_0aMliO15-tKbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_MK5otss99UeqSBlxwWlVCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_u8htPnnek06B3-QkyDCiAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_14_2023_To_7_14_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_8xJeZMuB3U2g_8i3Y-HmUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-14</startDate>
            <endDate>2023-07-14</endDate>
        </period>
    </context>
    <context id="Duration_7_7_2023_To_7_7_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_16ZP9euma0-A-zyLjLyJAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DleZZTmqnkqE26Xs8euChA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_4aJya2GEz0u8k1VFkbnZgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_ibjkwjeinUigCNCGceGaYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hzlZO_DQb0WzzjogYuqErw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_3_21_2023_K3ZvOjH68UyliMbYRqXDCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_A791LfE6c06Ffo0FaCMpfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_RrH2ndyoyUWCJiK_yzGWKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EkdrbNRlwEWh5sJiOa4BPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_JB76OZ74g0mWS8x6-0BM6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxPP66-FEG8RWl0rfhx_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_OdlZNkXl6UaVoC041YLuMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r_ehkfZA20uqfwPPaAkqOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_T2FJkJmPOkmmfxXV-kkOJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CjEp8-HoFkWDhnqgJoKWcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_1_2023_WxO4EWQMiE2Vp9QMbIQlew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_v67Atkda-ku71Q2qAiO_QQ">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      id="Hidden_mbkcZ_Nd20m45FPQ8bvgjQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      id="Hidden_uH3B7P4yAkaoJyxywZubCQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_WKImfigiu0il-Yb9zrSGyw_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_-rivtPWdLUCrPnB5myXwrQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_kx2QpFpFyUq6WhUlXv7gxA_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_1GIvMbX7iE6qvbOyyAl1gg_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_k8S2F6cOw02mltjOKX8RHA_6_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_4dK64nHMREqzEQeiIeJAMQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_G8ilk0hK40uQqxnLTGDHdA">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_roXtq4TMD0iHGroZsSBFCQ">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_jIyyXuqd_kydkCUfIwWB1Q">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_retCiUyRWEeWhzyQH0uQ_g">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_kuoPCtjybkKxxhhCOaBM2Q">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_UVsxDkbbz0yPRKUlPBUV3w_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_w8JQuPXc7kyKhJOmEKcceQ">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_DIYfSw3VFkC5Rfy0Z78TJQ">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_D4EFJiBAj0uOd_7HM2P1HA">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_d4PIaWBOn0mo8EvhWK9mwg">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_4MkB6E2SyE6Y-48bnwNIEA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_UHG_lbvPPUOXM9zm0sEJzQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_ZqUBHBo2lUWQMm1SZiOp4Q">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_9Z61G6d-nU-Ey_E9YIM9lQ">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_8CYPE57L9UqhtnO-baF7mg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_kdyPGYR6dEKDXcVHmQrbUw_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_6b-bEwHJg0CBm-k3RRW8fg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_PHwGxvRofEyzjv8M_un70Q">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_v-LA17o_cUGTZKw60TmwvQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_ecdZrdJXUE2DAtMUstWKFg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_JwVgLJsHv020MfZQobWHLA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tc_7x-OrhqzV0CP_-EwLDYT4Q_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Narr_ClU9Zq5g5USgVv6L-MBdEA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_1_2023_WxO4EWQMiE2Vp9QMbIQlew"
      decimals="INF"
      id="Narr_OCkIvtwYz0OASi_6kE1w0g"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">71580762</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc__ggndNuEY0q00Rnnack2NA_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">48184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_LgBjCAUuCUW5GjwfhwL5NA_6_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">17111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_kINlhx8B3EGpoZv0mKuKbA_7_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5069000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_obXESkiLLUerOBW7iOqZgA_8_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4049000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_h_BCyZapKkGCK0q418QQ8g_8_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4586000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_wsbbEPBZZEyKBABjc-ouZw_9_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1708000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_EjhY0pXpxkq81ba8bOnLOA_9_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1310000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_NZS5dFy0OUexIvWU5TdPAg_10_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">19635000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_NiWhLAVj8EWem2UOA2YKlw_10_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16804000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_9lIJZZi83EuVubISiuDa1g_11_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">73576000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_XlsGylpYM02inKzwlVXfIw_11_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">44880000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_9raEolIwTE6NiRlRYHCfOg_14_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1268000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_BGE9XHdi8UOUyneTRR8sfQ_14_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1267000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_26PPGd7daUWGF9MMo9A9tA_15_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4637000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_8oqpp-KcUUqJLw5SjcEzEA_15_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4553000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_gKIftPAe7UiKuOYBaQPxaA_16_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3130000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_qZW30Og26EueDGM_PiLBeA_17_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5806000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_dymNpoflskSYiN6V4cWcZQ_17_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5087000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_RAoufPrk9kW6pQdf1Z72Fw_18_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">88417000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_PchTUBsPhUeVJjTROzquVg_18_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">55787000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_Kn6wWMczV06PwNhEWlapbw_24_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3304000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_wjbIPtOonEiMh7-OXu82HQ_24_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5862000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_ZoyO1iFsrUG0GqJS1UbXGQ_25_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">18545000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_VPbEQJ_onkyojhjLjOJcgQ_25_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">12271000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_B4NSkW-38kO7zcqk6XbK1w_26_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1260000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_a6oIgCFR-kOr6l64LmYwTA_26_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1118000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_pKBuMd2MC0S4y1SCrOboYQ_27_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">13178000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_sR0BL8g-906ev0WcLEWOxw_28_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">23109000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_jnetS9k4EU292yua6Q4Z6w_28_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">32429000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_sSosYVK0qEKFkVRIQGTt3A_31_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20132000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_6g6MkomXy06nwDLidV9kEw_31_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">28187000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_fqlP8dZ1_kyBrYU4TJIUvw_32_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1598000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_h5ZEEPF6ek2qB4trUQdGfg_32_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1642000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_g30Fqpy6sUacH2_gqiPIOQ_33_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4577000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_XFYAoUSOTkqLIbApoAl1Tw_33_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4169000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_arXoDI8pHU-M38GnyndoJQ_34_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">26307000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_7c2MYTjlbEGyqRmEFtK11A_34_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">33998000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_0drEmCywL0WZXWpTlZLoBw_35_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">49416000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_dfk1vJUMIU6zVbenvd4P3w_35_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">66427000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_Kt1bVOYhwUGVWQD9ZN8bBw_39_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">39001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_xlc6R8Nh7EOLDLiYJpmjxg_39_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-10640000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_Jw0WY6k18ka-E110N_Fweg_40_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">88417000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_Sn1pzxneYkOCes-05cWPqw_40_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">55787000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_YISAxiydmUe42opqwLUlVA"
      decimals="-3"
      id="Tc_4-qKSm-1d0SGvB48LpLUVQ_3_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20141000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_oCwNjjGdSkSVxZt-Jq0NGA"
      decimals="-3"
      id="Tc_nLi5Ua9vDU6yFuRxiY_4xA_3_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">12410000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DbnmycSCC06iSdpupTbnrQ"
      decimals="-3"
      id="Tc_28tSQcsBOUe_yMOg3rzw1A_3_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">15075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_3xKKEe90x0i1wtZ9ei35MQ"
      decimals="-3"
      id="Tc_-iKTPhNKekCMHIPfzu2dgA_3_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_2OozcC2UK0uAy4FUBp84ug"
      decimals="-3"
      id="Tc_4VaQCYX-Pk2uG5i5zo0jKw_4_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">24522000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M8LWQVl8T0y-iXLLBJWW4g"
      decimals="-3"
      id="Tc_ONQeyfVMC06PwM8brxgKwg_4_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">12428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__XyDi3xaVUOhI8hK5ZkSag"
      decimals="-3"
      id="Tc_FntgDK7L-UaT5b3OgCwX7g_4_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_nw34ZM_veUiZ_WWpDb01mg"
      decimals="-3"
      id="Tc_fmEkvjS7zEWkXyZsL8ht7w_4_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_7nfxKRYll0mhnU1VsZfZ2g_5_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">44663000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_ZeHLlweEyUexmH43M841lw_5_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">24838000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_vFNNplfRrUKTTLzCkEUkRA_5_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">35075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_yxqmdjiLsEKbOgr1DdUTRw_5_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">8753000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_FcQpeS2QMUSw539x2sLD6w_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">9233000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_8-mg9-0bv0WqhS2MXDxbiw_6_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">10121000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_76HgycOXrEu1DFgY29kquw_6_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">6148000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_5WdWTblMjUeT0pK-FtB8CQ_6_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4087000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_0Ncf6ddh8U2WaWytFeW2sw_7_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">10322000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_Vmeaqo5FBkabe_UXXmL7BA_7_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16346000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_ekk8r0vCc0anL7WCzi162A_7_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4475000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_3FdqAtg-QkquKsONqBAcYw_7_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7579000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_7jNoLHuUg0CXsTnEiCT0QQ_8_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7146000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_6IrXNofQNE2QdNwj3_zx8Q_8_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5765000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_ukdMAx9UTkyI1jGkEE71LQ_8_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4031000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_ZbEKE5md2EGkbm08lQVehg_8_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2611000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_0xmg5XJzEUGTEY1OSKQwaw_9_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">17962000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_zgoCHrGPMEmnnn5vVR0wWA_9_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7394000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc__7cultcQHEOVrNcFpfdauA_9_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20421000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_Qkn8GvGz-0KWMl-D9nYrPQ_9_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-5524000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_pNchChBg906pLK3M6ZDXTg_10_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2169000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_8N0F7UZgAU-sqkZNtGKUag_10_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1242000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_jUsje8s8MkigasfQm2enuA_10_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1305000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_zFAzpOUR4E62EIi9Dm_1Eg_10_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">623000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_pZku5HU7H0aAR4DNH1AGNQ_11_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">918000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_82DqNpGfZkeUp84Xs_3fkQ_11_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1016000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_qgkhCiVR-EK-I40oH8MN7w_11_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">531000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_6IbSj_M-D0OYW5oDyZpe4g_11_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">813000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_76qiZI0W206PIvWOAuhdug_12_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-1251000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_Wdk0C2q0A0GoH74y2klkKg_12_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-226000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_Kqih_MxP0UmeSwDeA4gIEQ_12_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-774000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_2aPVOENwc0WPGcgJNL5n-A_12_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_P71HOsPkB0GPhDaXqf9QPw_13_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16711000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_V9wV6pVWyE-DdDMMF7ydEQ_13_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7620000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_Qzn7X_7GLUeAXs541fY90Q_13_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">19647000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_VZhZpFy3WEeSzIdzGXQB5A_13_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-5334000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_gO4f4LVqQUSrg6gDCh7QBw_14_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_A6xc-Ug2lkmjC_50Om_qoQ_14_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">308000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_x3nugp_ZDkGMQUzLe40SxA_15_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_TmtSaC0WT0uC5ZlyQeLxOw_15_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7620000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_O8F-HfyJFkK_0IMUMPQ2iQ_15_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">19339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_EocGnRW0HU-QHIjGu1bbOw_15_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-5334000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="2"
      id="Tc_V2zcm2OmVkOIVFeyAVlOhg_17_3"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="2"
      id="Tc_yCgNFJ7iU0qKm_658MTNeg_17_6"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="2"
      id="Tc_kDo9wd7XX0u1uBbfkBWufA_17_9"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="2"
      id="Tc_aO3LIuBV8Ee8QYcscQxVbQ_17_12"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="2"
      id="Tc_bpphsVuJsECSBqTh6PYfSg_18_3"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="2"
      id="Tc_teKIziyBEEKnwe_92r2JCw_18_6"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="2"
      id="Tc_5dqZxDXrOUupNm3tRhWnYQ_18_9"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="2"
      id="Tc_l1osm3-23kuU4lnvn_c2QA_18_12"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="0"
      id="Tc_wlMR0bNcD0CUugd8BUTTDg_21_3"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">62378745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="0"
      id="Tc_0Pb7ToQwd0m7V968R--ysQ_21_6"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">46589976</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="0"
      id="Tc_Xgp8fNnXU0WMJmIuMqiiGw_21_9"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">67158628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="0"
      id="Tc_iQ3lHPgFZk2-__kZpe-6EA_21_12"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">47327952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="0"
      id="Tc_HlZfkqdqT0qKfTvvtABMNQ_22_3"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">78896220</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="0"
      id="Tc_3WikAhkYdU2USNEfL2arnA_22_6"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">46589976</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="0"
      id="Tc_aKNCbvr4NEub6NOPMzmeSg_22_9"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">83200641</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="0"
      id="Tc_dbFrxJctgkWPu-VCkfQ6Ag_22_12"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">47327952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_FWuVkyQiG02-RIndYlC-aA"
      decimals="-3"
      id="Tc_cRA9HpNX4UmZYvhtdWf4bQ_23_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ENltzQ0-bEaXq264zzSKaQ"
      decimals="-3"
      id="Tc_ZRTV6M4GykymfPsZ9WedKA_23_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">22000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XAvFwxyFCEqwxJ0AjpLtzg"
      decimals="-3"
      id="Tc_NTdM3rL3q0qtG3oSMee8YA_23_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G4WzsvxhnE6EeNdK2xBSHg"
      decimals="-3"
      id="Tc_drUusfKdAEuPChNCcF_Lgw_23_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">28000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JzsNZYTG20y3XtcplisU6w"
      decimals="-3"
      id="Tc_6AUAD1hm5USSVV67-kPRFw_24_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">324000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NScsocUMtU2QHthjRxtAQg"
      decimals="-3"
      id="Tc_VOQTpj0f8Uq3FjA-Yyy9GA_24_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aD3nH1aLCUqeL-tmXCvk2A"
      decimals="-3"
      id="Tc_Lws4T0FZG06sY78-NdAu8w_24_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">144000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MMPQZ_UDMEiuFwLxSK6mJQ"
      decimals="-3"
      id="Tc_pi-OadTmg0m5z-sc7prKXA_24_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">85000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Y1sSF-J3QESve0bxhy5HKQ"
      decimals="-3"
      id="Tc_pGTv1-fg2kSx1OxH_kkc-A_25_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d5yjCdKWyUm8nc8BaZtkgA"
      decimals="-3"
      id="Tc_fF1e-ouIZkW3jzD99Bl7tg_25_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">941000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fpNYRx6x8EuZW-bIDYLU9w"
      decimals="-3"
      id="Tc_rvTQgiJfJkyEj7sbU_7GMw_25_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1_rwBZR3HkGX0wF4AjdCSg"
      decimals="-3"
      id="Tc_FoDnR_LXNUWLggsmFWB_Ag_25_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA"
      decimals="INF"
      id="Tc_TWaIr1fvkEC-wVKp7AvnVQ_6_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA"
      decimals="-3"
      id="Tc_txtYhnl_iEGkeEXMDCc7Kg_6_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TjGEUWhlV0-DICU_0AaPHQ"
      decimals="-3"
      id="Tc_EceZ7sNdnkW_ZLged9qo9g_6_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i4Rr-h0DiEmI3X2F-6HTrg"
      decimals="-3"
      id="Tc_ZW5VJqjGkki-tmuvTzrR4w_6_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_SZhJbmB8HUGxaWk_ZQO-6g"
      decimals="-3"
      id="Tc_igViHifht0OXXyFGatDmVA_6_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-6036000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw"
      decimals="INF"
      id="Tc_Gyd8m8j9c0ezUesMH69-PA_8_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">2395823</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw"
      decimals="-3"
      id="Tc_nJpyd5xLBUKFADPYWCbzCw_8_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ"
      decimals="-3"
      id="Tc_WQnWVRwQ1U2rWyy6f4SXaw_8_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2638000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_nx2LkQe620yrZ3fzdW4AAw_8_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2641000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ"
      decimals="-3"
      id="Tc_Au3JqBvay0GmltYHOW7mmw_9_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_V4dtQZSiHkSTW119FUFTgg_9_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw"
      decimals="INF"
      id="Tc_3qV8YCA4YkavB_dwU6GMcQ_10_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ"
      decimals="-3"
      id="Tc_x6Zi9tNvzEWN23Eq71KmdA_10_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">831000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_BINxbibYOkabopDVY6eCYw_10_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">831000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGAyoHYBDkyr7GLCoUVDEw"
      decimals="INF"
      id="Tc_NjCLqQ7KWk6Q-HmS7qZB5w_11_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i7bw3IH7PkmxMOCpBYhCDQ"
      decimals="-3"
      id="Tc_cR4zJbMP-USFlp7ljqkfFw_11_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_O2yKUS3pFUSXnFeP4PlQwA_11_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_W1NCM3GJAEO9AOQP2LXSDA"
      decimals="-3"
      id="Tc_rYMYTzq6UkGgWqiA9HuD9A_12_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7620000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_-p26mGeY8EmROqEBF9fZ2Q_12_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7620000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ"
      decimals="INF"
      id="Tc_480KZM66zEaQdZOjkNwHZw_13_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">48712952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ"
      decimals="-3"
      id="Tc_eXuyYAUNBUucZzSXAWei8w_13_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li-HD8Y0uUCsTeiv7eapQg"
      decimals="-3"
      id="Tc_dWtxgHLSjUqTQ3iyfkNhrg_13_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">372616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jB7j7aZTuECzxWimg8CXLA"
      decimals="-3"
      id="Tc_Q9ph2osHjUuulP55PWL_xA_13_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-382554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ"
      decimals="-3"
      id="Tc_i23R36NgfEa3qtgGdrVhaA_13_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-9889000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_piQqP256hEOa27v5mbImJA"
      decimals="INF"
      id="Tc_0jsdRZvys0SHbphZyMaHiQ_14_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">53790167</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_piQqP256hEOa27v5mbImJA"
      decimals="-3"
      id="Tc_YFLBym2ZQ0W_hUm9jUcveQ_14_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CAoUZ3xsTECjrgCTvfsWpQ"
      decimals="-3"
      id="Tc_o0LcMeKeOUaDp87ogSrwTg_14_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">379167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dL4kaY7_k0Gt7Ul51ddaLg"
      decimals="-3"
      id="Tc_pI0wbvv-X0iMwx-FX_j7Rg_14_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-389861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_DQAz94zO1kK71znHZqnS0g_14_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-10640000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg"
      decimals="INF"
      id="Tc_MNW3OH0N7EGIPLANOT9oZQ_16_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">12560150</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg"
      decimals="-3"
      id="Tc_QM7cXJReh0S5F3IsbZBIRA_16_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">13000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA"
      decimals="-3"
      id="Tc_xu6GReVjHUuyIgyouYI1xg_16_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">23941000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_oXqJuZS3QUmEynHwM6Lgaw_16_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">23954000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg"
      decimals="INF"
      id="Tc_gzYqSKO35E6BZW8gI3x9QA_17_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">4691623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg"
      decimals="-3"
      id="Tc_GCmu59bN0Uu50oH6gW4XVQ_17_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA"
      decimals="-3"
      id="Tc_o5do_UwRA0C3MQYGQwuSVw_17_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7778000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_wHnN3GwLHkyI84xcdhqohQ_17_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7783000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA"
      decimals="-3"
      id="Tc_kaMLdECPI0eapIb_M0qosA_18_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_mQ4RofHhYUC4lv4eDZs2bA_18_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA"
      decimals="-3"
      id="Tc_J24KzQtt2UOwmpG_-igKIQ_19_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">172000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_zVPCTPj9hE-KGfmG-09aJQ_19_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">172000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wOq58LStvUe0QIofn6vJKg"
      decimals="INF"
      id="Tc_MWAzutUR-kaS-S0-9UYuRA_20_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">538822</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MKGmbJZIkUuSG51C5oG5IA"
      decimals="-3"
      id="Tc_XXzmhVQ40EmH6LK-K59G6Q_20_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_ka12FmCpSkWobUFJsjdnGw_20_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rEn92dYq-0ijjN1WMEHxjA"
      decimals="-3"
      id="Tc_8Tt52m09VUSK7QBIi7f7Uw_21_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_wZP8nBGoYku-ialSfez_dA_21_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16208000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A"
      decimals="INF"
      id="Tc_H9dkt68onkiouKSwQwgAwA_22_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">71580762</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A"
      decimals="-3"
      id="Tc_QcFQVWKLkkuYqdyXUBAG-g_22_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2f7dHNiIfkWbGa0IWZYg0w"
      decimals="-3"
      id="Tc_IhGzRhScfUmZFNfc7J-Avw_22_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">412582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jMPvUoYVVEu_xO49zfmz6w"
      decimals="-3"
      id="Tc_PH2hHM6PP0-_cWicfNQ2EQ_22_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-373653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_iqnX9WLM50iv6bS9STbJzw_22_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">39001000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyjWpJkL4Eu5oaahwOaq8A"
      decimals="INF"
      id="Tc_AI2zl9qsRkisTpjggz7TZw_23_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">46316129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyjWpJkL4Eu5oaahwOaq8A"
      decimals="-3"
      id="Tc_X1iHt0wPJEeiSv_G47leHQ_23_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b3NmpKIJr0-JCDPkDs2yZQ"
      decimals="-3"
      id="Tc_ZOQDIiNN10GRVmfWM-57Ng_23_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">369688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsElhEMx2ES3jtK9Y9EB9w"
      decimals="-3"
      id="Tc_aHOzd5gos0yiOg3cJESquQ_23_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-377220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_FBZ8Tp5vLEKjPPGlg8URdw"
      decimals="-3"
      id="Tc_rVYOSszYfEql5XSZfwCx3w_23_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7486000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ"
      decimals="INF"
      id="Tc_DEzIZn9FZEqIkBHuDpg9Mg_25_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">2395823</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ"
      decimals="-3"
      id="Tc_3t7xL7rL60af0JxwGQLFYQ_25_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA"
      decimals="-3"
      id="Tc_Yp249L7cVkClJ9FfpCo_zQ_25_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2638000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_LzYm4ncx5kOuY2fy1jmJ1A_25_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2641000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA"
      decimals="-3"
      id="Tc_eYNv5lFyQEmYC7S97PXHhw_26_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_MFZF7pqPBUuQJNO9Oy7nPw_26_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA"
      decimals="-3"
      id="Tc_dGXCev7GbUGzryy-EPwY7A_27_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">144000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_PQMf-ntXWEGOcOpJOOAJUA_27_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">144000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IBlXgpJcq020I9iBX-TLWQ"
      decimals="INF"
      id="Tc_2GOQ0nsFekakUzpWtFzx6g_28_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lsRnc7ekqEGfmwcZxcf6cA"
      decimals="-3"
      id="Tc_Ebp7qinQPEClp5qitqRO5Q_28_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_mi6adTt3tkeqW753PLQSJQ_28_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GT5dNEEhVU-SSWfxxPmtuQ"
      decimals="-3"
      id="Tc_24V1PHNMG0O4JVHVNGs7yw_29_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-5334000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_9z5zEYxMOEKRWKv7n84bmw_29_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-5334000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ"
      decimals="INF"
      id="Tc_9XaIn3ucDkuPIp0sPbbj_Q_30_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">48712952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NWpBVPzuEEuLy9cdhCdWlQ"
      decimals="-3"
      id="Tc_LPDAVaGgiUmnjScSyWYmIQ_30_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_li-HD8Y0uUCsTeiv7eapQg"
      decimals="-3"
      id="Tc_qYoZqzEmOU2QAwlYcL6edQ_30_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">372616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jB7j7aZTuECzxWimg8CXLA"
      decimals="-3"
      id="Tc_pAkN05BFnkesysvHx30YPw_30_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-382554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ"
      decimals="-3"
      id="Tc_L4lM0PiAB0uLDeLSrWQG4w_30_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-9889000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_r6SoXt1a2UaK8KRu3WmzvA"
      decimals="INF"
      id="Tc_6U8Od15PWU6teh99Rpql3A_31_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">62002649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_r6SoXt1a2UaK8KRu3WmzvA"
      decimals="-3"
      id="Tc_nrOn92z5kkyme37exVQDMQ_31_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDq4696d-UOcccu_7Cvwag"
      decimals="-3"
      id="Tc_6FHxMp4QhUOR5IaEgGpS6g_31_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">393938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2xh1OXXKFE-Kulcz9V8NMQ"
      decimals="-3"
      id="Tc_w_kRU7htQk6uN6Hs9_ZViA_31_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-392992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_lBFN3DQNxUiobmz6_ZkcBQ"
      decimals="-3"
      id="Tc_rgKhBh0RekyGhNSmn-JFxQ_31_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1008000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg"
      decimals="INF"
      id="Tc_29Az6NLHf0aPkOOX7lgx2w_33_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">4347668</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg"
      decimals="-3"
      id="Tc_LVWM22aTNUevgQeS9z-MqA_33_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA"
      decimals="-3"
      id="Tc_nbX6mqJPd0qKVURb2QaOvQ_33_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">9716000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc__YRBf3k-TUaK9uxKDk8xAA_33_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">9721000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg"
      decimals="INF"
      id="Tc_yEDHDFZfk0KplkhCFGoCUw_34_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">4691623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg"
      decimals="-3"
      id="Tc_JqQTui0jWk2rYOKQUDW-SA_34_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA"
      decimals="-3"
      id="Tc_6N8tBUvPuUy7H_Smh99j6w_34_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7778000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_7dgRASNt0E6i_X9e90AHsg_34_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7783000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA"
      decimals="-3"
      id="Tc_ec2FR5WrokGQcJutBi5M8w_35_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_BeHaSVBmLUms2EZV_sjbDg_35_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA"
      decimals="-3"
      id="Tc_Mv5UFGETskKixN2l7qpWEA_36_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">79000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_3Rm2oatNSkOvuwVcbNdH6w_36_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">79000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XIuTXez0UEu1X56skKkwGg"
      decimals="INF"
      id="Tc_nSRgNHxWFU-H92c_4P5ICQ_37_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">538822</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ol_GCmY5Sk-b1zpQiOVZuA"
      decimals="-3"
      id="Tc_QQsClkXd-0OnIl2DJUbF9g_37_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_swCJG7atw06_SGaNY7JZhA_37_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WFc9oZvin0GRCHLpUhlF4w"
      decimals="-3"
      id="Tc_ilEwaURvak2tMXYmO2jufg_38_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">19339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_UYx6e6waq0GPcPA7dOa4Rg_38_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">19339000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A"
      decimals="INF"
      id="Tc_NQjCLbxb9EqEjpBgqapF4Q_39_2"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">71580762</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RP8y-FOsg0WnCSx3WlwJ7A"
      decimals="-3"
      id="Tc_pjLz9U9XH0CS2vJTzCDk-A_39_5"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2f7dHNiIfkWbGa0IWZYg0w"
      decimals="-3"
      id="Tc_4MPVsh9BTkiU39lSPRJL9Q_39_8"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">412582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jMPvUoYVVEu_xO49zfmz6w"
      decimals="-3"
      id="Tc_UOXuJ2ugZ0i5AG4120hM9A_39_11"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-373653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_bekvQPjFsEKqffTL0Dyu8w_39_14"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">39001000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ"
      decimals="INF"
      id="Narr_MOAunn053UWpC-mQh_J2lw"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="INF"
      id="Narr_kYctsxzKlkG1bTUs2xFxyQ"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ"
      decimals="INF"
      id="Narr_Vgr5D9fQH06M8cxxk6w8Aw"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="INF"
      id="Narr_A4bUizhqhkK3zbqrpM1UgA"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_Jgu7GTYfTU-x9R-eJxgB4Q_4_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16208000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_LqicAZw14U2rx56qfYn0gw_4_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7620000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_JNAqxXLDHUypUMEAxmMdXQ_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">984000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_DqEZmEDO2UKTJhFs_qd4Eg_6_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1124000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_balL8tToVUmXTU8yRE21Wg_7_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">573000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_xutU0ZTxBEG9vi-hONlAjA_7_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">538000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_Ra8ZEHgzGUGnlhr3qTGUkA_8_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">152000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_CxvCpcPuMkOesj4JOxsdBQ_8_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">952000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_CWgms5QIckeCBKm0THsxwg_9_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">36000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_UReAT2QOckiqPQaN-Iscww_9_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-449000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_SHK1nrep8kGRhAbHmvbVyw_10_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-3130000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc__U_VwaiUaUmFOTjoMDR--A_11_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">27000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_gd-ngNSICkO7YiYbkVhdWg_11_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-16000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_SBFnf1FWtEKf6iLAiDmYmA_12_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">421000</plx:GainLossOnDebtConversion>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_SJh9lLqfBUeUjzzmzKJWGg_13_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">148000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_mY2H_4nMjU2BUIsGiHKl1Q_13_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">146000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_7Bcx4lszrEyzqYrpZF4kHQ_15_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-13178000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_eUWer4q4706wxXPlK61ynQ_15_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-2644000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_U5RZGWLHhE63SLe3KxM9cw_16_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-119000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_ZwllQ6dNhUmbCeU09nxYGg_16_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-76000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_gRhBEm0MRU2CXaMP9hq7iA_17_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-3000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_kB2EdpWR-UCd4bNPPrTNZg_17_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_72ojakGjxkuFSjWIesJ0gw_18_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2831000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_Q5kdm1a4Y0umdWkr3tRoaw_18_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-1447000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_wSutqQOjCEufBhFDSxlOkA_19_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3643000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_y3gjqtGacUa8Ayaz1-40bw_19_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-4864000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_4PaoNV6sw06n-yzX3dvDqw_20_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1975000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_ksq1Lrp8mUygJZMS-wn97g_20_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-13185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_SHoIdTmu30WRqTQViitPfA_23_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_xjxTAo-SXE2IqIjEnrkZXw_24_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_A67FhrBrfEyIuyx_BFQBfw_25_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">452000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_BKlL8dGK6kaxEQzoRSNjIA_25_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">357000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_IkYHWCTGtEWXD7c0ps6NSA_26_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">38000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_Q_vmozBbMUu77Tn5M8vwqg_26_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-457000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_wcttmeosnkuksZp2Gg6YBQ_27_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4510000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_Q17aCUFDkkWPGVXPaz50JA_27_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-15900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_9kjOY_r-m0WpevbaMTWnhQ_30_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">23954000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_LGrN3mu8rU28UmTZDZLmQw_30_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2641000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_7_KvVxuHIEemG30b-anJaQ_31_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">712000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_flwPPnxHwEqbCwSHJMs02A_31_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_yxrKgl15ZkChN5xzXkS2GQ_32_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">24666000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_IKus3PV4xEieyzYXYKmsuA_32_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2643000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_2NaLJfCkgECICpqmrgp2DA_33_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-78000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_YHblCjTdGEy7rVJ5ZyFtCQ_33_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-51000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_E7XHBtjd8ESZRiPiHFTnLw_34_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">31073000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_epL4cDKtHEaKpL0rN-P_UA_34_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-26493000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_DJSnrCBjikWZS2V96d94lg_35_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_SZhJbmB8HUGxaWk_ZQO-6g"
      decimals="-3"
      id="Tc_TcJAZDbsiUygjNAbS28Xzg_35_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_9JzFimtaP0Gn-9FUMKUDJg_36_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">48184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_0Y2kl5LZG0S0wwnEqQOWkQ"
      decimals="-3"
      id="Tc_142x3DnkVEGEaf9-Icmd-g_36_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">12492000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_HDub6LWrS0OlQOsxB2GuMg_4_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">348000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_6p4JguLJyUK-xSeN9K7BaA_4_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">81000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_CKXenSxsZ0urRE0G9F66OQ_5_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1079000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_F-JIbNE0ykGWj6w52HT0Lw_5_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">99000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_6XoTJ8L4_k20eJLmq5BG2A_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7783000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_QoFmz4iBfkq2dOQqp4myrg_8_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1977000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_AkO5yXb1N0uqdJP-FseplQ_8_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1120000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_GoZXGar3nk2hyilpcFVDpg_9_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">78000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_-MbUTbdY90Sx1PX2DF6TAg_9_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">93000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_6jL8Cna2wkGt-gFOjcMx3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). The Company&#x2019;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), the Company&#x2019;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; except in Brazil where it is marketed as BioManguinhos alfataliglicerase) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company&#x2019;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;). On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Currently, in the aggregate, 126 patients are enrolled, and 116 patients are actively participating, in such studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;In addition to Elfabrio, the Company successfully developed taliglucerase alfa, an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease, that has been approved for marketing in the United States, Brazil, Israel and other markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase I First in Human (&#x201c;FIH&#x201d;) clinical trial of PRX-115. As of the date hereof, 13 patients have been dosed in this trial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of June&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug substance from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#x201c;Brazil Agreement&#x201d;) for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of June&#160;30, 2023, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash and cash equivalents as of June&#160;30, 2023, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#x2019;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_0Vcq21rM8E2DYpcvGwsovA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). The Company&#x2019;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), the Company&#x2019;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; except in Brazil where it is marketed as BioManguinhos alfataliglicerase) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company&#x2019;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;). On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Currently, in the aggregate, 126 patients are enrolled, and 116 patients are actively participating, in such studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;In addition to Elfabrio, the Company successfully developed taliglucerase alfa, an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease, that has been approved for marketing in the United States, Brazil, Israel and other markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase I First in Human (&#x201c;FIH&#x201d;) clinical trial of PRX-115. As of the date hereof, 13 patients have been dosed in this trial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of June&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug substance from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#x201c;Brazil Agreement&#x201d;) for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of June&#160;30, 2023, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash and cash equivalents as of June&#160;30, 2023, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="INF"
      id="Narr_REGXMh_xMkO45yD5E1FfMw"
      unitRef="Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <plx:NumberOfPatientsEnrolled
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="INF"
      id="Narr_N-wlShUx6Ua55JByB_BFGQ"
      unitRef="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ">126</plx:NumberOfPatientsEnrolled>
    <plx:NumberOfPatientsActivelyParticipating
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="INF"
      id="Narr_BMnwtnKhYkKnolcBV1nu0Q"
      unitRef="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ">116</plx:NumberOfPatientsActivelyParticipating>
    <plx:NumberOfPatientsDosed
      contextRef="As_Of_3_21_2023_K3ZvOjH68UyliMbYRqXDCw"
      decimals="INF"
      id="Narr_Dy3kyzu40EypwiNYp2SXoQ"
      unitRef="Unit_Standard_item_g6CjnKVNQ0-XcpLFMaX0lQ">13</plx:NumberOfPatientsDosed>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ri18SJ0PQE-p2S56WmoUmw"
      decimals="INF"
      id="Narr_G7YnNzWP3kODZzNgxorNvg"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_MK5otss99UeqSBlxwWlVCw"
      decimals="-5"
      id="Narr_X89trQ8cEECsOA-cXA0ELg"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_UTKUBS9fE0iLVZ9EFrAJiQ"
      decimals="INF"
      id="Narr_nQ6C_NpYLE6Nkegq4uRNrA"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_UTKUBS9fE0iLVZ9EFrAJiQ"
      decimals="-5"
      id="Narr_PxrYtFB5nUujt2Gq_z4awA"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xg4mR_srVEOznTErp8pnVQ"
      decimals="INF"
      id="Narr_5y-m0CHSPEKr1OiudLA0Vw"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">13980060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xg4mR_srVEOznTErp8pnVQ"
      decimals="-5"
      id="Narr_SmPlsAp_X0C3uwgj43FpJg"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Ta0zpsSnik2xFK3Rjys-yg"
      decimals="-5"
      id="Narr_rzZMOWduvE-ejI0K0fAKYQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_KuSCtZl5_0aMliO15-tKbA"
      decimals="-5"
      id="Narr_bZFPyrWdf02bGqBWNUrPAQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">6400000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Rk6iSTTZ8E2nfQOmpW14IQ"
      decimals="-5"
      id="Narr_mz-eUuD0Zk-stJDDHrNbeQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_f4fIos5PMUmhCLw2-9tJyg"
      decimals="-5"
      id="Narr_R9HOdvCDD06rcffvAbV58g"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CjEp8-HoFkWDhnqgJoKWcQ"
      decimals="-5"
      id="Narr_T0jGiwDAKkCPA689MSJ7Uw"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CjEp8-HoFkWDhnqgJoKWcQ"
      decimals="-5"
      id="Narr_Lq4UBrzRqES1fcYxRve0Yw"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_T2FJkJmPOkmmfxXV-kkOJA"
      decimals="-5"
      id="Narr_H-lpF0IT6EGIJ282j3tEDA"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_T2FJkJmPOkmmfxXV-kkOJA"
      decimals="-5"
      id="Narr_MK7v6S86h0G4GCTH4dKNdg"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_RrH2ndyoyUWCJiK_yzGWKA"
      decimals="-5"
      id="Narr_LXDpd5AXREK58MjrUxsD1w"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000.0</plx:MilestonePaymentReceived>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_ibjkwjeinUigCNCGceGaYw"
      decimals="INF"
      id="Narr_VlaL2wp7n06GMA5l4ewirA"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hzlZO_DQb0WzzjogYuqErw"
      decimals="INF"
      id="Narr_lHfbdLo2XUKM5ivaybg4-Q"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DleZZTmqnkqE26Xs8euChA"
      decimals="INF"
      id="Narr_vJA61wAle0aOMy5icF9GEw"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_4aJya2GEz0u8k1VFkbnZgg"
      decimals="INF"
      id="Narr_KcIbDZXdU0iSevgQrRnptQ"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_JB76OZ74g0mWS8x6-0BM6A"
      id="Narr_KNcAua-6wUq0QU5EjJBq7g">P7Y</plx:ExtendedTermOfAgreement>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r_ehkfZA20uqfwPPaAkqOQ"
      decimals="-5"
      id="Narr__t10HczutkqMtt4aDX-JBA"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_OdlZNkXl6UaVoC041YLuMA"
      decimals="-5"
      id="Narr_C2Vbgu84IkG-CsFEDBtQ_Q"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxPP66-FEG8RWl0rfhx_w"
      decimals="2"
      id="Narr_T9flW29aQECYu2NOxzPaDw"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EkdrbNRlwEWh5sJiOa4BPw"
      decimals="4"
      id="Narr_-wrATaKEY0eAG5Uq2w02cQ"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EkdrbNRlwEWh5sJiOa4BPw"
      decimals="-5"
      id="Narr_bD0_gp2uqE2CTX2hkdHoMQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_LBsTi4gHxUmsWEA9O07EFQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_qmcJlG6JhEaFt3pwCqTTvQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#x2019;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_u8htPnnek06B3-QkyDCiAw"
      decimals="INF"
      id="Narr_USqmp6VXOUCePxUYhPchEg"
      unitRef="Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg">2</plx:RevenuePerformanceObligationNumber>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_RrH2ndyoyUWCJiK_yzGWKA"
      decimals="-5"
      id="Narr_7bDL5-c9a0mux7yKwRi6Jg"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000.0</plx:MilestonePaymentReceived>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_rONcfdT-mkOxZ6YeiVP3GA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at June&#160;30, 2023 and December&#160;31, 2022 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_6EV4x1KiQ02yBMasY0XQqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_5svsUQ15YkCqzvn3yz7XlQ_3_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">4352000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_nY9SPnT4UEu5ovEMUOgAtA_3_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3508000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_CL_tLYBRwk-nCBI5YvMm-A_4_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3318000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_QmmPoqkuAU2aFRmfosLl4w_4_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2678000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_epwPGtR5TEWuo8-6TJKQEg_5_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">11965000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_YdsyhHo-a0SrCTCynvxcQw_5_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">10618000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_yfnS7o4mO0aI8ACf93gn_A_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">19635000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_Bcr670I-skerW1PZywwxUw_6_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16804000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_ZfTIyIfqGkajaMwJXPhwcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level 3 measurement, as of June&#160;30, 2023, the fair value of the $20.4&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $28.1&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw"
      decimals="-4"
      id="Narr_xFK6t9CTkku9o7iyNgjq5g"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw"
      decimals="-5"
      id="Narr_Dm6N8IoEKEussmMyUQ4DcQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">28100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA"
      id="Tb_0NUrzxe3Q0iOA-RPzk3tHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_KY-ma-SuxE6JsnDPAL7QoQ"
      decimals="2"
      id="Tc_C9a57KKHxEyiZw6q3BanJw_2_5"
      unitRef="Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg">2.00</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i364BLxb4EuwXvVZ-E3v4Q"
      decimals="2"
      id="Tc_nWv_aUq3VkejrkxiOiFTgA_3_5"
      unitRef="Unit_Standard_Y_v67Atkda-ku71Q2qAiO_QQ">1.18</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XOS2xaTk5EWDha2vAO2bxQ"
      decimals="2"
      id="Tc_H8KU9XPQ4UKcLv8bKIXrgQ_4_5"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">5.14</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_h_ZFDwKXEkyuUN5mMKV7ag"
      decimals="2"
      id="Tc_ERaBlByAVk6JoERUEYUKDg_5_5"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">60.90</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_HUfqWHV6HE6-7_b8ousHhQ"
      decimals="2"
      id="Tc_2hgQMFJ9EUK6eKDToEyQvA_6_5"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">12.76</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_HXimdGxHYUCdGFi6StNHkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_KkdaVx47-ke-iU-FDNCG_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6EY8ZLejPkaK5jN5fkWHzg"
      decimals="-3"
      id="Tc_w0zdve-DPUu1CoZ4f_R6AA_3_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3402000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_CNF4wwqArE-QJGN7-yi3Gw"
      decimals="-3"
      id="Tc_TqHBD8Rrgkao0WpxHhE2cA_3_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_KZqJ5slPPEGfEAtG9oUahg"
      decimals="-3"
      id="Tc_qNrZ1FOEa0uS93IgKotffg_3_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5668000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GYEteH5yxkOi3Fycl0MiGw"
      decimals="-3"
      id="Tc_RUqy6Q0UV02PirCrEik8oA_3_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">6738000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_cxV5YkmyMkOdKBiC71d5Iw"
      decimals="-3"
      id="Tc_8rZBBjRyp0KaJ26vDlJkDg_4_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_2htVCHKOakKxo0P6Mt-phw"
      decimals="-3"
      id="Tc_c9kX1cCBtU6Xq26rhOIyJw_4_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5454000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0fDfLHqQbUOjSUb7SXk8-w"
      decimals="-3"
      id="Tc_cvsFTLZcvkWQpxbba4OBPA_5_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">11673000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JGEYQ_-rNEe6Bkb5w86nqA"
      decimals="-3"
      id="Tc_puDzc2hZR0uMWbqwRmoz3A_5_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">11673000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_kHP60lRxy0Cl3Ghw5nGl3A"
      decimals="-3"
      id="Tc_MnRdIEmfwUatVgTUqIKUeA_5_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">218000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DbnmycSCC06iSdpupTbnrQ"
      decimals="-3"
      id="Tc_Ohbox0tDvUmmCUpuyGuvAQ_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">15075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_3xKKEe90x0i1wtZ9ei35MQ"
      decimals="-3"
      id="Tc_rFsAaQ_hYkCWilaOYZnVAQ_6_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_YISAxiydmUe42opqwLUlVA"
      decimals="-3"
      id="Tc_LqWYkeHdkkGHojrol9-gSQ_6_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20141000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_oCwNjjGdSkSVxZt-Jq0NGA"
      decimals="-3"
      id="Tc_0lLQ6rYk7UyCpjUU8ppeCA_6_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">12410000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__XyDi3xaVUOhI8hK5ZkSag"
      decimals="-3"
      id="Tc_09qDg4FmmEWNcHFIAIwbeg_7_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_nw34ZM_veUiZ_WWpDb01mg"
      decimals="-3"
      id="Tc_mlHxEFCRMkWhXuY4hWtbEw_7_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_2OozcC2UK0uAy4FUBp84ug"
      decimals="-3"
      id="Tc_nWZ8zYmdYkaL20XGFy1AnA_7_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">24522000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M8LWQVl8T0y-iXLLBJWW4g"
      decimals="-3"
      id="Tc_X7zdaM7jg0616QijzHcgUw_7_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">12428000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_wu7tq9xrr0CRzlnZYnGkrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;Authorized Capital&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#x201c;Annual Meeting&#x201d;). At the Annual Meeting, the Company&#x2019;s stockholders, among other matters, approved an amendment to the Company&#x2019;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 144,000,000 to 185,000,000 (the &#x201c;Charter Amendment&#x201d;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;At-the-Market (ATM) Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;During the six months ended June&#160;30, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $24.9&#160;million in connection with such sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Exercise of Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On May&#160;8, 2023, the Company issued 301,810 shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#x2019;s private placement of Common Stock and warrants. The Company generated net proceeds equal to $0.7&#160;million from the exercise of the warrant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On May&#160;10, 2023, the Company issued 237,012 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 845,000 shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#x2019;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;(d)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Conversion of 2024 Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;During the six months ended June&#160;30, 2023, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during the six months ended June&#160;30, 2023, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $8.3&#160;million.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_24_2023_Fc4rDyr3_EmtZXvFeu0hug"
      decimals="INF"
      id="Narr_k4gYxo-rv0ihyXqm5vs19A"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_25_2023_GhxIuEgHh0-KdnsF3PgcOg"
      decimals="INF"
      id="Narr_kymJG-_BAE6yDEPiR8qgLw"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_9vEHwV8JlEq0c99K7nQPGw"
      decimals="INF"
      id="Narr_P0EgSojbPUi1rJbgaa_AQw"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">12560150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_9vEHwV8JlEq0c99K7nQPGw"
      decimals="-5"
      id="Narr_nYiKMEeq4EOR_7reWgciwg"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">24900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1pbkqm0PNU-3n1SC2J0weg"
      decimals="INF"
      id="Narr_4IhlSE3yikil3zb6iwgSdg"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">301810</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_5_8_2023_To_5_8_2023_WubO3bm2MUSrkueojHRBdw"
      decimals="-5"
      id="Narr_1kGHtaTTREeQu4371ykMsQ"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">700000</us-gaap:ProceedsFromWarrantExercises>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_5_10_2023_To_5_10_2023_kzlqsZvS4kOBpSRWM3vhTg"
      decimals="INF"
      id="Narr_BoaIP353M06QHkkrRtXfXw"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">237012</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_10_2023_o66HQb4RTU6YeX4ytF2Xyw"
      decimals="INF"
      id="Narr_vY6y7zumjEW74tSr7Xoodg"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">845000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_5_10_2023_To_5_10_2023_kzlqsZvS4kOBpSRWM3vhTg"
      decimals="-3"
      id="Narr_WQt6tecbWUSo0SH4M1wRrw"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA"
      decimals="INF"
      id="Narr_rAmTB8IyEkmzXiM9G09qxw"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">4691623</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <plx:PaymentsToDebtHoldersOnConversion
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA"
      decimals="-5"
      id="Narr_nx5GYr8Ay0qP6eaXFTZQbw"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">900000</plx:PaymentsToDebtHoldersOnConversion>
    <plx:DebtConversionDecreaseInPrincipalAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA"
      decimals="-5"
      id="Narr_Sv0KlcsSIk6LT7Oh2PU_Ow"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">8300000</plx:DebtConversionDecreaseInPrincipalAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_HSUJlFT3XUyXb6owKoKidA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; EARNINGS (LOSS) PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of the Company&#x2019;s Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii) the conversion of the convertible notes using the&#160;&#x201c;if-converted&#x201d;&#160;method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 19,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,620)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,749)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,620)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 67,158,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 47,327,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 62,378,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 46,589,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14,355,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 15,274,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,555,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,243,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 131,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 83,200,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 47,327,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 78,896,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 46,589,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 16,158,086 shares of Common Stock underlying outstanding stock options and warrants of the Company for the six months ended June&#160;30, 2023 because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 1,896,733 shares of Common Stock underlying outstanding stock options of the Company for the three months ended June&#160;30, 2023 because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 32,960,732 and 32,982,043 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three and six months ended June&#160;30, 2022, respectively, because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_vQzs88IJX0iabDZ7ltLPXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 19,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,620)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,749)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,620)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 67,158,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 47,327,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 62,378,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 46,589,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14,355,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 15,274,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,555,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,243,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 131,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 83,200,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 47,327,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 78,896,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 46,589,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_GeTpM4m3uU2yVt4d4bOvXA_4_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">19339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_2c8Yq1NLRUCz2YmECNFnZg_4_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-5334000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_eUS5JKNABUuo2vtxNWySRw_4_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">16208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_615JsyBhHEqe4O4ynckIcQ_4_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7620000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_Qm5iCPfDoEC8k9ER0-Bb6Q_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-1749000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_G0MQ2legWESLb0eDLqyZDA_6_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-2053000</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_pCx-69TQj0i7OB-tyWnIFg_7_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">17590000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="-3"
      id="Tc_0YXpHVtpp06LXVF4cgBLTQ_7_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-5334000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_Mv3TXUhqvkCRxN3CPTHUnA_7_9"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">14155000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="-3"
      id="Tc_gWVtrTWMZ0aX2ZMazdhBHQ_7_12"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-7620000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="0"
      id="Tc_33Exhrx1IE69gTwlA8sJJQ_9_3"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">67158628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="0"
      id="Tc_tmGWS3dwdEKYdsIZzOOZzA_9_6"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">47327952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="0"
      id="Tc_4_dq9sq4vU-2yUEcJuG8TQ_9_9"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">62378745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="0"
      id="Tc_UElJaFQ6CEWmTMyTJd9uaQ_9_12"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">46589976</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="0"
      id="Tc_cQFR_0CD-EquRs78h8g2lA_10_3"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">14355621</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="0"
      id="Tc_9aEqQ4hxOkSZMWXp4Gu4NA_10_9"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">15274121</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="0"
      id="Tc_hFmHCEi_o0KneFQuAU9L3Q_11_3"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">1555307</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="0"
      id="Tc_Yw9t52uKP06jFGJBhl5kJQ_11_9"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">1243354</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="0"
      id="Tc_sgHkj1LBF0esFv_dXP_XEw_12_3"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">131085</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="0"
      id="Tc_NkcIgnfvX06v-22CES5f2g_13_3"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">83200641</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_mLIJF7DLgk-ynVN-P696fg"
      decimals="0"
      id="Tc_BIFp0yXfRE2hG98xlmUARA_13_6"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">47327952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="0"
      id="Tc_-tXb8XZf6UeWe9bb95X-qg_13_9"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">78896220</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="0"
      id="Tc_-AolbiO9_UG7u5kHue9VRA_13_12"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">46589976</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_giw5lYGyHk2z5Tsr-qoIyg"
      decimals="INF"
      id="Narr_OCtcaFBhl0quNE7Dg1JZkg"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">16158086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsMember_ORrJrQ2JFkyptwnKkDK9ZQ"
      decimals="INF"
      id="Narr_jwWN8GU2z06cP2PjmiYMWw"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">1896733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_Bvgp1anEpkieiOQvLEWBZQ"
      decimals="INF"
      id="Narr_TBWxTfWirUGQxZMZenjIFA"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">32960732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_eQMenfm7EU-xHazziK7JOw"
      decimals="INF"
      id="Narr_a9e0y-2nKkaE58vmSrNvSg"
      unitRef="Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg">32982043</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_qP4dqcrbDEegixppkqrvog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,130)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company had an effective tax rate of 3% for the six months ended June&#160;30, 2023, compared to an effective tax rate of 0% for the six months ended June&#160;30, 2022. For the six months ended June&#160;30, 2023, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#x201c;TCJA&#x201d;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In the second quarter ended June&#160;30, 2023, following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_niaLYGtE-EKXIOpUIfQfLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,130)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_w_L0zA53IUOQFYfWPn00xg_3_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3438000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_4Ah4D1Wmb0aZG_xsOqfEpA_3_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3633000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_De5g7Rdaa0GCVE8DKo-e1Q_4_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-3130000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_fFr9jDt3a0KGCqmQGsoItA_4_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">-3130000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-3"
      id="Tc_2Gl2x9wxCkCuDsqY5Ri1ew_5_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">308000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="-3"
      id="Tc_vopwg4oSmUqtM4Rbv8lXOg_5_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="2"
      id="Narr_5bBnKCZu8keFt-ZwzpiJgg"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_6_30_2022_GEnEspHwrEi2HdPeYQAQJA"
      decimals="2"
      id="Narr_pJ_kihsK7ECU_SQLYEht8g"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      decimals="INF"
      id="Narr_IPWcPDw8_UKgwsWqUb8-BA"
      unitRef="Unit_Standard_pure_Mze2rP9QKUSs5rjfyuVjiw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <plx:MilestonePaymentToRegulatoryApprovals
      contextRef="As_Of_5_31_2023_A791LfE6c06Ffo0FaCMpfA"
      decimals="-5"
      id="Narr_WdPsrUh300mgC5zA8Goeow"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">20000000.0</plx:MilestonePaymentToRegulatoryApprovals>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A"
      decimals="-5"
      id="Narr_j9IxUxoakkC5Ltg3kfd-4A"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_MqRSRJkOL0G1AUML_rnsAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest Payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserve for deductions from revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,909&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_iUMOW9FiV0OdgbwjIA3F3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest Payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserve for deductions from revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,909&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_oICPeBCYYESWx5AJKk2S_w_4_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1223000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_rAdPAiqJCkOcJ6CODx8pqQ_4_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1216000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_S9yAHICVQUG5R3fP40UxDw_5_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">506000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_d4oNDZiX0Ee25R555IRGdA_5_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">719000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_FL-EYjvPWEGyNap8HhO24A_6_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1526000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_kNtxubWM30GrQKA5-CT-4A_6_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1404000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_8ogcg10lY0SCfvOexUzvTg_7_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">8608000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_q4SPxrBz7ESQ-PdiP6ujLg_7_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">7478000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_8ISD99nT7E6Ccst2ugPeXA_8_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1262000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_T6onMbbOvkuWlbuhg-R7OQ_8_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">781000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_XVIt5HPGSU2MPW46oTnhKA_9_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">3163000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_Jjj_oodZUk2Wj04YGLzmsg_9_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">530000</us-gaap:TaxesPayableCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_P2jvqg9oFEWT6kdeDN3hfw_10_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1909000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_JT1YQC7Df0S8FikR63fDIg_11_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">348000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_8xTdpi9OiEq4IsU3ceUGsA_11_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">143000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ"
      decimals="-3"
      id="Tc_Z8aJ0XNz8kyWooHb2Dc3Aw_12_3"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">18545000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_oVQ6dV83ZUWybezgZaUHpw"
      decimals="-3"
      id="Tc_sgfGD37f0EqkStFmL1ukUw_12_6"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">12271000</us-gaap:AccountsPayableCurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ"
      id="Tb_nFKhYh6yOEGARPOW_luFbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 9 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On July&#160;14, 2023, the Company collected approximately $1.1&#160;million, in the aggregate, from sales to Pfizer. On July&#160;7, 2023, the Company collected approximately $1.0&#160;million from Chiesi&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_8xJeZMuB3U2g_8i3Y-HmUA"
      decimals="-5"
      id="Narr_D1L9PCUkrk2OVz-xxYwKyA"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1100000</plx:ProceedsFromSaleOfProducts>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_7_7_2023_To_7_7_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_16ZP9euma0-A-zyLjLyJAQ"
      decimals="-5"
      id="Narr_--a6U5K-qkqVPxgAlK89HA"
      unitRef="Unit_Standard_USD_WpOBNJJXyEKaob12la92nw">1000000.0</plx:ProceedsFromSaleOfProducts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_3qV8YCA4YkavB_dwU6GMcQ_10_2"
          xlink:label="Tc_3qV8YCA4YkavB_dwU6GMcQ_10_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of June 30, 2023 and 2022 &#x2013; 144,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3qV8YCA4YkavB_dwU6GMcQ_10_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Gyd8m8j9c0ezUesMH69-PA_8_2"
          xlink:label="Tc_Gyd8m8j9c0ezUesMH69-PA_8_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Gyd8m8j9c0ezUesMH69-PA_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_DEzIZn9FZEqIkBHuDpg9Mg_25_2"
          xlink:label="Tc_DEzIZn9FZEqIkBHuDpg9Mg_25_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_DEzIZn9FZEqIkBHuDpg9Mg_25_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_MNW3OH0N7EGIPLANOT9oZQ_16_2"
          xlink:label="Tc_MNW3OH0N7EGIPLANOT9oZQ_16_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_MNW3OH0N7EGIPLANOT9oZQ_16_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_29Az6NLHf0aPkOOX7lgx2w_33_2"
          xlink:label="Tc_29Az6NLHf0aPkOOX7lgx2w_33_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_29Az6NLHf0aPkOOX7lgx2w_33_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_NjCLqQ7KWk6Q-HmS7qZB5w_11_2"
          xlink:label="Tc_NjCLqQ7KWk6Q-HmS7qZB5w_11_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_NjCLqQ7KWk6Q-HmS7qZB5w_11_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_2GOQ0nsFekakUzpWtFzx6g_28_2"
          xlink:label="Tc_2GOQ0nsFekakUzpWtFzx6g_28_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_2GOQ0nsFekakUzpWtFzx6g_28_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_MWAzutUR-kaS-S0-9UYuRA_20_2"
          xlink:label="Tc_MWAzutUR-kaS-S0-9UYuRA_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_MWAzutUR-kaS-S0-9UYuRA_20_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_nSRgNHxWFU-H92c_4P5ICQ_37_2"
          xlink:label="Tc_nSRgNHxWFU-H92c_4P5ICQ_37_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_nSRgNHxWFU-H92c_4P5ICQ_37_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_TWaIr1fvkEC-wVKp7AvnVQ_6_2"
          xlink:label="Tc_TWaIr1fvkEC-wVKp7AvnVQ_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_TWaIr1fvkEC-wVKp7AvnVQ_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_AI2zl9qsRkisTpjggz7TZw_23_2"
          xlink:label="Tc_AI2zl9qsRkisTpjggz7TZw_23_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_AI2zl9qsRkisTpjggz7TZw_23_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9XaIn3ucDkuPIp0sPbbj_Q_30_2"
          xlink:label="Tc_9XaIn3ucDkuPIp0sPbbj_Q_30_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9XaIn3ucDkuPIp0sPbbj_Q_30_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_480KZM66zEaQdZOjkNwHZw_13_2"
          xlink:label="Tc_480KZM66zEaQdZOjkNwHZw_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_480KZM66zEaQdZOjkNwHZw_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_0jsdRZvys0SHbphZyMaHiQ_14_2"
          xlink:label="Tc_0jsdRZvys0SHbphZyMaHiQ_14_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_0jsdRZvys0SHbphZyMaHiQ_14_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6U8Od15PWU6teh99Rpql3A_31_2"
          xlink:label="Tc_6U8Od15PWU6teh99Rpql3A_31_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6U8Od15PWU6teh99Rpql3A_31_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_NQjCLbxb9EqEjpBgqapF4Q_39_2"
          xlink:label="Tc_NQjCLbxb9EqEjpBgqapF4Q_39_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_NQjCLbxb9EqEjpBgqapF4Q_39_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_H9dkt68onkiouKSwQwgAwA_22_2"
          xlink:label="Tc_H9dkt68onkiouKSwQwgAwA_22_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_H9dkt68onkiouKSwQwgAwA_22_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gzYqSKO35E6BZW8gI3x9QA_17_2"
          xlink:label="Tc_gzYqSKO35E6BZW8gI3x9QA_17_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gzYqSKO35E6BZW8gI3x9QA_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_yEDHDFZfk0KplkhCFGoCUw_34_2"
          xlink:label="Tc_yEDHDFZfk0KplkhCFGoCUw_34_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_yEDHDFZfk0KplkhCFGoCUw_34_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_8-mg9-0bv0WqhS2MXDxbiw_6_6"
          xlink:label="Tc_8-mg9-0bv0WqhS2MXDxbiw_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_8-mg9-0bv0WqhS2MXDxbiw_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5WdWTblMjUeT0pK-FtB8CQ_6_12"
          xlink:label="Tc_5WdWTblMjUeT0pK-FtB8CQ_6_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5WdWTblMjUeT0pK-FtB8CQ_6_12"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_FcQpeS2QMUSw539x2sLD6w_6_3"
          xlink:label="Tc_FcQpeS2QMUSw539x2sLD6w_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_FcQpeS2QMUSw539x2sLD6w_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_76HgycOXrEu1DFgY29kquw_6_9"
          xlink:label="Tc_76HgycOXrEu1DFgY29kquw_6_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_76HgycOXrEu1DFgY29kquw_6_9"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Vmeaqo5FBkabe_UXXmL7BA_7_6"
          xlink:label="Tc_Vmeaqo5FBkabe_UXXmL7BA_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Vmeaqo5FBkabe_UXXmL7BA_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_3FdqAtg-QkquKsONqBAcYw_7_12"
          xlink:label="Tc_3FdqAtg-QkquKsONqBAcYw_7_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3FdqAtg-QkquKsONqBAcYw_7_12"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_0Ncf6ddh8U2WaWytFeW2sw_7_3"
          xlink:label="Tc_0Ncf6ddh8U2WaWytFeW2sw_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_0Ncf6ddh8U2WaWytFeW2sw_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ekk8r0vCc0anL7WCzi162A_7_9"
          xlink:label="Tc_ekk8r0vCc0anL7WCzi162A_7_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ekk8r0vCc0anL7WCzi162A_7_9"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6IrXNofQNE2QdNwj3_zx8Q_8_6"
          xlink:label="Tc_6IrXNofQNE2QdNwj3_zx8Q_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6IrXNofQNE2QdNwj3_zx8Q_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ZbEKE5md2EGkbm08lQVehg_8_12"
          xlink:label="Tc_ZbEKE5md2EGkbm08lQVehg_8_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ZbEKE5md2EGkbm08lQVehg_8_12"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_7jNoLHuUg0CXsTnEiCT0QQ_8_3"
          xlink:label="Tc_7jNoLHuUg0CXsTnEiCT0QQ_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_7jNoLHuUg0CXsTnEiCT0QQ_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ukdMAx9UTkyI1jGkEE71LQ_8_9"
          xlink:label="Tc_ukdMAx9UTkyI1jGkEE71LQ_8_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ukdMAx9UTkyI1jGkEE71LQ_8_9"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>50
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$VU.RFQ5;6O\R,HR6U:',Y9,62X _/I#EI4O)Z*#[69=]Q]02P,$%     @
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MO@070!+2JTL)Q8<T%R4Q]RLRG*;>DPY54IPJABVK76%SP0NPF1B,H@^;5^S
MYMR#MNZ[=)_4<5+FX 9Z%#HV8"G3KB,$G5:%\Y."$1 S(QA_D/LMCU]\62Z7
M[^ABS_0OM51?!X*H/ %WV\T2"(V4C/1.LP)%00 (/FGO.1H_.?//[#V)D5B<
MFGO/I>UX%@JV0,QL803ADNWOI",NW>@GU,UM+'Q]MC)K.QF[AFZ ;*-BSTH*
MBD#,%&'*8X^Q%= Y'H=(N!!2D,S$!HC#5<)X:,:H5OSFH4U[V_\?70-2$ AB
M[AM,=QQV02+%!6$((0=;"YDVY!Y]6\5*]TJ/,X*R)=))T69%\B-%F2?F,F^'
M'TG.7Z&+C&A?GL:T*XL0T=1Y6B8#&B&K$E9!!8B9"OPB&_II@'TB&ZHEWFIB
MQ>M4*=C3=BLCIB #I'U2-AR.QO:X_YEL:"09)V>$,VD[GH6"4Q SISC.&_F>
M(MT^A2&XHDAB[R>2KLL1$#LTA]0BD/W,V2_\4^43A':;Y1Z/3JQEX8K%+6@'
M,=,.YXUQS\^2Q:O+N1M59#Z5,+2QDAU4H8IV"2T8!?T"HUAG7:!?1@Y5&0*Q
M6JUR=T0G=LB9CDTO: 0U]Q&<X=#I+^0)@/.O_@][_-U!,WOAH.QZCB;C[&C
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MK43Z3&G'N[CG.[SX JYJ#JFQ7H^?_ ]]?8(/A^!RA%=&I .739#\73;1JAL
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M*@G1T@OX?E[ ,MP?M$#X):W7_P902P,$%     @ 23@'5]G/UMZM @  <08
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M#?4[1ST'1-W@:D/QRC:5!5>Z1=EIKM\$%"9 KR\Y5UO#)&A>F?%O4$L#!!0
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MH W.=#<.-\G,52+#TXBZP*&]QVC^ZL7X(#Y^QLMI[^7T.?1_X>7S.)\^?UG
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M68"^+PVEI]VP@?X?F?G?4$L#!!0    ( $DX!U=NW+@&^@(  +$'   9
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M)(_DQ5W31ZIO.?A5L 6P^H>C08?HXOZF6%B5N3N3N;)6I>XU813LAP3P?:'
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MHU#[&X>O.6[%T1QT)$O&?NC%..U;KA:$%!.I&8@:-GB#E&HB)>/GGM-JM]3
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MXL-6?'B._=_%GZ>?/"QN(89W;V+?\Z[AKW:#$:&D3!#,U117AL4-KO]Y5!<
MS07XB D62^00>#:\?^S,.Y R2@D7D)<@,U8+4J;B0XO4-^9XX<,P25A=2@$5
MV9$E15  52<27A,JVKB9S)#_?0!3LN-*C^'D2(G$%/!)%5.!HG5Z"Y[M'\DR
M:R^"<2E1W1>I68RR/]F[;G1BN_ N8<K9)C<54Q5LV)"$F.+WIZMG=_U3 L\.
MW5!GA=<OB3V,L1VY\>GN=G@1PXSM")4Y/N?T=!,_\D_1L:>"3EB!(,G3J^#
M]J+@-!F!"[/F=9FP5:FI3=$7L.*L4.G?8%GCD81+]_+%@_/\:YW""KG<F9/#
MGW5>J28D5=NJ*IHC?\Y'$)YFP0M/Y:E#C>UNV#TV^+9_X1T,+Y4"YZBF%\C7
MIG,),!>V*>^MM6V.PZ8G/+LWG?6>\'6N<D%QI:!NYZ)K 6^Z5;.0K#(=8LFD
MZC=FFJD&CUP[J.\KQN1AH3=H_S(,?@%02P,$%     @ 23@'5R(A^(92 @
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MWMX/6+T,Q<WD3UK;1L4YN??5U54+I@ <G,*"075%;L!$CQ@) T3'!7?0@4$
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M*')%"$N&BK"&8,1H;FI5$HGZJ]&.O14LM4W60S7)(@&, N?/-FFYK)PJ5S9
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M5\$1?HZ_9[JX!L(U.I\7A@?8*;2;HBY<UR!T""C$::J1<TMD0J\5!""SQG7
MD3;D%0%>C>5:%GUP&+Y4$C<)0V^0+=3SB:C5%@/%QZ(F-1&I2^,Z)HT)?:[!
MVC%#@-IU-_1"#3S-B>@3MO4(M?BSX2:4;Z0$SF0K4+5S:S[,[\T9.4\</<@"
M$]\J;6='3&BJ^#"LJ8(#-56;$E#LAY]R7IG:@:$59ALA(14WU/H <S2]5XOZ
MVB ].7!?SX!2+G]"SX?/X+!W*B>R=:>P!46W,/('&!#['8X4TI.HB*-/URNE
M3^WWP>0'MKR@VU!&KLD='RJNT%5QR+GCZO^S</7_V<ZK_V?2==+Y_GY>LWWU
MO0BP>YK)4/3.Q =.?L&:(T4UN01@D>T0K;)]<\KFBHRUGR(MP.X2VUO%!R&A
M[#J4=UHLAK#@[NRL1?^9?0N!4"FA,@'QUX0;=:ZXBV7*;6EF:$:^&X]O.E#$
M-V+T(A(T2IR&=,^H@P(KD19\Z],U6>,P$&=<9+4Y&TE(K\%M:'67"'!>W*<=
M)A;<E',WM_F:MK\#.^ %9?HG<F&KS'V^V9;3R@3WU 8FA0!;8+5/0FX- =J&
MI*6X4ZFK=N$VF!F^:.H#N5>0S5:,-PC,UYZ;O[B&*%-R&L_\<-<\?(F-].B%
MTMRX3OFJ_H-:%R9<N.4LBSS>W?_@=C4%>$J>_#6DOV>5[HKTA%:5J2M;_PEN
MW:U;1U-_9T)GB&-[UK>*$UZZ.8:S B4X^-^P Q+>M:;6TU8DSDBMVUL_G9R)
M[9S>I6",XKS>WKKPN4S\&LA:>]!^W+WSQI[M[GJ#G[#SV:P0ZM^0K.7OL"].
M-&R_)E)2KUXXL.$?4AVO6\6!.Z<TCTR%KDGP+FP"N19&8M]W[YX1%T[=!?34
MC_G^,3WF$(8[P/DT@//I3E2]M52,W\*8Y7H;-.^>)!F*GGFZ>9S5C-V8XW^=
M+&#<JNZ.(IZL4GJC(V75VCKU/< G$:='IX.P')_M.=UBDXF/ON?\YB'=]O?X
M.KX[IV%19YBCK_MX8.]^\13A+IB; WZMJ<A>Y/3VV%SEO[F\M6*S#G>'W6@V
MF' 53-N"#(%*XEY-L;T.51$FTU!=>;+ ^#(!IY&NUAS[%8Q+T(6[6D]7MIY'
M$K0TP242W9N**20'!M9B5A!$0N^A!.89EF7.!,->54XV^]Y(*TY;4%P7*UQA
MM&2&IK3OB;C6IC?D1P@Q6%>FB2L-;072OI-'60<4/;%-R[FLUY"(JW#<6?33
M1N7<N&G"CQ*$^SQJO>ZR17Q:TH^-5>F-PIE0\ WC[DA3[&Z++VU9>HN$G82H
MY;.[!-YRB+:*%U)7NR3=_]P4>11)S3Y&K6]+:=R[5&LU'7+Z;TPL^D99[4%?
M] Z8M@4?[IR32P4IPKMJGC#S+:J.8I/6MWDSJ<HTO=#VQ&4FRK8 @K X*5^I
MJ-0T8^6YMT@M%#T@R+,%=;0_B*[?P8T<=+$S4ZV;%.NN,FT:O#:[[.T1IQGB
M57L<]QL30D4(EOXB>1>^^A*)5G%$6#Q/G&IZ@<V:H-U?T(?[<"V? J(L[*L=
M^+1?=^ZZJ+WMYPH;_=#0& ]5B\+4(M-?Z':"O_:U4/6\2 ?N=<ULY8V4Z]FU
M X Y@(^OC<4X(#LQF2RR,K:?F30+JF,2UE;=@/6-,TTX,]$_?A?-VB:M2*]W
M<HY.U]S:%^*"KK?H0=O7C,&T[0U(V%V1/1 ?O?'U<K^XI:912-MFEK'Y-%2&
MB'?Z9Y/.?-&Y"\M6/^%]MVWJX>3/R3$4Q^L8L%E#CVV#X-K%*$W.NBRVXE"W
M[AS-)XWK)M%U4/V$GXJKD-OR[Q:5Z8M][8;:G)\OW/6+$D5,E^AWRLE=XU^_
MK!\+UWUUPB4)WQ&UI?;VW6Q?Z"*OP,EOD=AP0=NISEV@="_PM<CAQ2)IX$^/
M$\CN]A$J)F9L_8Z8B[U\G@:JLW$WU96%_#W:JG%Z[5;NE]+$YU5T[U2$%YJC
M6=I;1>& U(*1R:AUEN'?6J)\SMFH?:F1-.8N<>\V5@^Q0W'=D3LL5 +##GID
M#DDEYYJ1=ER:[UL6P7+<X0T><V*7G:L;O1KKO"T2NB\Z#^^KK'7A:FI"I=NA
MJ7-L])JJLDV:SD,;=$%.$-VWA4Q[]@O\PG^$8.KBTF98V8*T^PFVJW; 0Z7T
M8H)DP\+,9@+PR("]] [;7K(I_>V"!![Y$&H6WEJ:N$76>5<NLO4P"<>=RK_T
MXQ#)OBMM_RR$%)PXX,M^36R+UEOTUA^ ;> =BK&C!>$%P*V!W/-:%T=#LM3+
MTG\D.INUF/S_)71>_E=O5(G]X(14W1-/G_B^9\PB?90P;9AX!-8;UZNN:?\.
M(MT[K/:905?[_/*PWW@<NA^WGGV9L[4DS@@H46A-E6Z]'=3% ?T,MMJI!T2W
M&;Z_(M\!L)6L^/;1CXMPLB;%+;\6\+9=J?/M_Z4Z'$?X+QR^Z2U!'49_T@EK
MS_@/5QG[_HK]ZT[AT_"WL<;V3T*UC]L_K'4MJQEU#3,UQ="CX?-G>[;8X7^I
MBY+_0-2DJ+%1_N]<21PI/8#OIP4\POU""X2_&/;F7U!+ P04    " !). =7
M#!P'N)4"   8!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RM5=MN
MHS 0_16+756MA *8A*9M@M3THLU*[59)+\\.3,"JL5G;-.W?KPV$L&J:?=F7
MV#.><WPFXQDF&R%?50Z@T7O!N)HZN=;EN>>I)(>"J($H@9N3M9 %T<:4F:=*
M"22M007SL.]'7D$H=^))[7N0\414FE$.#Q*IJBB(_)@!$YNI$SA;QX)FN;8.
M+YZ4)(,EZ*?R01K+ZUA26@!75' D83UU+H/SV=#&UP'/%#:JMT<VDY40K]:8
MIU/'MX* 0:(M S'+&UP!8Y;(R/C=<CK=E1;8WV_9;^O<32XKHN!*L!>:ZGSJ
MC!V4PII43"_$Y@>T^8PL7R*8JG_1IHG%V$%)I;0H6K!14%#>K.2]_1]Z@+'_
M!0"W %SK;BZJ55X33>*)%!LD;;1ALYLZU1IMQ%%NB[+4TIQ2@]/Q_/[YYO[Q
MUV)^LT3'CV3%0)U,/&V8[;F7M"RSA@5_P1*A.\%UKM -3R']&^\919TLO)4U
MPP<)?U9\@$+?1=C'X0&^L$LSK/G"?Z>Y+[L&/-P/MGUQKDJ2P-0Q#U^!? ,G
M/OH61/[% 6G#3MKP$'N\-'V65@R06*,Y?P.NA?S8)_(PS=&W,?;#"_2_5E,!
MJ"MP#0D4*Y H#-SN]!@]#98#E K&B%2(<J1S42G"4W72!=G:]0W<&0NR,8]8
M@Z2$J<[['0W=<(1[=NB._'%GOYC^ME>54F2F#CM@Z(;!^%,&V(U.=]Y;RJEI
MDQ1E0J0[:!"X9]'H$S;PW:A'^2@T8>;JMCH]A<&9&X6COB-RQ_YPZ]CW/KQ>
MMQ8@LWHF*92(BNNF<3MO-_8NFV[?A3<S\X[(C'*%&*P-U!^<CAPDFSG4&%J4
M=>^OA#:3I-[F9G2#M 'F?"V$WAKV@NYC$/\!4$L#!!0    ( $DX!U>Q4A$K
M<@(  /0%   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;+5486_:,!#]
M*Z=4K5II2D*@E%&(!"U5.XVJ@L*TCR:Y$ LGSFRGM/]^MI.F3")\VQ?L.]][
M?A?S;K3G8B=31 7O&<OEV$F5*H:>)Z,4,R)=7F"N3Q(N,J)T*+:>+ 22V((R
MY@6^W_<R0G,G'-G<BPA'O%2,YO@B0)991L3'%!G?CYV.\YE8T&VJ3,(+1P79
MXA+5JG@1.O(:EIAFF$O*<Q"8C)U)9SCMF7I;L*:XEP=[,)UL.-^9X"D>.[X1
MA PC91B(7M[P#ADS1%K&GYK3::XTP,/])_N#[5WWLB$2[SC[16.5CIV! S$F
MI&1JP?>/6/=S;?@BSJ3]A7U5V[UV("JEXED-U@HRFE<K>:^_PP%@X+< @AH0
M6-W515;E/5$D' F^!V&J-9O9V%8M6HNCN7F4I1+ZE&J<"A\F3PM83WZN9C"?
M39:KQ6P^>WZ%RU>R82BO1I[2EYA2+ZH)IQ5AT$+8ASG/52IAEL<8_XOWM+A&
M8?"I<!J<)/Q1YBYT_6\0^$'W!%^WZ;AK^7HM?)JF!\]<H3S6W$FL<<A0%B3"
ML:,M(%&\H1->G'7Z_NT)9;U&6>^DLJ5V7%PR!)[  Z$"UH25"!.I'5.8__!1
MQ:<Y+\X&@=^]A?^U?GW-)K54/-I!(6B$<+E:WE^U@UW?;X+9>Z&=BC$H%%DK
MI.-V!DVPH'('B4 $012V8J[=3@_.8<T94911]=%:V??=[[XN_4V1Q>T: O>F
M#^?'7MP[<&*&8FOGC82(E[FJ3-EDFY$VJ9S\55[-PSD16YI+8)AHJ._>Z DB
MJAE3!8H7UM<;KO24L-M4CV44ID"?)UP_2QV8"YI!'_X%4$L#!!0    ( $DX
M!U?33F$0 P,  +H'   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;+U5
M;6_3,!#^*Z> !DA1DSCI"^N+1+<A0 )-[0:?O>:26#AVL)UU\.NQDS1+V2C?
M^)+X7I[G[NSS>;&7ZKLN$ T\E%SHI5<84YT'@=X56%(]DA4*:\FD*JFQHLH#
M72FD:0,J>4#"<!*4E EOM6ATUVJUD+7A3."U EV7)54_U\CE?NE%WD&Q87EA
MG")8+2J:XQ;-;76MK!3T+"DK46@F!2C,EMZ[Z'R=./_&X2O#O1ZLP55R)^5W
M)WQ,EU[H$D*..^,8J/W=XP5R[HAL&C\Z3J\/Z8##]8']?5.[K>6.:KR0_!M+
M3;'T9AZDF-&:FXW<?\"NGK'CVTFNFR_L6]_DK0>[6AM9=F";0<E$^Z</W3X,
M +/P+P#2 4B3=QNHR?*2&KI:*+D'Y;PMFULTI39HFQP3[E"V1EDKLSBSVEQ]
MO?IR>[6%US?TCJ-^LPB,I77&8-=1K%L*\A>*"7R6PA0:KD2*Z3$^L.GT.9%#
M3FMRDO!3+480ASZ0D,0G^.*^QKCAB_]1XW.EM<CD>:2[$>>ZHCM<>K;E-:I[
M]%9G+Z)).#^15]+GE9QB7VWM#4MKCB SN)!E1<7/5QHNF:9YKC"G3=M:VP;O
M4=2HG\O_=(2; B&3W-X\)G(P[H2[Z\=^H09CS5W@LQ<S$DWG&M(GX547_AR<
M4QC/__O_IE"(1UT&MD>PZ9&#SY8]_,/C-=R.MB-([7Y0I8$)6[^L-16I?M.T
MFON0WOVIYCJSNZ9Z\27$?A*2(SF>#>6Q/YG,!O+$G\:/\EK17XP/S,T9D/E)
M#?%G87@4(ADGO7Q1,-1L8(XB?S*-3S(^<2'18XXWTE#>=P!D2I9@1RIW[91+
MF>HAT=@/I^,3VT%"/TJB(8+X2?18S>8H#&<[._L1[/G YHR6U?P2W VT:GU,
M&OZQ(_%T&(0D_IB0/Z*2OL3G[G$PF*<EJKQY-33L9"U,.UI[;?\PO6OG\:-[
M^ZI]IBIG0@/'S$+#T73L@6I?BE8PLFJF\YTT=M8WR\(^KJB<@[5G4IJ#X +T
MS_7J-U!+ P04    " !). =7"!3E$A0$  ![#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6S%5VUSVS8,_BL\===+>EHDZ]V)[;N\=<UNS7)QMWZF
M)=C2A2(UDHK3?S^0LEVE<MQVNVY?3)$$P.<! 0*>K(5\4"6 )D\UXVKJE%HW
MIYZG\A)JJDY$ QQWED+65.-4KCS52*"%5:J9%_A^XM6TXLYL8M?NY&PB6LTJ
M#G>2J+:NJ?QT 4RLI\[(V2[<5ZM2FP5O-FGH"N:@_VCN),Z\G96BJH&K2G B
M83EUSD>G%Y&1MP)_5K!6O6]BF"R$>#"3FV+J^ 80,,BUL4!Q>(1+8,P80AA_
M;6PZNR.-8O][:_VMY8Y<%E3!I6 ?JT*74R=S2 %+VC)]+];O8,,G-O9RP93]
M)>M.-O$=DK=*BWJCC CJBG<C?=KXH:>0O:00;!0"B[L[R**\HIK.)E*LB332
M:,U\6*I6&\%5W%S*7$O<K5!/SZ[/[V]O;G^9DZ/??I_/C\G=]3V9OSN_OR9'
M'^B"@3J>>!K/,=)>OK%YT=D,7K"9D/>"ZU*1:UY \5S?0WP[D,$6Y$5PT."O
M+3\AH>^2P _" _;"'>G0V@N_E_0^KIVI:+\IDS.GJJ$Y3!U,"@7R$9S9ZU>C
MQ#\[ #3: 8T.69_-,0>+E@$12W)!5943R@MR5;%60T%N,6>OJ>057RFD(I1"
M*B#)O*02]E$Y?-CK5UG@AV?D_QX_E!+@60@1# "P ?"E[+QZ>D'RZ(8378I6
MH<>42^ IAT8395QCG=B@H[I9@7ES/+!L0FW?8O =DK=M#9)J(4]_N--,+%0\
M%S60(V8C8;OS$QF-W3 <]Q:.8ER(GHDD;N!G?9'430+_F)P7Q8\'_[;BE.<5
M97A-6&T4*!/PZ,*(W H-ZDT?V,A-H_'POLPX"L[ZDH'KQ^'+DD.788TCQ2:Y
M<LKREE%;.GI^2MUX[!]V9>2.XGB/*Z^ "WS!_YMX^&C+$?*@CQB"*^ABW?KU
M4M0UDIIKD3\0K--*8S[@&V+I+^PKLX_\=DQ2Y)<AI6RP%:5N&*3N.!XF21*X
M89KAU<5#K<2-L[$[3I,A:GL;6+8)+)=8QY^'Q< 2NCZ,8X0V^FIX[%1B-TCQ
MQ@ZH? LHU3FS,1[;@\N-$5;HI]\.RPVB$,E$_PK5FDI)N=X#*!RY?C:\BI?@
M?&W]GT;;H63;CEF(3Y/O)M'PA@[$&\9:-L9'+?"'6I_C;;OT9N\3Q/NQEN/%
M5DI;3K0H,%$,GR59?JEHWI162F15M-(0U268:E.)PA8>W&:M[6E1NZ8/\/.Z
M%,RH:4"?:=+03]CUXDFZI!K;0<;(HF>U;5 5T:"GC963?6V&UVL(L02M;-MK
M.+1<=[WA;G7769]W#>5G\:XM?T_EJL*89K!$5?\DC1TBNU:WFVC1V/9R(30V
MJ_:SQ'\'((T [B\%^F\S,0?L_F_,_@902P,$%     @ 23@'5T.L6W^! @
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MW /F.MAQ<2\WB H>$I;*H;51*CMS'!EM,"'2YAFF^LF*BX0H'8JU(S.!)"Y
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MVXW/52V4ID%I.I1F0&DFE&9!:3:4YJ!HU6#8JXM0Y*O=DH:*#B1-@])T*,V
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MM[*2!*8,Y/<-I>*UHVJ5MC8=_P102P,$%     @ 23@'5WYA O]U P  PA4
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M@+R_H50\=]0>6+MMZ_P'4$L#!!0    ( $DX!U=@F:0F. ,  .P3   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M-HO#DG?J[?RCMF[N>:YQ_W=2[<=W[;S]M'S>7'PJ$\X:C@Z/OU!+ P04
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M+GAM;%!+ 0(4 Q0    ( $DX!U=.L-A,[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $DX!U>97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ 23@'5XG_:C/N!0  Y!\  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $DX!U=L/RC<Q04
M /$7   8              " @3$.  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " !). =7!-FRDDP&  "X&P  &               @($L
M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 23@'5Y;M
M$ +$ P  =Q(  !@              ("!KAH  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( $DX!U?6I^*"YPD  #9+   8
M  " @:@>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !)
M. =7 #H;?[H"  "P"   &               @('%*   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ 23@'5_[Q58ED"   \B,  !@
M         ("!M2L  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( $DX!U>38MH\C1@  %5+   8              " @4\T  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !). =7V<_6WJT"  !Q!@
M&               @($230  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ 23@'5Z;?@FQ1!0  U P  !D              ("!]4\  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !). =7;MRX!OH"
M  "Q!P  &0              @(%]50  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( $DX!U<]V9A5& 4   L-   9              "
M@:Y8  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 23@'
M5U"&#5G;!0  4!,  !D              ("!_5T  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " !). =7Z)WW-#0%  #I#   &0
M        @($/9   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( $DX!U?P1^$Q-0,  #X(   9              " @7II  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 23@'5R(A^(92 @  704
M !D              ("!YFP  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " !). =7SD\%0+08   ]3   &0              @(%O;P
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( $DX!U<,' >X
ME0(  !@&   9              " @5J(  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ 23@'5[%2$2MR @  ] 4  !D
M ("!)HL  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !)
M. =7TTYA$ ,#  "Z!P  &0              @('/C0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $DX!U<(%.42% 0  'L,   9
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M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 23@'5W6
MC<F* @  S08  !D              ("!JJH  'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    " !). =7N^N0ELT"  #X"   &0
M    @(%KK0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M $DX!U>T5DR1% (  "\$   9              " @6^P  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ 23@'5S2^O?:Q P  IQ(  !D
M             ("!NK(  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " !). =7G\ANU9H&  !R/@  &0              @(&BM@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $DX!U>:AA?1:P4
M (0@   9              " @7.]  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ 23@'5Y&EF82D P  &A   !D              ("!
M%<,  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !). =7
MZ_VI6&T#  "G"@  &0              @('PQ@  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( $DX!U=^80+_=0,  ,(5   9
M      " @93*  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ 23@'5V"9I"8X P  [!,   T              ( !0,X  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !). =7EXJ[',     3 @  "P
M@ &CT0  7W)E;',O+G)E;'-02P$"% ,4    " !). =7 31P*DX#  !M%@
M#P              @ &,T@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M23@'5^ ]"5=H 0  2A0  !H              ( !!]8  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 23@'5QR:"5V, 0  YQ0  !,
M             ( !I]<  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "D
,*0 6"P  9-D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>113</ContextCount>
  <ElementCount>180</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30703 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40701 - Disclosure - TAXES ON INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  plx-20230630x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="plx-20230630x10q.htm">plx-20230630x10q.htm</File>
    <File>plx-20230630.xsd</File>
    <File>plx-20230630_cal.xml</File>
    <File>plx-20230630_def.xml</File>
    <File>plx-20230630_lab.xml</File>
    <File>plx-20230630_pre.xml</File>
    <File>plx-20230630xex10d1.htm</File>
    <File>plx-20230630xex31d1.htm</File>
    <File>plx-20230630xex31d2.htm</File>
    <File>plx-20230630xex32d1.htm</File>
    <File>plx-20230630xex32d2.htm</File>
    <File>plx-20230630xex3d6.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20230630x10q005.jpg</File>
    <File>plx-20230630x10q006.jpg</File>
    <File>plx-20230630x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="352">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20230630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 352,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 113,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20230630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 284,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 38,
   "keyStandard": 142,
   "memberCustom": 17,
   "memberStandard": 18,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShare",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - TAXES ON INCOME",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncome",
     "shortName": "TAXES ON INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_QUjUUub4Q0qjc-8olcENaA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - TAXES ON INCOME (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables",
     "shortName": "TAXES ON INCOME (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_agreement_X7SYM2BmAUCWR3u0qzuWtg",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_KY-ma-SuxE6JsnDPAL7QoQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_KY-ma-SuxE6JsnDPAL7QoQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ko9l1NP2-0GXftXXSOU8gw",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.protalix.com/role/DisclosureRevenuesDetails",
     "shortName": "REVENUES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6EY8ZLejPkaK5jN5fkWHzg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_5_10_2023_To_5_10_2023_kzlqsZvS4kOBpSRWM3vhTg",
      "decimals": "INF",
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodSharesWarrantsExercises",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DilutiveSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - TAXES ON INCOME (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails",
     "shortName": "TAXES ON INCOME (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_myLlXY2cmk2m1VIFz6tG7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_7_25_2023_GhxIuEgHh0-KdnsF3PgcOg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_NnZfXFhDKUSpSEvAX5N1gg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_7_14_2023_To_7_14_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_8xJeZMuB3U2g_8i3Y-HmUA",
      "decimals": "-5",
      "lang": null,
      "name": "plx:ProceedsFromSaleOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XAvFwxyFCEqwxJ0AjpLtzg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XAvFwxyFCEqwxJ0AjpLtzg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f3Uy5FcUHk2MpNSiRIyOZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_rmHC3U-r_E6XgiKwYDwZzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_QuOJSbPH90ShvqTQ-JNTTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WpOBNJJXyEKaob12la92nw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_rSLqU_4fWkSNUOkLErfyjQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 35,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtmEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ATM Equity Offering Sales Agreement.",
        "label": "ATM Equity Offering Sales Agreement"
       }
      }
     },
     "localname": "AtmEquityOfferingSalesAgreementMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "localname": "ConvertibleNotesDue2021And2024Member",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_DebtConversionDecreaseInPrincipalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of decrease in the total principal amount of debt due to conversion.",
        "label": "Debt Conversion, Decrease In Principal Amount",
        "terseLabel": "Decrease in principal amount"
       }
      }
     },
     "localname": "DebtConversionDecreaseInPrincipalAmount",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ExtendedTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended term  of agreement.",
        "label": "Extended Term Of Agreement",
        "terseLabel": "Extended term of agreement"
       }
      }
     },
     "localname": "ExtendedTermOfAgreement",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plx_FillFinishAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fill/Finish Agreement [Member]",
        "label": "Fill/Finish Agreement"
       }
      }
     },
     "localname": "FillFinishAgreementMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_GainLossOnDebtConversion": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on conversion of convertible debt.",
        "label": "Gain (Loss) On Debt Conversion",
        "negatedLabel": "Gain on conversions of convertible notes"
       }
      }
     },
     "localname": "GainLossOnDebtConversion",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaintainOfMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance"
       }
      }
     },
     "localname": "MaintainOfMinimumCashBalance",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received upon achievement of certain milestone.",
        "label": "Milestone Payment Received",
        "terseLabel": "Amount of milestone payment received"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MilestonePaymentToRegulatoryApprovals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the milestone payments to regulatory approvals.",
        "label": "Milestone Payment To Regulatory Approvals",
        "terseLabel": "Milestone Payments to regulatory approvals"
       }
      }
     },
     "localname": "MilestonePaymentToRegulatoryApprovals",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_NumberOfPatientsActivelyParticipating": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of patients that are actively participating.",
        "label": "Number Of Patients Actively Participating",
        "terseLabel": "Number of patients actively participating"
       }
      }
     },
     "localname": "NumberOfPatientsActivelyParticipating",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_NumberOfPatientsDosed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of patients that were dosed in the trial.",
        "label": "Number Of Patients Dosed",
        "terseLabel": "Number of patients dosed"
       }
      }
     },
     "localname": "NumberOfPatientsDosed",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_NumberOfPatientsEnrolled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of patients that were enrolled.",
        "label": "Number Of Patients Enrolled",
        "terseLabel": "Number of patients enrolled"
       }
      }
     },
     "localname": "NumberOfPatientsEnrolled",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_OutstandingStockOptionsAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants.",
        "label": "Outstanding Stock Options And Warrants"
       }
      }
     },
     "localname": "OutstandingStockOptionsAndWarrantsMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_OutstandingStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options.",
        "label": "Outstanding Stock Options"
       }
      }
     },
     "localname": "OutstandingStockOptionsMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_OutstandingStockOptionsWarrantsAnd2024NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants and 2024 notes.",
        "label": "Outstanding Stock Options Warrants And 2024 Notes"
       }
      }
     },
     "localname": "OutstandingStockOptionsWarrantsAnd2024NotesMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PaymentsToDebtHoldersOnConversion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.",
        "label": "Payments To Debt Holders On Conversion",
        "terseLabel": "Paid to the converting holders"
       }
      }
     },
     "localname": "PaymentsToDebtHoldersOnConversion",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_PfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement",
        "label": "Pfizer Agreement [Member]"
       }
      }
     },
     "localname": "PfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromSaleOfProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProducts",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ReserveForDeductionsFromRevenueCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of reserve for deductions from revenue.",
        "label": "Reserve For Deductions From Revenue Current",
        "terseLabel": "Reserve for deductions from revenue"
       }
      }
     },
     "localname": "ReserveForDeductionsFromRevenueCurrent",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SupplementalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "localname": "SupplementalInformationAbstract",
     "nsuri": "http://www.protalix.com/20230630",
     "xbrltype": "stringItemType"
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Supplemental Information, Balance Sheets"
       }
      }
     },
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20230630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r246",
      "r313",
      "r321",
      "r335",
      "r336",
      "r353",
      "r359",
      "r366",
      "r394",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r246",
      "r313",
      "r321",
      "r335",
      "r336",
      "r353",
      "r359",
      "r366",
      "r394",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r174",
      "r315",
      "r354",
      "r364",
      "r390",
      "r391",
      "r395",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r174",
      "r315",
      "r354",
      "r364",
      "r390",
      "r391",
      "r395",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r239",
      "r246",
      "r249",
      "r250",
      "r251",
      "r312",
      "r313",
      "r321",
      "r335",
      "r336",
      "r353",
      "r359",
      "r366",
      "r389",
      "r394",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r239",
      "r246",
      "r249",
      "r250",
      "r251",
      "r312",
      "r313",
      "r321",
      "r335",
      "r336",
      "r353",
      "r359",
      "r366",
      "r389",
      "r394",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r355",
      "r365",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r355",
      "r365",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r363"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts payable and accruals - other"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r0",
      "r18"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r21",
      "r339"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r21",
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r384",
      "r385",
      "r386",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r69",
      "r70",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r213",
      "r300",
      "r351",
      "r352",
      "r379"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r87",
      "r99",
      "r120",
      "r165",
      "r168",
      "r172",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r278",
      "r282",
      "r292",
      "r363",
      "r392",
      "r393",
      "r405"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r96",
      "r105",
      "r120",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r278",
      "r282",
      "r292",
      "r363",
      "r392",
      "r393",
      "r405"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r98",
      "r337"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r75"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued to purchase common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r82",
      "r90"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r384",
      "r385",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt Instrument Fair Value"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r30",
      "r120",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r292",
      "r392"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r263",
      "r270",
      "r383"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Convertible notes conversions"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Converted instrument, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r79",
      "r80",
      "r85",
      "r123",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r301",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r7",
      "r80",
      "r85",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt Instrument Carrying Amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r23",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r24",
      "r123",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r301",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r39",
      "r73",
      "r264",
      "r269",
      "r270",
      "r383"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred tax asset",
        "verboseLabel": "Deferred taxes on income"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r77",
      "r86",
      "r236",
      "r237",
      "r238",
      "r358"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r39",
      "r51"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecurities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Financial expenses of 2024 Notes"
       }
      }
     },
     "localname": "DilutiveSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r112",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r137",
      "r139",
      "r152",
      "r153",
      "r154",
      "r158",
      "r286",
      "r287",
      "r316",
      "r319",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r112",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r139",
      "r152",
      "r153",
      "r154",
      "r158",
      "r286",
      "r287",
      "r316",
      "r319",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r121",
      "r259",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r56",
      "r94",
      "r108",
      "r109",
      "r110",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r160",
      "r181",
      "r232",
      "r253",
      "r254",
      "r255",
      "r265",
      "r266",
      "r285",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r305",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r288",
      "r309",
      "r310",
      "r311",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r206",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r288",
      "r311",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r206",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r309",
      "r310",
      "r311",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r40",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r28",
      "r76",
      "r83",
      "r92",
      "r165",
      "r167",
      "r171",
      "r173",
      "r317",
      "r347"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r260",
      "r261",
      "r262",
      "r267",
      "r272",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r135",
      "r136",
      "r164",
      "r258",
      "r268",
      "r273",
      "r320"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME",
        "totalLabel": "Total taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance related to deferred tax assets"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease in accounts receivable-trade and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r314",
      "r378"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r154"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Weighted average dilutive effect of warrants"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r148",
      "r149",
      "r154"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Weighted average dilutive effect of 2024 Notes"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r154",
      "r248"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average dilutive effect of stock options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r114",
      "r117",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "verboseLabel": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r50",
      "r340"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r103",
      "r338",
      "r363"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r50",
      "r342"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r50",
      "r341"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r120",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r279",
      "r282",
      "r283",
      "r292",
      "r346",
      "r392",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r81",
      "r88",
      "r363",
      "r382",
      "r388",
      "r401"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (net of capital deficiency)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r97",
      "r120",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r279",
      "r282",
      "r283",
      "r292",
      "r363",
      "r392",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r7",
      "r8",
      "r120",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r279",
      "r282",
      "r283",
      "r292",
      "r392",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and R&amp;D Services"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Share Price."
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r40",
      "r84",
      "r91",
      "r95",
      "r106",
      "r107",
      "r110",
      "r120",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r150",
      "r165",
      "r167",
      "r171",
      "r173",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r287",
      "r292",
      "r347",
      "r392"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "totalLabel": "NET INCOME (LOSS) FOR THE PERIOD",
        "verboseLabel": "Net income (loss) for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r138",
      "r144",
      "r145",
      "r146",
      "r147",
      "r151",
      "r154"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income (loss) for diluted calculation"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES), NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r167",
      "r171",
      "r173",
      "r347"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r104",
      "r363"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts paid (funded) in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Goods"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r95",
      "r106",
      "r107",
      "r115",
      "r120",
      "r127",
      "r135",
      "r136",
      "r165",
      "r167",
      "r171",
      "r173",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r277",
      "r280",
      "r281",
      "r287",
      "r292",
      "r317",
      "r347",
      "r360",
      "r361",
      "r374",
      "r392"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r52",
      "r89",
      "r318",
      "r363"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r71",
      "r93",
      "r413"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r94",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r181",
      "r253",
      "r254",
      "r255",
      "r265",
      "r266",
      "r285",
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r111",
      "r120",
      "r162",
      "r163",
      "r166",
      "r169",
      "r170",
      "r174",
      "r175",
      "r177",
      "r180",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r292",
      "r317",
      "r392"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r304",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r15",
      "r16",
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r100",
      "r101",
      "r102",
      "r161",
      "r215",
      "r216",
      "r217",
      "r219",
      "r223",
      "r228",
      "r230",
      "r353",
      "r373",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r56",
      "r94",
      "r108",
      "r109",
      "r110",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r160",
      "r181",
      "r232",
      "r253",
      "r254",
      "r255",
      "r265",
      "r266",
      "r285",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r305",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r160",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r26",
      "r56",
      "r57",
      "r63",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r56",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r27",
      "r56",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r49",
      "r363",
      "r382",
      "r388",
      "r401"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r119",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r232",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r138",
      "r154"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED",
        "totalLabel": "Weighted average shares of Common Stock outstanding for diluted calculation"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r137",
      "r154"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC",
        "verboseLabel": "Weighted average shares of Common Stock outstanding for basic calculation"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r368": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r371": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r372": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001558370-23-013483-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-013483-xbrl.zip
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M#DF65H54E[?3F+;3V+18ED%FM%ZDY25^)S8DGL__P,BQTPJI22Y2*YUO@NO
MC.42B7Q"YJ4Y$:0L\45J*F0UEO($8VQN12H9:3&E>)=P%I-=KKOI?&S2KXBG
M0=K'4$ESD= -"4<4L;#,1O8$\5UPS&IZ(8BJU^!A'C5PJ6Y!-'R2U,9RAE;B
M-167BLRJZVXV4"=BTQEC<#<."N06YR?PN]1%4KKBD#$?V3T_W&$"ML%Y8SH
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MUL.NHS'\N^WTQR/#O#',06?8&G<AP9Z/O?:Q6.V7R1/A,:J[D4:'W8?GUMR
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MBUKO#Z)(5HZXY/KI1CYF(ASE/$A37;$#]/L0@)44LA*[2KV)]B.@/2L;KPE
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MQ"6C-@=(#6?HWNFA[\A20DJU0Q&)2\9G#I :SHO#I\$R45IZ YP/IX;Q$3P
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MK';7[]^_OXQ_W8.2X=UP#UO$YKO+Y$<"&L /03S4 W+L,)92+0D6%X)^N\C
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M26LQ5+?T#EP7TO%L;^PO$=[$!D IF>(1U%$W R_ CUJH7Z4#A?.%&I0%MOW
M=MHI$K\G==B.;.R3F1<\H""8 CQ?D^7@:(2%G2GD</0<@#\BHF^C%VK-CV<P
MKZ,4UQ@=&SL9SNG'PR% L+'?@@BC+?U?O/>Z! %87J;PEU\@65TN?!MC] 7@
M-[6TL_98'L;[_NB %^D7PJ3K'R^NKR_>Q9N[OQR.520EHZ.Y(MJ^:V-WX+O#
M* C19O *@SNTL2&9W$L[\L*@P?20[JO,(!8A,HP,LCWWT@Z>8U:2X\[*MK?T
M-/'N$I !Z5]HEP%%^EV,, #NIJI0E2X2<1#8R]%K2#8<D*R^(Y\<FY+=U0,,
MPD;JM!<W],-+%V[V(K<][SB]*9PRZ#G@NYBZN#<%6)'/E&CD7[B)[!3BR.A;
M+<:QSG6#<-JU"GSCKBXV8/-\K.5@(UON5P&F:X(4=J)G<+%GA$)\F;T7L29*
M GV83#K_]W00BEC;R5LD 5 X%[C[O\*0#I WMPKMK<2J68\QCX.FZ"HTRD+D
MW[]_?W5E75AYS^1+UKE%>K>2[BW:?T;3?H28I(PH#SFE$3WJRD#X:)M,_Y*;
MY/0/O^6'/,\.R%$NWB91Y+)Q//L9>+%72PS_V_4!*Z1:7&H@N8C'7<EN'=!:
M!>02R08M4Y=KZ0"7Z22S/NMWB=&F&;=1'1910(9 V^0HD35+#4V;52GA0$[5
M!PFLK06RQ-@B3+9<']^HU(T AP6](-]RG2!??IMBY$9..,%S@%^@ QC:SP.K
MZ(,(L&=Z F)M4@P"IIH+8464L:&/5G8)YB*)\7M3<SZ^5+MK\>Q P1L8O[%/
M5C^PGZ&9?UQ@\04MN.:PIHU!A L7 &&;IL0K7!;D1((:H-3[&B$DH;A*U**N
M=S[M$4O=W6BS13YU?\CLH5AMZO=1O%8ZR#_ 13B;F+!<<KG0ZC95->Q'$LCH
MVUNQD2_.'"[2>F?,X LY"BW( ((94H+AJD@%2HL!H'[9^'J><IJ(,[%C&-,K
ML?A^[':7PTSM7>S:IYCGZ/ONU+/])WL#A!.HBZ'XYJ:CP5I/7YYNH.YQ[WVV
M']!:G-U=T:C7.-R!YW#L!R&.@V4$%J(*R-5D-JA^ZFKG.P]<DE+%\T[(<22'
M1.\3B(5T<1:)D-4[$^@$G2P+\UDP&9BP7"WA0FO9#10,%K%'3XA>MF5_*5[7
M/I:<]H?[A6:]\'<4S?MI/:_JA(=:H=?[C..04YQT1Y"A;BX&P'F[0B^7+H")
M?I(/N5J2+[\]@)7MC7Q"XHXQYQ@0%77BP'2/>C(><U$Y_)F)]"' T<HMYA)B
MC]:;KC*QHQK*PJI_A_3^C/<)H!6VMVL:3<CQ2G-AF0Y<(71OY('5(0I<_S07
MEDV>"+J5?UJ&S4@"B5Z=U *D,T^U$-G^-7]&5P&.IN]_8XJ^]&NOZ#(W)@>_
M\E%6L)'@,0<QA^E5 PMH91IW@(YF[VWT'$ 7VG@WMVD\:>WM-P^>[T81M=!"
M<HX&/>Y,EH4-E]C[5-N0SP2IINT=NQ+204VQZM_#RZ>BY/^1PE[_]"J$A-8X
M?3G0PJG%@3>$6/%\XL$W(5CQ[!&S'TFBHF7*,%$O31@1ROUO=8;TF0; 6QN'
M.SJ!.;L>%AAS-\$#[&TO!+81=M9V  8K#-)W0V64N+M\Z;;L?523UJUV637"
M0$?@T^MVC(W_?F?6!&^-I^*Y WP;0U1W(B["B4_#AY"]D92.^]D/ML")7^?R
M3\(\6#9I(F@U)V$.>Y$$ GI.P66$]R=@$:*:MT]KA,,%P!MZ2U&W>6+!"BYW
M.=!&D%ES"<Z$EB=5Y9:IANE("HW^MTMLM,NWRUQT]<Z)_4/)V]W^X\\08,*.
M]>X!O "6H[198ZXJR3?7RIG"$]*@BJ=P<C7JHYY/LKVTGHB-!8M:8-O[?)6E
MKCB!&U.E=UH7L!S[VZANM>.!<U52U, 4>H4SD]^@$<T*YYR$#) L,KU/*3[R
MQ4DD1MJD2*D9<$&2_V *R&;6E8Z<8C64C"_B-36/&PVBK-A-C^1(9]%7-5+C
M1F/Q$=0<F<4FB!^IQ2=$[ZQ,,N&,_3P-RR@(X8:<0&]W-6N:3%/^^T/)QF;Q
MI';5DVEZ!$\4KX0-)8>:H]C[[)0CJ?2:4Y*4_AV'"TKE9#GV7?@"W8@;2L.$
M8WK7N)#:2/H5ANL9\)(L9&NX72!!*-@1/<BQH;Z/5J['.@&AH]'JU2')(2-S
M2!Z!OMXU[Q.V_1#$3_0BT;.W"AS7<C,AM9,F7*D8D'+D*5R'1 Q&M</WOL8P
MT"TN*!PT]>IZ]EY&H.9%$*X*' +II$6HUY*OQ3IXY\7A(Q(-VKL.EY$LJJ]I
M+ZNF&&T!#G<4KW#@N_1UZ)8>I6H/)A(M^7HAU]8HAM2>2B1:-F>(XC-),Z&A
MQ@CV/]-D""I-0#E"-#^&=O\O"L+$.8_P$_A2R-^*D4\^.ND[&<%CZ29]\)\^
M->U%XZ,X-U$\X9,P%FC=D[@*</O'RD?*!M7CUO]CY&:T%.<BCP:]DV\&0IAX
M]ZF-J%D%V<!<C>*#FT&I<('C@3>@5N%25LMY)(=([Q.&AWAQ9H@0UCL['I"_
M"N6"CUB@7%WA 9M HW!6L(&EZ50X(VKXC620Z'TVL)$NS@4^LKK7B0#0: FR
MB;RCT18HWD867C$/D1]BVPD7: HP3=5.UL=)N 8XJ#U<*>E;8)<5]7YB;)=8
MX13TW07;E:^=:M4+=4"DAG59"5/*R[@B9NB..&8E%8K_&@RB<(TP_!.XGWV"
M8_SR;))<P9.="^',Z!5@!P9@BJ$#>"]Y.QQ)$ +<R5@G)J J(4<D&VLU4A<"
M$HVE(+Z[2R6M35C6F@$:(LL[8%A]UK/6C-(<-)0DPOXUSH(33O ,KM:B=$]<
M>'XHC*B%,23+)&-GM6A&MLK 'PE!5-.S\]#I/\B'CSXC3SL/;=UG,X]6HYO2
M%XK%U%&WN^(OP@.8; >"[7Z3+G1SJ>9<= @H1;72$\L1\D!U:&DX8\B343Y(
ML- W(6?\PGY-5UCA?&(#<[6(#VX&I1+YX:O@#:A5GA5>P/E*0G@V(IIRP5<1
MKZ:!9R.L(WE#7@@U#L:#@'5#*P)E1E2*@'72Q@TCY0-+TZ<L-T,MGY$,$CTG
M9. AG46#BI'5NR[<VAZM43U? R!32(0'SK66H@:FT"M<'_@-&M&L<(V0D &2
M1:;W=8*/?'&E$"/=_UKQ:/\?PDG5-X!YJT05B&D_V6!]49+D&2OAP%T8N+!,
MNH30K98%(6.1Q.B]K@<L;+.50(BEYB@VLC"YT(M"^ +FP(EPO$R-7ATO<H%[
M3X1!O751&,_%R3*K;)Q5-;[=L3L0Q;QU-R(_0J[;,<T17&U0>%VSABQ472"D
M%]U S:CJ/UJO2RZ4LKE+4']HGGZZ/!#N _F:_')L+=>\Z"3R7<(L>D.0;YWW
MOP:3Y62;UI25*^EZ=?4N+NFZ[X)\'DZ>[D9/\]$=_32?/(SO!@OR9;X@_WL<
M/2WFUN3>FDQ'L\%B3 #RPJ[]UB1;V,]YC6!>$;(4Z%(!CMT5VBS@)V41I&<6
MLQ1RKJ[,6T$F>P]J5!Y@?S#]^V-VNRJ@G;&]6MZ;S?,ZM:FM#-H)ZQO,Q10Q
M8:CZ 4Q7+(_YL2]27LMOON8</!<IXJZ7V0\$5V+Y<\2%;.="]RJ =RT%P*5"
MKRCR@IW0!V/RL;889@&P(P'8GB=MVRMHE\(U#E: P\T=0< -/SC(#\F>8N3%
MH$2T2:V%_'</D5W*QS<ACA2MOXUN!%^ 'P'^K6CVL\[)T$PJ.<Y;#.,K@EC,
M>N?!$ 7A9)FBQ@MM*,/TRO&;-AP_0-P@MK/C,4>O-&2()X::-KV*Y=MV$T%(
MB$%BF@./=+?Z!'QR)/,(O@-W0W@;A/2 ]@+$\I)MW*O@OFNUKDA29) $T\.T
MOTHN:!]0P%M2F)"]RN;[-K)AHF^2(&@P^1/R48:G>/+PP7L5R0^M1,*EP62Y
M)/HC*Y8,NE>I_*A4*AD)!@FEBIYXM@C@>Q7,^S:"$1!AD&AR\YKXJ.G[\HA@
MG'MM;\$28; /"*).;;) $@Y!W\:[F'Q"*CU]$4YZ,;$AP" (.<+M=,1^G3E7
M;?2C4SX8IV$$_U3];\EV:PG%VL& [E>RK?P57!H,DLH3"&NWD <P_4J@E6_B
M '.#^%ZY^+,#Z'#XSX'M5PZM/!8<"@R6QQV]6LTO)6LDLH?N5R:MW!5<&@R2
MRJ^ /GH![N"%K(4K\!11^B?+Y.'9) J#T/;)*K@2S9Z&??0KP59^BX:4F2_7
M5 4K!#23++^7?F7;RN_1F+9ZZ?YTJ3OP8TJP]LDY-:0%KZ6C0+YK%P5B?5,:
M]J__*5$AC;?FN6+6!Y4+6YQ"S(@4(28<F"JH23R-XK;1'%;20-\D9&1&I$ER
M&4?+0@?"L <&G,Z(DT9*5KU\+-%A\)VC4"12+4VXB&\L)"G*3N$.4CRG&O9A
MP@U_8U$VI%'S*7JS]= .@#0FBITV9.!Y*=4TB,%!*Y\F#TD*"E'K$E0VQH>G
M;]6CZ M\ZHAA7UG45,J ]-Q3X8_X$DFVL0F&O@=UD&6'N>?)I.11,/;C5$-K
MY!&.!C3->+@;VEM(^KTC.#@0^,Y.\I!Y<]Q3@^'/@Z=/H[DU?B(_3(;_^'GR
M<#>:S?_7&OWS\WCQ;^N;X6 Z7@P>K+O1_7@X'CT-_WT^?@IP3(5(U!'Y-=G7
M:]J<TA&TAA3-*WH9)^'ADP-KR*%32LM*#G(V.;J/FYL-2BQ?S7&S F?"<5.H
M3N5C9@5_O8P?N"Y,AI[:T!W[Z5(C%$)-&R-V'+("J:%%MP\@)&@#-[O3JCGV
MLX%-.!Y*BX-'Q/GYR?GYB4@^ASMFKGRJ@":8*UE)5;$WZ/93]GY3]PUFJY"/
MHZXH946P]5XI6V^NOK^YBEE+_I!(?1P$$7#O(DS+X\1'XE]L+P*QOWJPP@"D
MD['([Z:-S7^2TI0B/9))5.18T;!;F__JI#%))EDN@4X-D?]"[&WLEDH^AY"L
MDWEN"M%2<WR?I_.4I26AYJM!HKZ*]4"ZT]-Y0-.64H,TH5"<;H$X1\28KN=#
M1_,,D(U9 ,/,UYWP(/5G4X!X7G /UET/>SH/?[KG1=>[ ^9%Q P$(89.[/LG
MTV7PQ<9N\ 3"R?(>X26 880KIJ1U;^:_*FI-HKG"3.R?6I%F?>KT?2K2<072
MS[BA\2"6EC/8EP5ARKM9^Q-XZW4$53J/9"V$Q.U ^PP\1BFESFN="N_K?^#5
MRB?;^(&7VJ"%.QA0?RZQK?<VQ+$N/0*;?M_[B>6R'=Y<D?^L"ROOD'RY'XQG
MUB^#A\\CZW$TF'^>Q9$'UC=)O^=(@BJ.M(3IV"<K8137 >2'#[  3REF@(6_
M7CM3QJ@VERT?W)!P ;XJ\>50)*.#)9LF?)HB0M@]?*&'-8<,::_(Z<TG5B]V
M$,1!4YG+X F%(+B+ .GH6^:%J*I.30@LJ%.__4JN@%[=SK?S':O)=ZS[G< @
M"$"<3?(!VL_0BYUWZ>[ G9 #&U$UNI4D $_(Q]E7^E@SH.WC8]T".&L?_A&!
M(&;(@E!]2]#^G2/RGL8^G9O@GABB;]\YARL?+J%##B #QT$1S1ZRFB*/QK\&
M=S1(Q)/;@7Y[=7UU?;@#G8\_/8WOQ\,!V78.AL/)YZ?%^.F3-9T\T'#6N?5-
M.D+#O2A[>1-1PMISRC;J>?XO2-^39:$&M6 ;RH'5OQ-M)I#BC..0I/F:(D<G
M2*:XG?^E6"=0',[7M!=#MK)"C2Q=)30E4/TF=[")C=-T"?\$>'\)SMV^BL%-
MV)@>J7K9?E5,H'K^#]=D<L/]0.P)(0(T86_0DN<\TCIVR2;#?I[7:ST74K>3
M5:P]9?XRT.^*IZ-7>:XR874J=5.^,@E0S]E[Z'GW]"'JNIZS E@3 AI;F@L!
M=9T9B3P^C""\EWL@;3IDVYL0ZJC$FDM3K&ZC&@#G[0J]D(,?3/:HY$.^-25?
M?GL *]L;T?*BK-+.3 @-1P.&/6IV-& 2TB>?DW&9_NCJSYHW[0*]R'A9QE>]
MC9FF_H9;B!9K@.TMB$+H!/2B#6]1DLN):V":--:Y7>'I168VFM#1?YFIO??K
M$T K@MR:IK;B%/82P&JP)C=MK4D-21IDD7B?BZAP2WX)8 TH^56K57O^\\E0
M;]=CC<"[1 3IEUP"Z1]^NYT=L+OX@^[:7K4J0AE;1+A_+9[1'17'@A1^TV Q
MOE5A,0HD:.(M<\6L_&J %:AH0HF'^M:\1\*/3;3A\O'@=]USGB'TC)$'F&I@
MI?TJ9F7Y=YWNCSI6EC$U*0;&_/"C[]I:UG,XTG]N.!([2.9ZX+O"@".Y9B;<
MW,B&%,E1=(X'Z^\6HH%F?D5Q8=%S %UHXQU]0#Q9)N] !!FT^/ :EJ+O52U%
M K(TRR='A]J2R;+@NA:N33(-#5FE:G6P)"D)NCH(, @?;?P[2+. 399+0 .]
M^ $&0G 3EBEYO=K'% AIZH+EF_)0Y0P' MY+M3,AXN 8(4@1U\&V0616'S@Q
MQ4T:]A]CW)RL_;(OL<;T'X/,E%M6 N23AYYM+ZD_GT2LSJ/MUMOET0$,V35I
MK#O8X3A)-J&PXT">#)6I'4(ZX,@G#/ JQ:3$H#H#(]I+H4I/SSP?.#0[NK>;
MVF2_[L!M7'Y30@"<=CKC(-1)@T-<SZ*YHX910A0IG,Z,3NI8GQ+3,:L_;PG>
M?A@_85A&OFO')U7?(6=7&-(O4WM';> ,. "^<&+JC^E$9Q:FXX5T#*4&/>T6
MODI_ E_BGXY*MU1HK#.MTG&2;4JA01(M9#TF-GJ"XPOY)$=!5J:1(TZIECJ3
M&K63I11Y7:?,R,]XZ:U3=G2;8K+=9)V8ZEKHS#?4XM!41Y9!,VJ*D0. &]?6
MIA/>]AU $ZOMU8DSGR3::<T[TVXZ25!GD P'A#"7%KXDF]<\#][HU?$B%[A)
MU?3--@K3FBB'A6T'&\H:CIP5]:TU94H[75#$@8Z-;Y[8+ADP(%NS^!$N&J(7
M@ M5SN(2."QO8M,>^I6I,D=(8SH[EMPH?6^\ )BL$Z)$OUS(?B6AS!G"I:?K
MN;)_Z4 ?#](/,L<^J5;]2D*9(T2*MLZ?]]$HIK&?S,I\X'N$!\X:DFE)$:(E
MO5:11_O<T8<J9$FF6<5L[Q%Z( B1STS&IK#O?B6LS-^BD ,]KV2I>5:A!NJZ
M[E<+E#ETU#&@8R78#U6R0TRW*!^T7R$I\<V(">J8Z>EX$_\)A/%M:Q[FP^"[
M$+I?UBMQI=32U/7ZASS"7924K2V\Z9S1R*N(GCB22K;T5)$XZ_BR:=%7OY)3
MYG-I0;%!)_ER2.78#P$FIF!FATE%9)<K]&,ZZ/<>6ZE_I@F9'4_;5,'(B$N$
M-[&CZ-F#J]@;D%QR,>:G3*-^Q:,L8D2&-&-GW-#&>$>C(D0N,7&3?L6FQ"LB
M1UC7.SY"'BW9-UFFKW^&=K"^M3VJ0:Q=GQ"\7R$H<XB(B3(K>?/<60,WHA<=
MQ1R"T29&J6%FO9MJ9CU>;N=L6 LM+3JP%8]L%8;^Z[%9]XS.;,FQ1=T.>7X>
M=DQVZC[4X/RX[/RX[/RX[/RX[/RXS(S'97N;?[O;?_P9 DS8M]X]T"M%P7(F
MVUA_;BM=2YPLAPQ1@L(V.:CB*UP+&_9AR +93/V9DI6CUQ !C_UM% 8Q83?"
ME,C"%B:LLT?I+%. + KUBJM 4HP<S?,L,,-\</UIP'097CY/S!.MT*Z*&AAB
M1.O4M4XN9MC(0\SB(+@X[E5H*.N;F6 MZ]5.)*0J36:)BMZ1T0J9-!ZKD;!8
M#4UX==Q.7"RJS!+8# :_WV, BA=@C00GZL"$S-/M!"BBSBQ!QD;A%^2199DL
MY;M&,N2T-2$S=3OQ<0CKX.KI8.!_0^"Y7">-$%KG8\QF7*\EQ:!+VJ^ZI%NW
M6_H3+!!7=OT>ZJC4'4*UD0G;$3E]J*/$K&O@/*)T[,<!'W%&EX:WO^]D;W_S
MT:S"<.<;WU.]\?U:W>:&W R?W>9GM[D!+J&SV_RDW.:G%H9CR!WE.0RG:W-I
M7AC..0KD7'+^[)_XC_9/G-R3 76^B>Y>""A(%+4W%Q3GO0[G7@;>%)5J:<+=
MB)S$I,C1YU+*GN<U\QA]6WTO,!O],GKZ/)IK<P7MQ2%RWAP"]5#*9HJ1&SGA
MA"RD^ 4ZO!)6;#!S7"=L]F95;MC8]U\W*,6#+I(I)@&WU)T UH B5R*U.> Z
MBP+M2<TH8D(7PP&,[FI8M9ISD)ZLB+M>9B>II$&.N)#M7&C=-;0:"8!+Q;G2
M:6N_C=C2GRN;=F+NM5<V92<D6<(_ >:74B[]K-N"2]4PK:)]K@?+,,;]UH/E
MI".#((#\EW2EGW6>!QOI7AGML]>L,Z_9X2IV@GZN[&S.D4K^\^GXKW*<];D\
MXOS!A?)'#7T?WU5]'_/%9/@/:S$;/,T'P\5X\J31"[+/"A&3>;L;>G8@C&<1
MMNC;(IUTB4">O:H7B61]P'S.O-.^=IR+!1Z(35.QP*^G<IW"\H'=5ZY3X"*#
M+V3%G'JVPQ=5'; 1"W\C^=119%+ QLE&WC1<<<Z!,UVO).? F7/@C)&!,[%A
M2,U$G1>  ZO/$2!$OK0W$]G#$W0,?'UUU3@+F;R$3[J46H+F( K7!+D_*TG6
MI5J8$!$C+2XA)5U721.IRJ\VS5P=!J-7FG$_8!8Q:-J!"0^!:R5S#&%Z!!5'
M3[60$Z^]"2^'VXB)1Y=!)J]8U2W%E"= N2:]RNS[ED9/3(I!8DHI2G&<X!E<
MK<.L7G!>@6UHT\+9M[M,YU+ FNWC\;WV*NP?VJYP;:DU2!_H<2@YQ= C;WJ>
M 6Y^0DI6B,0D77/$W[237J7]8TMI-R6NGSHRP0)1Q'Y&'B$RF/@YAJQ8COHV
MO8KD?8L54H*6CB505H@[X&!@!V#L3\EZ3>O:>\S7"HU:]NLHN6HA#FF2#+)Y
M7TU9WK:^$R65>+NZRL]JO3Z@8%_OM=EM_O?5V_S18/8T?OHTM[YYF,SG?[6F
MHYDU_WDP&QEPJ=^R%JY<'(":07J>L"V1OMVQ.Q#< 74ZHHGA"RJ53V&!9S$C
M3:P,7GNA5=_,D(NM'F9=O:9T>U,VB<(@M'V7QA'0]6Z25+D9^&YV:./>A\DW
M->'62U97LVV=/'6]"24;."UV$-^W-96.J \3[D04B4E$9F_R:BH;$\*]%<O!
MC'O@EG:\<H)0NU5Z,.&V636+V!?4:O98)WBG_03"L4^.>(">Y0;/08AMAY?-
M@0-KKG56HR4<L@WRFI0PE!&>&3L?H>YQ)6 4Y^\J.L?SPS, 39@XTC)@$6"0
M(,ITO-C0HR9Y@0H>LW7BD(X)X09['-&/";NBXZ:2''T&2?E70*_I@#MX =A>
M@?W%7GS-4]CIU2QDS;LQ0<9=KG'-.7*"6D%3<CDM52+MPX3E\]C)<(S<4[(-
M$CJQ8DGZ4=M+;5<2T1:&&#Z329!:M>SZ:[*DUV&URW3K7DU8TU4H1FM&G)JJ
M)(Y1FYS$TFOL 774K)(,MVVTI:9C$U:6WA2FAA>GIC,TC*CJ?FUE6C@]FA#,
MVI]9X3#!(/7@\"+=,U=8TFS3P>_%A&#9#K<=?,(-$GW+;;@P7ZJBODVP%EV>
M5A2Q26,NC.@Y ']$Q Z.7NC2URQXYCTC%<;GV_GHGY]IL1B:$'2A,1-&F31A
MZ L3M.?I3*N$39:%?8@@](0#:U#0B(#YQ0G$(42S82WL!9-DVG;^EV+B&.&;
M_<:]&!+2(=3#DO%K2F!7^>GJTUUPX$QPGARI;.5<=FIS6PC2L>T'XE_=\P!-
M<$BT9#:/-,VI> YL[4Y89)T+;5#Z"LG%@TN*<?(09T3BPQNR)-1H6(U,S$A)
M?8"8<.GFP)JP7-0JET 81IJKROE*+(L'$T*!ZD@038B3#= YY7P%<@N-4(XZ
M4Q84W^ DZ;:R9.FLO:X V 0?OPS3Z^@XRF'RTV7"*O+/LQV O_T_4$L#!!0
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MGQTG&'^\ZKPXU8CC4\/%I4853NXGJ2:<[!>2CC.<7%Q#.#><K"4T*O,T$-G
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M&&%S=*R62_W$J_=>,L-%:,+4AS%)U:=:!X )*2B0DL0DZR&"U\SH+!EGS>8
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MZHV[+S+J'1E#T22W83HPL>Z]&+&EON%2HD\RPQ^#_0PKXZ%R$V8DV8%F%F6
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M@C'[I.1-=6$T7/)I9NB,&5Z#A2GFZB'P'_D4)))@)7[(!,G^JL!<E'SZ[\9
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M[^)E3/-_9S_F/['_>7 2^N__#U!+ P04    " !). =7%ZIBN(<O  "2_ (
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MWE?IHEO#AEK; -U'<64//0M3'GN!5C/WUXS5DYP>R/'L,Q,+S+Z[B+P-]9O
M^31QC=]^>OSB/9OJ&LIEN#A=]&YKN-^-;(]+2A*K9"$I!V:V8G'WM9EB"1I_
M9BW;*?30[>15VYM!"@R1+B@-QAQ8I0%FE(L(<JUX3=0MN+>WJG&>^#>KN'38
M,<*0A5^&A()0Q-]QH WXS#8L[\%X!3/@:$B%:[  %MP.+X &IQL]>DEJ0'XB
MOP_WW@>PH<LGL'T!SAF&8AJ5'.D,P))FD9*TT>@)_##IP7T8&,,?21-XNJ!T
MU,@U@3/*)<CV40_(AYU+F/90L4[SC$7[9WUJS=$(<,+7\!/;<N)? Y,1JA^
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MN$G/"%R>S3GGBQI<G&^N+@?\;Q*R.NKL[U03)2):; ! J0R2,-"\KW*T(LW
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MGC35IH<<LTB-CMAX+B7\JHQD\IC2LB--QBX;=IJ(;4.>GF">5%YZ]&D0,A&
M(J>@9/*BT:1F$\>6;0**%!PR<:1(*0N&2,3IZN0=*64FQI:5'D..>9A=P$9'
M@3M]-0S/"Q/8\^-?EO G5]7(X5!SMB(=3]C!QAR-!,@N: ; YR1:&?\ 1UD[
M(.@1,;PIMIQT2(G0=M(DPBZWH.V6;FM!SJM ;4(@'F[@P=XXB$ .88LO^ Y
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M9ZQ;J&?/[TAL[OT%G_H3?OT(1M/=N2D'=Y9M@1! 7]^%HP%G^U+7-&!%+R%
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M7@:_;,PZTR(G]B9F%T/SY9PH81FY64J,V:>S^U<SWN'6JFT)GJT:.PZWFVR
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M[A3;F_SUE&-'K)A!RD] Q*WT+;'%X7Y>2B0Y*!S)LV=H].&=95O@KU^>,'S
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M[9>H<_BE3CO3$,JA]TD<TV6BT%?\TI$G0D*WX=V+T]YOA%LX6[?Q_.\C-=&
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M4)U4^!E7557PGKV&"XH10Z,80Y&IU.G-BW>3^U[R8F27?CM(CXP$8CN([4V
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M,0ZW7]N^N>LA1V%T:&3:8.QO[YA !+2#_!%^F=I)"4$2MSLP;Z)'[0#F83N
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MLO,+)J<3]9,)*XGMJ#',L>4Y3RNC-*MA,DL"B4D#1:+@6DE*J_A(8FAR),N
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M5AOBDA%DG8%(=2IE<0DM(K$MFZ?3+U7L)#8AL0F)3?CH@.?R1F%"#SFN66"
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MK)]>>!7U^:7SJ=H> -[#W4?I89>'-^KUQ^%)Q0#/ Y%7 11%YPGF+^7D.A.
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M"Y4 U^V51)RP!;S8*F^RJ.URZ* \)KN#PJPW@: G;,&@OYE4)*4X$!G:\+.
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M@<1)M;.HV89FI3%;F_Q6,3?S"H$W&0*=K6-LH!("GL$_1*[-X^4R,R$00""
M0/ IZFV^;<SZ TR?.]@<[59+.RHLTV<!@E5)$!:S<=M7ZIU.8U=P>,5I<S$0
ML _?<2AD@]@ L>':V/";DS!O5&LENMBPG-S6[0JY%L52X[,P9]O-<FY,[4;
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MW"]-BG5%7LC\BNN3 FJ=^I8+\@ZM6R]9\J;!Q=.G6:80S4>F+XX3W5L@1F$
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MKRO79G:N4F0&2*04@HYIKVA36T@G+@7].P 9O7!C51KR5%EV)-S>CAUAXEL
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M'X'QV\.<JP?0K^U?I(3D_ />)#[*V^'FI]M2+LPCDAT)B!*1B%>AK![1[TH
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MB$G"]$FI"=3""K;0GJ ]07N"]@3M"=K3S2P=:$\PF]]IY6<I':7W#,K-":Q
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M7/1:X6Y6C(UJC8;>J0TF(/ )/X$/0FQ?*<3V7;;]@Q^ ]F1U):FFILO!U;W
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M!OZ%8DDK9$Q4TVA)AJG+@BF)\ =6%?<_\(PLJ8)BP:[D9&.A&;Q20-N[0-]
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M.38I;KISH\>QZ3J=Y/+HH1+BLP5Z+!(5":E*TA?6V7R,J\(XEK<PI)_.#SO
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M,N3I985TF&TWL":%JP/ <&?O+N&A\[%*DXW7-,H[1,F%SZXLV-#<^T"T#PC
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M9LJBD<Z*SIP*6%+!AT"^9TXV!$4SD%MQG 6HUVO"6.R$Y[/Z9I!XE.2'1K3
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MIEBF=.8SF]<M^7O-].Z,[0T4[9#])0S-W$72P4;<P$9$[J*)8"-N8"-2=^E
M-=W"1C!W#!-LQ UL1.0N'DC$+6Q$^BZ1##;B!C8BD(C3;@2.2NZ'C?_(?;C<
MJE,?6/59@?H?+SEUM.+1WB.] 8]OOUZZ(O*??T;[JT5N*I  E]'\36&C[Z)N
MJI\;Y%QL*'S#E7*R",],FC=2P%XEUE[(Y04ZG0<C?6&NB-PQB4_-%4<1MY-R
MQELFZK(J\FCY']&9OV<=KLP9>Y3Y_A_9)P\7"@K) OHSE#6@1(CGZ79>F&89
MO"H:/_[SC_PIC,?EF"$P*5AY0 S]L]B0S\8<G]ZRP,E-8$9.9$8\E>L$09+&
MX\M2H\6OW<HPQLE,P;57M;?'%_&?2'S]VNO^[Q.LA 2HK[ 2CTK"IX+>0^?H
M+F'E7RC^>=[ZG/J\F(UVP_J02_0G<GG]F%L/GO>;0T4_4+3;/5M&PE9U9*TF
MX99"Y(*^FZ<9_>;D1<2-E=%M1N*/L^SR>:5&M\_)O@*9'M%OOV*A:)PY2M4\
MF:V^-A=?0WKC-Z"+3R&])(;[%TIOA"'M81AFJ#TT$^)#*CKH]K8CZ7DRX+O%
MQ?JRXJL^IML-M1/K<E9<6W'5;GW"FI#\E?CV*QJ*TZESB.]ML/%OB^\G"-/V
M-'T&+O1"UR:Z9)P.,7V.'3I;^L$9%NF$NTX$B+ZZ_CP_^@'9*:D-78.BJ&_I
MSVQE:%8>,ZWU+*QF,Z7XXZHZ#[/#&,"?:"@:.8O^O':HXH)8YXLO\JVC[*\A
MLQ? /!\2VN9\WM"6,XOM,GR^-1]K1D6)K9'0(M##A!+),X*>S\'/GS-&1%J
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MN7UHGRF'>_W)T!V91_W=H\*OLTUDE=O1Y6E^OZD\)+/MFE*['>C7)Y<C[ K
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M,S23D,*V*&Z)AD70.,>8U"+TTQ!'+LH9_(A*A.141^(-#GAWYKVND8[&M@G
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M1LZ+A,!=NEX;VSL/N7+]+%[3]%K6NSU&(8"!E%@Z]Y00^'BAE'-KHAH($+\
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M2]__>?:QXNFN=%ZI'TE[Q5*C>EX'@_OD!+:S!C-;@.?)>]2N+4]R>I9GX)4
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M#/\OUB#^!;#8L(4.;,6RG41P"^RJ[:OR6(4]LX#8'X.;4(F@.#R7  [FBF2
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M2Z. !@K"3J"TOBS .ZINH"5(G?"POB_H";8@-KC>YEZ7P7S-3Z$)$/^P%:Q
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M&I%+:OM>N]/3AP$[?(#JG6Q4O1-5[SQ7O?/EQ("?)9@&><(%$XO."@_D8+H
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M#@35NOF5=)1I1EP)]B$/#M$6\Z<\D%P1UH<?=L5!\%TQ,EZE"_6H\0XI<R9
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M9"&G"]AA:MDA"=$*>N!6\EO:IJ@!FJ5O6X.)A4U0X$SU1#<%]U_HSI?Y%2N
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MV>W9W >)PFX&X**"Y]>1F8P%STAMF2C^NBHHU][FVIHM\R2J9(["N%$8=X/
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M,XO7>?JO4KNJX>@:&"%2B[DJOC(A-> /IC=H 9# '*?5'%C\UG-<O@Z@0)J
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M2LX Y=Z4.H,W.SUKA)!;M"!@.\N$DSNRXJAA?"E%S)F:%4JCG@7DWF9P$"W
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M$BP"#161N)@C$DB"=":'>([%6C/66%*0TTVJD26]B%-5>"_WT2IF3ZD6Y]6
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MR\#/";U'1QX6F#^8:O.(Q4ET'B1QA&($H\CR8C"M=&H%M>3!MZ)S6NI5"!O
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M\KGB=!JV.,!(2.(XF:DH2.<R(4<)S@S9XO"C=Y_ _B.M0)P&Z*B%Y\:!(,?
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M\$W'))8$[G2"#()K'V^:*0%M$ZNWT!C*W;LUW&MJEWYK@7KX\<"&@=T2@]B
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MV)5"DH4:# (%_3RH^#V;SONB*Y ]8<H%,C,AK$5AH@$A8V(.+K$6SY\J_+C
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M!7/!]2#5'\W!,/2Y43<,"Y8PF!CDADU?T^]VB$)K MT9 E5I&F,>'9 HAZW
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MGJ*-7O5X'$11;E3,)<_,WTUK^BL0'J)ZK6T>L[W USJ)B?TQ@LER3=5/_WV
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M<OVAZG7=[NG Z[JGW<YP=#J<*.]T, 5:5,-.9SQ:T3WUG3]5>#=^ R%Z[$?
MCXJ=/>VU>NU.]T>A.>RPJK?#P?UP>$,L6OL1Z6JB7'_<FPQ/O?X878X3=:I:
M'??4'4Z5VYV.IQ-WM$17W8_ U(]!P<NNBC2QTW:K.QBZ/PH]888L;H/#^V#E
MRSTL&66H'Z)1!5KG+A)4KS5I#3O3\>EPY+5/NZ/^Z'0\! GIC:9>>SKQO*GK
M+A%4[S.:$4=%GM1I?S!JM^XWO+/#Q-0#8J(M<*P]N&<ZVFSY#\"R-I[ XQ5J
MU%-]LE-] ED;W3IKH\[:N"EK0\2I/W;=UG R.!V/%.AGP]X0]+-^^[2#!D%K
MT%5JU%L2I_W#RS.X*UEZ.FR/>KW[S2K8_!8_I.3L@^34JWUL@;DK?7WW6\U6
M:]3N#=N#RH6UEU7MYJLOW_>U\QTT6T^D,=?M6R\!ES)UP;WA(ZYN>4G(0!^>
M?ZZ.TV^G47&GW^P]D?[0=USAH-E^W@L<-H=/I(_H'1<X:CZ1SFMW;1;>:XZ>
M^0H[S?93E5N"6_5C2.TG+MIJ5:)6)7X ,G^B^LUSVO6GHW0]IUU_,IK@<]KT
M)Z2>/JMM?SHZ\]/8]C6*?*?9NT]=?N?:Y-!0'N)R4-AS/PPB_Q5E:.._EKYF
MWSR!9-Q/AYW;Z^3UUGV7>OT#;Y_IF-F]5?_QKMOL/^Q6?F]SEJ,(MF41$U('
MYJQ_]:>(03'Q-VQ?<SM)\J-2SH:0Y _.^K^7:B12YWS*L>SPEJ2R1?Z\(SV=
MML1.[^LTW^F2)2MGZ1[] X^^3BRDO<O";C+!'W]A6#VXT5W<Q-A]].4)?=Y)
M(MUD4C[ZXMZ!Y-U-67L?5.EA8<;[/(F"] S^^!5T"RS4V;0=7"$ZMF,555..
M3,91I^GNEJ2[?KKWWQ^@6-J6S(3U:U-Z_/W4G^P#H29JDKWRF5F\ME_ZYW_G
M<?;ZQE?SSU[_)$EE9UFV2%^]?'EQ<=&$-S1G\?G+@V1RAIAS+WUOII*76)G[
MTFVU^NVA^[+5:KENM]MN=4%5&+4[G=[+\VZG-VSW3_W+SK[;/,OFJ[33#7>&
M5-#K4MK>XHE-J=8;$]L*#=_"+G[+0&Q+R6ZW//L'%_4WZOD58ACN_WVC!3RX
M2-]T 4 [^QT@F<%&RWAHR;WI*C9FCP\NGC==P<$B"4)!6T$8%;>_V8(>WP*^
M+Q&PVHO9;M_HQ=PA8=VNA74MK&\4UJ[KM@<=$-;=3FO4/?7\J=M5VY+6!W,_
M\@@M(8N='U%TO_.GCML]J,7WXZ_B8+'PHZ:SV5GLG@S_6QY>U2+\J1G6G5I6
MU[+Z)ED];/6Z[?;H97;>:W4[P\[^=H7UL8]X)4XMLVN9O2NK>"8R^_,DBPV"
MJ3L@N3VLY?83D-O=6F[7<GN]W&YU^[V1.VH-NOU6^V4V=T?M?K_=\MSM.L5/
MSH*D%MRUGWPW5O'T_>1ER'%W1 )[5 OL)R"P>[7 K@7V6H'=ZPT[@U8;;G.G
MUV^]7(27^]A,H-7OM"Y!8GN];4GL]S'"0=<B&]MQUC+[\5>Q,>/<.9E]D,_R
M-!.)W>,F(;7$?@(2>\, 1BVQGZS$%G';,>*VOS5Q&TQK:?NPU+MS@ODA%[MK
MXOLAU[I[HOY!5[MS6L _GZA<WTPAKN7ZTY7K]YQ+WMZ65O#F*E07Z7IA[SQM
M:5^[PW=B%1LGZNZ<O*W3QJ]/&W<[BR>2--YMNKBT=O=U+9QKX7R3<(;_HL_\
MY7G''0Y'0Q#.W>W%M+&>&47S5Q]; 5);R6-L<N4<8$<TM.)??HKA3/UG8YW7
M\GHG5M%]PN%KMSG@ B8K2WQ((OM']X4_89%=UWG5LOK&D':GU6J[K;8):;OM
MCGL) ML;;$M@6P KU')$+8),A2RTGXV,=ENUD-Z%570W=2_NHI!^[X^37"4B
MJ-N4%][>L%+HV0GJIR&3ZWJN6B;?E!?>;K4Z;;<_>IG-40'O#H>4%_X(-O0?
M*DE4E#T;*5Q;RCNQBF=A*7]4<)G%5&Z3!&[5$O@)2.!N[<BN!?&M!?&HW1GT
MM''<D@2TKC?<MB1F%_9GMI*-)]O9.[ST)SG"QZ<OGHV4KG.[=V,5W>:&M<:[
M**9+Z=VMAY#33T\$UK5.M>R[N^P;[8KL.\Y4Y*G$JR7?[JS@N4B^#8MV:\GW
M-"1?73-42[X;0Z)NRVVW!D,M^=S6L-TER;>U!..C" XXRQ._X7C4@T91MK%]
MH]M=NM%NPQG[V87O1\Z7),[@F"^=-T%\<N8G:N&#93A)&UBCU&Q0KO(L5^C0
MC9/46:@DN\(/$S^+&PX\X;Q1T3=\#R[@?^+DF_/1#T.0N2<)O%;G.3><3\T#
M& ZFE.'GON^ &';^",(YD$\&/S]6Y_"OU'F?P^?'\23P,WCJ_?$;>F@2AR&L
M*5&AHV9^[5S>G04\%]G]=-.F5\KN=I]O>NU=?@(*1EV\5"L8=U<P.MLVK0\O
M)V<JFOG.ISCSG3V83/?Y6-.U0-Z)56R<]%(+Y%H@WY,4<%MUX=*/)I@K:"%N
MR]M2WM183;[-DABLWE=_FM)_7DLG"[3@P1;&DB0RY\%47VVE.^AG%X<W_ TW
M&-0)YTNH(K*=%0_V;"1TC2M2XXH\:5P1HQ^4%LP_W _]:49S>O90(S^"*M%Q
MZRZ7/ZH.T7&WI4/8C2IU0=19X*.E+HE>SN<I?.LGSB)/TEPQ*-G7//0=MZ/V
MW>Z>>D&J@A<O4-6P?W7L3VC03JNMP4N.53)6D9_N?[X,_2OG8)+A-Z"%M&LE
MHU8R:B7C!UGMSFD43Q2\S*V+KG]@'6%K^0%K=(3W0:2B2:#"6D?8(>9:ZPC/
M=*VUCE#K"'?0$=JU'^&'U1':V_,CN$/GM^9Q\VW3B'2WTVLU;I+[HU;_9KG?
M<&[KI:@UA%I#J#6$'V2UM89P7QI"[47X<36$K7D1'D5#6/)1/!_<]%I%J%6$
M6D6H582MY#6ZS:-/Q[66L!M:PC_??/W@'$5I!J+-=][%DYPJU/>=TJ(G<1@G
MK_[4H?^LSA9$H1KH<3P]CA?#-*,X<]1BX:L$?D'2]P@I&[01-+??J4R!; U]
M9^Q/5)[",%GJT+PR-0.!GO@.MB;V,!?Q(LC.S!AA$/G\0_V^NYQ +8R?ZV)K
M8?QL5UL+XWL3QL=O?ZV%\6X(X]+:5DI96^B=J,LXBN=7SN%EYD<IVJK'DS-_
MKHP8K\5A+0YK<?@#K+86A_<F#M\>?*C%X3,1AV]5.,E#=N-^"*)O8Y7ZM7"L
MA6,M'&OA6 O'.PC'=X?O:^'X3(3C.W\:1$$M&VO96,O&6C;NRFJKLO%EIL:A
M#__O!>?__5_P/R8D%?HJ>36.LS,9;!_^G<7S5QT<2);7:OVRG55@[I-@D]-$
MZ7__[_^Q)USPZ'T)I[7H/Z^ME4BKSC8=Q,S?'R>^^K:OIO"R5RJ\4%>IYC_#
M9AL8T#A.//BJI6>":W=ZS>'P%Z?X)^[ TO;-U>6^M4ER[%SXST_ICQ*:DGP6
MIR0Q7B4^FE7G/HY=&I5. @CLX8ZA2CHM.^.),Y/^=/+Y[:HTI)L3BTZ0VBCE
M![Z%0TZ7LH"OI</RGJ[:+")G0Q)T?/N$*[I(_5?Z'_:2^[ T(0L<?\+STC1/
MY[7?:B+D>6_8'E1.TKK1<H[+I_)TM,\/!V]J[?.9:)\?U-@/TUKSK#7/6O.L
M-<]=6.U3\LKT2G+QR]?#W9>+O6<L%]>L[2YR\4OBIT"HSR]FL9WSWQ'IN)W%
M[H9TW,Y:=T4Z;FFU.R(=>T]>.G9KR;@;DO'MY]\/OSI?#OYZZ!Q].CG\>O#V
MY.CW0^?=P<F!\_[HPZ&S-T4G3"8]8VPQB0"TZ/=0\(F'*>2'7,/F@/+SHED+
MPUH8UL+P.:]VYX3AO8#&3N(0O_W+3\.?;MX"]-4^] :4/,?N4&])0!V]7NW3
M)S('5^^)_D=U4\HA&1<#&K?<IWHM]5KJM=1KJ==2KZ5>2[V6>BWU6NJUU&NI
MUU*OY?'7\E3F^9U[+HWGN&G@NO_]J"(U\PGF [VSB.>1.G$"?\P7?I1R"',1
MJH@^54F"[3KQYRGZ<"_.@LF9XP6)/Z&FWO 3WT!PQ@RP)> ?83 +,&LNBZGU
M=S )%BKSFQ6WBLX4_?X-++FQ:3=PN?=/12OHIOAA[_8D\P1R8_MU;FR=&WM3
M;JQR N\O/YV.NIWAV&UW3[N#;ONTZREU.FZ-_=-.MZ>\WJCM>\/.3_Q6?N+X
MZ*^?#DY^^WIX?-H;= >MD7R[);^P+0/&I5?*#H[CT(,OBVG^U\OQ?3)[F[6W
M>\U1E<-\L: 0$3DI\?^= ]]E5JSQ$('U)G D\&+365E $=U1IVOW<&S((+,@
M!:8/PY[!=UX>7CD$W^3!UT$*WR_BA%XY]IT4=@^^ 'F V$YC_TR%4V=\10/!
MI0=.SS^ OQ,_C^ A&D_EV5F<P#J]YE:X[RWY[4/D<,-28_T!<Q7ZY!;9W#2;
M_5!=Q;D\5,WOUE.5*;B\\%M$7KJCIGMMG,FZZ];@,0PX#>,+O8GZ[_V+1"U>
M,=^^@&V[D66:[]4XC<,\\U\C]WQXYKE>*KN;2F7YW]L&Z6^(=-7[?;_[W1U<
M'S7>D?U>6IK$$:MS:]_?S=X15GM?%^>)+><FNGR Y7SY^OGDX,/1/YTW1Y]/
M?CW\>O#E\+>3H[?'#>?HT]NJK;5,>JUFKR:^Y[&<[1#?#1;CWE>C7[ZXD?AZ
MII=Q37U/?3F/P/J^-YWGR9'C.Y7YKYR#?):G&3NW!@T'H?QWG?#>7+VZ S&)
MB::=L8M+![2MP'.TDVFK2WB9OG3>)7'BO%$IF-DW$5.[U6SO-C'5O.UNY(BJ
M_B/38I4.'T*M3/PT0,\497&O;;7U,"_?^Y($$48+PN5WWJQ5#.J;]VR6\PRT
MBLZ.6UBU4O&X2L7A%;"YK_DXN%&GV'E2JAG;DU4I*E3X &\X]J, U);?08@[
MJ[2+I39=#><D\56:)WY"/SOV)XF?J>1J"VI',1E\\\%D$N=1!B=P>RVD7]_5
MY[*<)Z>$W%]*S0/$>W9DM^IIU-.HIU%/HYY&/8T;I^$%Z2)45Z\"0C?8'X?Q
MY)M6#GK#IL3O94)W$=V[GPDZN-=,4#N%BM,P2SE4I8],YN5R^NAY''AKLD>+
M](MQ[%W!_YUE\_"__S]02P,$%     @ 23@'5Z^UZ#/K@P$ H[L! !<   !P
M;'@M,C R,S V,S!X,3!Q,# U+FIP9^RY=51<3?<NV+A#<(<$""Y!@D,G(7B
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MZ.5YLR,H/4^NSX"H# P@!:BR!_FC@W0$1D'/)5?1+FB:?QE_H'\<AN80ML
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M%:4R=<+QBXVG^=?IG&C,NN'$7=2 AI5>V3*9?W1ZDX,&V/N?Z;1C>N"J41C
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MSXW^@V1,VF9.-@?9H1+%3-DG(1,3I$8Z\EP^I31[6G+ P"M3,\V.B@K[3/0
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M^C;38NP6[R#PE);G1'QE(T*47O,OX(,K>,@-3 MVEV4R7ID_D?LQ+5*1!X#
M-6?X^3\U7^N>ZB?4U_76$*?]R9,_T(0L=WO)]\V*I;FJ <^#U9PC-YF_/U6^
MY<E&XTWCB(J&SDW3J%CMJ^_NU3/ZK#FP=2[QUK LS+$AE8>;=#]W#%0_U>7&
M'L?RS13"Z7/*^ VFTXVKCX4";7)4*CUB'ZSP%/[Z^]H5&$XPV1J_MAGN9;VV
M_,A.$7BJFJ-LHK@%>.%<&-?FEGGNA%32:&]O;IK).2BL,^!CM>2Z*!]N:=>*
M(U@W4T%;][QT024KS13JY:I170&390F!MRYF/4Z\'_,/_)DO<ST.W@J9(@7/
MROZEZZ+QAF.'I4*>@:QB%0,%M2%#NAYHILR)]AV.FKF]9)C$+0__E'Z(<?"Y
M>^R0W9.Z32$"TA97G$-!-71: 5/.&A_1U:N'8ILB-G,^P4WK*&B=W]C5OAK2
M19HY//")Q3T8?>-WZ%BDMWN>@6N.RP$O\F]"N:TYQ$?69^WT=L;ULL0I?TZR
M!ZQZFT&V*%%X:=_[E69CG*N3.3;LOQT+9EL$>$PC[7S"P^LB?ZH\=E/PME'O
MSB[SAQI,;Y7H(.5K-#7+FRP7KJ+[C:BC#^N)*U*#8EMC# (.("![<C.=E65Z
M2)8:YBL::1,;^-@2>MB^6&RITV@Q=.P*-+IV[%$(+#!,ZW8,%;XD.EEF]I-'
MB7<=@!2G;M[XI.DW]V#5"L&T7T8ZMACQE3?;:$I\<P-&^R/\=-$!->6V6F3[
M-+S##P?9$PR\%3 R%*WH951Y(.&12..[BZOK=T_!_K/G8^/*A%M,;> =,BJ,
MT9AV31IM/@E]%5EC=7P[EVV2C1RW0D-L0; D4?DY > QEEV?Z>6(TN)BC@@;
MK>K2WVT_5;34Y%EU95W//&ZH179"JW#HZ)(WPTDFF@,M@/0 VU!]4 IDKQS^
M:QZ/7JLP,#*U(Y$A^J?6\Z+T<N?$'*@VS),!J^,IMTVJ+)7[LT>KE5UCC<N&
MO:J2XH,:3FDI+I1>(<Y=T29>5_'1A0G>R2H2+@(??O 6Q'>5WJBT4#>'9HS*
MO]78!6?>9J7R.?J]8;#?UU2@]?PDS_P='0_U #WE76UHG/1KW4#^BV\'3Q<?
MJ5PQB(J4E6UZ_99MB/?I^<H*RUW!F;[YJ;2KX&@LSW,CBO$5(:>U"MN\(%[F
ME(\?CEJ1>PYI?5-0'QNWO?FI8?(/&2C+A?E/\QV "#(_@/%]IC<\!<+8>30)
M\%HHO?3TPI4\Z "^/][2DIC1FBG"Y*#5!<.SGD^X1T?GD<_-#7HY//MWP$J>
M(>2:+Q,G^PJ<?%OJ(8;6[VO38SZ(-B;V)60+>]CLQ<P_(TG_,4X=#$=QECW&
M\L[XF4-?L\</AU^\:AB9_!/=E>ORU:A550\MFA=][QW]765UY!O:XAC/H?0#
MJR9]KZJ<?5;([%:[C7?5W6*S9@I^5VZ=Q7L9LR%_M*6>_K6H2V(7VJ7^$##%
M_'T>.\=JX8HO!QK0NXCS$[D#D+6J_+S_2IT!Z8:9GQFS[72.W!('JD#:'T,4
M4//Y^T)9D?'VF\=N>7O:$.OA\9M75WT_>4;DRK"QUFW18M3>5EL_5N([$'@V
M^A49;[H\OSEY.)Q.@=B47?M)AB^L<_Q>HY<*W#Q*1.L'! N='*-K#/P2.Z?B
M]HU/J[4Q9V6+1GX"J,#T1I-'SVUUE88)TD/Z)#;;O6<=8\AW\,5X>%U-A!+_
MKCW6S[]QF!58ZAI9.K;RCJJ@<FIM)#@>U5@WBWW\H;#\O:G^KJX/]],B&FC>
MMO5>@$0:0O6:([E5O+S&Q$1LI1.'^Z%W/]>1X!T 0K8*/7J$P0I@5.O<?(G[
M2S2$AMSL1^ 7/%\_4HP->S%WZ"<:%D@M/=YH[A&^ ^!"(4ZT9^)Y/Y2)JJ0!
MKRE'&#ZT%1I6_D+_<UF K\T79_4L<:5-#.ME94#7.BZI1U_CG*U,B<BJZEA,
ML:8=&,@DK;N_?[ORF+SW3>6GW<Q!+-5KI5ML7*5M1NQIOJ_*RUL\B9ETX/)E
M,K?=+,QIH,7?ZP%VV&?"-2$\%29"Z))75ZPN;"CWCN#<?9+V$"GM-4W]E/"W
M2D_XX=;\;$ZU9/BYT4S0-H*X?W8+.%GK:#%_+0KQ<+NHGKX#K/]&3(@TF>0=
MY\H(Y&/1?Q3PTWC-%::M6-(DK_F%QX#]H#I0368?_/=%]T^*##8Z&V2O9_()
MW.Y&M>ZU??X9OGK>$=UMS6VT(M"R.AQX3L)\);B7A3\%Y>$/PQ3.B.[ZLN?P
MT&M?QYZ*UG*][YMN7_<G\>5*L[-E/B8)V0[,J$C5^/^,]@]2U5YF(C^^=> S
M&SG669'2(X]84GF.T"%I7 J/;5+Z7,4WG9O-R!<%EI\6%T[N#11&Z 2$R5I5
MT]BO6=@^]X0EF'G'--[NENHBO3\Y^Q =?[S-;=6U7F-^-C<_\G").6IT0D:6
M]\3U*4]>';&A3\.S?[CFAP>[;ZJ+2W_Z0D6GKFX$?LCJ9FS),4]XM 6NO3/C
MGA$)1]VVY7Y'^NDE+RCQ3DD/5([Z%5L2B@&$7%U=\25'$*TX4! $OJ9V(U8Z
MBT2$.YQ><PF5"GVHD+!DD]2Z[ME C]7[]#XK3$D7J%X//*'SJ\+FA<('4'RJ
MJPUM3@4[Y#M+]*V_T3)T"M!"L^>3'A&KY$-TY@[3END^+[D CUP?K>CZLZUL
M19Z21;2SH*?%=ERJ!BO?HDN0'Y5\+1P^1SD_:R"'5;QBQSTF_5O]TZ9BTV_4
M%+0[=2NW)JG/'>]T7-/CIX7J*U@CYB,]48UT='+W5V=4L-](4.1_L"&$+X,;
MQFX=$S0%]5Z.Q-)"\GI/,-$@*>MS_\V*P$)"]S)'<UM66%U*RR ;S[,E+_B?
M0E3%(!?NTG9AVW+['2#]\MG9-?36?XL/+=Y-@6GII,O-L?+<Q7LX&]_B.#<>
M'K,%&R[(/*'$&*YYGXZ%7U#K)8K5.)4O[C8OS4U';&3.NDNK!WRB>V<F[:O?
M,J'C\!]U7+(0'HA 3UV=R7 +A >\F))CN)&=,E;/_<\XMH/Q^ZDC\^ U3:TN
M^Y3F*ERA---UYT.7D-A5C9!<KBD_E=7K.1$;]VM5)QJ3/:&WZ9$"J0X<*34O
M1UU'VCI8?)('-MOC\J'2*D-7B\#QM*JF0&CFK88L)F1UQ "#Z#+CF[3/,W"@
M=80>BOPMCGO)$>>NU2[\G+C)D#IX*$%#DD92[?/:B'3?V#KY:@CD*NY[ X6M
M'O(;)UA/A;;@RZ$6X?/1E<($)?HK1,6$#NQL&<L0B#B[8.)"C:V*M:P<T?X%
M+14*O;F-=GE\+/^"._WIHLB24<@))4Y-"X#!LW*,Z$8('1A6=P=XZ.U)'CU$
MS*C>M_IMXE>]]\;BLTKBS^.?+/@U9'F6MW_N0O<PRS=_CRH"9]/N &Q;@8]N
M!-"\9GPHI@*WU;G]+$584[A.>_O,TTV5?Q#/PTCY;$4#!K*4F* Z'.- 4BP-
M)J3["MAE(% Y*>D'='!C^O%P8$E'ZK-+R$D ;;5#_KWQN-K#6A29;_'<9Y4[
M>F#Q,\V<RQHMV=4[?_[%8<8[0 3YZ5'4G$8HEB?Z#<;2R?8957-8^.JEO:-E
MVCMW6)-8-)V%Q1%.OWT<S^*+4B.E]"D4_/)W5FM36R ]</QR_C5&?XT+#0RI
MSNOVHO,ZM\P9:?CI6V97YL'[>Y!J<3#<:3%M[$)#(P''< REVMO.@D)\<Q^*
ME15I.G4B'2P<9$<(MCI)B7 *B0G*&5\J95O@#A!$7=E%M;3= :K@FSUUL+/Y
MFW@\3/0*D,I/JZZUR>'A=JV13;J41UOEA7/+XMC+#PE:496?N/ BOF@LTE1-
M,A/8E:&-NWWF@A1S+%=W*CG3ATTJ1]@_4-,.KM(G]E-N3VNKCXAN_2?GF<VP
MLZF;Q+5E"CFZ/2P[6C_6R9[O*=A!H\O%]I[J68\:#?^Y%E)T(/<&US-G6U#M
M;:MYU#9F7%.G:0@9**$-PLA/G+R7]P.CJ84\&S=Y0F<3 0V;+,_T=IF1T2+0
M^ YP_*',=V3Y"B9P!V"-?XS2Z-)X G'KQ3).\^>'KD6_GTD[R/].&;:VNRF9
MQ$&0!'@LCA,G;56".NKF"U2/7B4:L8KPDQ6=VI7(($MA6GIG\NEFSHI1V&Q.
M0=M3#S0+Q>;[-"R#CFNV EA1 66E?K:HHXA/0<;O:\?KB6F+A%[P\/XVKC-W
M='5E"U#"I>S;62:640.7W/!$.N2'^>/O7AG/"A40ODL[*;2FO6RW-L/W0;1H
MJ>X?WP&,85?A>O>>O=(/88O*ZM67.OK*7X+:KUFT23\9*;?SRBQTH[V85V/:
M?B+98YGC2OA63O/95^7=5FK4&&CB $L!7<QD@_@MT]]\B/WGG=!<_"K /NW^
MO6<4I'<^B[IU^5&BJGM\Q&-:>4I-YPH]&^C"8"[.:^X<VAOQ["L,V>LP]3.^
M]*X[P)/.$@@WFS7=8#&D85VOF<G5+^WH/+8:D7S=L^(V5N\;^XP+[&V,\J*?
M$5VZ T2!S^0<9P(H(;"/K9,/KQZF^X3&1T'/C&/-_-6!SP_TM@*O9*2/"Y_3
M:E=<&.-%%@=V9:)[%)8UHI!]IX%=KS\U97YTCSW,IO?D&7USU-GO@FQ/R4^:
M,$:@50)"VEN7\D*<SJR'?>"==P *L)O)F.4J./85,-2#A+VAI$+)S4UTN.9K
MQF<VDF];.<N:]3M&^D$>T2!:/^ T.TP+7&@C9+ $S"PL[&7%>3VJP;T0QS-=
M6JZ^C,# +[DP3V8F00@-K *3=?GV$@L*UC.BT].L&(5EA<W481P>DR_VXL#2
M.+_0QGSS^P;D\"*/;P93&Z'BH_9+T(MM<9&DA>VO(@F;C'O(#=X[I!$8>AU8
MO8&YIFBK*W.W@>=*2W_;C4UMG-7D.\A9PB^9'KF@O$!U$P&L.PWC4*2=D5Z&
M><F?DQ?B) \?B'-Q_=L(I+2^\4$U0$L4UN#DT09+'1"[R3XQV]<D4J9'+Y0T
M7RE)]/I3:RT8]WH1*\BHB*A=)"D\+MDET7$8RJJ^P8=KLZ;H-MMBC&_B*= "
MW<OD?OK79C\]2N))1(R>3T'Y#AV?ZK@(JS(4?>\Q((2[_[#>E/Z>2M-9C<;M
MR.7#Y#CP]622G?,VT#$NY>&U(A*E31?4_L64*7+7 +*IGT<"W;^T+0#P"1ZD
M)2,T0'UW@$T1).)J!ZL4?O,6 X1"$#I3K+':2S-^+SV*5)VMB'^O+N$KK!QV
M'L_S$E!&^J)"3!'N>YMT) <Y_]K#/4I>(_O@?"=#(C_Q6? ]E=<N)?EQF=-#
M.[FVFU\<G]TX8>VI6\#NL%6G8Z4H3-YJ&+P2W/QXW+B/I0$5>IXH$B_T-5WH
M-N_+NB3+I<, S5J970#!K..I*3E\]?&T@Y\\N$C)DJJZ$.P\OV \D$%OU5UJ
M4QM&(V3-]8)P:W&[>/&>'<7N .>;[-!;;XXK-O'NM*O0JJ 2^0KU=*-L9]:%
M$9JNUJ\D/0&B10K/Q+V<W__I5'BF3:.E\ SPOSEPQJK_6\J@Q@*M[V$W5@'@
M=W8'P'M>%W=][I3TTJ!4JKZ!].Q-MDI,K3->@,V-Q.\I!\?]9X;S2R9%J)[9
M],G:8%+/U YMV3[P:1Z6R+ D5N<<#/;DD =3P5]9FOC]=CMY C2ZZ43E?>,_
MY?-5;)PX&AF.]2+GC0A-<*0/'SCH-\_L2IU]B32!&6>-+ 5KF&K88Q+7?-L"
MCC'&R.*4M  3MWYG\4&)0>Z/L3]=3D6W@7B'G]!DX:RHX>'$^JL_:%I@.U,C
M<T3FQ0U[[G,T^X,9/KR,.(#\4]##C20PF2J"$W430-\2K!>G?+.<00;<X_FW
MNR8I>*CEI:<*]K"N58\QHTC<0;C]OBWA%=5'']8\>U%&F5.4-")C8_C<(8?,
M/M',=IW&_D@.#S+"F3%K4_4<,OZ<C0LW&=FFNKXO%=M[L-E43!M8XZ'\Z=I*
M_7$R'L#"'\_[7WJ81R EA*N72HS#+[(PR$+Q$VY,3+PC#])G'<']&[;MK3+_
MR.HJ6WI7_)PN+)'_)U[;;^0<*Z_>3^?M9WX]<1O,DY5^UF(Z)COI5\:EDTA"
M,\:-HW1"W3"I!R75 :D:_6:TZ9W-"TC=68WTQD<LT@EECRY4^G%WC+ O)WF!
MJ\9=?#WI?(6F<58T2W$_SJ^PJ7;''CH<=4UTBG> , ^P[Z+PQQH#>?;$-RZ.
MA<?=G]C)_#MF(V&Y5U/&<=**5HDL8-OY'Y^Y7&6S=8VCB8U5ETEVJ;9Y#_XU
MP#3;LM(>^OOH:Q3OP?_^8GR9_&50JM%2%L>/;(/'V]"P]L6R,;.[C<^Q+9:^
MWG>0\J'8ML7G\<^*X.YV_KTE'$R!?[');IJ [&B\>)ZU6PN8X*%+OWV0\1)_
M<UL3QLV%L=&;XSA]^".ME9DX@$#'C++\;Y97SB_S^*/B.\"T/[@Y25NM-DUM
MX:JEVTQ4@V8;"/[[:Z!2:T+]=?\=H%+_SQV *>T&$UIB[+IK:6FE1$.$^_3U
M&0U^F_R*>NL)<ME(AI7#)FF54))FT 0+G&R%K5M'/H#$V?38<B.7!"UEA*VH
M=PY&O/_6FU>3WJ[WMTI[N3FXD$RG38K0?WKX0O*YO+0YNM<52;G67E% >P?P
MA+I:9R@#79A=;@EV3!=\6E^NL]<?(U]D<GAH.U,+ONI''&)U\TH,E:'F[N^X
M]THR  $QJJ5.96PR^G@\/+L>8^.'=P!+?XNE!4A&U+Y>!J.^S O)CO[)-HK^
MBUR/V4RW;.- HQ.GN13> *;IJF\\]!F_#/7I?PD!<SS:69O%M6T/YO=;L:+;
MFECB4XF*>Q-EWNWG[K?CV!KC&.<<X(CO<@= 5,%7/4X#>-%5U:L1!Y^GF(W'
M4_?7;<.8;,*'E?>-DT]%XZNW!:KVW(PZ/1R<) D[^1E^F(_)APQ6(!VC2_WX
M,9'G&?E!1Y4W@NS+MGK+D>Q?2O6G_JVCJA[+,,OJ<Q3%-0U*Z$3YY(355^X$
M4,W6 4F+166Y9]>H9QP=0+PGE$3M!ML=3PBTEEJ+S^>[Z,3[Z%O0;I6]%<N#
M(L=_QQQS3>@7@P&K0=?E9&QM#A"?KBWMV>=12*I,W;1914U)9(LJ\U#F,*9^
MK<(4M!83P)SWH0X61DM>/)VJD2,HP=VT+_[)Y<API;!\(F#"%X9-;'_.[?$T
M9!:9IP""$&WU^F@$U],KYS("; 557+P[#"*6+&G/%NYS&L@(_K7KTZ5@+L6?
M49*,5_@H5_>+2V*_SN!F"]2W-YT.V 4'V(AY'3S6/Y\8<0/(?LQ'^4=NH:N?
MU6DCRMT2Z'3NC6ZAZ&!$&<V75 FH,>)PVUWS6XE\KJG8]9@$VF,X+6E[B(%/
M:,B%UW'E#E"N_7PHS\2CUS>P/UJ S-3VBG7GJKRG@FDK:4V2X'LW#9'DWF U
M-9KFX4YA[KT&VWZ%J N8I/(\QY*@S!6_2O]B#[H#?.A5)^]=W?6M<)I>IGSD
M:Z=^"]KP5LS[,LZF;";)YOS=9IZ-)3G>2%ESTY(AK5[&WT!7E4NLR_-OKTJH
M;DV'_?VI!RLN:IP'Q9P= R3O@3Z"9W3BCQ2C[8V7!6+@7G%I*5XO:<??1-*6
M01E*IVYCPF)U@_=\OG-AG($$(%1YGUK#^3OFU80[P'H?[/U(H.D'SE.GJ[].
ML0SRU\(+5<YF:_S @QK19&^WS8 Q,^IOGBW:2C?X1C7HIV^8]Q=)'W$<KA*@
MK8&3O\SN4T<$[B9//LX(ZE\Y.Z/ TI_*2/E6ZWTQ>$ZE5>N2Y@H\*@ U!-9$
M].\WH?:PG?!KK3VT>N?;.87<U7BY U#]':#FU_SU*S]IYC,2YBMZ?2H\H(.
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MMAV#1%(MWG> ]'_P2U(CNY; O"VGO6H85V\UOHJK Z+GZG,V@33>GZT-=O&
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M U'Q4S7_1;'TN<0<_#C'U_ET5_5.*&;FL"XU182D X0'?"N?@)= $S0L@Q.
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MQ#&X9_EGYF@'K#@XJ/]^BW0^]$C[6(BZ !E]-?$N=$+3\0??FD#XS>9=OM
M\NL"U\48SH! N,.QRNX/JG@RP>"D0V?C'V_.3!Q+1\2:]_D._5A.;QD/[X!
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M:?B<)"NLKB%A:8Z8W70+(C;[IZ;^M#7LJX$ 7>-Q*0;@%/S=2;8OUW%;'T+
M)36#J($WD@;8?9*'-$="J<@V5-\>0,8^?](N%E4;.A/R?[4()&S 6E)+>:G-
M]H=9Q/3C^5+H T#)5/NG[ .@U:"%$J[2C?#*8X7]Z&M<D./AKSB#83$0N&QV
MTW!//[_-3F#FK\EKGN4-4)V]J1.AOM4=W?RB6N@-LGXL>YB6.@;5\^EY:@7
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MK.GND8 PS<A/I%V':>:LXL2-)M-;J ]V_+C&>=UJE#U(3VN $$X[Y2X.N'@
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M4$**4XOW*,>T(VL3Y&H-%0<'>N@^>N\2Y(9II;+9VYHHY@C%35 XLY-W]0
M_=S@>W:4-XHIM:LCR@1X77T)T)6OZ=V(["^G+,5R-A5%:9T>3J+4$3T[(46]
MX/?@UU5/>VKQKA)7;73>M#NLJA._=1W7\8PP[=+5N<T'2U 4 ]7P;#DK(%:5
M3$1;Z"/K/A1L)3/LYG;G;TONR-9C?GP ).3%[ [M(0O1UE.E'!]QE70Q@VMW
M0I*I!W$TNWX']U>2;EB'EJ/$3S.45 A[5WN/=Y6#K+YM/K?*;&^3^$[T,V)?
M36BK];D8)ECP3# D'/S5F $NWAUHM,_I_><F=)<N&K;,CQ@\W"0OF&,N9%@[
MA0R9:LDS2GR]^^_PX?"MME7,M7V"ZFH]4UR%R-';]1RAMV*HKL@;5VU'PF4;
M'Z?3E\%'"=]2N[J_#G^5-_W[9\D[5G[5X2WSS7E3G>U)J#^]EXLQ:*- \UM=
M%<&CKQ^SM,;D#ZXT%K;VIC%>1C<M/3U3]"KU,1U"%3P KB8J['?_VWL;*Z+Q
M&G\RR1'$S]^N*UKN=37T :%2'-8ZY.E=NC*O5M*9 G];1?<I<JAA1>:KA9%U
M;,/K5JO3ROP-G6DI"N7-A2-#52G*:2;%F5@S+IXOSQ@]AZX5*3W!YIE:-)>M
MN10YQ=R'KL4HC49$'3  W%,GHDZ%:9UYX^LE,7X!NV]!ND+.1&AFEJ80CR6Y
MP.&S8^W\B(+[KOY?-R[\QPS+)+BWI&H"BI7$C6&29-F@G2/J9DZ<R$M9!+V]
MG+)YD4A8S*DY4_=+VMEQC/I^EM$-"M/D,:I*:;A)1?$R;X3CY,Y@7_=5^K3B
MXJ@>_N*P>GF)Q,K(>1?&Y\P 8LP!YO164]_4VQ7>.4W29N^VBK@RP3@*F\:=
MXG(] [4=HST!+DJSRB?BK^L!V<UO=Z Z6A:KE872S43D9SG1@O_<CJSA7 8J
M+2$QJ$9TEGM)7(T_XJ*&S@346$3_BS=KB\X)?<G%U^]F;'N@VCKEV(Q[7U4D
MA#*AKW6;2IGGNU/^'F9_@"X9J'T*D#;-((8JW_H+STV9=ORX:!N[G)I3ZV%4
M^(<6FKH<(STP(/^3MK+'B:=ZF#_TA2/%N(!$#3,ST- ?;%AW$]$TY33B!6GW
MEA 0Z6&,X/>2-\@BO@\>! &DAOL&[=+J4(60%?@C^=,YS?[IF0?R*4AAOR]Y
MK*V7HK8'1_^T+//U1VXFZRB:R;Q[F3GU\2S:=PEAXY_G,# $NQ&Y9=0K+^DW
M$DMF["8BP\VW6*7_>+'\.'UT37%E3"4R_U/0_*(7QUB/&#B],#G3\DODQ*^A
MQ(A):8$AWEB^^FP!+0EWQR);,<56"?Y7D"<CE?_X%K,$X2,[=Q9?S3'44AV$
MMXJIQWQ>-Z0#RX GL!LT!J\'6KEM##%^FW*G*9S2^8V[<!HW@8EO2<(L^L_3
M" ^-P,QLU\!VMB>_OYEP34DH\92D"-R$J32"Q!.[ONF3R[ZT+NDB!.U418BI
MP,+ :O *MH^U<6J3H<4;0\DU4)GX")I+D7J-=C9,9O<>R=H56J699B6'68\4
M'RU_@7.4+-;;<@L]04#O^5/ #8,#+MOV73<BG>F$\S$XK5'SV_FPR]J<?W&E
MS<@KG'/2+VCN+C*\\ B-'5;#9-HPZ8\WP.Y&AZ3* ^*./#E'U]/;W1X:38/"
M7]B]^L(#N^'.9U1C@[2.@ZI*%7;(LZZN[&>([>%;[W&HI"P+U- 1;]40VH*2
M]0AH=.4A7(._PC ZQHK]]O'JW -%>B^[!P&BN?W#IL@T,>,)^8Z '_XW"6]W
M<I#LQR=(*^'%'K6KF:J7FTB+JI%'PJ4?Z76VYSICB("W?6A;+WYC>F5IANU<
MOICT   /F&:8UKPX0S-]:KG*V3:Q:%N=/)-\9K@_*<8;;J: T.VF5N_X]2D8
MJ>U'(<#=TOSQ?77C_@H.>>EFF70=V&3F5;\I/];3.,>4OQ6DAU<:]98N//PR
M1P&@]NZ>^Z\G]I"+ A_!MH"*+1^B@/44^)5P&A'RHEY3MQ@OT,0%_39L8RP"
MLL&8\G).K#U(H8/-C#?:>2WRFC<4 ;%'2AGK+3U3Z/WY>@O_J8/NK6Z8%ZQS
M3JRJC_&9TGVV%:XYB&G%?K0]GRVGL[63S-QKT#!'Y,@X4]V4X,D0O 65,K$R
M4++H_6L)&$S,%<Q\W7%1T1;,9X(\UO934\T6M5]4XQXIC7P#Q[+7[D=KW56%
MI5=%H9GW:;*^3QAT7.4(*^]J@GO;G_\B;']^&]<IIIM0)).$99,LXZ&]2'7W
M?&$HPUQH.:<CF_%; EXI ( -FA4$D83G!TB694X<!;QTJUQ2_<YE9AYIHZ>R
M'+I/_ YKI[H RN"@QMJ(]X=?<9F$D^=# QJJ^T+5_7Z!#E]':_;W;FPR5-"4
MMZU"YZVU4(:<(J<>QEZ<3Q 0H+7U?-77S%?;F[M/"LK]=-3AD0\$:TZQ_?WI
MR5E*?1MY1@!:OYA%FP5KM'CV+QJ\]S>XMJE ;@;K77N<X0SLJ4]\N"'M%J/(
MW1BC]W)?UV>IKVTD"3@)4MW>72MT6[S*6C=T)#?U2D3?>IM#H5^OI$QZ]719
M8#[XN\6%/D)]G7N5$DZ/K*%T@%]^.Z_.O5^CC_JB?P0\AV#ZG*&*L(Z[XL_O
MR_..J+>@$Z6[TW3Z',>IP/ZN*7_"NF4:K/9[CZ8TAH?+HO7[$K0,)_(=SC*
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M5I?Z.,-:^TI^V@BISY=5(SF!K]^T\O7/[FUW.#-FT4#<^'?);Y4> $\Y5!X
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M5R4Q,OI+40C*A9ZY'ZV.J9F'*]%'8^]&!;3<'@ XWVA4:SS+YO_YV&=7>#X
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M9=$8.S;S73X'>3AOMD<)>M16X*().F-=%X'S*C,Q%&O_GHR,DBRPTFFQ *B
M@P.+;#KM\X6WT0?N#ZZ/ /K]IC+?8@/;</)58]G/"8I5]&HT;\?Z7^<^82+
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M6-6GO+R\L,6[ UIL!75AW-1$.1AVTJ:REG.>G9M7?B6X ,0Z98DZS:8XBC%
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MTD5?;'@ '2P XOU=XORA O)VM#^Q%Y.EES^<ZI_?CJL^]]C-@U%WJ;WVJ!A
M3DR%G8/;^EYFC,PU/Y6W>U&96A6_J'UCD\9%RG-VD8M#BGB;FRQ4&X@B'=W7
MEC[X=3*'7]$[+DL()-VQ8@QEH0(FY'/'EM/VS+637VJK"F7S(W^94%'P-<J;
M-__ RJYJ"*%)?Z8!;][0#9%P=IDGZ\MB.!]\5O>STUVRLB$T:V6$SA7O]R"M
MZ5=2$<*Y2=EY_Z.[!DZAIS!%X8]@DT;WQ.M^B"L0_6(VK4>ZPSP0'/G^]^D
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ML?I$5TG=0T+M=?@Y]Y^8;@V7W="O559AOY?Z;%:749Z3N8K<)*_[5=,DZY2
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M;?.0QKBLNU^U+/FP?:-9S3K$DJQK\U%K*)B&==L\-W+]+)A^^I23;.Q\>^R
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MHP(6NE9N[F;!(Z(G&?]-F.-8]^L'1-+MJ#M^#1[^P=&^Z1<1WTI7S.PE<Y#
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M%H+='WN+>F'MEDP-R=9DQ[H2,;!G#O?__=8IF=S_I#8+\5'O"8A1E=4088^
M+4-M#3<B>3&X M DN?T6]RD%SWH$H/7]>@1(K=WBMO?5?<XY:] G]8=&VZY=
MG#T"8B'PIZ*S2[#0?[P=^=X!5B;&TGQ*)&^#H/=R1]P_+7B"%/#O$BZT04H^
M F#7CP"RZ9S(RFJ^1\ &V73[WMHC@$[X7RN(%CZ+K?D7O6"A'/$G2VMJK(-^
MI/&_,TG_!S7UOT0\:9 %C3Y8NSCU/]ORCZ:%SJ7[[_S[K!)+,P8]!]Q&A?Z_
MB[2%UO]40'C[;\L__9G[1S[O4I>8<A2YT1,H/P$%632",%=*6'^/^G+VZ8HA
M+#D;EF;^71C96;=.CX"!BD= K[8#]*;[G#I-;?RA/O$1$%$>$\'5-;#)W8;A
M(:RI:QA-/8)S4^7,MW?NU6NZD+B1,W;Q=$T"9>Q;7/,IF!XDE)85&CEQ^E3>
MU!W4SWI)WD\,_=Y_N?T(0!@+^(VO/D>5_ONDROR_!KP8"4Z[!BZNX!CKVJ)D
M;\8K%@L> 9N'KG#F]1X 5W24E]'HDS[SSO]LDB/S>G]0^/BUS".@H[@=WF3A
M@P^U<)UL/[=S0'(UIS[M$P4W@I7Z)4K6L;W_T>'38-,#LU+=Q.4^!T?..=C,
M.+Z_H7[RBB$5(D=3V4^HXP%!T44;Y4T4_6WM(XQCK73"]?UR7$EW[BE3&49%
M].IY?_7L0/QI-D#YZZ<-&#^!/5G%V6V$&EP1%7'?OLNJ$G9)G<3\-_0WH@CP
M"/C^S7^\&6D>^^^S+/=OGF:IS:F"SG^C(/&>_1NO] 8-]<7I(^!G[K'LA)^V
M;Y@7SM WG/]@^<]%JG!D;C6N:?>EV0#_R?+?5Y'JD43=4?@OP?\E^+\$_Y?@
M_W\)SNFAZC[_C<K50/((*/(?T0[5M"5&)]7T3IS*->1YDJU]X!#U]4EXS"H%
ME;.<T7N4.H)GG 2:UM^((CY,I@(,6/GE/S_[G#=*^OME3J+ _]7A=XUY"R>J
M3X.O/"VF8CF\M"Z>J#+U+G.'J7X@GN9MDB59SOOSI9\82'=BE22J#M3^GR=^
MB_E$2*5W6<SR&PU1=:"0+,FFI/3_#M7^OTK<+%G\;C/E:1[3/,* Y3D?O(!4
MH4PK=9_EZ.XCJR @[^)._57C3^Q'0!F5QR. J3(FCW_^\BD+LJVH.'A+COQG
M+%;"/U&/>A%T=*?Q4-#6G@]PN-U"I$K D"IF_O^0*5RGWB%_/&O?BSW_?-%_
M*QCP+ZI_,:B_>@1D2@_FCE-OSZ'^B\S_O['WG5%-=6V;0:HBO7>4)EWIO:B4
M@%2EAJ* 4F(HTFL !>F]2)<.0D!:0D<ZBH"$)KV#](0:((3AF?GQO=^L]YV9
M]:[OQ\RLY\?^=\Y]7_O>>]_7=9V3=?)WX+\#_QN!"9:N 1<[^)<Z@5 M@_)X
M:V2P-'9TYV(L305,*$FI9XV$J?HPQD&U +^-5](EC67?DS?PHN1_$81]=8SE
M//DRILO09IB)X?\K>6FF(M1<[Z\LD'*\Q?_8[ O_/]7K[\#_7P36OBHI[?CK
M8M>3*T=C?3"!D]G!Q0NT-?Y?6WW6Y'M!>;>,\S6@F!9OQ9KYQG87#D&*MXXD
MZ[1R[6KSSVNR 62^M]%*57[;)M9GQU/VZ"&$3\DLKNWCD>0F+5[I->"V%.P:
MH"I8?7GA<".)THVO 9]C1ZZN)#- 072HV(,8D2KA77.Z-!+S=[PVTGB_7[([
MW.K <C<CK@B<H0=;-]K*$H0+E58^.QYO9T"U'41[-M:W<#%; /,R;1X_8 -R
MTEP8OYYH,;<8Q$^PXGN@=3P@\YET$96TO7A,U70-Z"B)QP ]72Y(YJX!BV-F
M*?I$>?\T^.3K_P%6Y"^P+'G_,]C,0C?\J:C?$ZV/I&)/&QI;ZH\@,2^[:MD.
M79A^A,KB=Y2H 9[\Z[LSU ".UX N[0KH+_5-'"Y3>9EGHN,/E_LU *JC6K0E
M;3Z/-3;6S]CGD3$BYC $+N%M@]]8X^O^FI=,*RUU2C;/3P*#92T&OB@=D?W(
M#SZHSY3"E_X/Z*/_F!@LACB^!A N;$L]G.\5;NX7$O^9/UT'YYF;7BUG4RYF
M?[7V_!^A24#_ Y6"<K[V"LL&/,H' G]ZI%"W__M+=%/\CZ)CMC"1_")S,]!Y
MPHX7PT&VK]26*\O.44_AR6>"?Q7K9T&PQ#7@'Z;)\0\K4O?@,YGR/ZR*QG^L
M2.6/))+6\\)XO_ZVT /W,(LS/F2PZ+\JG6$K_))M[I=OC=YZD[44_5Q\W+9_
M5/B_F_@!OMZ_K&D48.R_?J9_)_PO2CCSGQ-";A+^U8LF8/+]S/L9'NF4V]XL
MXYODZRF7E. [48!+_,Z+:P"66XXP+A\Q*-['EJY(+LN1XR+1(;J\8T'15:J,
M^K#%A<LP<=J+N ;< :PK<6.JK$E];/8O",E<[_2S^Q'9QN25\K9#&M%!#9[B
M@R+E'L/]W.<?3! !+@$8,;=K@,XJSO-HZ+\?>IV;66GM_+-#OY%/EYIB \H0
M;S";( 8D#U(2 TXDO7:ZY')*<H31<;?W[G,"A6'CSR..OLW7Q"DS S[^.\4L
M/#5K'SJ-Y\?&SBK\#&AI$]\Q^%<]< (BK=LX46U;WZ#*?6CO5!=&C*\(Q&\P
M^C=7N-+QE&8[_:NY>6F&FSA!K!@1\(^8SV=2Z+_HS0:F#E.9N86GI X?TGU?
M<BU\3I(+!G8J>!RHYQ5:.:6+=4+P?&W4DU0T]:/:@-S!#VY9_PM0,UK_BZU5
M_KHADZ0@23.'*X4^]M-+&6*">"N'6V?_M!Y(1W;V<<DQ_EK$$355!H^WZ6H,
MM'Y7A2.RT!BUGY]?*>H-,"UABG)8,^."6L@E46RJD/YK#LB.L/,T8GHC<ZN^
M09G,24[!$.CMLL[MGN4E/U'#R5+3>:SHIW\+^L\;G;(>JA=7^G*JAM1G[VFN
M29:;-RTG7#RD+=SGBU]XCDC6PRB3D-\Q&PO+O-9#MVGQ[/_K#YW 4&Z.6T Z
MQ1TBD ]V6JS3M:G/5^'DSX-;4_\.F_ZO^/"-@0KSO]HB_S9]_YWP?Y/PKQ9:
MU7&P52H:Y?F!,U;W#]7(Q9C9"WWB42@AUMUW!2*U,JN?/-S<P$7#7E7D?5;0
MI#>-AL]O=^R7GA0$/U*2SL84+.+:^F]$G]&?/)9KP)H#XAI0[88=\IT'T$UC
MI<>YD7GFK1]63(5:>R\^/K=X;=K0T5@+1-XVY\E1:+IU#:"^8';\;=P6;XFL
MQ[2*5XF40T+(FWR=A2+V:%: Q$N:YIM"26!2^<N^W!&]<(B6)G)Y[^<9=>VA
M@0D!(=,PD&G(K;N'.4)'46E:9/:63MG(165V=I D3WJ4IZ4L-\A_*M8NX4<W
M 'L-6&!BY7!3GX6"H E74-C(XZD/2FS)?4G3,RI)_3QY*<C''<TB&39XP^+)
MO33;R@YH]C [B##]S$U3CP-_FB1D!S=+F:([ESRJY=K0],5E5Q5[TDDZIP7A
MD,VK5ZIA([^>*R-$<1,N;J>E1WNKE#U7HX!O^$<2S:"+WW)SQR#YDYI6E&X>
M77'U]/YGHLV .WTO7WMV4\OCO:!;0[/GP50FTY"#X++9X@*2+L*[^\5B#[T2
MB,U7;F)B=V3;D;C7F6$(9W0P\!L6J!PK)6QS2IACV^1!TSS(.Q;[LRA5.80W
M#]2QH^_OX*?30V6U9<47ON*OW22T;&):N?M#S6E%C=&,A "EV4?NNQGW%LSL
M?1HR92CO4.6<>:8;)YGRDK4PH&D;;U5R$\$N,;D/VPC5>?R$]H?Q"SR5!+>S
MK[(*G@H3WFB1<KZLYE.+'^B!31FA[UT<W;SI6(J?&I_GN\FN 1^QNGRYDZ<@
M+M+[,V:?5N NLB^^- %R;S/VMP'=O1 +,N/U)@T-S"Z_BZ]^=!7>_<IPEUR,
M7*7JSF9?YL1\_>3A-K6$^%T@XQW\0W)=8CY.]\GR6']]YICTE2W<]/U:B?D!
MP?KXP2A+X:NW!L@ L9\(O_5*(?J+3:U<06OC@%LO_%/O"I*JCGH*/]=/8J'\
M-<3J?*CYTY;J\_,6=R_&573OFTZ%M#'N&GD- <H??UQ?7+PW3U\0G904=!3>
M%UWSL>M,5"'MN%H!C*SJG!U> Y2/J'>]U76D56[.FM^D<OUWVE/T($^KG)WW
MK:VL Y'3!&K_E^0"^[D)&B^C(;1?0=$04PW:5?+HK\NF?G&I&Z=*0A/'LT9P
M>'O2@^?R@$[^W!8@DW57_L<>N=A605KO=T).M9P6UP#2&!FL&O4DSAO[6 ZT
MCF&!DEG:3HDRK5(7;$T]S><F8G_NECCT.L>*HA[T_57Q$[ [:]3VCP/>%7DZ
M&]4OYF\JO LM PN&;0EFM9P!K*$/U2EL!&X$#J\<'#-G\:7U+9O9RUC-5[_6
MA)7*HPLU\G<R+>0\AQ-/(4H+R@@G2GA)Q<=+B9[R0[F PB0WC->7Y\\N2J,"
M](H6S%2)<ES8OL=)!O,E/)=GI!0?X;"8HBGPR=S1&4<Z.O/Z^XK8YJX3_[2;
M6:X;"6JP[PF2&O>L&%(17EM\U9@Q;>N*3RND54'U_=M>LN'IY35 ;XNV8_!$
M/LW??Y'N#[,0',6;=Y7E(M_/2MKLJ)#0S1<*Y'1+S.NK33;X.@'9! I+DCF9
M[MLZ3'@T+E'ES/69<3LSNL68W%:J]G?W)/R9+B;90Q+)FM%]OZPK.#"XPF1!
M8**!VZBQ/7'"^B>>:Q/T@!4O>=^I^J9?PKYON>S8-G:\F%QMRAUZ;H" M\2N
MC;VI/13Y;(@Y'*]ZXF<K>UIJ6>2WJB-<]'4$XN)+"K3WMN/,G7B6Y14J5BEW
M2QQC0NJ_T@;2C^$^0\J%D[N%\7Q\K(G/-X><QR!,VHW,JHM<68'?\(7D:$*^
MLQ^GI>%:R+:]< _=EK,X&ASU']=9;GL#W423JNML@Q-C8O#>9WL/F4[0LQ'K
MH>G6&U);I2$NK_C58T&[AYHL0;_\H"<[P7"T%<Q1N"?1:H!Y14_*\MM#>]PI
M25_@=F7SQ/&63Y(E\/Y\;>ME7$!7*6=>B8Y(&H?U3E/+:D*RZF>K<[=^-^_2
M2-Y'9?J[W)[#Q$S?Z'Y,1%=<1O_>6\TU3A1>/2P@PY(FN2I30^6J]1I;_OIH
MT7_%X-#%"JQVFNM=N5=-#]MB!2,Q1M> ^[K)UP"+G0;H"30,X/NQ;RR/6.\:
M8%EXHY#7 PG1=;BG6]> G7KH<'O@9_**Y?#151#;4LJTU.-L5E]1\W9FB-CE
M8[1P;C+9! R;IB.H.%<AH/"@,T=]PK+259;S^*Q*7FU21(),2W#',C? /_B(
MX=U2^?/$8][JCAA1PM@A6+U4VJ.YJN\ZE?>8IBZ+3OK9'OA5)PCO>[5SH/9@
MZ_.Y.8$E6_"'0PY#Z]I2EU,N0E\3(!RB7#(R*U^K8]/#]HXUU5,A95=?YIWY
M?$.$>5>"C)2[XYU/M,961*I?2[CW" >-)T8$(7_Q)R;<A?!M]1K5H$OR7[E
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M^4AN?UO:*>T;J%.;\ _'N(YJ/>$3V3WIT_!)CWAX=]66.72F2D$UL,148J;
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MGE!(]O[\=@'\ ,<X!^TR*0?[24=4'8ON&5"<?J!\PG(^Q#A36=F]!NG@EU'
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MG.JHA?1%E_XQ+S+/:FBV,E.@9FFZ4?=O?&58\KC%#UBI!E::_K+*W#H,%NC
M_;!E,TA)[52]XW&DT.YO7P&[Z#T*(B( E_<GD[+A[2IKOZD=ET'KGJS+*HV)
MU,@RGT$@\B05:=^8L*T#:*+_"M(6_W3V8?[#\[X5\:UQU.WJ-)KE@ZA]%I /
MW\1;I7M7A89VK0V_9I3KB:C/[QT,$CI$?3HMXR['7V<<,AEOI7/D+8I=5B8
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MC(\@=VK41YJ+"V867:[Q@O&0BF,K#*O"?+:XKE.9+O S)%NW 9PF@#7=.V0
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M;N%<A]L=YZ495SY-D$9(\J^L==VGS^)7/FGE/ZI1Z3M803 *L?R *?AWS W
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M'P#/XG;0<@(@V#V'X0/ $*F-1?4?/?UFV_\MA_O[T8=RQ]MWXOUY'G;B.%%
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M8V)KX:<W*#S_\3YP++D,P?&%*&/<4C5O0B5?ZN*O81*>1V4I. BO-(,\K8-
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MB=-%5>9%+E-),YG[W4DF:KAA([]HL&)U$S (+_UY !@(;U"<))R_=<Z&75:
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MT]T$G..DH^>DHW4!A,_J/$_W7P'XWX/NW%F-C$P7F"^RG%V Y "<HZ.G/\=
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M1-Z,R.W@-7R11U1A5HST'VC_A>Q_#ECH_R-D_R>P_PL7#G")GNZL>?2< &W
MZ5V2>((/^N)Z)D]*\'(PPCKC&W)GU&O+-*5^.?IM&8E%?[@9G ^UF1^BCHT[
M)AL&)RUI7.]W?T?"( -0F*PO>S1 E/#%RJVK.NZ9GTM'Y-H8OM'?RIB7%SS<
MU">>WDQ4QUM-Z]\L%GN0$'O\MLEU./:SP%HQ#9!<A%V(YQ]?9%)H]+*E3KL*
M+5I!YO"/23XA@DJ';TF; [U?'\+>?YL_?^Q^@$@1?CCF*PN /20Y0K.LPP]U
M)BI9/W/:<5Y^C3$E()[.M4@^)=TJD^W>Y('7&FDDS-+[@ ^SDPUKKVT.WC-2
MCC!-D/<?I@%6-;JDS%,63>M*9"FL.KD/AX&7)VWL"# >DTA>H7OCO%W\<>3X
M(-\F///IJI"5<1<=K@7>SK]1!8.01"T#/\:X4!0A*O'6\=T:[C"N#ULN)6$+
M9C!<S^&^OO;8<U*INV2ZOLUT'/+X7= 4-^D1%-^52\R#"3H6V[U\.5#N=OC,
M\';+CKW.9:6QW:RM94W0A/;;I+D6<3N24%3EN^B.?YQS->G6$<_JD5X!EA+^
MK&W+2_2%SXGNG"E>-L!E<(?*^.V>.[+ CD/40F!" O4V%#Z+;)8M?_G$.5?+
MJ+#\K?4BQNZ'VCA[!$% 0YYTDQJL;92\AC4/@_54C4G_YGI')9KC,V?W]3>E
MT&XQ?A/1=%K)O ;R,[<HE';OGCDX?P68I&Q>0R8()961>8U'?=7[0;DU:XF$
M@E']2T\&&UX(RVRP,3-E1H[$% ?9U4ZO@N%HL$%VP)T$6S'1.DA0,/Z?C^9Q
M--FDTX;0)>T.,N%_)!>MCQ3A1#>1KG#@?Q(^LO_[&GO-0[4/83*F<=N?Q#XW
MU&6H/A5D,?INHW9%W-:6)2]F:5/TVO$Y=GJ^LARN?Q0SFUN$U KJ&_.>$V H
MNT^ZX?3ZWJY6=GD"-[G,B&CQP;]\[5#X[<\Z0-\M^;'WC)KZURU[U1#Q&L Y
MDP@TFX^ZZQ9D<>QWWUW#Q9KD94?NY[M9W]LH;MH<J_8BK626>9 LI_&T?50P
M6/KK71 G4)]3MFHN(U\T43[Q*EM(*NB\LZL^!$+)>!R68(Z2$BJE =25DO8'
MAN+>52"G) WNVNLK%7*F\>6_KS5@.L23C7RX=W^,XMN!'%3^51O?T_WN] .?
MG=2&!M=+GV(I&#32F\HT/)10.P7"V"QW"0RQKM6I_4Y;EYPLQ=GJQI[+[^FZ
M/?75"Z1=UKV6DTT#;*Y+LUB52(H+].%-3OPSUH+%YX:X_D'E.U&XB?REX.A?
M\E*M9EO@_#_^"/D1&L -R +BY4FR=:&*O?9:2_KE4[1#=7SO[WQUN0(,"_(4
M;Z,!N*I_U7Q\U670(ORA]QC+1XPQ)C?1 !<(86^H6"**(H)V?O\%%M4ZNO#*
M\ZNCG_:ED7QCMLN?C]4A[CFQS3HV25\=34HAH(-=NZ$@B^GO$0_E!Z1A[>50
MLV5,+D^K*/XE^:/%S^K13<=,R2"!%/YMED03U,_N5S;D%&O24%@K.]3[.79K
M0TH1U62[_E=L9S&KST'$Z#1JQO2:K)J185#P@/+1K=N.JM<0@MS8,B/9L6.,
MS;C#G[VRBH?0Q30!E]^QB;<.K_N]V')MY*EBC_0)TC285OT>OB9W1ZSC7=*#
MC?Z_)Y;]..M&XMEN1)59]8"&G[Q _1RY\D#J\'S.3?4WGO4^O04GM[[/LP;-
M3"0>+Q4Z0N!YDXIC::CS;SZ?9TKV'FI8*GEMCK/]1^A/,SME3I/#6 IF6>PN
MQ?K3 *B$<A=$XAN2?Z26,$61G%[DBJN86CZPJ$Q32E<VVTJ3((3ZYRX;$@=W
M,2'T).YYHZNAO\ \00=53:1+O+M/VI5%5SY\#!-U?*^GZ1IL/O6Y(36Y<7<T
M:R?$\7BQ\*J*.LIY K=##8G UO8M<CP2+6=^;M8ET:<B6#8G&X%+[^)# MG(
MI<H2B@)MU7;VY/A)';^F5I>)J<@[TYV9>[GT9WMS-_HR5=3-'S?](]&E,1PL
M-=OH%.,9N>RQI>:I\U2\VB33\#'^2 %M:M9S8O'YU;ZK3%:).@VP4(R&FG0K
MM<H-IYC5AJY-\_H]$%RX=?M>,=.B9MG;5@WP(XLQZD6HF,B$+-B]LOGA'T7<
MT^E79N0U$^U'MCU@\UGA!*T;+L?&53_6>)*@_B?&-WX\?0M=EGK^4YRD4FQ^
M,24U!UN]5W.J8W)U\M6BX)@[#="%LX$EE("R2=AXJ59AEUQ<^@$*ZQ%0QIM>
MC,]8Z&-8=MG$V!S9/A]>_ /CGA'FL(4.F;>T3NQ?%6T,-:QV3(U:=HN_+X@Q
M.)&I+GM@6N-^C,2#@+O*WR-]MY+KHBJ;I@E)\U2!TQ_-XG,5#JQ*G<8D>A.I
M?G?KO0EF@92$K\N+%-!?R>6$</[NH8@]DUC^U*\AX/'*?(4J\3(&44LNP19L
MN ;=K&R4DOV],0A%OW3Z(8IG9'([=/[W.PU#88<6E;V*:2&NY&>CL[L3!NO4
M:TOQMPIN3IYNQ_0_4=>VK(O (@>A^9A,YT^*TI=[:(#!W?V  23J<U8X\9[_
M-:*</=,!<ZL,&8.17V^]-:9 /[O#\VMD<+G/*GSR*%X[\FW-9K-U";2_$\ZP
M;V='P4^,RXB PJ_N/G1_1@-$/G.[$3ZA,82DNB(1O2/0%K%?3?^.,,'L92N(
M:,J#6TUY(%QN]#ZK\_.FFH^F0O;H;VZF=KC'656++:VSH6I>WIO MW_M,'!'
MB#?749(1?V]"K#O#FVLABG$V0H.<V=OPSK<00\Y-<0F;"8IOE>85TY<8*U.=
M*X#_GR==V+PL@TN.]G"N(;9<!%WMV.2XP*U5JG?])+J+R-0.8:+(U6?.=^(>
MXE[^:N*?T^>W5CIF]'HB-#YI:E%J+.=IHNM\Q^/SY\4K.)6_5$ZR@RS;NAK_
MW_I1WZCII1U9K:>]&UY=2EZJ@HQW-B,Z*YB,L!O[94&Z1@\'>UV)O4Y>/)P)
MZ0PS>VL!E6G1F@4G-( %:K'X6Y"*'W 4O8PHF05>I@'>LK.Y9;[-]Y^-NSR"
M[U+V+FA]5_TSSN.?0ZG7#Y.?W'_7<\_!A.<E*R1-28PQW%O%SI!KMXPVN$,_
M= +N>W[=9VRY'#V*'ZM.4"(L.LJ6F7EY+=IL+U=0=\,39G(_FK>SS(KD%V1>
M;#)(&WGRV_1+LD&5^H<^3587,LML;H06G^O./ZB_D>&%HE<C=4O^B?%9&5'B
M?)I&OE>>-]:X%HM74M]&QRF,FMJ BS#*\_"($"%R7%%%0J3"7^2%*XLL3G;L
MI3\7X?36(?1DR1E">$U+SX>\;I#/3$E#4J;U?<W[_J(?-C.W) K^,Y=&_SZ5
MF/_77*X%3,)K#M_GD2 4T:A9LF[)4D 3"O59^&3:WF^9P#V,@[+K5&-]XQP$
M+.P>64:];DX9<!"]?P%P:<974_)[7H29EP6DL-4NO.2A-)([F!H\>'%WQCET
MGYW)%FH_KV==&_36.5PYM;^G:R$U13UBV:*6\)'*.0+C]I]5MQ.2V%/_"3OQ
MZLI@%Y:74X^:>;4L<JY)[?;_!A=][P6_I^N/L@J>;/5KQA^)H(X<_ER==)/1
MA; ]'Y\::4^1@->#MJKN\&L3[L4GZA3M"0US&H"9%1LQEV)VC]EJ^S47^C#S
MKE_5<?1>].W2\2L-G[-/'Z^8>2YX6FRZX_E";A(G<N<JSFWKCKVZMXHU/3+K
MBC677+G0+AP6$%>\D4K\U;,D$.EC&);&:\U! [B\O,;AI4*P[]:1>%%B,I-B
M_[%$-]4VZ$FQ^\K21JN0BTT(HFS-PZ9ZVFU82MG=R4OP?AO F3[!8&<[A@!X
M.Z'!]!WJW\$SH?WOV*[3P&=3_TO4HVN)MQ9'DPD^L1^C#VTDXJS;2\21:-;6
MF51^[Y@86P*)L*TA.4,#M-EFLU O&^9R6:]..%JC;)5&]M)>7S)E:Z])-D'8
M[,7(AN4(C"*%V0D/WJQZ?[=MJ?C(-WED^K/SG/RNSYJW'9C;&V%6T)!%K8#T
MH9L'<_A3578*X<#G-(!";M^U"G0'#<!JBT%@3C.KNRM_O1T3R<#I9$3V>'1]
M(+]@/P>[0H1T@K*:LNGU#&UC"F^+5C\9J1L=?^#@T=H9O>52?EJP,3Y=5/E9
MP*C;#K2KL:M+IIO19B>742]+"IZ[ZGM_22=XPU3@Y->G3?.M\SZ!LN_W@.QV
M('\>I8$KC;];?=?YK)M[\"@1\<7Y4>X_IH]+C0U&P*N0]%=Q=SS]8\TF:  M
M:C$7>SOZXH.\U4PSUQT60;7MS;KAT[RG!0V#&UM]RU5SY>O:;#[X*4M++%B$
MXTQO&(.U-[U21%^KWKGDO"@BGJ-:61<MJ-]"@&/@S=P2DC:2AB'\B/HCV0YX
M]7+4#%9A!:G.RMC3,W$$N36VD3$PT&N>^)V]_ZI6- !1(9&'K+#WW1SZ\RN<
M/T>(D@T_ZT?670WU&3N!CJ'2NFPW![6"I;D-C=@Y/1&&V2C,'\^7K0DG&E#Z
M!R0]BBB/O7"X]&/5)&8_EWS(B]CLTI#0%J'HON=?[<9R(4EEA<8&@[?+".XM
M0]HD1!N< ?9@?/3YQ-[CAM:7] I>&CIM*P*N NAK$]/?B<N=9P1](=W$:O11
M\#',0R[NAKH?L?2^B&"<3ZWIIOB;RHTZ=B<CE,P+?W3&4F;QQCSQT)HD DH/
M$8HV/( KMB5-B$,L8@6+2=RK!M^OW'E?R@@0!!3F?2Z^+<:G7J R^LGVLYG1
MUA53G0??_K^A U.L<R96!YTYZ5X?S^32QM=_7J5@*K4G=2H> B1C9A L:_.&
MXS!]1^<08XT(+ROA1Q\P\W9.A9.\!\.3M@8I[=<GDW7_60A]PWZD#N0P$Y>C
M0C@>E;IE!E>6E+@E:&2&C8\PBSI/MRTF2+Y7M_R*(V/LB0GM%0["K&XC5C%
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M2)2WVW%?<RC^496P0W/4/QME95:Z)QERO<DO1%RZ50HV<NU"]@6U>0^#!VV
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M^CN&(3-L@<=5HP_"F=%QE-R ^]&PIJ]!9PP>B\T[3*<([UX!,_<8;M  ;32
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M>VW6FPDYBP( HIB%EK'<YN90 T3&YJ8C#I>KQE^MTV[(?#V5'P^XLUJ$T1W
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MV,\(-GWRW@NGTN7B4*:-*48T-5QP\;O:UKWCGUP>$< '<QI<\6:MR+R"<KD
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ME+$$ C<%0-56GCF9^F4,%'7@&T4!N!IP.;>^<9*NE7_"M-?8N]JJ=&S_KGG
MAD@!$.B[A'MVNP.B<[?N,+&/DT^LK^UO L?".>-4PA_L_;039U%^6(7;J2EV
M-DZO@+N*"BC9:M,SZ8VO)=;06_?U'I=.)A3_3+'3IP ^A\'/O4&KP$#^>*O:
M0Q5+D@H%<)=;AMR21P&,J/N+X9Z[+^(4[L *8#J'< 8*H(_F8@'"'9$'EVQU
MSXPOCK.*8"C4 3RZ@P)HUIPXI^<@;ZFHK8SRQ<=J+IF!I5QFZ10'7!J^PW8U
MECE+U(.\DY6YI6L51(!+-+&2'HI9/COJW(R^^\S!-S)V) UF$KI8W\<43\^@
M>TG/2RLI@.ONMD!USV$&#1BSX?AUTP#8]>G#M B8$^2Z<S?CB<-8 >1D7>8N
M!?#QVD&+4)>\:].U@2*TJD_LD^OZ#!N@2Z8M"F8M8T),%O-Z3@_DYNE35 K<
M3 9>D6GL)@J^F<2GL%R\](.;T2>Z[10 HA:9QXZ97-)[,_&*387_>Y FS1[)
M94&1C1#8:2MKHJN[4M<,.?%J[-#.49U&7G;I*_]4JFE6T90_FQN7#])J4OZ#
M<\R+7OK/JWI^.L^HI[846F_,I)3)3+$9?BVJS:+JO7\[I(R!^O9,^;A0MH*C
M[<L?%GGJPCMKUR[DTA%S5GGQY&ZNP8L1KWDKK62=ELJZQG%^5:8977;'=!KU
M"W]QN:%>^3KQYJQIA'%,!Z=D0*S8:J]7K1:_9AO7QQ[/#S2+0,[9HRB\<A'W
MW_$:N9W5Z 7=;][R0?T"F]_EI(=&PS(#NT"AV2D=CKPU1]^"A$+TR F!+A L
MNQB_CZY"48;,!WQBV[U]P3G:%4VX-6=!X#SD G[(SVV$ Q71#,T2GL&HL0O;
MD1;G>=2353[1\,W10$+V;/8IQP$+%4D6/Z<R/6[I!].-W]=9.'T?YUQ?X_-;
M0+Q_.3/33BJ) KA#8FYE'S\\F%Q8[2!K1$\I6#U<;4R9P(Q8Y7'X/J1^LMU_
MW&TZ@72$7'(RXS2=F_DS5E$";'>Z49'CZ:Z8]'U XW6\=*+US9_]##5"A5D?
M1H@@_)$!=6?9 NBWDWO%EN\P#*;T14,V??@:B[;0I:=W,C/?U<&A'-\WY0\X
MYZ<2WKJ7MC.ILAQ\!CY/_-5Y][T#M3>+>1?HEA<O'=&5.]"LQ45)'AQR'Z_U
M-O';3EX7VQ]16".;\F0(DH=TD\R=8*GW1AO\HT%:&\P=U[F 6$IFF_XGV <O
M!ZR^ZSF>P>LZ$^!5MTYO$[BUA2+3M6!@$<JL>+WN/Z<T$0<X'I?D1B?A\E3!
MSV>?Y?*[T3<5198PKHK:F',%:];EKZWH]U7;0A5/9"MHNGD1KBE%=>'+(]_U
M7%'F29L/.34#G41LV8^9_;)D@ XA9<P).MO!/'XGS9[XX><$NY?T,LT(EV1'
M@04FKOKYC]E9[MI-ZK]QO%L'G+9[NCXNZHLM5^ES/7D2[-,NSVX_,_VH1JNR
MENU^[*_H!9<<IP#>J5Q3)W"9H>!>>IS'FMEC,_3<(MLFY3\2%6-M/-N&T_^:
M)H2!$#GAP?<=;7FR-[W&I,!OJ(1]8JL4N7H7XEROT4ZC[A0K1+A;F?'RDFZ4
M^$6CU"/,,FULGT]-5>L567>[>#Y:>\@RH'$_L5X1F!TQ5E[$X9_HA3V#@99]
M6%LYQM[7O/16")*>XGYF8;:@^R.2CE/@K-BJ8O2OF7X:'MX^(Q0IA'JO*%[P
M<DMB9Q^2BU!//P[:_L6Q6N4E%D^F)0C69^B%5PU[WG.GKIH>9JEI-T N#ZWS
MI7$?B9=XB<4M7"<(-F<HQ9?A?('-;MI2F?C9>7G[QG:%[_%O /R1TPDT(Q/E
MWJ"Q3>.QC31)^"=ENI$:^B:<0D>&>LK*3-6<P94,8#_7[M6[GAG5&)7P5F8\
M/TK"S[>ST35*9)A)*:ZJRWY-\;,<7'$*Z:QR71.+O+YN>3O(&0PR)@_+7*7#
M?+CIJVB$"+;^RT=CQUONJRQ+K,3D1)BSUIY.KG3,S^4/L)3'A75OKTKVG%QW
MX_NEWC=P"]"WEL$:I5N(+IYI6@G</0V.$!.[<+IY+BJLBJI8"N#62Z?&91F"
ME4!YS7QQ8GFV ."72.*0@GF>I9^#]J])5RD%L/34C6=8YKK43=D/25K)"K?J
MC/+=VW#)%MF<%[=78;>>5\W?$K=MJ2GSK6+6O';//<6M"]#)\VDI=_67J(H3
M;T1MU3_P\C^C5:4M79;>$Y]G2\5-G%8L^I^QAX;>>Q$0_[# Y6GJKK_*%H1(
M8Y /?8)/B_ N+0?IXA?27_^T<1ANKJOY)_7YX<"EY(QRE0Y>ZKGU8_GGK<QC
M_..BKGK+4W'OPN6$E.R!L:S*-;WK,(1/6!!VF&MC)GJP8&.!RS%B=@U1;_+U
MR64M$7;J98RIMO!C#=7R4<)QVP"FQ<HFQR*UIU-G+VX/_=?:RMJJ+)95VI$_
MSOY:UZ+TW!T>/\E&H;&!G76SYJDM6-="**8N#%SV_GT>?N<;=T%TXTQ';1_C
MK<[KS':Q\3?T%>DQDQ%:D8ZIEY7NLHR/]UE;7@ZC34A(>Z2U5%G!00$X\T:(
MUXQ)PZ%"M9=6Z^1%=C,3$Q/%TI9W]@C#Z7&MA_FEP2/!ET==<T.6K)VH/W>[
MH5AKS=E8\9IBI[49CDOVGV3L^$2=-LGVVZY$",;WDR)WR7#Q>C#GV,&WDSV!
MANH:K67HX6\J*9FH5AX_NYXTZ6/.HX]%+DRSO?PO?@>Z5B$<EVY^3VQ[W<Z]
M%?S0R"])ZZ^B*Q7P8=_= \E3T/?QS<:OR42AIPU)_=I>+AP\_:QUM0X?M<.E
MV>UM9:G=/[[D%&N'7_;S6*6/$^N0E\Y1O+FG+M"2Q,?W!/>&]@YC,Z_S=O%W
MQ=@@FO93WC!$@^0\KW;UN.0)1Q8._-HD+KV5\.BJW*Z%-"]U\Z6"/X+5>-<H
M\*/^<9KH'JE[TSK5-^53WO$^<ZG-BSNDNKS5QL/9@N_P\UAZ-KXZ8OA,-.-H
M\Q7].A-[J3('/C5FL47$:YY&!S&ZS1)#[R)K)DE]*,M2KJZPNTISKQ1Z#Z_1
M4M8*+R8::[5,<J=D[ 1*^M,9IRA$#JF64^/9PK&-X2N2"E?JPW=TUU=8MQI$
MN7V:OR]%O&Y7TBH_?2@B^?1PKKWJXKR#E2K61NZP^JKT'9%//INMS^-I?6UE
MA83XO7_..'0RT*XWSJ]6OL:4BPZ;-E^O8_L\DS?P0$GM,8=<178TE6?L.)F>
MR*"=7E"-#XYS 4+F""\U?NQ> =41+JL>#CK-D%3PD_'YA>C9=4LH6R/X5U55
M??R\VFR;O$8$[Z,$U6XO9F/DX7E ^*K 6@CBAJ:-GO.61E7]9!)KG=7T7;,O
M&IU79.QDE5-HPH*Y_4!MPQYD'CPY*Z]EP#6]#)S*=^_P_4V7O+RD\5=SJR0K
M_&Q'JV*@#X$W C$/+A]ZX[+U]DOO01^VC(&*Z&_?]-FQ]MZN2.H0ICGLSZ\'
M]^Q<Y5[0 ;Q6ZQ[D%X3^(0Q?)P_RL(U!W;$W/%^,'@1IS.Q8^4O.FE<9'S$\
MM'CMV;8URPV<>(U?2(&4VFPF.DV-;LJX\[.QZ=YBU.5<<Z[VOFN_&#B5PKQ;
M$%KJ ,R#/L+[AA]R-9T#.SG-<@)].!RR%T9OK] 4OZ&1*SY0^61+AQ^PK4W&
MZ/'IRQ3;-4A/.69[9.?^DF-!&6K=A'3 ;I" BS+UD)M^@?JCG$OG[I6U%K$Y
MUC>=P9IMP7<FX04M+2/;HA4K20^S_<LGL[+%(_\FR1<K\DRVJ"L<LL2>01@V
M4BU;%DJOA#7+I\P(^[(YL3/JE&;E?BNA$N*U!#Z+5E/V)Z*+@G*6D!\/(RL@
M4YLHS8FU>%K79:WI?).W7)?:?RN>+CI\KPC\A\#3\L,/@NF-0W4W9A?])"98
MUE4CQT5%,W1?WL^PB4]LT__[QVZU_T.P<<:I4)?RE1&2>?%&VFG!AX;F<9OL
MJ==\/:.I9YV/-%3;^N1HQJHD$T)YKH] GTDU<=]\X,WBDR3]I&^T"W><(9L>
MS<=K^L+_9^C*BD$^2706I#!]2GV^-?NS#O/VV#6>9LEN4[ZH>S?"ECNBZS0M
M C&HH=#3J">/*Y]9>J57VJ!U=\]-4\FE_V#WME]^-^_M9HG%*!*HO"*!(=+[
MAA)\>S<;&-/DA[O^$_[HLT6I>Y,<W)U8@C=4?@!]B@\NA=Y-4Q]=:K#ZRNG_
M.CWC:=-S, ]MSWARO7=%Z7.B*4:)!\QJ)<+*Y>_ED*3+9@;MVGNH^7YM5?A'
MB)7@%^&\AF8*0(GW</33H>L\4@.ITG>RJN=IF].6+47(]QLVKYXD*909O'[[
M!@+:QCYXMY<H$"&;F*6A^Y@_V3JGFQYGC$UKRXE6?C#5;%"\X>O#&&/AY5B1
MH6 2RP]>:9;KE$CC<^>X8U<09%Q"8L?;5F)9IW8E'Q1,\*@"Z[[=[^:+CR=<
MO=T46)5LJO@2S]1F*]O<V#!%4F!93GM*'\8TP.QIE^NE>:W+A]\^8)3-Q=,_
MZ-2&M$VF (PJOE34MI!MV 9RL3*P6]ZS_VIH64A>: Y9TFZ-%I$;;#>K46/F
M%X:2OB\?'$J5+#:5.V!SHA6?>ZMP;2YP\G!'Z+'"[)KV\A6PC(K5?-Q5.WR0
M(=HMVR8LPT=E:H)^@=)1$898X2K*9[%Z3BI."@.('IA?ZP(\UA**KQ%LP*NU
M\_"WUC9->+$79=#F?WKC9&@?)UYI;_JJZE(\57@1V[MO>R06^"8%8 Q\:84B
MU&9'#/_&&D0%*TPUORY9W_6],95<IOW:@8\8!A;^'B\SHSAK)-VZ*)&ZE0U$
MGA<B-% D<3P>/6\S/9?#Z!0E=N2]U-&4K7Y=]9E$:%91G:%MV$\2(UZ_IJ*V
MTC=7XWBH?XPYVP+[!3XOQOA+DX]J]V'Y,*L?WS^$H6C)+-=VB#"KUHI%:+,Z
M-ZW]6_M[7T*NTM[_$C3)L%./;"@]/WJDFSXPJ!VT,;NCK'$F6H3)8EJBB4$@
M;SL?R32"8@2DCZ:.XU-Q9VU<?V+O:&=2 *PN(#(C,BKGMI08YV:&R@P.[A78
M7?L+0M1B[>]'W>8+5:ID3[&H7&GRZ@%N,!!-6AGEI>$_LCBEQP]=0KV#Z'7O
M[:_P,W;M#'G0J)E*Y83PT*(.(3@@CDZ@\:UZ,KBKLO>Q0:- G#7_5PK@/:?A
ML8GQ>M+9%V-8Z%FOB%70+"P0+-:+5]1\AI*2DX)%9]\G:,9ZS\LS,,SSWYK=
M0,5.7= 6_?L8!5[A.7MS#NPN-S&_?::GP:EPBT>PJKH9KYQ;4G0T]!,E4=[U
MYDFRQH]D.JYAJ@3]E,.OQ+<8[UH4F *H+/_#N;0[82<0/2<]\CTQ6Y:J4-Z<
M:DEE.KFC;N$ZJHPD4Z!FA^5J$5S3JYX0@X@*['TJJ7.1D,C*O/G8/?Z*[JAC
MZV KM#PX@ )H%Y5N1 :2*G*6,Q3A7:U/"#+MYPJ=&?%QV"#C;A3G4(2[MS>D
MV$:J_R2*_6W&XZ[('NW%5^Z&?S=YF0YV:2N05R:7I=D6>%H:6^J1A+LM_O9G
M0&WFVLH+ZP]U^PK@";AVC(R 44/%%Y5$KT1H?]@4' 6["CK99VGU<+S0TN]6
MQ']G<*[#H$.RK^$+]N<W&IG=G_<1+DGN_4G,7_/H29(0?K4<PGQ3MOP1</_'
M<0MR#])I>@RNS!(<"W5Q 0U#>C6/3[/9L :LFS,+$?AO!LE=G"$5U7DVRKE'
M@;W:HK1U?>_>7BB[K52\6+1W0H0R,W[?B3/L<,(-JCCI;5+36.\_,L<_0OU>
M7,57B*K6H#P(F$>Z8/B(0V#@&2]#+\MD*X&^I6N,-C3VR7>'>R8)&"J>2<].
M]%42-\:JH'Y<4FLQY57VI.\@_\]??_K'-%C^?B@SU >T];+_+A+R%40@9; _
MTN:66Q>C5PP-K*SPSA1  "AJ$,HZ(BKR7C+.=:F7L[!&N;3HQ_[&\7&(W\*S
M)_9Q5@* C1JWULE5SH/3H4HL.IX-MS3HH*O,JN4JV43O<A3/=6%2WMD^=EO_
M4S_C(7\LM<O#2%3'\%(Y>SAS"L:F^L:'B]_+T(8B5#H^_OT$>MM6P:9W_NV@
ME *(:I4CR$3A1+QU@YQ7IUP>Y-6GZ_QPO_(V_>JDF\5EYAU>G?2S,5=Y1[)E
MJ=7HS9SZ%IS/R3'2)?LA!4"W&ROEJ C#3C>KE5G9K#>"XP8+TZ_,1;DPPQG3
MWD7>>;PFR\>")#R[H=8Q$U080Q,KE>7:V45FG=B!8)LF[%.FM+Z_9/7[)A='
M]Z; _)J:'<M!>5TG!7!SQF;S6-Q)>DNT+(K[2/5MEJE/\2/]QS1W+KVTY2&*
M+2+I6Y8V9NXXHMRDR@K]"S(CK7;_:;63[E*9M[Z9Z:X3?&!M5)N3#_IFL+(N
M#TDR3)X:)B%_GY.+AC@U\K'I.R2NQ:Q;6S*6]LIW$@PO,]R2^K2OT\LA<:?Z
M$07@=L?4@-=O"2L4X?4IP0S%,_XRHD,>07Z7%<!O1%BP*GO"]ISJ?CX+O^_\
M%DAK#DJ#EQI*>5VD'-TQT^E6\S#0+:F+ZV<4]<<C"J Z,] T!AF23=M:'3T&
M8;"2:C9[LE'*65W,NB??'-5Y?<?>2'N-#RY88624''2"9 $&H4"^N8^M2T3G
MD&'PX^GSM7!;:R*R(YM__$"$J?LT;'"A!>,$B3U=V=>]8ZYS%?5L.;+W5UL%
M?%&_);"0N "[L84*%JQ%"8Z-X3=F)H^/PA#?0"[#U&N?Z8![UQ_TM<'-)EO9
M_:QL&NKJ)R0=15="!A'$/P615C[LCH3,6T$&4KRAP<Q$JS89H[GU@->U#:GB
M]'I2?U W^;AO6YJ_*27WM>5*#?JNG?2CO5'SZ[^K5W0K<KY 3E20D[SR)!?"
M6IPD+RLQIYU3L,D?4K;I:W::FOPPI9KE9QR*-COZL<85LWIB1#E4#T62PM('
M.1A6XZ<:2F#OK&9FYIJU"(7?A)/J9_SL)&-_Q,,\6E,.K^8O,C X+SRH(7"O
MIMSHJ7-Q/?JUH.S+;W#\Y?I23H%QY;\TPI/.?ZH0HR(XG*3V<L,XYED[>-FM
M_:_GD!K2^K ,6T[#X7)NM:>[YJEQO@7?,M@G,22V<A%%O+ER0CBA 3UPQ[1;
MSD^T%=GVZ"; T)_:67T,9_SFH[S5OE%2>I .GGNU$[L54MJ2X& *0#=D=5.-
M?_BZ$?3;W[TNJMAL?>#/D>";?@J=\G$IY&_Y C63R?U'PVO]'4QW[QV5B@/N
M9 .ZP41(A[SFIWLM,9I5NNR[KLNM]2;OE.WW[C1E)O]6SC2K,(<,JK0@*( K
M7FI65OD@[X*3VIP^8HPA,6=)H9R^BY<)B7DWOS$SE5ZFE((,H8)/V\?9S_ Y
M&@C_49C4\^TABZ)(NH0<0U@,)_+3,KZE2R;#YU.=SNW?'RUZ3!L>-O$Y$S)1
M*!2L>K?S(L[O%,6Z*O(5#6#5P=B3E.JFLVY/1(Z'A"T$0P%,,ZA.!/,3M[JR
MY<<D$VYUECJ/;LJ_N'$O==Y,P(@?HVDZ-/>K+'\4G'^BT.NZJW$H^4UO7P"%
M/T;LZ:KG8I6OR*,B@Y5LB*6&!-?RUR761#DI";NU3YH^UO[W8/4,?P"[ILUR
M6!4>Z+,TC&L<A$ /&C$[:V?C3%GI3OF-EBQ1_" ^I+$-D/%N@U<=YH0LT!%H
MHMY#56&8K9>',>PWREO^BL;=^>=5!?,'#=EE8R]8B"WMB"BB*4[E:?@,6,P@
M2'1PZB5#LO.?E_D<KJK\F9DY 47ORE+JZL@&D/-'*NZ/-@H/1V&X'%+,V7!B
M\Z6EX<@^)!W4JIAX9CR1/^7=^7W>Z0F.=9B6WS\6</)#]JPG;XH46&P-99[R
MOJ&)58E"B+B*L6W6REMS*JW'NXROX>(9K?+N4JW?" IRPANW2\O[Q+R^^O&Z
M3X84!ODK4E?P;H[<@O+[Y&&U1 OEN^>IP2S$GST*2N;M1W6IH_,&T,KF?8!@
M>J@.278EDF9\G%EW8?QT0>P YI?7\/X,]B5MB[?^XC5G/R;FX <PO1\5)61B
M:]",SHV'?\;1SI;*>7&!M^A3ZK3G4JR]5=2L6"D EE:!K1P&*!4FX=961M%'
MM#E*U.ND65=R]/S73$\T@34EV&;-9VR^/^/40VS:$V.M?".Y(V9Q@.F[(MI1
M^OW>8T:8GSBX[9RV7 '^ <0 @5ZA"2G$%X02WUR=Y\D)OU9^OMBV,]SJX81^
M*0WW01H,0)2_UR;H"A'1H&Z51"RH,BO9"7V;_,1*)M*J6X2GP+7(S*.@J L\
MP+*88P3<G%EJY2'=Q?MV)$(5!7*MUF.@_2AZUZ%_PC28,5$]- 4^DLL[>4W\
MK2NOSO2.7ZLSF_Q_)ZT75[B^KJY+"HPRHN4SVA6.93'5--)>O';"NU2'^_I+
MJ2=B4>.EQ5N!J3O05NP]]/G2">=Z_K/"^]:_-$7YF QN\#C''B=$(WD4@?C4
MD2PCO$'QDV36'%<U'0H M)/@"6*&OCPO(=D0'J[4A& 0>AQ55PKR64159EV+
M-L::8XPF10^_34/$*MXV-7[9\2_T^-.[Z5P>I,%[22<<;@;U 4J41Q[;[729
MO>E*Y4^>R-!Y '].^'_WV\N<T'NW:BB BE)2MWDIIR_IDPALZR<%(*Z]+=5P
MBKJ(P1/ !O(0QT;^ /P-<X:=,"%V3T_)*5NVO!3 YYO?* #;4=CZY>:THR(*
M(%%!GP* PS= 3&$4@%]"R2F/Q/E4<,2 EZ%ZD#^^79WYQ:5_#?UXC:C.?.;7
M?7<7H\',E[9L >>Y-</T7W$U&F"0P9W@0V1 Z'33^8T@@44*@&=]0;;2*NX)
MSOX]%%_9F7O,@L^R'3ULPET^51A4WM35_2+'P-&[M@G\ _]89&ZQ/@RZ\74B
M?V=X 11U>DG=+Z=C>(9GO$M01*)+75B**DRW(O%Y$ 70"#,(GL2]#@6H4O.H
M<F^M.8]E<7@,\IIJM,@35@MW1)@-+;[]NZ)53Q@C5,X=2P%$+/"/X 1NV3C+
M0X\JM?0O5_>8\/Y!::O_@RUB8YNHU^[0T?6"=K-%*.HM!:E@%CY2 +1A.Q]E
MPMX(GN[A+C]]^4J<=O'U<2>/9R_ !$2OR()]T S!5[CLWG1F?>S(:EE>L(QZ
M$:8U/V1W=^WS]")JPL1L#O?[]\[A"0*U:=>79&@EPI9+B"MJ1S,Y!<RG18H=
MY-RF !QFMAI_IXX_:TA:P*LK#2@::Z[\$O[A,_S<W 8#"4MC56$,YMF2=PBK
M:5'0US,C[Y%MWA$JBJ[@N!E?ZB:]J&SK,7 ^#8G^JOQ/TD:NQ_$W2#D%P$4!
MI"\C>9O%2IT'%L\==,:7)WL^EA8<]N0 _B3U(D)_^?+)=;OQ,AZ  [$TD8KW
MEO@P$*8-2_U$7T_JT^!TKZF9Y%[A0/6.,OO']^J!V289I^^B4XK0L-_!6F#T
M3MT:V:&O$=ZA>P(G*94X\C 3;I1Y@M#SMLK5?L?F^K9S][4%CP3H;\<U2&VH
MT).YB4@#H@$FT)QPY>C#5  LS3LW*'R>U#/75:I0XCU'>^=V_.2.Y(O)1<P"
M.L3ED!HG((I>\UQ6N>IGT"/?VZD23KY% 7P2/7LV"550]*V32:ND_N#O[!,&
MP;[CM_=9_;D9S$O\B#VWP\R=UD9@75HTM0G\OI9?,Z3".]CWMKXF^GD#X(.Q
M'W,LSSBC1_OWUX)V]\=)B7=:MR*204*P?8??IYHABJ972/)LG[S@3'X@G<PY
MM6*GF0&Z@S/'::U!1!&__=[E15/()1)WZI8V?BV\)N$F<6*+4_5S4..Q1<Z9
MZ)2ZIFE]E&[*^YVS#PS-0<"M#*""S4L*P":FJ84"*/=5UAN79&"A%_NDS)S<
M-A,KX0<RCCE3,]F+F$ZYK;7/!R6U-V8<@.);>=ALA49K'"4-F"D QW87R<=;
MK2Q?TG/G3$Z,U#YSLQ>K2&N8%TGA$*;]^@$M.^C!4CH![MH:Y 58&R]1 )'*
M/,300D>>2Z@*1C'B<RE'"@##/3'ZXI[C6Q7@DXJK*QQ#LJMUBD&+2L8=G#6G
M?ES/"!K)\!@N%Q<%G/BGTW??1RLFSDST]BH65/F90MQ!_Z#])#0GFC7?5LQ;
M<M3H2CZ$ /4$_[9O/G.=SH$Z+-2N(U?1)(;6W=5.^, I*>F$]S[T&=%J2>R6
M<ZN8YI@W6S;V6&\RU4;NC_@\[1O35,D4K4<G-)<+"!$=)XJ&BP8<\^O!C(2/
M4Q"1;1%6"),SXYRU]7V;7CZ-2JW!L*?L.\.>("M#;06K 5(2*27TE 0YR5'9
M#+X\57"A8VZH2D9E#&UUB%O,#MT"^X=[LA_#)<9(=-@$.J*!/KD+CX[Q8N#B
MYARZY/FJ ZR\9V_]:+ZK]\W[W]2?]>FZ@]+5Z69/]Y,I@-F+Z]Y''HVEQHI=
M370XSZW&+>B<D"TZ=GL'$]Y/SCS(;6J* @(O($3K]?\#?_\3@P:X)!:=?9OH
M[PZFB8*JVN4->G+I7K/Y_:L1OL"W8>T01P$X)5SS,U?#I];8*=K>'6U6*^TL
MT(0YN.4]H%\[CC5XVWN_.?"HJ:5V/%@)^JBI!9_5&P>^&[*C[15C8>1D;QAO
M)G-7CG<>+F+PJ?&H)=^1;8S(:S0.E2F'_H- QG2._\TZ\GG*DK@:I7H[=UBN
MC=G0=@RU"R&EBW7;D+[JC(+]5<X%D.T%Q_D[-Y@N0#&$I(T9P,&>$Z2S_/,M
M4JU*_Q9>E=4YO!YHYI-^]A0J-P45+_&+[NV1MQF**DQA2ZL<_+K(O^AZ\%MJ
MWS8?L\L(E2&(]<HIBN!)SIPF*-8GEAOE!;LUZ=(,<IC(#TF_R.M*+OV'2&IB
M@@U^N(>K7*$M6&A,I":+\7<9XBR+^YY_NJMQ\-_RB9^)(3Z,5AQ"T=K[X&F5
MK HCVSV#D_*]1E#),15Y#'2=[Z,@A&N#GKXYL2P<EI*N3*29@?\E>1%A)<[R
M4F'P&$3)KE3*?%%'&J"FC0*P-P_U0R_.QU( S,$W9JR(H@\EZ:TX9O8>(.9F
M->^IACZ@1XBK+"RCTAQ5KHH)*[,[R1@2!7=N!*"QSXWY8PKEY]3?B9J$\XIB
M:*TSSQ<.R]YD)@7A*(#D!^2Z _%5:/.".07PVQJI&U"]/3 <1[[\BY!$U%_J
MSK!7YGM'*SF5Z=^4\#[@S&2FJ.=?O?1%:_ 7-!UU, NZ-7_KU\:8/G6%@6J"
M);$(.U\70_+$SLY:)82=MF:5.K4*1KN7;' * YV/0O3Y90 <[SSD%#2NZKOD
M-8Z(0L66(.S$0! 1^!.J.G5X[@P\!UI;=)GEB7V&I_LI!P:%>7YXXAYK8GP\
M8;5% <R<SU[@3PH)D=.XG&;0&41"@ *4$03>'@-J/\TNG\:KU=@X&;TIUU_W
MJK+=JI0#W,E24>Z$_:?CBD%8@YN;!5Y->O1Z$<8Y9O7I_UQ/DGL!V,I6N8,:
MR%; AQ=A=IF@.B-2\$^G1;&'2-8%#H12\-"T*QAG]_;2[;4WG+QB/%FE7#V@
M:@H@P57Y[O!/6HC40R@0@WM$V!:H\4%,%=:E><[NKF\S2S,["+FJ/W#I7\D+
M/!]$JOC"W;+3#-%%"\B#THV_9R)D";]@M,T$6!125GYP)B*OI*^[ULAQ"ZGA
M2$@!!51C0''*5P@]"*\XFFY+U](26O7VFMJO$B<.Q,H-D 3I^>@ADIV8CS6K
M?(T9?&6YV4I7JVL/5C9]EUP2^=!ZEQM5?%#F0 06KS>BVVKP=>&NDE8;4)62
M66?SHR,1CG GX4@U-TRP<4L]>BC@!=S!NX9, < NQ!+(WTQ_"C;Y'4W^0E[:
M'!"+M[TT ?<.5%!AV4@SSW@.%MF^_9P#8[JI=714(=.!K(D()7GF_G4.8)FL
M^6-N.1$@H>GN\TM>8N=OVRU?UK]:AK]9]D#;&WCC;B"!0>L72D31W,X[[T?'
M*E?.M9>=15JT]_)E.MSV2P-2( 40(JA#'A%\%>_Z$;+([:(]@0!%L1ZSC7/S
M]R0_M?6H*GV@D*_>)NQV%;-E3EOTH/!XA62?#/.42';2F1<CJB-:#X)RQ"Z6
M9?L2/SXS6VC<N"NA8Z/0?35Y(P'D_)< BY,4 ZPG;?'<GP0C@I[<IYJW4>ZB
M/F A%(4WJWAC("S.P8RHX&O.MJ($=53DCPEP\W,358=E1%BJ68O1RVNAQ^+#
M <<J,]764P=BM(Y&&V1Z9?'Q;T9QWK+@@XF)"G#N#%KQL3*5M%N#TB6I% K
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M3Z)*[Z_N1<AM"TOGX/OC$)&#@19QTYD; PVU3YNNTKR@FUUH&>Y%T[R'PYS
M#_GPUL9^;U#M,NY=3,\',WT%GYEJL+WZO/Q9?C\CW?%+$QH?(;/V'9L,AH$8
M0<D-!S>_$=+:3GM:'/(LB$7/&R<A]]A8CQ+UZ7]S<%R_HF9'Z&R3SXE=QJ?
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M'&G_G)_A $\1V%R8$].<W#1?>.KP'-@)30U3  (>/F=))[D3" '^1J<+62H
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M,>SRCC7_C ;B'H['/2A6=TP8WIS,<FH8G/^5%PU4N_L?.ZS^]]OJIIL]613
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M*Q%G]!.H6=YK9 #1 */^,TO^MZLWH[A@K@>5#MI =1LX.LK*;Z).&_V810/
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MQ-P?1(A)$V*T-N-]@%*3R*.Z&GF&W--%#PNSA>O_6F4K @5;QNI.LW37C%J
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M#$7/.O>(8]R;\:-O #8U7-DDUWI+T:;)R:/0TA['0?/M!K25\Z*:)%CWVU)
M!0?YP9)E9GF269#BL6*I>"+>IR?G"OE)XJH:TU8]*C:%/!#-Q:5=R7E1NQ';
MNHL=P<GG$NV?3-"%>\5)OR8P9G4;JN1O;C?:7YONL.Z^Z,]BPLTF(JNO.3]+
MH%S-OOU-K#E>=X 2$%S4.&K5%]>J[X49B21E-WU,4)FO2VM\]NUF>%4F\Q4%
MLE-WQI)!CP&#+TB; /M2NWO-RM>&@-F_/9[NV7+UUF]!);8_(R^A%8J>(J:;
M<O-2&3,L9C>NZ3P6K?'W-FTA&Q3<K10P(B(7VWC,J?T(Y-O:26E..1AO^-[2
M/04KWK4ZR38"_#>5$SG^;%)9&PPN::)?EENJS<[X?K&,F/"JY+5WK4V[5C8J
ML<7=$E+9!]%T7Y BYF% %[J<)-LJ9L$;7C!1;RM$X[6K?0A=3#L_V;\>Z7D&
MX'8D'<['%8;^1%>T<M17-3&RN)9/W]<1C@\)$NN-7<U,'(6F@X*F"RPSA7\L
MP,D9I^5IVZ]-1?KB9(#Z(/VQE?;7B(F\1ZBGAC7WXO-YWP0KE,L19Q8_$)[C
M,021G*-^J-0V6DY^C<=GR<6C5SH]^:7[Z!U@V96R)BE$T^RHC5(^=531M(X@
MU*W*&AU@SM]Y6T+DZ_.%P-)')YUXCC/ A--_TN7R/,1W#O;8W)V2^?XNR3=Q
M[[=N_5^-7Q=H0OT4^!Y.\)HH2L?ZI>.("^B$3*?Q)+<8U-;.W &W>,(_U?M$
M[1YNQIV: J>4XW2O]-3&Y$N7F/ETC.2#D_4TB6N+:C><3)M?9F&!>A5/-VB^
M=N;VXH,&EE2[UU"IU27>33;9F@&.ID:KIL'V/IJN.=QD2$F@,C$ 6K'Q$*@?
M1'^[-S5ZB&MN>EF,[A"N#,,BNA&7MX*Y5.7&R=*J<95S(N7Z/Y4[?>=_W^M^
M_EP(*9!3,9Y[KY2P"S'5M'IVMT7W%#3*3]%T>T6VQUOW1=%^XF^[Y$2[B*)\
MU;YS!I _1?@(P S\X]KEB6R!AN=POD&0^#YY? *U'[3UT6\A-#Q>XBI^7:KR
MDXJ==]0]3AS7)V4-L?WQ'<2BPU0%YCH@6$;OV9?9P4;R#-O:)=>NTS65D#4)
M:IWM+/\JZK+,K.IJQR5#'EBY2(H(;(?3Y/Q^7:R3/S979'2U=KFR+CC24-.]
M")L3UA<V$H5H<%;[U0<<ZG,)>AB[-LN5CX?W@*[ZSNJU3'A:>Z..AO^QN D.
M^&EP#=("/G6LL<X_SI\UT"=_,BE$Z>I9UZ'_;:Y72G6"S@%LJ<)47_XIX7)]
M;A"G\._<T7C%)5<>! ,2K/OJ&U]^N<*PM%EHHZ$FV^7_8^P76^@2G,LB4!6?
MG8=E?,H3M;W]2JG'H72LWOSN-<Y/F0D3T<N>Z/@4#\=FE6PX!LI,M):-8J?G
M:;,1=V,8^S50^"[[Z56^1X#C7,?M3^N59X R%_\/;,.:!*%.XSX/X6"QT??Q
M,QK#&\5/G^GZLRNUOPK2MP9Q.!CDUE<W3V6B%./Z7G$89KBJ!/[%41SVF80L
MHS&MLH2<SFSQR;H6<;Z7?.FO"4 =/^'1&/#"L^N?Q2XQGS"H/![R@E2"JT:\
M+FVRE\B6OP-^07U@O,:+R;1?X>4WR,W[X+KU[I MRGD)=MW&8=_QGQ/)BO1:
M.$HJKRWNA\:<= 1*C<5(-.9 3$:CO+"N2"X^3_05AUN&J]I6H3>U]B-M&YNV
M-E)FEWE&9#6YV'+3&](Y9_&WNC<X-C_ZLQJ[0^*6<]Z=FJ+VRK+&C2W/B$4F
MD)12%=%PJF/5<=1\RD8&3RT(\+('5VZDFGF'9,3X2@GYW;I4>4@G#O,O1MQL
MO;WZIOW>*&<71Y8@=ZSH>[_>HY-&J^RB:,#&W7(>&#_Q'=*@ 9'3[?]"3OZ:
M#4^:U$_S L.),O:.2Z@:+[7H9MJL2J*!G@Z*0M:__VO::OI;RD7;J()WPSR%
M$PI"RN,UT\K#G=&]M82BR-W=RNV*NOE'JWOG2PG"MNPL+.BU\&/%;==4B' G
M2>S7U5*+QXC^6GK72)P"ERI(395.V>XKMXRI:1VVC:7+^>(FJ2<B93SSF91+
M(LNM ^MN>WRENT!L-GM&[U+G5K&69':O$A'.4$5)>>_W0C?JSF[:X*7?K!+6
M7U58(*0I=-J<X>L=KRS58?#M;!+JJFW,B&?B!U-S$D0PFP-=\*J!@(B4//"K
M\Y6E2#K?8ZG76]^U=6 F_=?</.'Q-'U(R(GLC:)4>\W+@ 4.F$_?0^W/ (BT
M6=)$.C3Z0-\:E])G_JO-*1_\!AB0__5O]!.[%RR-%Y\(>_[)^\-H*9Z0@4T)
MYX#A OEK9%#E1V-SNV%YFC=[70?6O$W:JHR&"-J=#U&.'CU8_3N[IW(<V9OB
M3NM96).M1MJEPL=],ADZ'BJ(/]X^#<8E/QOAC('O\*E?R!R%OCFG'@;C!T-/
M@C=V(;=C::D8D:J665E$*;%!XU]YQ:ZLA+W!.,[E"O.(EV="?GYL2'DWK2BJ
M5"]EXT!$:3/.43R%Z$?@>4Y,PW@1:)/6[F2/Z3 [)9L\UOCL^^[A;GI+H>]6
ME^7D1LTX6:, -!^V_X(=6:4C:+#K;"K*?U#_SVZ%;5C[/QM+VTLX^.XYT)N@
ME2ISKS)7NJ4JM1MFKU:UOB74=-HPCM>*;\79#*^.6[8!>71PE3\=9KX(U^.F
M40\_:[D^YUO?1E1HD$X;E ;$^2&<#G*D6D6KYH4L]B(%1K:D^=X[7_G#C1^K
MA91>)? \C;?6D=K%U897-\O%B5#FKE0KQ%DE=T=R7E=PKNAUB[UY87S4/&X)
M>KWRBVP*\J JG^53,<\?ZK !Q7.^X;"L'G64YE? :(0VK,UY<??]Z4>/,HU:
M+^?%)?Z3'_03)IR'0W).WR66)B1L_+#2FC?_%N3'>GEQ]8/<>EP7Y(G'YXX6
MM3"WR?'\:*IW/I!863&@._;']H)V6LO*O9[J'V]X64)#*T(]1M?A:F.JBD1Y
M4P)M25Y]E?-;KS?X7ILC[-V\QD=B'_9TH#F?-JR)@B'J?U0VILW8H^_F/_CO
M$:;P!(1SD%4_5N+2"SIQMIJ7VKEV0B=WX95.&#@*;2@/Y=BI.#D#:-9'J ;]
MDZ<.69M_\(^$I0^F,B"]8>P_H\6G5._^]U@%\8,\3 XY"7W]#(",52-=@0_Y
M4^X2SU>O\'$7XG")B?I9/)2C6C7F#G%M/=+WE*HY.$):!:OR0O\DY9]_<D-O
M:?>$0TIM*RV?Z'8&N/TRZ0Q@I>G7-YDE\?]T^-'0+7!"!T8?4@2HGP]'4=!B
M@Q^5'E@F<FCM+HD*.P.H^Z_CU"9$_[VBDR=H4Y])@*A-<&I$W;Y^D,3_;/]O
MX6D!D-]ZXW?BBBV3<B1=%_TOYI$9_;-\<WXKQ:57EC =8[7(4>>4YV@ <*\^
M__C&QK$$^*:!IY MJSNON)P"#<FN?%1G4S87W][F\U.?87_#G[UI\0P0K086
M!/L[ZAUY)_G89+AJRVXN"#>G=JEQJG)M!=^M3OA+\D!9#?%5?:5/><7A36>5
MW=8$SR^&ZVT%!+2 X%Y.DH.[RO!BLLW1T09*URQH(64C=Q_6*75-+C>/;)%(
M_T36*<[N2,DO6UG-(!6L!IIJA6%RPMKGL4Q7UU.Y(Z,%;,8/+Z<'/?XX^J;Z
M[LDCKNN/$!K93CNE8L:]BLZUS5(=0!*YLY!6]G92T/LS %XT^'QB;#&@&/GT
MB+H27U*GDU+%O4,IR]>_?HW3!Q4^\$VWJ/H'V[#)68R[/FM)).3K!-@UN&HO
M$G5K1W=>D<6VT#3(<4\C$G*'D@[3:C]\UU[D'Y^7LG,&.)%_2/@0&2&!.P/8
M\_B-Z],'G0&N"JJ^B3G^SO+U<:];B'@C0:)V:.G<8K&WW04Z"E[CU!YV+ :<
M=V=XWSAKIP&!3:30FS_+M P %MFA-P,KWN9)YDG]5G#9)A.-_G+=?+[WXTN?
M(546MB1%YYA>KL8K@Z,=,+'U>?MH=O8.^B''JFL> I!Y[90V&L)YTI2X2^S7
M.ZBBIVGR ^*(VJG4JX2U3BF&'BR$W<K& 86(\M*+<;X']&E$U.KYOO.VNM)R
MTV/.3 PK =(-77RM>AW*N" :4SNOSCC7.U3%M>_WM3_>YU(#UR[(Q]"TJIV4
M%!\]$CS4/NOX@9)SVG!9PGIJGENOG>3B"F5=LB<^KOQ98J\(OO"D7^TN7)&H
M>:K@JPB]1K2W:JMO;VG;$VI\8&W=TBF\R93BNXC\)V,F+#Z0^?X'S@?Z%Y?-
MS<9K-3EA# I"_,'GT!']%XZ/$@FXGIYTG949X'VI^W[7O,\-*[M:O>GO$RH#
M^V+#0I"*E)(BFU38S*F$Q=B-44JLWDG X^723R]&CRG$6,@6)*+K8A=X?#C@
MTBGS)&#)GOWT':()=N32YH+\N(N7A*(*XT>]_#M+?W($/(OITGO&/)L.SP"A
M4$ZD[NB.A&G02['%ZH=LKI^Z>*7^L42?RD6/+O%,H:@"''(+A8:_B^O #JUU
M1#^?@XF3=TR\Z@11;$Y(SO-J1#Q]D*(#8\]0R[-VNSGFJ[R+Q^7_N3,GB#\#
MA!T(+2)N^DKN PD.4_R@&OI'+_(1@P^^Q0+H5 +,I@Z,2']-HQ7]3QH0?U5+
MQ*U'0/IR]4A5E]K&.CRZSX!G9@&\UR$'+RR;_M4@XLZRRA/RNU*NZT5++5$>
M7V39,NXBRT>GC6C*,*Z)?]0MEM#YW+C1.(F(G/8TBA=/%I<PDZ+J>9%2\-%6
MR!181M$^D S[%E;EBS8C'$>WRA;,F?LZZC/B8MJ:PJQ?T+T7]"P"$5UF7^*9
M?F\XRZQ$+#NZ<KV/OZ_V-[]^*78OR&FS6:S<3-RJ[!G2!GD&>/0A=,T@W;).
M,@M7O5>UC*YCJ[$)Y)W,?6TO):SA>/&E?+1]"-3>@);HLJ0[M=30UH*(%DY4
M:[!N[>=)YOI@NLA]."">S5;T\OH-[Q8$QK;0U_=U<9%L@'BP:$@@%QYE[0O#
MUHW,O :U%V_0[&GO2PVXU>9 =?>*=YQ9,#(YC/GXR:U 3:>I$^J?&4F[.=%]
MMW%(6U"))H37X'[E5/8N:&5V=S-6)*SU8W9#JAX9N+$RFB.^,#]#%B>6E:&)
M6SI-$]MU?)(\ <"P.OEKPX"YS$NAJ"JJ!)CQ7J J@4;1!;X(N]KAK&PG+NYV
MOYYA^+D(K:^K9M G3=EH<*_I9-!4#= '29I(_?SR4:0<;!"X?HPK1$<1%K(6
M6V[A029M*4RLZ VD?[JUR'@7]P@[^L1%B,^L_:$IE=-J!&M!]DP )Q$S-'+T
MKMXI88--5ZZY]24/RS,_)JML;:6+#7+\S4]'DQ,IBN:&'7<;925:&R;;J4&0
MXQR>0.$V7ZH(T;3O6?26=<1HNE+XI.?(G2 YU3- 6^]U-<O3.]'BW(>4EI=3
M5>T\3(>>D[O0+1+Y<_3=2N-?_Z<HO7T!E V7B^H5WY\*5UED'H;?:_FBZN@1
M?YB6'R@X63>);\_#PCGTX98;_":'A3E\8=[%-:6!L3TZ$@TJ3/Y'W/><\ZS/
M !<:/%/A2Y ]50%B$*9"Z0G1  ^SGCBH@W7A'<V,MCQD'E^27# >ZKM[?:>5
M87)PO:(R$"(?A7-^#PD3Q^KIQ7Q.R*E6,+_#J& 3<4LL+&E\9<3QU"AZ/'UL
M=9]B3)%A;5O>G3H#P$]RKF[F:4_:$Z/*B:9_SP"=2A!LVR/*2L.7+W_UKODE
M%O?-]0]K<\I"L5JEP;>(2=B(,DRN6ZG#D/-/E>Z4+]--M?';=;]?!&%6=H95
MMG H,>WYE0:#/3V0!'L(9:L!29X]/9PC[F,K<S%2-U0C2WVYGWN> 9@L-Q/:
M$666X':O(M(O(3NZ*QA%^2)_X @]\=U:1_I.:6"0GU?14(6%=5^I>F[XN& C
M3.%=S)Z,=LC:C]]#0>&:$O6'Y)R-']Z(HC6J_1?J$&HBO3<'6_NY2^_TOD^W
M>H5#U7=<W>U7++=+%IF#C1MBH_<0#*J?Z$*]S@#7'>68Y'L:)F3E?ZF[C/@F
M->LLCS0R?#E*YH$-B&_?$]/WL/8Q)=?M3;L%(LZ]D,KI3J"5W;]#&$.@ZAA9
MR(Y +-/Y;( KQGXI/ZKZ\CS-Q7=8S]NE,.EW]N4Q,F*F)CB!W2Z%/)\2DT8W
ML^HJ?,B3_)+)51QW3]P&ZC<PVT(-\'/4EL@;'!N"=ARJTH]+MJI@$'Q$,^K-
MXIM23#.^>5;FB9Z4O]=XMX4]KZC=J[D#*[/Q'=1HPD](6VXT1R J]##85Z5W
MG>]H6C![:T@^QX'>^H9B5G.P:IQ$G^Y4Z;F^@-P3A'W\'4.>DQ#:A6N)_FZ?
MQ4O*D?@)D!U"(LA3 A'4[X7</P-(8T?"4"Y1,JJ,W+#8?&M;+=/$TV?U_T8E
M;]]ZGBR9;]P"7DO9LH36Q(7Y:_<<(:8\MP;UA2PB5L@W&]Y7 ]577;( 5-I@
M/G4JL]/V-?&7T( <)(&*D)V(Y.E+'<=3ZU3MB+D^/];5V,EO/9;^W#B8I3#>
M&GW?!/.7OJSZWHWTV,5MJC4 TQ"23SC\YA\4:Z3NV0Z(6--/[J 5_UYW53@R
MY]4 (@T.#X3@<UL_E/3[,,60M3&'V4PUUI8;J3<X)84.Q.Z[TZ@T:->U;=E)
M70*"LVEC.DEL.'2D\YL&H%- F8!$T2=MKT=Y):*9*<83QZM5T6YQ4UN09L<S
M@*03N9E;Z3$PKXY*5.M+&2%I#YCYI*_UC(1F"Q).-XX=CGWD4A(M[^4\L #^
M8@FA$Y:^.-FVQ ?"'%5@#:XY9?.,CX%HIYUN]&/%9Y5,V9]14DP:P-?E?FD)
MRA_K20:8C6??Q+?!0I65;//  YUC8P^YN:Y(+I1W7TCT3[(\+ .K^3BA]\X
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M]EZ+#X.Y&1T@"J@&5(&5B<9*NU0?2,[A\8%JX\_V#P:HP>Y_X&;^+"<\PIC
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MCRWK8!S&/Q"+YV5M5Q2OO.]P!L\#4RJ:\@FYK8E]/S:)V,Q%):XCU_T.6F>
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M"UJ#O^=5_^A8QK4>H,0N+?9L4]\FTN) ?D1Y\'"DS2E@.*8^[W=X[Z__=8A
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MJ"CWY'9>,W'YI\45Y4WP;#K%RIH8(-(0M>=[:ZB8;_&M7I;[A?*7 95*T;G
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M9KG'E#NS2":*^7&+M6.(PKK,U4,#VW]MW.PO="Z[+)55R$W,$RK1OR#6$L1
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M&*<8!A[AZ1\#[)+SGCO>ZX9;L$[T[C^<;$AV4U)3^EK$ *+@?]PNY0U)RD
M9Z=28K]$ESQK-0 YE4]?X)0J<YNY]?%?U^)8 U[&=;;>;ZT:?U0]^6'*>:.Q
M[KYO=]NC)S3*B5-&;%S[3*N+7"CM\N)=7157:!;M8%X;UDQ(I/$W.8J>"K_%
MLCX#HI05$0F4W"NM%ED3Z-[S]][);2+0E-A#4P)HL%N]WN?J$?M:!2.(WZ8F
M;*5L_;6)'RTN<N)R>JW\YO L6' 7D1OK(?>Q856(PU(H74\<GMG[5\;PD&Q
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MWZ$%^'Y46(FF,<4Y"DX[QL_C" P($87S>&%%6><FHB@:.SN8LWX40&X&#9O
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M/4FU"?ZG3N&HDXN,((,B <A543ME3E),]VK=K(;M,S]%^[7Z/B!*]2E?B',
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M,N$+\J4S5IU8%_3A#_8=OC-%GY=ZZAT\)L,0(R^BUF@(]\%O)PE[5UZ(+%I
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MP*[ADFR4;N:?!TO)JX2&'Q>?MG:T[^!T&JW\(Q$#Z -1/ZN4&@(]HC]PJXK
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M+"A=PC=8G)=CL\:J5>:6H2/IG\/XM 5U4+:[W/'5XYB_,R85OH/\A:.:3M/
MVWO%D)B 9RW$E22? X+FDR]"4=<>2H;4\:;?%@E]\T!YK]"._@5U>R81M$)
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M^;[>X%4S88AW)XOUP&TO[Y-YF16F)]/K5#.-+B+VL_P@IY4-*'_ ]69-/7)
M6Z(WTOY-F0I-]B5'U 3E,8KLSNM7#4RN"O,;F13Q$H5WJQKKT="(!"<%)]+Z
MD_](R<K;T6GEKQ'7&X*^!2P"-P/-;6#F]&\<F?-:KT)#W-9_H;5KB3]'@UCA
MYA7U6$](O[0J9UW-SV&U]BO?[CS94DP1YW;0!@A<'U/\8GTLDK601MF3TMY=
MVIJB6-HA42.G8 C-+TZL9=9'>6#C.-!'X0M(0OTQ.W?I<;T.TD@F^XOH(+LT
M3HOM)?+_=8^___9'W3:*=V,6B"RSF)8&7JJN"]=J]%T)_=-P-S3BE8Y0G+'-
MN >"50TH$ZLA2(YK'QI 5KHTP _ \A^2']]BIW^P<05RIZC!W7BN:\PRQKP>
MZ@GOI ]O3;7[(-VDA(\Q,*LC,86[%HPS=)[,^&W4X$)_F=HOQW=$E]&ZYOR@
MW!_26J7<40>^Q'KEHGP+!O";+Y VIEZ0Z8CD:&/:^2_\1LQ%JI U3+CF9;CL
M A/CM,7#G/6VTQ+[RI;&L)G;#6V7WP0L['8W0S<T&9JDBLFN\^V'J9=#!R)A
M<6)MNA>BU/AB<JN]#,O\%'Y@<'Y@<D$SHR5\)@%DJ+ _:F?#O7.04&H'$63^
M3@[TP3,\LKOP&$\WK2R#)(U8A+AU_7[G>H%^VF+)>FO&V]V(P=[7 MNF(513
M/;Q?7._92M+@]7--78_[QOV)5P1.6?3F7!EX?S_U&+^(2PG9:I+E#'<@'F2)
MA7,HFLO3+<L,NS1I7E6[ <-M-E^7H5MW6SMTO^948>7 HKO(]48U\YQ]+/!2
M=0(L(]UF'@W<KG>W_EV*1B2/(;/(G+AU6*J:VV*&,<5KD: Q;=L0KE-',LTH
MF)EYZ/ZW)KATM._E.^JVY%W=;I'#<YQS452(!2DD>YQ73%AC(41 )T*,":)1
M+4)X$]0I5P)77+BFI:DB$AV]$!^XU8W3^535?^?0L)HXD78Y=,VDOM; Z]I=
MD^N-X7  +<[X(3&@E6/*L":%,[2J;N\$DN##T#!=]G>%7T20P&0I-*8"+R6+
M8+2QA:"YE5T0"7-$I>W79/2BPPB0!Y\2:R/VF[75+^KM?TY^TI)(6_]-QL$$
MI&"NR'(1]Y _\$Y62 &&=-@)HO6U-R9=*0W %<IX%9MGTJW?5*HA=M_0%G@B
M5#,AJ423E8*V/,XR)H,69JUT>$Q6PZJF,Y2-#F]-&7A)B'I+;L<]UQ,Y&3^1
MN4@.,*H?V9+RA #]]NKF>+F%0Z[4Z'!Y/?[+? 6L_0?[CQJ$D&K6P/TAU#0T
M'OO!#_?5*A?84JC"9'M\*>OBLX9T"Y>&V&2PFWS?J(@>,._5[XR.0II$CTY?
M]</.,P ')).WL7(4!I/:MPOW%SUQJ02JB&UJ/*%O)Y-NJ&$4M5\*C!^T?,;-
MRK4G6.OD_WWXFK]CV^/.K^#'?U8]ZKO/)YE:7$ 6?S"\71TPS2\P,+%M]FHJ
M9/@1C0WS7?IP<IV(AX$9!M8U@<'/EX:E6OE@?C=.;U5H.),RF@1H&X9+*"IH
M.Q?OJ7,3B'8<^U[?$E#]55*H]-=,MZ.>\');EOX@61P/WNO5O*'E]:,7X@0E
M'G>M7%VNNY/ 7QF6<$&95M5=ISI0*@<N0?0)FSCUQ#" :VZ=ZMM<A8[#E]4?
M^T?%&9,U%S*LP3F';5,V/:-O=B0[D'_@$6> AI9/L5_RM[6-;4R:-61ZOUF-
M?L_-_1RHR?_F#,"+:,\2)K,"Y_G6#QF*-J?&/CLLJ*H_8F',ET>L\^KMZIE>
MRE3=WTYMR;Q)XFP_E?OE?Q!9M.%?4(\F:[YL;C;H166X2M^JU;OEQJWZLHBZ
MQLWO;A@(0<&5B#7QB:+(X-<NB992GR*^FS"X8KR%J3U[1=^)XN&E^2,.G[4K
M8@W%.&M_.H0X3BE=L+AQ\OW#!8'Q?.V\I<7\;?+N&6#'8&OG453E9_^I^7"9
M(TW,V-'B0E<2GKR?=6DSUVP(*JF@^[0VFV+F@= HX7[XQZK7-2(:E:[]B_$K
MN@B23#QLPUSU-3!+>SG<I(("-T1/[DI#OU\G)"7U>[W4UR.<(NQ&Q&0A/J<(
MV^QSMG/\[_)7QPW&/L;Z6 TL?^^V6:S6N6(_>[@!Y+ #^+[QE;J9TI[Z)'XR
M?5K[0);]PZJFT/3.[KH6VX4&-@D  +!PP1P;1$<\R/Y1@/+ZOIYR/]$>NC3A
MUM0;^]5=[GA82^#UDL=]5.NLN WYF_AGKY=5X[>@&JKLHVC)Q)>/ROI$Z#MV
M=^UY [S**DV)+3%H\VZGHG6.^S'IOK=A/N\2N^K60U\]R(FZ;W6\Q0\[]1:I
M)5)3P**5K063;0?E7[\[+VC=S=XH?'"D\_.'\"\!+DYW&R9&\,4-"PZSM'^R
M,!_:.YTU2_$/A(ZC)')+VWLR[6C7Y$0W?N> 1Z1(LYZE8&Y.V@DC#5BW0B0^
M+HS'MADGC$N3*-U3YP'G0HHA= XQCA%W'3_3?<@F?7SO*[YY_M38=E:KC@3M
M;&. B?'?ZX%LSWC_EYJL_'\X!,\F_PM02P,$%     @ 23@'5_I*N'.1F
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M= _??ZEHN\HI\A1%_]QMF)R!2W2!&_T[M#\A^]\#%O+O0O;/P/Z*:QJX1D2
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M)3W8U%2ZH4WXB8!-JDLC<+Z93&\\:VSWT%\F1E7@97T\_0,AZ6?#;%+.HUA
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MKV>IGHDL((EPP,NBQ8";*&-9#!2$ ^#Z!*@C^A/ABSLX@ 0V5)V/ ^:*%!9
M&'YL6*D"]O()68<^^!<<E7]!CP,>(C)P0% !#@A3F"\_8ZC" >='BAR4NA9N
M^/TJ P6^I#"!79YE8^E^_T!WW604!^R- P%B*H%].( <UF9Q*&B/ TXVXS!Z
M6'(<\.4O^L?_:^DO6OV$@K;N?U^XN)]_CZ@)+\"3_@P_K^2@UHS#NQOPD]4X
MS-,@8KP"L#9>@2C!Z:5*T"N\A0DHWDOR!N?+4[R%&<$*ZP:CL+U^( BF:Y&I
M@,JYN(I74):*5V"'!\@[#SJC]Y@[/U#DR!@#KU-?W%$@A T5Y^'-2U%8T,!<
MQX:926 OALC6COY+*_><O6!%:9HVE(=[H,@LZ97_X*A7\LQ9+2M_<+?:'QP%
M8!RBSI/_X&^./X0*T4(1_Z[%'_P-^VND9%*'%Y37P_[J;=W_Y.I-_&!M,"(-
M)Z8FX?S[O<M=BAQ$P_^#@^??5$YT08>ZJ<K9/NWDB@-DH=?_-C. GR'*2SV*
M2Q_PAVNQY&OPO+*BZDO+N7P W8G[7SLM<@E1_F7DQ<C(0E*[/8/Q3<:.>^LP
MD]S_64GP_U"_K]HV7NLM$"T.:'3& =5VY5XH[U /$+EY_?!A7Z#D8/"=8/&]
M5LG!4=Z#K%?2R-2Z':\]8X@W2(@7-F@G60"KSL0!Z=X6F*O".. ZV"Z3W&)Z
M"#8H4WY!G(P#(K//3:A/U_#UUJMX'( 6\XH"<B]+R2X.&G! JP8,DZ+PC^'_
MEX;O9\0DH[5=<QUIRX@N,68*'^FW/9<MV-R/8WC7<<#(*TEM\84'3;67^[#V
M1KF[BP_(N&"M( R8+2^>?+'13"#D1OH8P8CQ(/NX3-SO/%5/%T1._O1?P12^
M3;7O&7M"&)BGL,=QO@)O_W2,@3=*7&)@J&*Z)R2PVJ[+*?@>OIL-XW!^>_X-
M-A>!7P 5*@#X/,!B)A5[H8#1_2\TP&SDB.^IV@]3=AF(.BQ^S "FC@,@O".O
M>+&(4*SO#&R>"WZAS?$O75-<]81$>,=.82UM DNHA0,ZA__@F485X.G_L+'N
MW@VOM=V6N7! 3%,H#K ID)^[<?("G_^HL?1?8#B  V2P3@A'+F*WYTX6\-DL
M[J_3;Y3UBO^R17BW'Y_[."[X_ME?!E%\__E'5(ON/*6K 7)[]$:F\156Y;CT
MY*C"TEB@-B#QA^4K"H,JX??)73B*U@++4S:L2 ?_P^I7.Z[B.!C8P@$$W#A@
MT6&'CD#KO_EXKO%,OCGN0?RD"57^GM\B_GEYEN6!CAP/Q0;_L^>-_W\&$%4U
M5B5AN2GX>!7\>'2'3FY'I>+KB+CO^#6TH@(X3L@LX0 FY7EJ<O.M9(:1614'
M@GL/%;UZNTE]RJ*:EH[#*C)T,1IE$"1RT)L_:Y'?6IB3LD.2Z//P>$"L@*/&
M</MX(6@QVGJB2*>36;A;4.\I;9_O/)NW1D7LU*[VRD3RR@+82U(.Y%#J??YP
MPV72YZE6H-#N\4FG5@L%8QKQ>UZOYSHR6+GB_@O6%OKJD$U*3A7T3[^F,VL4
M49&RBV,H8VP0^J:;Y&+J@G/$_5EH!NFN\(4"5QSE:WQS[%LZZ>O([/1&JN>'
MLIO(;&.:M(-?J<*\QLF^6GN'R$^')U&YNIH@K?4=WY$X=<$/J=] +345AYF(
ME^P;.T^/9W:':!%;=S^1*DP-0(E:<0#-X1S+5+^H9&623'TI2=.^\,=5\;9G
M!,O@@6-#B92,3C,*<&C;1 -I+FD=^&D2B[C1S\<_;SQ83O[>QA60O5_2+](!
M$G WAOBH&;WMIO4),=[Q="?*T:!.C?=.![I]>L1^RTHK.\$!P1CCRQX#G9N=
M=Y/#%#REA%KV:S)>;((;JDL#A0+!Y3X-/:JCSDZ<\?SGJ=:VYW0BF8G?-S.O
MMYV-O[6@,9&/LX'Y<OD]_]5=1KMI\#0G>F? !332XL-!Q;#T$%-1]&O]FW:9
M6.?PU,^AEI.G;S,$O(G/]/UF(]ABYB+*92T7 O4Z@]APP.L@"G\H1,LK>7OB
M9@!RB?@W=:S0>$I>*=RY2\+FU"\M?N"^KI-;7CQBNI$?E+0?4&MFGCRZ9]ZW
M!'MKXARR9UGETS(N&T9V-A[C=CKY)36DQ_XFM>;FH=P+2IAVU#Z)AQJWIOJ]
M[ZWSA>R94>@YX(*Q8>SB:G9+O2Q"NI+TA\Y;EUZ&D_T/NP-LNM^_+[]HCE >
MSAP2G2PI[6NX)6"NG.3%RQUYQ#7RV8JER]D=T6K8_9Q[IU@MB58C=QJ_'UP^
M%>7+BNH\;O^WGDMMLCH.&=^N0I:R.94MU B4Z6O=--V7@TYM+61@^'95J^=_
MP@;Q+<DA=ZF]\K36!_1!@'_?/?<NO@,WI':METRS1)<?7\^%=@E\[PROUHL9
M_/90;)JJ_+G"S@*L&RZVXQJKT?]RVNFH[;!LKDAX5>%^8<_X1O&E&6S> D4]
M^E:!R4Z2 RWU%;^IX:.5>03$;$=$=NZ 7[B$UR^@!SRT+J0.W??'5JN-&''
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M? <K%OKW=V^RBT=%^(J%'([BQ:IM1%SPLK/C <YFX!'>P8K"VET7]LXH-W
MAC9CR>+3H>X1_44;OK*]"[\D+/_]^/7]F>7?"/Y#S3"Q&D@7J *[!^O4+,<!
MBOC:@A"V'/3QCW+5_JA5[#1#A4/7XB?'_WDM\@\T_Y_1Y/AX&U4@G(@FS95\
MWKCT$P>W?_:0S&H)O P#7>C-WL(!OW]W<-@#G&K(/N#$NS4E_NS E$3 .OO'
M:LU<:5P17U;=8#0[;QTJKN/R*7;XIW>8X1563[ ;'4>'6'*\G.:XU<//18-V
M>7-98]OKY>QC\GQ;L_3CC@%W<C#/U[I2HIGUO>/<>3)O"U[NK+2MC<:#<E]
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MBJ3-_\(89VG ,[>72!D0RC0:T?20DPAZ7Z<![WY0KDBYU%T+W]I[_<<:]$8
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M=J^XS?#LZ>(IU4[!;+^&F!$TQE,]3*Q(B)5R[86][38GR+*8@YRH[UYV(*5
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MH2VO)\L"F<(N[1MK:9**'"K8PMH@7GXQRUE83I];D94*65$S&]?Q9'[+XF;
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M4O 18*'B)OYRZS0.#CNI\QQ* -#;.SKH:9432(<O'_ZID3_&U]P9_Z  I.F
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MOYR&I4N&@HL@DC0,5L)ZX:N0D-@A<;;N\V%^)_(6DAZ"XD8#<*I42!AJWZ$
M"TT#>"_L#\BO?WFB]V=NK'<O?YM[ "ZWT+L0WG%K7[0CGL56J!"^RUIL7:]M
MR$BL+>=#0'S.!^)>5QU=!:,\+>,#+SW&QK82]'W&V/7K$TY4$JF8P+4OYY=5
MSP<[^=AS/HO8I^^Z2 FI(1("[>TIRBE&,T,G2H@5!G;/B0AE+E587V^4=5K#
M5HO' +*ZLCID>GU=3=Z !F3D-J_9E)2JK*].MU,9T<X:0;$&B$ 01M@7Q)V-
MXWAG KH4]U^Z,#FI4']MG-T]V]KT01FB%YG[PEB/_:%'7!^3J=#][?<?!S0R
M5IG79)T$B-TU![ TP":,K<=:>F.S!^[5?:H>>7 F\/+0H[@Y9/WZJB2/7P&3
M555,=UOWVJ4J/BM/=+#SH/35]J<Y@JOC"^*A)U<#13>K3-NCPAD-1M>6 /=\
M5:E%],DDL3*7N=UL,X)Z>\-OYSZ]B[$<>FU$2A 8F,Z^K1\MVA2#[MX4+IE/
MX!#E_MQ?A>Z>VDB I+^_PN0<$2QF#JK9%.'#YU%0ER:\\R\F19P\MYS;2'CE
MD5HSNCWWNH*;&Q>$$YG&%C0_LPC&5E3FV=8KL1_B\/C67?I5?^VU#69L6W3K
M=1:7;B&%Q9D&7/\H@@KJEM)%/<X6=+XC*+I_,A*W>'S8]MG!MZ=.GVKH*A5P
MR0,_?5W0EU?H%*1<96O&GE-@.?4R/F-DT;>7?9_ ;,CD7;+5:*B=T_8]0;9>
MT:/@W5=T-9Y^;^G(>L1ZKR]?/$#Q[>?\=QV8TO'"U=UK8/8];XM@?$Y!9H)W
MJ)WZT)U =3'[!KG>\WDNQJJWB+@Z8T5=!,/L5F7TEZ>WDN-<\*_$=RM_XCJX
MNJ"H5M0Y_R"_(L"BZ+5KA=W7 +7#JGN4V8ZDA3 K.#V6TN?B3U.,SEPB]U/"
MFUX:37V.+Z*<I@&7FPK?""+'+)X5E&8%0'%FH8!\<TZ4^J+\E.%S6[.""%GR
M%Z>R]; ,=[/1XA!O86_S2IB5_SQ+JC ?SZ5&C+7?AW/Y'V3GAC(2WB??F<5:
MVX_< ;]<&KA>\O:BOX2M6[V&01MKN%YT9:?#QV$GR=%2G,#V<&!7O]DK<FRJ
MB8FW:(<M]GW,.K$_X]F85LLW,PGVN6AE401'\V@\'#PVJ*%8V,X5;O,&JW#N
MJ#0+Z]6HMW%K?0(2>A.&-EYQZD_>&/0:#'-.]>.#^MK(U_4Z;"_RA-XQS'SU
MI?1Y8&E11,05=HU[?$-G6UW>#/*HM9D30XW\$Y-_&U(T8XI2E&O14^;:4\^T
M3B?KV(UZQXOU+13*W,J-^EB_H;%5"24H,-DY7^;2(%7B0AO93:^\LUWE26_-
M3,20X83BH'/4Y#5&K=_KKH_C]I*A^*'9+BRTVK!\O[UM$+OZY=+INF+?V6.-
M^Z4>,3*OZC*KLG MV=. 8$:ZD]C/ZX@ ?./*H&%-=ZLW*UI)M[2RRA FJ)FT
M6T_FH:[J8>J![,R/76V]9&VE)^Y]?$D%81SBK/S7GC\1N!<R$:W(U3Z[Z%(=
MXA]JS(P77C[(FY@G_OU-I4W<>A$-B(@-PL^]1'_6;XM><5B LH%S,$8HR/'!
M7V53&$EC'J6H[8(JQ.L)-(,PE,@M%J8_A<JSEU8O-K4L8!+W.3DH^E9([(PG
M[JGS@OH!LT!PQ;@P;KWCJ)A29"/[!W#.7-WKA,F5S"AU7&+\7LF58CO4"XQQ
M]9F814^66J4E^S791R[MJQ-Y7J7FJB77-K,23,_E,:@KFDAWB6&<3E"DOIYE
MJ'ID8G3YK+W.T9(+I=;\2?)I=8@'DGJ/[/J=O10*O1RP9'7W[+4][5B]+G;T
M@[)P+\G]'ZIKFSC$Y^*K G-EZ#W>AS*RO+*U'RMDDSYP[\7FJ0DY:Y^NY<>(
M3YF?T[+&@PJ,'$H=C@\DB17)HJZJ[:8!5XD=5J>OCFYT# Q?]?CMQ54)C:B+
MNY\\]6+$VO4:]/1;G\QKQIP^/;BQFR\LK#)\FE*TZ:IX[J+L:5B8^Q&FE*#)
MRA3\&M6#^;"^((X=CYLC: ^M?F&\Z2-H%QYLXW+/^;40O*!-PM7CHS*0>_W<
M0V0_'37.Y[.K0>VRR4#_51</:IBUR%<&])[M-X"Z'F?A??/Q0!Y+&8;.$1$M
M]P>#FQ!&C6LQ@MSVB#D-88&M_'X'YS!9M)Z/@"(T53T-LUUHZAWHOZ*@>HPK
M%+#0M;7;]'+ZD'U]7,F<9)Q1$G;?6&[0^%Y]Y]T*OW")['TA;4Q&]Y.AK ;7
MV)1Z3EV(7PR_MA' I&FLR*HISP3L?/0U1XXHSI?E%IL]C7<DAT<W=U8*? ;;
M"Y>171ZASWVL#<IR-5U?6.2UCT];^4N<FM- O<^^W Z#"E= JJ-R]EQ7RI).
M().F_*4G(;SO]K);=7SMBM=JNH898CXWH_G]^U;M!J/*PQFU50S#RXF2<Y:)
M(0I/0S?D)7V)J;A!IHGM:K\7FD,ATFU>3'(AO%D![)]8%D,BG)G9J%^U&)Y$
M]7RU9_JVW='WR&?V<T>T'#&=7V2[.OD=O:!PROFV+2WS\U?;4MCWWI#227J7
M9G;RK92V54W*?DL(^K54!]]&QOVY6QO"[[:@X:'1 ^7D4M$W4>F85M'2\\X8
MAH*.&75V&\ZKG;S3<M',*E*,*3RY2II=\6KL5IW["WCGM#JN8U6OLXZVA="K
M\/G]M@"U"U7O7);/T<)R\[<>=N&GCBJKX-UOG5>)\/FJV>&_&'+SO8:*U9RZ
M+!\&>S-DEIEW1E,G*>7*SM]8';!2-%#1['K,OE/R0Q^Z]A2IN'B^SHN[HWV)
MR2F("KXC]JKR3#IQ^P?Y"B9GU/Z0Y?=-;,Q0B8?*=,A$\O.B03EL%9:2]NZ0
MZ&>* NEP%2LQ8&V>WJYES\.HWIX16%>9]435!4MM]]"/Q>M%GR:-TD[<>/SH
M,^8L8U/VR2FC?J/@E4=RQ@OO)ZN$2$?J7X]52JMU4"R\WMV!O)X+*W/E!%?E
MRL<,<5"\"ZIS#A+G-_K66EX[R&6L+V4DVKU0O<O Q0EKJ[RL1(Q=CWUF6Z'V
MR'6I_<5@EOW9&H&'RI(SJW4(DH4_2VUWW)[$^\6AJA4L"IPG1\_2G?9\[ELX
M[67@Z/@\%C=$P8]P('(SN?GD5]M]FPG@@6IW%AU\U]J"AFI[A88/;KKM]A);
M5G N=FKP<4;/J?&W.G)[2(K/O/7'"EH7"\\=M.2N^];:*&X2\;!T?2V[3"/(
MS=,^,W. C-11NS"L_32K*/7(;!22H%-S&&:=DDIA+VZ]\%5H]<UPWNS).RS:
M%5Y5/=B-FN?AF.64!3[IJCDUJ;E,2M54JV]37IXQ1]EBP5?C80)"-%^\0FW,
M(SS2!4HCQONL/9^8WQ:LC@0^-N?0RYBE./99A%#4A#\V&RNT'AK44K*PPO%X
M[]=U.TY>=/_ /-SG#E=J:R//E+D4/MUXUGPQYP93D=.G!I/"^/?N[ 4.04NC
M2>[<#XKC& N>$>5\!A8(=D.%GU/4KB:784$WJ0%^E42[WCL+R\4$IY9"Y*G9
MN5$X76%7OF-RS^S)5-7!>R)#8U?>920PB+/E)WLK=$P1J_RSFEV7+[*];E_,
M*V'9K]YY3YKC:G;V^.A0"NSIJJ" >G=?]=3-YPH/ENGJ).H9IC\UM"<("-PA
M'LMM\Y8>;5::*E<6W>7FX:[]W+_T];.1^R.[C$.<[R]@ZLC&FZXKFV>$XMTS
MYXB@V-I2]O#ECEV-7P3/LC(53G T_A%(_K.//E1)%D:T)(U"5=[-9/!>501.
ME%Q*+.L?8Z]'<VWD]9V^;[Y;E-Y5:2V[0E"I+2-%,/R,G:3>N]$CA#C?,T"Q
MP?Q[G4\GHR^_-S]2Z']A_Q?K:15OM9'MX#4 ;UG8:7>NN/P@,^G"R,R'*59M
M<G>:)6)7(G'A<[N!C=9BW(4G\G%#DLP1XV<#][@R/]@8*4<(QHF5<_W6IW0A
M\)"796*8$?)DYZT#.#WWLDMOK);LIX(U]CY[?MRQ;\O816;%D.R4*E,6UR?3
M%["EZE)NVYC'>3$;6&X\'<C"A3+ "->$G6]KXA42/NR6=SOTH^1+,T?CCS(5
M%JSCHG,$8M/:X#>'HY(E9GPL^]I@HM[U%T<-[:]PHW9G8JH-HW,,$60E[KLY
MKTX^*'KV.9<&.,L-]E!LF$-G")OQ,"VO;7@SA2 8-!KSQLWF(G][OS%WG%%6
ME$IYSXMWD[\WPL29C:M8K3:DI-0P0P.(@5=)9A<OB 4;/]MK[%0)$(8DS^CG
M*A*;UB5Z%9_!O&Z<]5!+EC-[5[_+KE3B0UHR6=>+^V71>"TC[,W1)\KC!<$/
MW#_NX8LX4OM0NE/Q5'8^5+(W!ODYS/LB)CWD*HD8M3:]+<Z,5SQYD<>5A;B?
M)B>=E937&_B]F[XMK\)NQ)"1<>;)BD;<[*RP=//*IW E([.T^Y+:\_)>YMW5
M;YH+?/HVE>^;>UB$MW#'Z)D$#!PN'K\U!Z>WZ+8U:!DW^KV_(L$YV,&"Z9HB
MN&)'QS.G?^:>7@54C<I4RE^D<YO S&2LK*R"Q9M/0K;HP%-Q#:"_.&QC8>=<
MF@>0U-Y]::!N&\QO41EH@-]'ZIM@$%$'@W]%7$'67+Y- UH?C(-4+(SXN0N^
M>JJ$!N!M%+NGW2ATV^(G*/@0.61BU>._(8*/OLY"3E]VI &^72A<ZQ*9?MV>
M9Q/)Y$T#Y'UVT8##7\R@_.$-:GMG >\O R#>#Q,9YP<TED'>3?!OA%J] #\7
MI2A&8S]C$W#[.6&ODN;(R$G*WA^D<NPUAC]V7BJTGG0]I<0"#YXQ28(&J4>O
M<CA0Z&G ?":RA@;0!?K9DBYD< GUA[+^3@/RM6*D @IB)W4NS:N\L(>'2(9X
M^QQQ@Q$S$> 358APY#;_(XHP%+->A=" 8338E+/5"9NDM!#2NT%$XQAO]CC(
M[ ]1+H]<@LIG<^T^[PM>J:;4U$P_]-HI&M";]AV\9A;"$+LLL0N:WTV":<#!
M!QI;AX1!.AJPKK-$UGZ!;-5%+C5 _=7N3=, \4GX=^PK<0)?\:/JGR AZ4+2
MAE&C843,?4BZ&1 I*+ )_7UI#IZA_S\!B\*V@@Z?Y=(1FTC.EB #%\^SY)W3
MC5[]?!P+,JVB5YD1VR2(9AVJ/6K%U_PBM\,$!26M4<%_O:T2\(9%G*$!UL)4
M,B3)](91)O0JTQ_@UA#XO>\KG2A9*"^)GH81TY*AL1-_('\K=ZP1/LF+WQB'
M4N)4D@[RS<K>IU@*/G*J0_\=#:A.C@*?A$*RAF_SPT>UE"$6Y'^PH-&5MB,-
M1*<-4OC;0]7O64[VJC=/Q&&D%>X'(8K5P;L(ZW$_=(/^ 0__OFHW:KED/$7A
M+X5/<^$WIJ"1DT!F(_3J<<0V%#I[M=PSQ,CX2U58?4@@_U=[5QK5U)*M Z@H
M#H@,H@)1 4$0 0&9B1/"A:L( @%!HH)"0$1ED,D<%1%E,,HL4X 8$"(!E$'&
M<$&9',(\*F&2&0E"0B#)21^4[FO?U=W>[O?G]5OOQUZKLE95[=J[JO;YOJI*
MU;WT,C+3*A=2+ LI1BS[[H?^ITRJESTX#SEJ[VOE3Z([QQ2?)58I>^S"3J?E
M4QNYL,E68&#=9:"N"RH*</S-A$QZ8_/: R3>:QO0O7"TN\5L#I:U '$$ FJU
MBC;+YGLVK(=9269>5M=HZXQ 9'%=4+P$YQE )8,5NJ"0&!>&2^/" @'Z&&.>
M%0+EJCJ#,J%*+2_+*1\%(;LG6R"WR5#GYA$S6+!"J@]W+5M45]R18*(CT WA
M6EORZ#! A7/\K]+>0O,,SO>M3)M.&PO;93EUH37$9#G71?)H_[=<Y@-%\*^T
M;U4)%!KT/[.<<LSLRXK*0>>&B,/I0^#BLI&=AQ2 3BP+<F2NQ>015MR4<]<[
MJ*LS.7>!T3PNK!)8FL<?VPF0X O0/'"(*PJYQMK&4,-/H.FII:JH15?$# ZL
M4&8<YL)2\. BOO?H*X734Q8GHP<Z2*1H2R"'"ZMS_9P;LO'U>;!I:Y*C,U3)
M2\:C+^BIT:[Z+*/#\SDXIB&6S<:RH$&4>U)JFS1\_+M9+=[2'UV3RL3Q.3I%
M1O?N0_/L]C??C0,#.Q!SW\TR20J(3MM?JS)IT9')EG8&,?P<:.1V0CBPV@ 8
M??6]^=IUKQ9ENQHEY7/.IVY&K-AJQ( <F++B \;C+Q*14\X/VY4<MN^"?^T"
MJ B./_!7FYZ-/G#=]X%PI@FL1\RU 53UC3+89;L3[.NU;8]#N)1([98#_;&L
MD6CT,3@=QYR6J+=_GF4A6*I 87APU#E[JVOX=G!A)O;U)&NK9=![EL7/ @B[
M6N?8 $%.IN[2Z2PCDYCG![-TES;,9Z,@\NE,SRJ5?'(A-)=!9@!G##I!RJ1A
MDVT<!(ZS&#,,Q)G53/XOF(*SJY_XA&9Q4A&O !U$ ?^"X"B4*78L&]?#QPJ9
MP[,. 5=!+RB3G\[I[#L3AXV67BY"X\M5<'$$T$&N/T"'@+DEHI"?/8=(EF^'
M:7^EC)H,_9+@97V# 7DNQ0A<PK/L 8HT%W;3,M9%T\3=7.<5XFL]-"4M<3TU
MH!^<-7%+G?^,]Z4(&\%%)V F&S4-?1+TL!SZH>WJ_Z"24ZNA"#DTT3M!;0S-
ME1SM(?4O'IRF!#+2;ZF[/-NOU'.SS#E6 J#H>=+K-009@;@YCN<BU)/"A[:Z
M9*.ZOP(4.F4$QSX!_SWY[<2E,Q0;$9V(!&!6_<<TCT\H@8.3@[[2]B#ZV\/J
M/_QH6MVC$/>#"J/_5P>I>_[)WE/2],>:VI4LWC0+:\9MI%PG0SFLTXF<&"YL
M=,2#?8,MSU+DPBCOJ,P9ID7>\S 1*^ %F<V&8.S#Y=,R%X'%Q<1O*[L"^\0,
M0Q7(W2@0<PD*!D U]H=\*OG+@WSY3^Q/R+-4&GX*"M8(-6"(/'#H[3^O$99O
MB/Q=N_GOY5/7_^\H]/W>,47IW\U!>I7)^<&W>N9*%BT_VLY386@!4J) @ 2H
M<V&#+C^F>:=%35D&9HM@";MU^73E#^G4]056RE.+B-&ET3DS< _V]^2M_<V6
MY)?#4/,F<>\1S 3$#VE8V7^!,@%-R"_S=(=(QON.SW4]F0:C'DS+_ZI._X\*
MK=PS1@)^'RIG2KW#"O-V,P;\]'B79YV;^7]WS_YGRHKEEHJ6MH\2K4\8G(@
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MYR+&ANI \9@DU97:L ':&L*0\( ;(&2XI[@"O]GO0+"SI*4Q\KR>UT;S,:!
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M#\B[.NFAN\]-V)X48,]=$!YTK;%@.F,D K(U%(27A3_PYR;JCIHMO#GFZ\P
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M%(0,\(']5@3[,9ZQQ*YU[U HO GKBD1_?N.MX97HS.ZV29QX])I435=<#UM
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M8BJK"B\<J+PSKE5(&X!GSL\88S*MZK1ND!!+?YS1<8B?![1[+HC>><)$>*?
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M_.S )OUK>R1>N2.$9=\W[C&U4&1[!1!\'EO&%XU!?29UQA!;5HMV]@M18(:
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MB2[9BCI_\>PQ4VNMB"1X5#2]BN;9< WUXV?/SP];)_W>RYE<2L[D\VT<IHF
M+3( 1^JO?@WYV#X!A7 +'G"JD;?!BY,O!?E?>\)#: @L#OAH[(VA<0OS2YH[
MA@RCRWRXX-#/?::&NZ ;!F;]\<7CB0J01 2D0)^E+R5F9]OR[TJI7Z(1<DYZ
M4D@U;%:NEY1<5KM#?R'KO^/BV^*(VU:<>^!Y'2'\W*%Y#Z*KH&\',%SVS3W4
M5[N9$E,;]\V;J%D[:WX/E?;.,^UO[ $K'8GP^8.[H]2;%(R^[&8(9M(W?E3
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M_Q;4:XBN<0^40D-JIU#K!>)Y,('4FZX.&JJXP9M:6ID9U'Q63FON/GI*F,D
MI=03BW!CYD%:DG''?$ BFS _JX0=[*\+X01!'02R:$L-^P,@L7=[8A#&GBE8
M2>):GP@HT"3%>MX]#B)8U(\%-VHJ'.@FD&7$VBY:J,[N5=SUH('7MX8JPTGO
M[R3>.J1A!^J>NM$]V*8%'WU%>7NH;R!OX<)^!!=&6X3IN^#!Z<:VO">,HD\W
M3BH C\*M0/N>P]=KLDWU8+:.N,B;RG9&-LEIT^/;+SOL&TDW2MH?W77GD AN
M&"W$<C=NDC P;_9WMT58146ZXW%>2']M,5JD!W6 K8+Q!HD?4^-M4SPQ8\4(
MR_T)Z##? /\;O!XNZ\\T#&.&QU;?&P4;]FFK^L*S0_-SK>P./J4MCOVWJ=:^
MIKBR]+'"4813&"[08-5?HLE_\OV#8$WMA62@M$+"7NTDH^"HSM'GNBG;G2GL
MSW&QQ,0T!8V'# Z_S2-G9 9T5[B8O0)?:CH75YQK-#%\;"A^#?-0%89Y5Y!N
MMZ1B*#[%(><!2_9NMC>MX*Y9S<.XS&V+$6>QS^W\)+./EL((M__^GR;K,;5N
M:*56 A(* 25)T1#Z>Z79[[S=>:OW+W_L*SZ;(7(\^_T))N_@<O:!Q)'8H@E.
M]/ ;"311",XS&N;SNQD-2=%@)/*[/T<=&V&@ H 9@'Y_YV'L11$0PX44>B^C
M27HBGZP=B#\\%-KE[H%]C7L5$^U<6:,K4N/M?&* 96AY$6U'8T*_Y %2'&6J
M\9:L9SFYV\K>>:?9.]FXV%S"G&583!>ZZ1RI*4"J"EH60Z+-M&IN^U-OB"#"
M8":&#^T^/[#/?>N5XX&SV8^+&#T ;HO.*VT--'1\T!.A+.S,.&"T$>U9!T*3
M:QO-ZK@B+DQYF%C"^SX$#-M(\4 ZWU_;3O55O\ZE21?MQ&MN@F7>-(_ISMV2
M6M:(B\T^?&\UD3@)_79;JP\*U_[TV&(Q1HFF&JZ>&T74DX\_C?["?(S)P-Z(
MW?ES76+M0DX*#*L7I9"JYZYQSXB#4] 9?4.&4'MVO).Q/4.M-R7ETSNH*0J_
MGC$!%&<2":GB04]L92W>)*4:-]2CF((4W>C#X425Q]&"3Z^DT0;58@9B7ML4
M\_8.;*@_0W<6T<RH"GM7.]1;'%!C>?-?,G.W#,>OD0#U6N-H#'U*+$6VH,E+
MAJSP6>B_JGV=*A@_Z1A-ARL2!S*9K)H1_V=*[#8K4SJ$)PL''(+]3%-")<[J
M(]6@T_Z+@T+M*0*54C&:@@7 LE>R#_"A,?/<X:5CNG5;NO7)F&X=TZU'T1KT
M" V '5$MEQELP9RF!XL:YY]\Z*:NWKJZY3RW?J<?QD2?/S I.D',P;1,>/H@
M#2@W((.36\_1":&C1/*JSNQW@:(:&R4B^:P?!3(^N[08+6U KW.TB'\#KO"Z
MCAW#FG!%$T:V:M*:.:K*$ID).$A#\S!K))4M]!2QF3G;W!0.MIEFJC6,6;FN
MCI*]#=\?1T013/8.*."(,0.-31@D66$/J-YS*0STV0ES--.8Q"& *Q,VPEE/
M#T7[SJ%C32J??!?#$9W*4DO!HV)K<*HR/DQEAA,8T:QV;25[[9%2KV%IQ2P:
MM!/((0O-IH&14Q8-7Y]8Y.&_WICO*QSN]6Z*8YNS';+*25@7E88P&%9,CI/J
M#E](ND(N']R.=9D:Q2),<R*T+59CD5[3,2C"V7C0K /_O6^C#$;(=HZ,!:CD
MECL@.LVE-(VJ#.[EM)2RA.^5PE)N"M56\#+X3I4)J+@Y4:77;?*TS>-WQ]$Z
M$O=6--Q.0C &7JODEO7!=[$%DFA)@N"A%6\Q(21W/@R;\M_;_0;9871_)FP\
M1>YH"UJ/^V(B,A+$:9)B3(I9PWK9*D4_+:T=;X?_VI^Z-O=4D_RPFR;Y!0]]
M.4H#7$+_"A+1N"P@:Y5:?9 CP3JUWO:W?1V&^B'0 6D[)F.]/>$:D@;WI_J@
M.?4W+7*%A$U:7'4M9R8'^IQ-P 4?$LK]R5;<TJ;U(@0>9(YVL)?C",YW OT[
M;J[$5M;T5I/U-(>64LO;"B:.9']^7?#"YBB*Q@:2:%Y![($@"KQK^@J/"$I$
MU4&")B)5YQA:/*JSVRHGAV!2AK.N=W^W$%@V#']Q%E/?\#4G.(<P6WCDB*;P
MAR4OBV#6@*17@5$ZQ[81^.)@T&;J.@SO'S(-W$Y'#J9CTR"E'\U005:&FLDT
M<)A2Y3^99=QRH64_!QQNMN63?U])$/N^!74[[9CBRIA^=-=%HPSA@6GCH&S#
M"9QT#%U*Q)$R!612L)GDPJZ,93&%:'=.0-LLCD_+XZ5B[WVI[>&59F_A.K)U
M;,-^#1*][4?5^80A7T*_&3\YT'-M4.B0L@N(L;9KM0%>\]FR*#AA(% <9ZGU
M3]]61BV62R'$Q)S/6XEWD!,3\_O579R6#S(P-HW)>YOHD4T[62K,-D&*K7]X
M].)5%<:Q.G19R),^[RD@Z*'G#,<[Y2PX DHQ%#27/CU+R3 +P%5[G;9<EQTI
M0D"[%7[:"[?HYSD?^5F^=J?;;X.?I072.!"GTS\%/@-C+A;,?&1SL^OBVNN
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MBYZY/9VG6\WL>^IM/CN M_G9KN6F2)-MGN7#:9'<P'^6]2K[\_\'4$L#!!0
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MXK1Q^V#0[1ULBHU?B]P3LG]G=@_7QW\#4$L#!!0    ( $DX!U< J3;#? <
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MU;2Z]K_<S+_-'?T-4$L! A0#%     @ 23@'5]QF;=2$#@  $80  !
M         ( !     '!L>"TR,#(S,#8S,"YX<V102P$"% ,4    " !). =7
MC+(6:R4-  #[J   %               @ &R#@  <&QX+3(P,C,P-C,P7V-A
M;"YX;6Q02P$"% ,4    " !). =78%B0]U8?  "OQP$ %
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M2P$"% ,4    " !). =7K[7H,^N# 0"CNP$ %P              @ $C80(
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M,2YH=&U02P$"% ,4    " !). =7YMXN=F$(  "T)@  %P
M@ 'T608 <&QX+3(P,C,P-C,P>&5X,S%D,2YH=&U02P$"% ,4    " !). =7
M/P >374(   <*   %P              @ &*8@8 <&QX+3(P,C,P-C,P>&5X
M,S%D,BYH=&U02P$"% ,4    " !). =7]"BP/8P%  !Q%P  %P
M    @ $T:P8 <&QX+3(P,C,P-C,P>&5X,S)D,2YH=&U02P$"% ,4    " !)
M. =7B=$U 8\%  "+%P  %P              @ 'U< 8 <&QX+3(P,C,P-C,P
M>&5X,S)D,BYH=&U02P$"% ,4    " !). =7 *DVPWP'   )*   %@
M        @ &Y=@8 <&QX+3(P,C,P-C,P>&5X,V0V+FAT;5!+!08     #P /
+ /0#  !I?@8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
